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Chronic Constipation (CC) is common in adults. The effect of symptoms on quality-of-life (QOL) is significant. 
Trans-anal irrigation therapy has become a widely-used treatment despite a lack of robust evidence. A 
randomised comparison of two different methods of irrigation (the CapaCiTY 02 study) will provide valuable 
evidence of superiority of one system over the other. This study aims to evaluate the feasibility of conducting 
CapaCiTY 02. Data presented are interim findings from a single study site nested within the large multi-centre 
CapaCiTY 02 study. 
Methods  
This study was a mixed methods study involving a) a systematic review and meta-analysis of current literature 
data for trans-anal irrigation in chronic constipation, b) a randomised controlled trial, and c) a qualitative study 
of the patient experience. Participants in the trial were randomised to either high volume (HV) or low volume 
(LV) irrigation and underwent standardised physiological investigations. Data from the first 10 months of data 
collection at the Durham site were used for the feasibility study.  Data were collected according to a 
standardised outcomes framework. The primary outcome was reduction in PAC-QOL, measured at 3 months. 
Qualitative interviews using a phenomenological framework were undertaken to explore the nature of the 
participants’ lived experience of irrigation. Descriptive analysis of data enabled assessment of study feasibility.  
Results  
The meta-analysis of seven eligible studies reported a positive response to treatment rate of 50.4%. Trial 
recruitment nationally was slower than anticipated. However the recruitment rate at the Durham site met the 
target for individual sites. A total of 19 participants were recruited at Durham, of whom 11 reached the 
primary outcome visit (3 months). The overall reduction in mean PAC-QOL at three months was 0.39 (SD 0.44), 
with a difference between groups of 0.04. Some outcome data were incompletely recorded. Of the 19 
participants, 5 (29%) discontinued treatment, after a mean time of 51 days (SD 35.2). Qualitative interviews 
(n=5 at 3 months, n=3 at 6 months) identified important themes regarding participants’ experiences of 
irrigation training and home use.  
Discussion 
Collaboration between participating sites, combined with protocol amendments, has allowed measures to be 
taken to improve recruitment and recording of outcomes. This study demonstrates that the proposed 
methodology is feasible and acceptable to a majority of patients.  The qualitative study provided a broader 
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CHAPTER 1: INTRODUCTION 
1.1 BACKGROUND: CHRONIC CONSTIPATION  
Constipation is a very common and troublesome symptom in adults across the globe(1)(2) 
(3)(4).  It has an adverse effect on quality of life (5) and incurs significant healthcare costs 
(6). It is commonly a result of diet and lifestyle factors (for example, inadequate dietary 
fibre, inadequate fluid intake), medication usage (for example, opiates), or neurological 
disease (spinal cord injury, Parkinson’s, Multiple Sclerosis, stroke).  
 
Where no definite underlying pathology to explain these symptoms can be found, the 
condition is termed ‘functional’, ‘idiopathic’ or ‘chronic constipation’. In practice these 
terms are often used synonymously but for the purpose of this thesis will be referred to as 
chronic constipation (CC). It remains poorly understood, and there are many interlinked 
factors potentially contributing to the symptom of chronic constipation including disorders 
of intestinal motility, disorders of the enteric nervous system/autonomic dysfunction, 
visceral hyper/hyposensitivity and disorders of the pelvic floor and anorectal musculature 
(2).  Many treatments are available for this condition, ranging from diet and lifestyle 
measures to pharmacotherapy, biofeedback, trans-anal irrigation and surgical management. 
The purpose of this chapter is to give an overview of the epidemiology and clinical 
characteristics of chronic constipation and its current management, as well as providing 
background to and rationale for, the use of trans-anal irrigation therapy to treat chronic 




1.2 DEFINITIONS OF CHRONIC CONSTIPATION 
There are several different definitions of constipation in the literature. Physicians have 
tended to focus on frequency of defecation, with less than three bowel motions per week 
being considered abnormally infrequent(4). However this is often not what patients mean 
by constipation(4); therefore, factors such as straining, incomplete evacuation, and the 
passage of hard and/or lumpy stools need to be taken into consideration(2). The Rome III 
criteria for functional gastrointestinal disorders attempt detailed subdivision of symptoms 
into distinct disorders; these include Irritable bowel syndrome (constipation-predominant) 
(IBS-C); Functional Constipation (FC); Functional defecation disorders (FDD) – subdivided 
into dyssynergic defecation and inadequate defecatory propulsion. The features of these are 
summarized in table 1. These criteria have been updated with the publication of the Rome 
IV criteria in 2016.  
 
There is evidence of considerable overlap in symptoms between IBS-C and FC and it has 
been suggested that these may not be distinct and separate conditions(2)(7). The American 
College of Gastroenterology (ACG) definition of chronic constipation is broader and simpler, 
and is also widely published. This defines chronic constipation as ‘a symptom-based disorder 
defined as unsatisfactory defecation characterised by infrequent stools, difficult stool 
passage, or both, for at least three months’(2). It should be noted that the term ‘chronic 
constipation’ is not intended to correspond to any particular condition defined according to 




Constipation is also classified within the literature according to physiological and 
radiological parameters. Patients may be described as having slow-transit constipation 
(STC), evacuatory disorders, or a combination of both(8). Some patients describe symptoms 
of constipation but have normal colonic transit time(8). For this study, the ACG definition 
given above was used as it is clinically relevant, patient-centred and encompasses a broad 
range of symptoms of constipation described by patients. 
 
1.3 EPIDEMIOLOGY OF CHRONIC CONSTIPATION 
Constipation is a common symptom; a majority of adults will report some degree of 
constipation at some point during their lifetime. It may be secondary to other disease 
processes, for example, inadequate dietary fibre, behavioural factors, concomitant 
medications (for example opioids), diabetes mellitus, neurological conditions, or malignant 
disease. Where no secondary cause is found, this is termed ‘idiopathic’, ‘functional’ or 
‘chronic’ constipation. A recent meta-analysis of adult populations (>= 15 years) suggests 
chronic constipation has an estimated global pooled prevalence of 14% (1). A further 
systematic review of studies from Europe and Oceania (3) showed prevalence varying 
between 5% and 35% (average 17%); prevalence varied widely depending on the definition 
of constipation used, with self-reported constipation having a higher prevalence. An earlier 
systematic review of North American populations also found that prevalence was reported 
highest in studies using self-reporting of constipation symptoms (27% compared with 15-




It has been widely reported that chronic constipation is more commonly seen in women 
than in men; approximately 17% of female patients in a recent meta-analysis had chronic 
constipation, compared with 9% of men(1). A review of North American studies found a 
median female/male ratio of 2.2 (4), while another review reported a mean female/male 
ratio of 1.78 (3). It has been hypothesized that factors such as hormonal changes, 
gynaecological surgery and obstetric trauma may contribute to the higher prevalence of 
constipation in women (9), although this is not fully understood. There is also some 
evidence to suggest that women have slower intestinal transit overall than men(10), and 
that they have longer colons(11). Other factors with a modest association with increased 
risk of chronic constipation include older age and lower socio-economic status (1)(3). 
 
1.4 CHRONIC CONSTIPATION IN SECONDARY CARE 
As previously discussed, constipation is common in both men and women in the community, 
although prevalence varies according to the criteria used to define it. Women are more 
commonly affected(1). The majority of patients with constipation are managed either by 
self-medicating or in primary care, by making diet and lifestyle modifications and taking oral 
laxatives as needed.  
 
However there are some patients whose symptoms are severe and refractory to the 
aforementioned first-line therapies(12). In these cases, a secondary cause for symptoms (for 
example; medication, an undiagnosed neurological condition, organic colonic pathology, or 
psychological morbidity) should be sought. However, there is a definite group of patients 
17 
 
with no underlying cause for their constipation who have a poor response to standard 
treatment(12).  These patients may be referred to specialist gastroenterological clinics for 
further management of their constipation, and it is in this patient group that further, more 
detailed, investigations are generally carried out, and different treatment strategies 
attempted(12). There is also some evidence that patients who see a doctor for their 
constipation are more likely to report poorer quality of life compared with patients who 
manage their symptoms themselves(13).  
 
Current evidence suggests that there is a much higher proportion of female patients than 
male patients in secondary care populations(14)(15), with reported female:male ratios of 
between 6:1 to 11:1. This gender difference is most pronounced in younger patients (less 
than 60 years old)(16)(17). This contrasts markedly with the ratio of approximately 2:1 seen 
in the general population, as described earlier. It has also been reported that female 
patients in secondary care report significantly reduced stool frequency and significantly 
more frequent episodes of abdominal pain compared to their male counterparts(18). 
 
There is some evidence that a higher proportion of patients referred to secondary care have 
pelvic floor dysfunction, rather than slow transit constipation or IBS-C(19). There is also the 
possibility that patients with pelvic floor dysfunction have a poorer response to laxatives(12) 
which may contribute to the higher proportion of these patients seen in secondary care 
compared with primary care. However, this is an unproven association, and the reality is 
doubtless more complex. 
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These differences highlight the fact that the patients seen for refractory chronic 
constipation in secondary care are different from those in the general population or those 
treated in primary care; it appears that they are more likely to be refractory to treatment 
with laxatives, have increased likelihood of pelvic floor dysfunction, poorer quality of life, 
and are disproportionately female.  
 
1.5 PATHOPHYSIOLOGY OF CHRONIC CONSTIPATION 
Chronic constipation is classified as a functional disorder, meaning that there is no clearly-
described disease process to account for the symptoms reported by the patient(20). Hence, 
the disease is primarily classified based on patient symptoms, as well as radiological and 
physiological findings. The Rome III criteria (now superceded by Rome IV) are a frequently-
used example of this (see table 1)(21). It has been suggested that using this type of 
definition leads to heterogeneity within study populations and that this may partly explain 
why a unifying pathological diagnosis has not yet been found(20). 
 
Nonetheless, several studies have been undertaken to investigate possible causes and risk 
factors for developing functional gut disorders. Many published studies look at irritable 
bowel syndrome as a whole rather than chronic constipation specifically; however, much of 
this research will likely be relevant to both conditions. Proposed pathophysiological factors 
include inflammatory and neurological factors, genetics, disorders of the gut microbiome, 
and disturbances in gut motility. 
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It is worth noting that the subset of constipation patients seen in secondary care generally 
do not respond as well to correcting lifestyle factors (for example, increasing dietary fibre 
and fluid intake)(22). This suggests an alternative pathology in this patient cohort compared 
with patients in the community. 
 
 There is evidence of possible inflammatory/neurodegenerative processes that may explain 
symptoms in some cases. For example,  full-thickness biopsies of the jejunum in one study 
showed several abnormalities in patients with IBS; there was evidence of lymphocyte 
infiltration of the myenteric plexus, along with neuronal degeneration(20). It is difficult to 
obtain this information in routine clinical practice, as obtaining full-thickness bowel 
specimens requires invasive surgery and there are risks of leakage from the biopsy site, with 
associated complications which may be severe. Additionally, the associations described 
above are not proven and demonstrating these findings in individual patients may well not 
lead to better outcomes. It is therefore not practical or desirable to carry this out routinely. 
 
There is also a strong association between risk of developing functional bowel symptoms 
and enteric infections. One meta-analysis of clinical trials revealed a six-fold increase in risk 
of developing functional gut disorders after recovering from an enteric infection (23). 
However, the precise mechanism for this is unknown; it may be related to the inflammation 
hypothesis alluded to previously(20), with chronic persistent immune activation in the gut 
leading to abnormal secreto-motor responses and thereby contributing to the patient’s 
symptoms(24) A further association is between joint hypermobility and connective tissue 
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disorders and gastrointestinal symptoms, including constipation (25), raising the possibility 
that abnormalities in connective tissue in the intestinal wall may be a factor contributing to 
symptoms.  
 
Additionally, it has been noted that immunohistochemical staining of intestinal muscle 
specimens in patients with slow transit constipation reveals a significantly reduced number 
of Interstitial Cells of Cajal (gut ‘pacemaker’ cells important in peristalsis and intestinal 
transit) (26). Colonic motility studies have shown significantly disordered patterns of 
peristalsis in the colon in patients with functional constipation compared to healthy controls 
(27), and IBS-D patients exhibit fewer propagating high-amplitude colonic contractions, with 
correspondingly slower transit(28).  
 
Further research has demonstrated disturbances in gut microflora in patients with IBS, with 
the nature of this varying depending on patients’ symptoms(24). It is known that the gut 
microbiome plays an important role in healthy gut function, including defence against 
pathogens, metabolic function, and nutrition(24). Several factors can lead to disruption and 
alteration of the gut microbiome, including GI infection, surgery, diet, and medications(24), 
and there is evidence that the composition of the microbiome in constipated patients differs 
from healthy controls(29)  
 
Genetic factors may also play a role in developing IBS symptoms, although evidence is not 
conclusive. Although there is some evidence it aggregates in families(24), twin studies have 
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suggested that genetics play little role where environmental factors are the predominant 
factor(30). It appears as though genetic factors interact with environmental factors to 
produce the clinical picture seen in some constipation patients, but that they are not 
sufficient to explain the disease on their own(24) 
Despite numerous associations and hypotheses, a unifying pathophysiology of chronic 
functional constipation remains elusive. It is likely that a complex matrix of aetiologies is 
responsible for the symptom profiles seen in each patient. The lack of a definite 
pathophysiological basis for diagnosis complicates treatment selection, and often a ‘trial-
and-error’ approach is needed, starting with simple, non-invasive therapies and progressing 
through to more invasive and high-risk treatments if these are unsuccessful. This process is 
not helped by the lack of availability of diagnostic tests to identify key abnormalities; for 
example, full-thickness intestinal biopsies are not possible during colonoscopy, and surgical 
biopsy is high risk and not thought to be ethically acceptable as a routine investigation as 
described above. 
 
1.6 THE IMPORTANCE OF THE CONDITION 
Chronic constipation has a significant economic impact, both through costs of treating the 
condition and through loss of productivity. One study estimated that 29% of patients with 
self-reported constipation see a doctor in a 12-month period, with 14% undergoing some 
sort of diagnostic test(13). When the high prevalence of constipation in the general 
population is taken into account, as outlined earlier, it is clear that this will lead to 
significant healthcare costs. It is estimated that the annual direct cost to the Health Service 
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in the United Kingdom per patient with chronic constipation is £1,700, with a further £3,400 
per patient in indirect costs(31). Constipation as a symptom has been reported as incurring 
Emergency Department costs of US$1.6 billion per annum in the United States, and this 
appears to be increasing(6). Furthermore, there is evidence that the costs of treatment of 
functional bowel disorders in secondary care are significantly greater than in primary 
care(32). It is unclear whether this is due to the disease process itself, or due to the 
additional costs inherent in secondary care.  Nonetheless, if more patients could be treated 
effectively in primary care then this would reduce costs associated with treating functional 
bowel disorders. 
 
The impact on productivity is also significant; in a recent study, 51% of employees with 
chronic constipation had one or more episodes of sick leave, with a mean of 5.2 episodes, 
mean duration 25.9 days(31). Presenteeism was also a significant problem, with 82% of 
employees reporting productivity losses at a mean of 161.9 hours(31). A recent Italian study 
also demonstrated significant losses in productivity due to chronic constipation, with 
approximately 19% productivity loss and a mean of 2.7 sick days per year due to 
symptom(33). 
 
Patients with chronic constipation report a significant adverse impact of symptoms on their 
quality of life(34). one recent study reporting ‘extremely/very bothersome’ symptoms in 
72% of IBS-C patients, 62% of CC patients with abdominal symptoms and 40% of CC patients 
without abdominal symptoms(5). A review of quality of life in patients with functional 
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constipation has shown that the impact on quality of life is comparable to that reported for 
chronic skin diseases, musculoskeletal disorders, and mild asthma(35).  It has also been 
shown that symptom severity correlates with increased adverse economic impact and 
healthcare resource utilisation(33)(34), and that healthcare utilization correlates with 
poorer quality of life(13); therefore treating the condition in order to alleviate symptoms 
has a positive impact not only on patients and their quality of life, but also on healthcare 
costs and economic productivity. 
 
Patients have reported dissatisfaction both with the effects of their illness on their quality of 
life and with some health professionals’ attitudes to them and their condition (36). There is 
evidence that some clinicians hold pejorative opinions about patients with functional 
gastrointestinal disorders (37) and that this is noted by the patients, leading to frustration 
and discontent from either or both parties(36)(37). The view that the condition is ‘all in the 
mind’ can lead to patients being labelled negatively, and patients’ feelings of dissatisfaction 
at not being taken seriously are well described; many feel that a functional diagnosis means 
their symptoms are not being granted legitimacy in the eyes of the medical profession (36). 
Psychosocial factors do contribute to symptoms in many cases, both in terms of pre-existing 
psychological morbidity predisposing individuals to developing functional GI disorders and in 
the negative impact of bowel symptoms on health-related quality of life, and this aspect of 
care should be addressed(38). However, dismissing symptoms as entirely psychological has 
a negative impact on the perceived quality and effectiveness of care(36). 
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 Table 1: Rome III Criteria for chronic idiopathic constipation
Functional  Constipation 
Irritable Bowel Syndrome (constipation-
predominant) 
Functional Defecation Disorder 
1) must include two or more of the 
following: 
a) Straining >25% defecations 
b) Lumpy/hard stool >25% 
defecations 
c) Incomplete evacuation >25% 
defecations 
d) Sensation of anorectal 
obstruction/blockage >25% 
defecations 
e) Manual maneuvers to 
facilitate >25% of defecations 
f) <3 defecations per week 
       2)  Loose stools rarely present without 
laxatives 
       3)  Insufficient Criteria for IBS-C 
 
1) Recurrent abdominal pain for 3 or more 
days associated with at least two of the 
following: 
a) Improvement with defecation 
b) Onset associated with fewer stools 
c) Onset associated with harder stools 
2) Lumpy/hard stools >25% of defecations 
1) Criteria for FC met 
2) Must have at least two of the following: 
a) Impaired evacuation (balloon expulsion test or 
imaging) 
b) Inappropriate pelvic floor contraction or <20% 
relaxation basal resting sphincter pressure 
c) Inadequate propulsive forces 
3) Dyssynergic defecation: Inappropriate pelvic floor 
contraction or <20% relaxation of basal resting 
sphincter pressure with adequate propulsive forces 
during attempted defecation 
4) Inadequate Defecatory Propulsion: Inadequate 
propulsive forces with or without inappropriate 
contraction or less than 20% relaxation of the anal 
sphincter  
Criteria fulfilled for the last three months with symptom onset at least 6 months prior to diagnosis 
FC= Functional Constipation. IBS-C= Irritable Bowel Syndrome (constipation subtype); FDD= Functional Defecation Disorder 




1.7 TREATMENT OF CHRONIC CONSTIPATION 
1.7.1 Drug treatments 
The mainstay of chronic constipation therapy is drug treatment. Laxatives have a 
variety of mechanisms of action, including stimulant, softeners, osmotic and bulk-
forming. A recent systematic review has found these treatments to be effective in 
approximately 60% of patients (male and female) with constipation (39). However, 
as previously discussed, some patients are refractory to treatment with laxatives 
(12).  
 
Newer agents are now available for the treatment of more refractory cases after 
laxative therapy has failed to provide adequate relief. Prokinetic agents such as 
Prucalopride work by increasing colonic propulsion through activation of gut 5-HT4 
receptors(40). Placebo-controlled trials have demonstrated a good response rate, 
with 43-47% of patients reporting an increase in spontaneous complete bowel 
movements (SCBM), and 24% of patients reporting three or more SCBMs per 
week(40). 
 
 Linaclotide and Lubiprostone are newer laxative treatments that work by increasing 
colonic secretions. Lubiprostone acts by stimulating chloride channels thereby 
increasing secretions of intestinal fluid(40). A meta-analysis reported that 




placebo, with 54.9% of patients reporting a positive response compared with 33.1% 
in the placebo group, number needed to treat (NNT) = 4 (95% CI 3-7)(39) 
 
Linaclotide causes activation of guanylate cyclase-C receptors on enterocytes, 
thereby increasing intestinal secretions of chloride and bicarbonate. This leads to 
increased luminal fluid secretion and increased intestinal transit(12). This treatment 
has also been shown to be effective in chronic constipation, with a positive response 
to treatment reported in 20.1% of study participants compared with 5.1% in the 
placebo group, NNT = 6 (95% CI 5-8)(39) 
 
1.7.2 Habit Training and biofeedback 
Habit training and biofeedback involve adjusting patients’ behaviours in order to 
achieve more effective defecation. Habit training incorporates advice regarding 
toilet routine, posture, breathing exercises, and answering the ‘call to stool’. 
Biofeedback is a more formal assessment of anorectal function by objectively 
measuring pressures and muscular co-ordination. This enables the patient to re-train 
their defecatory muscles in order to achieve more effective defecation. The goal of 
biofeedback therapy in chronic constipation is to enable patients to increase their 
defecatory propulsive force by enabling greater coordination of increasing 
abdominal and intra-rectal pressures, and synchronized relaxation of the anal 
sphincters and pelvic floor(41). It incorporates verbal, nurse-led instructions in 




electromyography (EMG).  Other forms do not make use of EMG and employ verbal 
feedback and/or balloon pressure feedback. 
 
Regarding its role in the treatment of chronic constipation, a meta-analysis has 
suggested that biofeedback is superior to non-biofeedback, although there was no 
significant difference between EMG and non-EMG feedback(42).  A recent Cochrane 
review(43) found biofeedback to be superior to laxatives and ‘sham’ biofeedback for 
the treatment of chronic constipation. However the studies included in both reviews 
were of low methodological quality due to small sample sizes (a mean sample size of 
48 patients in the Cochrane review), heterogeneous or poorly-defined demographics 
and symptom profiles of participants, and inconsistency both of the intervention and 
the outcome measures used between studies(43). There is some disagreement in 
the literature regarding the effectiveness of biofeedback in dyssynergic defecation 
compared with slow transit constipation, with some evidence indicating that it is 
significantly more effective for patients with dyssynergia(41)(44). However, other 
research had demonstrated improvement in intestinal transit as well (45). 
 
1.7.3 Trans-Anal Irrigation Therapy 
Trans-anal irrigation therapy (TAI) is in widespread use throughout the UK as a 
treatment for bowel dysfunction. It has been used successfully to treat adults and 
children with neurogenic constipation(46)(47)(48), and faecal incontinence(49). 




constipation in adults is not universally acknowledged; this will be covered in detail 
in the next chapter. 
 
Two alternative systems for delivery of trans-anal irrigation exist; low-volume 
systems delivering approximately 70ml per irrigation, and high-volume systems 
delivering up to 2 litres of irrigation (although typically only 0.5 – 1.5 litres is 
required per irrigation). The low-volume system is cheaper, costing approximately 
£750 per patient per annum based on alternate-day use, compared with 
approximately £1200-1900 for high-volume irrigation, and may be more acceptable 
to patients. 
 
Trans-anal irrigation has been shown to be a low-risk intervention and is widely used 
in a variety of defecatory disorders. Serious adverse events are rare, with one study 
reporting 2 non-fatal bowel perforations out of approximately 110,000 irrigation 
treatments(49). Other potential side effects include pain, bleeding, painful 
haemorrhoids and anal fissure. Minor reversible side effects are relatively common, 
with one study reporting 74% of users experiencing some form of adverse event 







1.7.4 Surgical treatment 
Several operations have been proposed to treat chronic constipation surgically. 
However, this is generally seen as a treatment of last resort, because the outcomes 
of such surgery can be highly variable and the risks of complications are often 
significant. The multifactorial nature of the illness and its complex and incompletely-
understood pathophysiology are likely to be significant factors contributing to this. It 
is important that all patients offered surgical intervention are fully aware of the 
possible risks, the potential for failure of therapy and also that they are carefully 
matched to the correct procedure. 
 
Formation of a loop ileostomy, in which a loop of distal small bowel is exteriorized 
and the stool collected in a bag, has been well described. This can be effective for 
the relief of symptoms, however it is associated with complications and 
morbidity(51). Some patients have persistent constipation despite the ileostomy; the 
reasons for this may be due to the systemic neuromuscular abnormalities implicated 
in the pathophysiology of chronic constipation, as outlined previously. 
 
Resection of the colon and either joining the small bowel to the rectum (total 
colectomy with ileorectal anastomosis) or leaving an end ileostomy has also been 
suggested as a therapeutic option in cases of refractory constipation (52). However, 
one study of 40 patients reported successful treatment in only 75% of cases, with a 




An alternative surgical approach is the creation of an appendicostomy to allow 
antegrade irrigation of the colon. This is known as an antegrade continence enema 
(ACE procedure). Initially described in children(53), it has become established in the 
treatment of adults with both faecal incontinence and constipation(54)(55). This 
procedure has the advantage of being more reversible than the other techniques 
described, and the surgery is generally less radical as no major bowel resection or 
anastomosis is undertaken. However, outcomes are variable with a successful 
outcome in approximately 74% of patients in one study(56). This study also reported 
surgical complication rates (all complications) of 38%, although this includes patients 
with a colostomy and neo-appendicostomy as well as appendicostomy only.  
In patients where obstructive defecation symptoms predominate, and where a 
significant structural abnormality is felt to be contributing to this (for example, recto-
rectal intussusception, rectocele or rectal prolapse), a Laparoscopic Ventral 
Rectopexy can be considered. This procedure leads to surgical correction of 
structural defects in the pelvic floor and has been shown to be effective when used 
in appropriately selected patients(57). 
 Overall, the evidence for effective treatments for CC is weak, leaving clinicians with 
a care pathway approach based on trial and error which is both costly and places the 
patient at high risk of adverse events. Therefore the case for developing an evidence 
based care pathway is clear and urgent. Thus, funding was granted by the National 
Institute for Health Reaearch (NIHR) as a programme grant to conduct a research 
programme to evaluate several treatments highlighted above, The CapaCiTY 




1.8 THE CapaCiTY PROGRAMME 
The Chronic Constipation Treatment Pathway (CapaCiTY) programme is a series of 
interlinked clinical trials and qualitative enquiry aiming to evaluate the effectiveness 
of a series of treatments for chronic constipation (Biofeedback and habit training, 
anal irrigation, and laparoscopic ventral rectopexy surgery), in order to develop an 
evidence-based treatment algorithm for patients with chronic constipation. It 
consists of three interlinked studies running in parallel. These results will be analysed 
and combined to create the treatment algorithm. CapaCiTY study 2, within which 
this MD thesis is nested, is the study of anal irrigation therapy, recruiting from 
September 2015 until October 2018, at approximately 10 sites across the United 
Kingdom. 
  
1.9 AIMS AND SCOPE OF THE STUDY 
As previously outlined, there are several areas where our understanding of chronic 
constipation is limited and where further research is required. In particular, the 
CapaCiTY 02 study aims to provide high-quality evidence for the use of trans-anal 
irrigation therapy in chronic constipation. It attempts to evaluate not only the 
comparative efficacy of high-volume and low-volume irrigation, but also to evaluate 
the impact of tailoring therapy to individual patients based on patient-reported 
experiences and on radio-physiological investigation results. This will allow a far 
more detailed assessment of the role of irrigation therapy in this patient group than 




In this thesis, a systematic review of the current evidence for trans-anal irrigation in 
chronic constipation will be presented in order to assess the strength of the current 
evidence base for this treatment. Also, the quantitative data from the first patients 
recruited to CapaCiTY 02 at the University Hospital of North Durham will be 
presented with the aim of evaluating the feasibility of performing this study as per 
protocol, both at this site and at other sites in England. 
Additionally, qualitative interviews with selected study patients will enable an 
understanding of the patients’ experiences of using irrigation therapy. These data 
will complement the quantitative study by exploring patients’ lived experience of 






CHAPTER 2: TRANS-ANAL IRRIGATION THERAPY TO TREAT ADULT CHRONIC 
FUNCTIONAL CONSTIPATION: SYSTEMATIC REVIEW AND META ANALYSIS 
2.1. INTRODUCTION 
Before describing the methods used to conduct this feasibility study, it is necessary 
to examine in detail the current evidence for the use of trans-anal irrigation therapy 
in chronic constipation. The following chapter will describe a systematic approach to 
reviewing the literature, as well as providing the results of a meta-analysis of 
currently-published trials on this topic. This chapter has been published in a peer-
reviewed journal (Appendix III, page 308).  
2.1.1 Rationale and aims 
Trans-anal irrigation therapy has become established as a treatment for neurogenic 
constipation(47), and it has also been described as a useful therapy for functional 
constipation(49). It is generally safe, with a very low incidence of serious 
complications(58). Therefore it has been chosen for evaluation as part of the Chronic 
Constipation Treatment Pathway (CapaCiTY) programme in patients whose 
constipation is refractory to laxatives and nurse-led behavioural therapies.  The aim 
of this chapter is to summarise and critically evaluate the current evidence for the 
use of trans-anal irrigation in chronic functional constipation in order to inform the 
development of a feasibility study for a randomised controlled trial. 
2.1.2 Trans-anal irrigation 
Trans-anal irrigation involves instilling tap water into the rectum via the anus, using 
either a balloon catheter or cone delivery system. This is attached via a plastic tube 




consisting of a hand pump and a cone may be employed. Patients vary in the 
frequency and volume of irrigation depending on their response to treatment; 
typically, irrigation is used 2-3 times per week. The low-volume system is cheaper, 
and may be more acceptable to patients. It is not known which system is more 
effective. 
Proposed mechanisms of action include simple mechanical washout, colonic 
movement stimulated by the washout, or a combination of these(49). However, 
evidence for the use of trans-anal irrigation therapy for chronic functional 
constipation in adults is not universally acknowledged, and there are questions 
about long-term benefit(58).  
A review of current evidence for irrigation was undertaken, and is now published(59) 
(see appendix 3) to define what is known about this treatment as well as to identify 
areas where evidence is lacking and further research is required. 
2.1.3 Research question 
 What is the strength of the evidence for trans-anal irrigation therapy for chronic 
functional constipation, with reference to effectiveness, safety and methodological 
quality of studies? 
2.2. METHODS 
2.2.1 Eligibility criteria 
Primary research articles that include patients with chronic functional constipation 




outpatients, and published in English in indexed journals were eligible. The following 
were not eligible for inclusion: articles solely studying patients with a known cause 
for their constipation (e.g. neurogenic constipation, opioid-induced constipation, 
other organic cause); conference abstracts, audits, letters and commentaries; 
articles studying antegrade irrigation (a very different treatment involving the 
surgical creation of an appendicostomy) (Table 1).  Reviews were not included but 
relevant review articles(49)(10) were screened for further relevant studies, as were 
citations of retrieved studies. No protocol was registered, however the review was 
reported in accordance with the PRISMA statement (2009)(61). 
Table 1: Inclusion and exclusion criteria 
Inclusion Exclusion 
Primary research Audit/letters/commentaries/opinion/review 
articles 
Patients with Chronic Functional Constipation 
(Obstructive defaecation and/or slow 
transit/IBS-C) 
Studies in children (<18 years) only 
Full articles published in peer-reviewed journals Studies in neurogenic constipation only 
English Language Studies where all patients have undergone 
colorectal surgery (resection or rectopexy, etc.) 
Retrograde irrigation using standard equipment 
performed at home 
Studies in stoma patients only 
Primary outcome is patient symptom 
improvement/response to treatment 








2.2.2 Search strategy 
The following databases were systematically searched through Ovid Online:  
 “All EBM Reviews” (comprising: Cochrane Database of Systematic Reviews 
(2005 to March 2015), ACP Journal Club (1991 to March 2015), Database of 
Abstracts of Reviews of Effects (1st Quarter 2015), Cochrane Central Register 
of Controlled Trials (March 2015), Cochrane Methodology Register (3rd 
Quarter 2012), Health Technology Assessment (1st Quarter 2015), NHS 
Economic Evaluation Database (1st Quarter 2015));  
 Embase (1974 to 2015 Week 15);  
 Ovid MEDLINE(R) (1946 to April Week 2 2015).  
The following search terms were used (searched in ‘all fields’): “bowel dysfunction”; 
“defaecation.”; “defecation”; “constipation”; “irrigation”. The Boolean Operators 
“AND” and “OR” were used to combine these terms appropriately and refine the 
search (table 2). The search was limited to English language articles and to studies in 
humans.  
Abstracts and citations were screened by one researcher (CDE) and potentially 
relevant articles were retrieved. Articles that fulfilled the inclusion criteria were 
included in the review. Reference lists of eligible articles were searched to identify 
potentially relevant articles missed by the original database search. Another 
researcher (Dr Helen Close) reviewed 10% of the citations and abstracts, as well as 
100% of the full-text articles, to confirm appropriate implementation of the eligibility 




literature search was not performed, as the likelihood of finding appropriate studies 
not identified in retrieved citations or reviews was considered very small. 
Table 2: Search of bibliographic databases 
Number Searches Results 
1 Constipation.af* 90438 
2 Bowel dysfunction.af 2264 
3 Defecation.af 25606 
4 Defaecation.af 1921 
5 Irrigation.af 55773 
6 1 OR 2 OR 3 OR 4 110886 
7 5 AND 6 517 
8 Limit 7 to English language 452 
9 Limit 8 to Humans 405 
10 Remove Duplicates from 9 292 
* af: all fields (includes Subject headings and all test fields) 
 
 
2.2.3 Data collection 
Data were extracted from eligible studies using standardised data collection forms. 
Data items included study methodology, patient information (including demographic 
details and definition of ‘constipation’ used), primary outcome data (including follow 
up period), duration of use of treatment, and adverse events reported. The 
Cochrane assessment of bias for non-randomised studies tool (ACROBAT-NRSI) (62) 






The primary outcome was the proportion of patients with an investigator-reported 
positive outcome to trans-anal irrigation therapy.  
Secondary outcomes included response by constipation type, duration of treatment 
use and safety of treatment assessed by adverse event reporting in studies. 
2.2.5 Analysis 
Both qualitative review of study results and quantitative analysis was performed. 
Rates of complications are reported and statistical pooling of proportion estimates 
was explored using fixed and random effect models within StatsDirect © Version 3. 
Both Q and I2 statistics were calculated to assess study heterogeneity. An Egger test 
was performed to assess risk of publication bias. 
 
2.3. RESULTS 
 Of 292 abstracts and citations reviewed, 19 full-text articles were retrieved. Of 
these, six were suitable to be included in the review(58)(63)(64)(65)(50)(17). 
Reference lists of these articles were reviewed and a further eligible article was 
identified(18), giving a total of 7 articles (Figure 1). All eligible studies reported 
outcomes using high-volume irrigation only. One further study using low-volume 
irrigation was found, not reporting constipation-specific outcomes and was excluded 
from the final analysis(68).  Studies identified were prospective cohort studies, or 




study the patient case mix included patients with faecal incontinence, soiling and 
following colorectal surgery. However the articles reported outcomes separately for 
each group, making it possible to evaluate outcomes for chronic functional 
constipation. Reported mean duration of therapy varied from 8 months to 102 
months (range 1-216 months across studies).  














Studies were small, with an average number of patients per study of 36 (range 10-
79); there was no evidence of a power calculation being performed for any study. 
Database search: Embase, Ovid MEDLINE, 
All EBM reviews:  




7 articles included in review 
19 Full-text articles reviewed 
Duplicates removed: 292 potentially 
relevant citations screened (abstracts + 
citations) 
13 excluded:  
3-Results for chronic 




2-Inpatient irrigation only 












2.3.1 Outcome of anal irrigation therapy  
Patient-reported satisfaction, either subjective or using a visual-analogue scale, was 
the outcome most commonly reported (5 studies) (13)(15)(16)(17)(18). One study 
used resolution of symptoms as the outcome measure(64), another used a 
combination of patient-reported symptom improvement and ongoing use of 
treatment(58). If a patient died while still using the treatment this was also 
considered successful. One study(63) reported both patient-reported satisfaction 
and change in Cleveland constipation score as markers of treatment success; the 
patient-reported satisfaction outcome was included in this analysis as it enabled 





Table 3: Study characteristics 
Study Design and methods Level of 
evidence* 
Definition of constipation Definition of successful treatment 
Chan (63) Prospective cohort study  III Infrequent passage of stool +/- straining/ digitation/ 
incomplete emptying 
i) Improvement in Cleveland 
Constipation Score 
ii) Patient-reported satisfaction 
Christensen 
(58) 
Retrospective questionnaire survey 
and case note review 
III Idiopathic constipation including slow transit, obstructed 
defecation and ‘undetermined’ 
i) Ongoing use 
ii) Resolved symptoms 
iii) Still using irrigation at time of 
death 
Koch (64) Prospective cohort study III <2 bowel motions per week, straining or incomplete 
evacuation >50% motions in previous year 
Resolution of incomplete emptying or straining 
symptoms 
Cazemier (65) Retrospective case series 
questionnaire survey 
III Constipation according to Rome II criteria Patient-reported satisfaction 
Gosselink (50) Retrospective case series, 
questionnaire survey 
III Obstructed defecation based on; straining, incomplete 
evacuation, digitation, fullness, <3 motions/ week 
Patient-reported satisfaction 
Gardiner (67) Case series; not stated if 
prospective or retrospective 
III Obstructive defecation and slow transit (?which criteria used) Patient-reported satisfaction 
Crawshaw 
(66) 
Retrospective case note review and 
questionnaire survey 
III The inability to evacuate the rectum when desired (includes 
obstructed defecation and dyssynergic defecation) 
10mm increase on VAS (10% improvement) 





Studies report variable response rates to therapy (table 4). The proportion of patients who 
had a positive outcome to therapy varied from 30% (64) to 65% (63)(50). Overall, 254 
patients with chronic functional constipation were included in studies, with 128 having a 
positive response to irrigation therapy (Table 4). 
A fixed effect analysis of proportions gave a pooled response rate of 50.4% (95%CI: 44.3% to 
56.5%).  Although there was no evidence of publication bias (Egger: bias = 0.259, p=0.91), 
there was evidence of substantially heterogeneity between studies (Q[6]=18.2, p=0.0057; 
I²=67.1%). A random effects estimate was similar, if less precise: 50.9% (95%CI: 39.4% to 
62.3%), (see Figure 2). 
Four studies reported results for different sub-types of constipation. Sample sizes in all 
studies were very small (10 – 37 patients with OD) and differences between sub-groups 
remain anecdotal. When results from all four studies where results for different types of 
constipation are reported are combined, there was no consistent pattern of outcome 
between subtypes. Methodological weaknesses, inconsistencies in outcome measures and 
small sample sizes limit meaningful comparison. 
2.3.2 Safety of anal irrigation therapy 
The most clinically significant risk associated with irrigation is bowel perforation. Only one 
study reported this complication(58) and this occurred in two patients. If reliably reported 
this, represents 2 perforations in approximately 110,000 irrigations, or less than 0.002% risk 
per irrigation. No studies reported mortality associated with irrigation. Studies were 




Table 4: Demographics and overall response to treatment 














Chan (63) 60 46 8:52 39 (65) 6* 10.7* 
Christensen (58) 79 52* 25:62* 27 (34) 21 (1-116)* 8 (1-85)* 
Koch (64) 10 55.4 4:7* 3 (30) 3* - 
Cazemier (65) 12 46 1:3 6 (50) - 102 (30-216)* 
Gosselink (50) 37** 54 5:32 24 (65) 56 (8-154)* 
++ 
Gardiner (67) 41 - - 21 (51) - - 
Crawshaw (66) 15 54 (41-61)* 13:35* 8 (53) 12*
+
 - 
Total 254 - - 128  
  
- Data not available 
*Whole cohort  
**Obstructed Defecation only 
+
 Inferred from study report 
++












Figure 2: Proportion meta-analysis plot [random effects] 
 
0.0 0.2 0.4 0.6 0.8
combined 0.51 (0.39, 0.62)
Crawshaw 2003 0.53 (0.27, 0.79)
Gardiner 2004 0.51 (0.35, 0.67)
Gosselink 2004 0.65 (0.47, 0.80)
Cazemier 2007 0.50 (0.21, 0.79)
Koch 2008 0.30 (0.07, 0.65)
Christensen 2009 0.34 (0.24, 0.46)
Chan 2012 0.65 (0.52, 0.77)
Proportion (95% confidence interval)
Plot illustrates the proportion of positive responders in 
each study, along with the combined positive response 




events and the level of disaggregation between pathologies treated, thus only a narrative 
summary is possible. 
Minor and self-limiting adverse events were commonplace in studies but may to some 
extent have been tolerated by patients, with up to 74% of long term continuing users 
reporting some form of related and expected adverse events in one study(50). The most 
commonly-reported adverse events included abdominal cramps/discomfort (33-40%) 
(65)(58)(50); anorectal pain (5-25%)(58)(50); anal canal bleeding (1-20%)(58)(63); leakage of 
irrigation fluid (30-75%)(58)(50); and expulsion of the rectal catheter (39%) (58). One study 
reports a 43% incidence in ‘technical problems’ with irrigation(50). In one study, 28% of 
those discontinuing therapy gave side effects or technical issues with irrigation as a reason 
for discontinuing(58). 
Therefore, whilst one or more side effects were experienced by a large proportion of 
patients undergoing anal irrigation, the risk of major life-threatening, life-limiting or 
irreversible complications was very low. 
2.3.3 Methodological quality 
Generally, the studies were of weak methodology. There were no randomised controlled 
studies or case-controlled studies and most articles were retrospective questionnaire and 
case note based case series (Table 3). Two studies (63)(64) were prospectively designed with 
fixed follow up points, but numbers were relatively small (only 60 and 11 chronic functional 
constipation patients respectively). A further study(67)  did not state whether data 




Risk-of–bias assessment suggests that five studies were at serious risk of bias, and the other 
two were at moderate risk (Table 5). The retrospective questionnaire-based studies also 
suffered from non-response to surveys and missing data. This is likely to lead to bias and the 
results must be interpreted in light of this (i.e. were responders significantly more or less 
likely to have responded well to irrigation therapy?). Given the limitations of design and 
size, available studies are unable to provide robust evidence for the treatment effect of 
trans-anal irrigation. 
Patient heterogeneity was also an issue. One study included both children and adult 
patients together (58) and the proportion of children was not reported. Neither was it 
stated whether there was a difference in outcome between the adults and children. One 
study(65) included three patients with neurological problems in its constipation cohort, 
representing 25% of this study population. As neurogenic constipation may respond 
differently to irrigation(70), this may have affected the results. A further study included 5 
patients out of 11 with chronic constipation who had had colorectal surgery (one resection 
and four rectopexies)(64). Another study(66) also included patients who  had undergone 
pelvic surgery or rectopexy in the chronic constipation cohort. It is not known precisely what 








Table 5: Risk of bias assessment 
 Risk of bias by type 








Chan (63) Moderate Low Low Low Moderate Moderate Low Moderate 
Christensen 
(58) 
Moderate Moderate Moderate 
No 
information 
Low Serious Low Serious 
Koch (64) Moderate Low Low Low Low Moderate Low Moderate 
Cazemier 
(65) 
Serious Serious Serious Low Low Serious Low Serious 
Gosselink 
(50) 























This review brings together the findings of seven primary research studies which 
examine outcomes of trans-anal irrigation therapy in patients with chronic functional 
constipation.  
Studies retrieved are small and not of robust methodological quality; only two are 
prospectively-designed, and there is the potential for reporting bias in the four 
studies that use questionnaires.  This finding underlines the fact that the evidence 
for use of irrigation in functional constipation is currently weak. 
The aggregate success rate of irrigation therapy is around 50% based on these seven 
studies. Given the chronic and refractory nature of the symptoms in many of these 
patients this may be considered adequate, especially given the simple and reversible 
nature of the treatment(49). By comparison, response rates for drug treatments in 
this group of patients has been reported as 20-40%, though these are prospective 
RCTs reporting symptom based primary end-points(71)(72)(73). Additionally, 
reported response rates in neurogenic constipation are only slightly higher – around 
60% (5). Mean duration of use of treatment was reported between 8 months and 
102 months. Inconsistencies in reporting findings, methodological differences and 
weak study design mean that there is insufficient evidence to state with any 
confidence exactly what the duration of benefit of treatment should be. 
The majority of patients experience some form of adverse event although these are 




success of therapy: the need for high levels of patient motivation, as well as support 
from specialist nurses, is recognised(49). The rates of life threatening complications 
are very low throughout the studies: Irrigation can be considered a safe therapy, 
when used with proper training. Since this systematic review was carried out, a 
global audit of bowel perforations related to trans-anal irrigation has been published 
and this reports a rate of perforation of 2 perforations per 1 million irrigations, with 
higher risk in the first 8 weeks of therapy(74). 
There is insufficient evidence to state with any certainty how best to tailor therapy 
to patient symptoms. A recent review based on expert consensus(75) has proposed 
a number of regimes to overcome problems with irrigation and so improve 
outcomes, but experimental trial evidence is lacking, especially for functional 
constipation patients. In spinal cord injured patients, it has been found that 
emptying the rectosigmoid using irrigation stimulates colonic transit(75) however it 
is not clear whether this is transferable to patients with slow colonic transit and 
functional constipation. Scintigraphic studies have suggested that these patients 
have a different response to irrigation, with reduced colonic clearance compared 
with spinal cord injured patients(70). In addition, none of the studies assess 
outcomes of low-volume anal irrigation systems. 
Two previous systematic reviews examining trans-anal irrigation were found(49)(60). 
These reviews, while valuable, have several limitations: They focus on irrigation as a 
therapy for several conditions including neurogenic constipation, faecal 
incontinence, idiopathic constipation and mixed symptoms; also, one review (10) 




from home irrigation described in this review. The findings of this review are similar 
to the previous studies with respect to the weak nature of current evidence and the 
heterogeneity of the studies included. Subsequent to these reviews further studies 
have been identified and this review is the first to address irrigation therapy in 
idiopathic constipation only. This is also the first systematic review on this topic to 
be conducted in accordance with the PRISMA statement. Additionally, this is the first 
meta-analysis of the effectiveness of irrigation in chronic functional constipation. 
2.5 CONCLUSION 
This review suggests that trans-anal irrigation may be an effective therapy for 
chronic constipation, and may be considered in patients who have not responded to 
medical management. Irrigation is safe and its effectiveness is at least comparable 
with pharmacological therapies. However, the evidence to guide its use in chronic 
functional constipation is weak, and its long-term benefits are unclear. There are no 
reported data on cost-effectiveness of irrigation: whether treatment provides good 
value for money from scarce health service resources. There is a clear need for well-
designed prospective trials to evaluate the effectiveness, duration, and adverse 
consequences of treatment, as well as to assess how best to tailor therapy to 
individual patients.  Future studies should have defined outcome measures, for 
example improvement in validated quality-of-life questionnaires within a defined 
time point. More evidence about the comparative effectiveness and cost-
effectiveness of low-volume and high-volume irrigation systems would also be 




to address the gaps highlighted by this review. The methodology employed will be 




CHAPTER 3: QUANTITATIVE STUDY METHODOLOGY 
3.1 INTRODUCTION 
This chapter aims to set out the methods used in the quantitative arm of the study. 
The trial overview, design and follow-up procedures will be described, as well as a 
detailed overview of what was done at each study visit. Ethical considerations, as 
well as safety and data protection aspects will also be discussed. 
3.2 RATIONALE AND OVERVIEW OF STUDY DESIGN 
3.2.1 Rationale for conducting the Chronic Constipation Treatment Pathway 
(CapaCiTY) 02 study 
As previously noted, there is a need for more robust evidence to evaluate the 
effectiveness of irrigation therapy for chronic functional constipation, and the 
CapaCiTY 02 study has been designed to provide this. It has also been designed to 
compare the effectiveness of the two different anal irrigation systems (high volume 
and low volume), as there are currently no data demonstrating superiority of one 
system over the other. Given the differences in cost between the two systems, a 
randomised study of well-characterised patients comparing the two methods would 
provide useful information on whether one system holds a clear advantage over the 
other. In addition, the short- and long-term efficacy and acceptability of therapy in 
chronic constipation requires evaluation. This is timely and informative given the 
rapidly increasing popularity of this treatment and the fact that anal irrigation is an 





3.2.2 Relationship between the MD study and CapaCiTY 02 
The CapaCiTY 02 study will run for 5 years at approximately 10 centres across the 
UK. This thesis is nested within this study, and reports the results from a single 
centre (University Hospital of North Durham) over one year of recruitment. This 
study was conducted as per the CapaCiTY 02 protocol and should be considered a 
feasibility study, aiming to evaluate the appropriateness and feasibility of 
implementing the CapaCiTY 02 study locally, as well as highlighting potential 
problems and solutions to inform the implementation of a full multi-site trial. The 
aims of this thesis are set out below, as are the objectives for the CapaCiTY 02 study 
overall. 
3.3 TRIAL OBJECTIVES 
3.3.1 Thesis/ MD study objectives 
1. To determine the feasibility of performing this study as per protocol at a 
single site and to identify/anticipate problems and solutions to efficiently 
deliver the study at other sites. 
2. To determine willingness of patients to participate in this study, and to 
estimate the likely recruitment rate and whether the calculated sample size is 
achievable within the study timeframe. 
3. To determine follow-up rates, compliance and response rate to outcome 




4. To provide a descriptive analysis of initial trial outcome data. This will include 
an estimate of the standard deviation of the primary outcome measure for 
CapaCiTY 02 (see below). 
 
3.3.2 CapaCiTY 02 Study Objectives 
Primary Objective 
1. To compare the impact upon patient disease specific quality of life of transanal 
irrigation initiated with a low-volume versus high-volume system in patients with 




1. Disease specific outcomes at 3, 6 and 12 months. 
2. Survival (continuation of benefit) and acceptability by type of system and for 
the whole cohort  
3. The influence of patient characteristics (urge to defecate, balloon sensory 
testing results) upon treatment success, and response by type of system 
used. 
4. The acceptability of each system to patients. 
5. Strategies for tailoring therapy to meet patients’ individual needs, and the 
factors involved in this. 






All clinical endpoints were recorded at baseline, 3 and 6 months in face-to-face 
clinics (or by telephone call if necessary). PAC-QOL, PAC-SYM and EQ-5D-5L, EQ-VAS 
were additionally collected at 1 month; this was to capture reasons for early non-
response to therapy, as well as to better characterise the patients group and provide 
more data for economic analysis. The analysis of the primary endpoint was at 3 
months. Further follow up and outcome data collection (up to 12 months) will be 
conducted as part of the CapaCiTY 02 trial but these results are not included in this 
thesis. 
Primary Clinical Endpoint  
 Patient Assessment of Constipation Quality of Life questionnaire (PAC-QOL(76)) at 
3 months. 
Secondary Clinical Endpoints 
 PAC-QOL score and individual domain scores. 
 Time to cessation of each system of irrigation; total time in treatment with either 
system. 
 Reason for cessation (of each system). 
 Patient Assessment of Constipation Symptoms (PAC-SYM)(77): aggregate and 
domain scores.  
 Irrigation journal: volume and duration of irrigation.  




 Symptom scores derived from diary records (taken over two weeks before or 
around each follow-up contact.  These included number of spontaneous 
complete bowel motions.  
 Generalized anxiety disorder questionnaire (GAD7)(78). 
 Depression, anxiety and somatisation modules of the PHQ-9(79). 
 Global patient satisfaction / improvement score (VAS). 
 Patient recommendation to other patients. 
 Behavioural response to illness questionnaire (CC-BRQ), and brief illness 
perception questionnaire BIPQ (CC)(80). 
 Generic quality of life: EuroQol (EQ-5D-5L and EQ-VAS) scores(81).  
 Patient acceptability. 
 Use of healthcare resources, adverse events, and concomitant medications 
collected using patient journal. 
 
3.4 OVERVIEW OF STUDY DESIGN 
The study is a two-arm, randomized controlled trial comparing high-volume (HV) 
with low-volume (LV) anal irrigation. Eligible patients were consented for 
participation before undergoing a series of radiological and physiological 
investigations (X-ray colonic transit study, anorectal physiology testing, referred to 
hereafter as ‘INVEST’) and were then randomized 1:1 to either the HV or LV group. 
Patients were trained in their allocated system by experienced health professionals 
(irrigation nurses). Patients were followed up at 1, 3 and 6 months (or until they 




patients could switch to the other system to see if that was more effective. 
Participants will continue with follow up to 12 months as part of the CapaCiTY 02 
study. Follow-up up to 6 months will be reported within the MD (feasibility study) 
timeframe.  
3.4.1  Inclusion Criteria 
 Age 18-70 years. 
 Patient self-reported problematic constipation. 
 Symptom onset > 6 months before recruitment. 
 Symptoms met American College of Gastroenterology definition of 
constipation(2). 
 Constipation failed treatment to a minimum basic standard (NHS Map of 
Medicine 2012) (lifestyle AND dietary measures AND≥2 laxatives or prokinetics) 
tried (no time requirement)  
 Ability to understand written and spoken English (due to questionnaire validity). 
 Ability and willingness to give informed consent. 
 Failure of previous nurse-led behavioural therapy.  
 Ability of patient/carer to use anal irrigation. 
 
The study used the American College of Gastroenterology definition of 
constipation(2) which is reasonable, simple and extensively published: unsatisfactory 
defecation characterized by infrequent stool, difficult stool passage or both for at 




3.4.2 Exclusion Criteria 
The study interventions necessitated the exclusion of major causes of secondary 
constipation. In detail; 
 Significant organic colonic disease (including undiagnosed/un-investigated ‘red 
flag’ symptoms); IBD; megacolon or megarectum (if diagnosed beforehand) [the 
study will provide a useful estimate of the prevalence of such cases in referral 
practice]; severe diverticulosis/stricture/birth defects deemed to contribute to 
symptoms (incidental diverticulosis not an exclusion). 
 Major colorectal resectional surgery. 
 Current overt pelvic organ prolapse (bladder, uterus, vagina, rectum) or disease 
requiring surgical intervention. 
 Previous pelvic floor surgery to address defecatory problems: posterior vaginal 
repair, STARR and rectopexy; previous sacral nerve stimulation. 
 Previous use of transanal irrigation therapy to treat constipation (Note: this does 
not include private ‘colonic irrigation’ in the community/complementary therapy 
setting) 
 Rectal impaction (as defined by digital and abdominal examination: these form 
part of the NHS Map of Medicine basic standard). 
 Significant neurological disease deemed to be causative of constipation e.g. 
Parkinson’s, spinal injury, multiple sclerosis, diabetic neuropathy (not 
uncomplicated diabetes alone). 
 Significant connective tissue disease: scleroderma, systemic sclerosis and SLE 




 Significant medical comorbidities and activity of daily living impairment [based 
on Bartel index(82) in apparently frail patients, Bartel index <=11]. 
 Physical disability/impairment which prevented use of one or other of the 
irrigation devices. 
 Major psychiatric diagnosis [schizophrenia, major depressive illness, mania, self-
harm, drug/alcohol addiction]. 
 Chronic regular opioid use (at least once daily use) where this was deemed to be 
the cause of constipation based on temporal association of symptoms with onset 
of therapy; all regular strong opioid use. 
 Pregnancy or intention to become pregnant during study period.  
 
3.5 STUDY DESIGN PLAN/STUDY VISITS 
3.5.1 Setting 
The Durham Constipation Clinic is a specialist tertiary referral clinic based at the 
University Hospital of North Durham, accepting referrals from across Northern 
England (including Northumberland, Tyne and Wear, County Durham, Teesside, 
Cumbria and Yorkshire). It has been running for over 15 years and provides a holistic, 
multi-disciplinary service to patients with chronic constipation. Research is integral 
to the aims of the service, which is focussed on furthering understanding of, and 






Patients attending the Durham Constipation Clinic for chronic constipation and who 
have already failed to respond to nurse-led interventions (biofeedback or habit 
training) were eligible for recruitment screening based on the criteria outlined 
previously.  
 
3.5.3 Visit 0: Pre-Screening: Eligibility assessment 
A GCP-trained and delegated local researcher screened potential participants for 
basic eligibility by phone (or face-to-face interview based on patient choice). 
Potentially eligible patients were identified in clinic, from referral letters from 
GPs/other consultants to the constipation clinic. Participants were provided with 
adequate explanation of the aims, methods, anticipated benefits and risks of anal 
irrigation therapy and were given an invitation letter and a patient information 
sheet. Patients were be given at least 24 hours to consider participation and invited 
to attend clinic for a more detailed discussion with a suitably trained researcher. 
 
The study screening number was allocated as follows: 
Study Code 02 
Site Code – 3 letter code for each site  
Participant Code – 4 digit code given consecutively and attributed at each site 
 
For example the first participant recruited at County Durham and Darlington NHS 




3.5.4 Visit 1: Screening, consent and baseline assessments 
Visit 1 was conducted face to face in clinic by a member of the research team. 
Clinical examination was performed as per protocol by a clinician within the research 
team competent to do so. Following a detailed discussion about the trial, potentially 
eligible patients completed written informed consent, followed by a more thorough 
screening and confirmation of eligibility for randomisation by brief history and 
physical examination (the latter if not already performed within the previous 3 
months).  
 
For those patients entering the study, additional baseline outcome assessments 
were conducted. These included several key validated assessments that profile 
patient characteristics, informing disease pathophysiology and potential predictors 
of treatment response. All were selected on the basis of trade-off between adequate 
detail and achievable brevity. These instruments were combined into a single 
booklet. 
 
Confirmation of Eligibility 
 
Screening/Confirmation of Eligibility 
 Standardised history by interview including previous medication usage. 
 Clinical examination findings (carried forward if performed previously within last 






Baseline outcome assessments 
 Baseline outcome assessments [PAC-QOL, PAC-SYM, EQ-5D-5L & EQVAS, PHQ9, 
GAD7, CC-BRQ and BIPQ-CC, see endpoints above]. 
 Baseline 2-week patient diary and journal were given (training and retrospective 
completion of the patient journal occurred at visit 1 for collection of resource 
data. Prospective completion occurred until the end of the study, with review at 
each follow up). Training in completion of the diary was conducted at visit 1 but 
this was completed at home and returned at visit 2. 
 
Other baseline only assessments 
 Constipation (2006) and IBS (2006) modules of Rome III questionnaire. 
 Cleveland Clinic constipation questionnaire. 
 Brief, chronic pain, autonomic and joint hypermobility assessments. 
 St Marks Incontinence score (for concurrent symptoms). 
 
Randomisation performed by a member of the research team 
INVEST radio-physiology investigations (See section 3.7.3 below): These were X-ray 
colonic transit study, anorectal physiology testing, referred to hereafter as ‘INVEST’. 
There is no defined time period for this, but it was suggested INVEST should be 
completed within 4 weeks of Visit 1 baseline visit to allow for diary completion 
before stopping laxatives for INVEST. A maximum of 8 weeks after visit 1 was 





Those with INVEST completed in the previous 12 months did not need these tests 
repeated and could be booked for visit 2, commencing in a minimum of 2 weeks to 
allow completion of baseline diary. 
 
3.5.5 Visits 2-3: Interventions 
Visit 2: 
 Collection of baseline diary completed prior to randomisation and before 
stopping laxative (i.e. before INVEST in patients who need this done). 
 Training in Anal Irrigation - Patients underwent a single nurse-led training 
session before starting treatment. 
 Training in completion of irrigation journal and provision of irrigation journal  
(completed weekly). The irrigation journal consisted of; volume of water 
introduced, frequency of use adverse events and side effects e.g. pain, 
bleeding. 
 Start date for home irrigation agreed with the patient (this was to allow for 
any delay in delivery of equipment). Ideally this should be the same day as 
Visit 2, or within 1 week maximum.  If any issues or delays were encountered, 
a new commencement date was agreed; This was recorded as a note to file 
(CRF 8), along with reasons for delay 
Visit 2.1 
Patients were contacted by telephone by an irrigation nurse 14 days (+/- 3 days) 
after Visit 2 to ensure no problems have been encountered, including a review of 




Visit 2.2 (if needed) 
If there were problems expressed by the patient or identified by the clinician, then a 
further face-to-face training session was offered, including a review of adverse 
events and concomitant medications. This occurred any time before visit 3 (2 weeks 
+/- 1 week from visit 2.1) or in conjunction with visit 3 if not before. 
Patients continued the self-administered therapy using a commercially-available 
device until the end of the study. Patients were followed up until the end of the data 
collection phase of the study (up to 12 months as part of CapaCiTY 02) or until they 
decided to discontinue either the therapy or the trial follow up. Irrigation was 
performed at an agreed frequency initially. Once established on this therapy patients 
could adjust the frequency and volume of irrigation to suit their particular condition.  
 
Information about treatment was recorded in an irrigation journal. This information 
consisted of: frequency of use of irrigation; volume of water introduced; adverse 
events and side effects e.g. pain, bleeding. Where a patient switched to the other 
irrigation device or discontinued treatment (patient choice) the reason for this, as 
well as the duration of therapy, was documented. If a patient chose to switch 
devices, which they could do at any stage after the 3 months follow up visit, they 
received training in the other device. They received follow up by the irrigation nurse 
as required to resolve any outstanding issues and to check progress. This was 
documented on the irrigation diary and a note to file completed (CRF 8). However 







This took place 2 weeks (+/- 1 week’s tolerance if needed) after Visit 2.1. PAC-QOL, 
PAC-SYM and EQ-5D-5L were recorded at this visit, and irrigation journal was 
reviewed. A new patient diary, journal and irrigation journal were provided for 
collection at next follow up visit. 
 
3.5.6 Visits 4-5: Follow-up outcome assessments: visits or telephone consultations 
A full standardised outcome framework was recorded at baseline, 3 and 6 months 
(+/- 1 week) after initiation of intervention at visit 2. To maximise completeness of 
data collected, follow up visits were conducted face-to-face in clinic wherever 
possible. Where this was not possible (due to participant or researcher availability), a 
telephone consultation was used. 
For patients remaining on either irrigation method, further full outcomes will be 
recorded at 12 months as follow-up within the CapaCiTY programme permits. These 
outcome data are not part of this thesis however. 
The patient diary, journal and irrigation journal were provided by the participant for 
review at each follow up visit to enable CRF completion and accurate reporting of 
adverse events. 
Within the planned study period at least three attempts via two different methods 
(e.g. phone and letter), were made by research staff to make contact and collect 
follow up data at each time point, after which the time point was recorded as 
missing. No patient was regarded as lost-to-follow-up before 12 months unless they 




3.5.7 Study Scheme Diagram (CapaCiTY study 02) – Planned screening and 
estimated recruitment numbers across all sites (n=10) 
 
Adults with Chronic 
Constipation ,  age 18 - 70 
~2000 
Secondary Referrals, f ailing  
b ehavioural therapy no previous  
anal irrigation ~1500 
Patients Screened: 
~600 
Patient Randomised (1:1) 
~300 
Low Volume  
Anal Irrigation  
~150 
High Volume  




Primary outcome analysis  
(3 months) 
~270 
Secondary outcome analysis  
(6, 12 months) 
~215 















3.6 STUDY PROCEDURES 
3.6.1 Informed Consent Procedures 
Written informed consent was obtained at visit 1 from research participants by an 
appropriately trained member of the research team in a face to face setting in clinic. 
3.6.2 Screening, Enrollment 
A brief screening questionnaire was used to determine whether patients meet 
inclusion and exclusion criteria (see eligibility above). Screening was performed by 
suitably trained study personnel to minimise logistic hurdles, and as determined by 
geographic availability. In practice, at the Durham site, this was either a research 
nurse or a doctor. 
3.6.3 Randomisation Procedures 
Patients were randomised 1:1 into two groups; those who commenced therapy with 
a low-volume device and those starting with a high-volume device. Patients were 
stratified by sex and females by centre. Randomisation was performed by a GCP-
trained member of the research team using an online system. 
3.6.4 Blinding 
Patients and clinicians were necessarily aware of both INVEST and treatment 
allocations. The need to collect data on frequency and volume of irrigation, as well 
as reasons for discontinuing or switching between systems, meant assessor blinding 
was not possible with respect to these outcomes. Any researcher collecting CRFs or 




QOL at three months) was concealed; the patients completed this questionnaire 
without a researcher present. This was accomplished in one of the following ways; 
1. Direct entry to online secure database, with built in validation and prompting to 
ensure data completeness. 
2. Completing paper questionnaire by following instructions on an information card 
to ensure all questions were answered. This was placed in a sealed envelope marked 
with the patients pseudonymised study code and was not opened until the time 
comes for data entry. 
3.7 STUDY INTERVENTIONS 
3.7.1 Anal Irrigation therapy 
Anal irrigation training was provided by trained nurses with experience in delivering 
care for chronic constipation. They must have initiated irrigation therapy in at least 
three patients independently, and be a nurse/therapist of good standing within a 
clinical team regularly seeing patients with chronic constipation. For the first three 
months of participation in the study, patients could not use other therapies besides 
anal irrigation and those rescue therapies specified below. They could discontinue 
therapy at any point (elective withdrawal from intervention) and could choose to 
switch from one system to the other after 3 months.  Switching anal irrigation 
systems before completing the three-month waiting period was discouraged. If it 
occurred, it was recorded as a protocol deviation with the timing and reason 




then other medications could be used on compassionate grounds, but this must be 
recorded in the CRF/concomitant medications log. 
 
The course of therapy included a nurse-led training session (or more if required to 
ensure the device was being used effectively) followed by patient-led home 
irrigation therapy. The low-volume system commonly used in practice is Qufora® 
Mini (MBH-International). Various high-volume systems are used, all of which have 
very similar mechanisms of action; these include Peristeen™ (Coloplast) and Qufora-
Toilet/Qufora-Balloon™ (MBH-international).  
 
These are commercially-available transanal irrigation systems available on 
prescription in NHS practice. 
 
Low-volume Irrigation 
This system consists of a small reservoir attached to a cone. The reservoir holds 
approximately 70ml of water and is squeezed to inject water into the rectum. The 
regime used was as follows: Initial irrigation once daily for 14 days using 1 -3 
insufflations (each of 70ml approximately). This could then be reduced to alternate 
days depending on response. Patients could then adjust frequency and volume 
depending on response. They could irrigate as much and as often as they felt was 
necessary to give them benefit and this information was captured on the CRF with 







High-volume systems consist of an irrigation bag connected to a tube. The water 
flows into the rectum, either by gravity or using a pump. Some systems employ a 
balloon to hold the device in place during irrigation; others require the patient to 
hold it in place. The mechanism of action is broadly the same for all systems. Initial 
frequency of irrigation was the same as for low-volume irrigation; i.e. daily for 14 
days, then alternate days. Patients commenced with irrigations of 300ml and 
increased this by 100 ml every two days until satisfactory defecation was achieved or 
the procedure became uncomfortable, up to a maximum of 1500ml. Patients could 
adjust therapy depending on response, as for low-volume irrigation. 
 
Training sessions (45-60 min) (V2-V3) 
This used a standardised proforma and was always face to face. Feasibility 
questionnaires were sent to participating sites to establish what their current 
practice was with respect to initiating irrigation therapy, funding treatment and 
patient follow-up. Views on the proposed laxative rescue therapy were also 
obtained. The following training protocol was developed to accommodate these 
views as much as possible. Patients received: 
 
(a) Regulation/standardisation of laxative use: Bisacodyl could be used orally as a 
rescue therapy (up to 20mg at night), plus glycerine suppositories 1-2 if needed, 
if no stool for 3 days. In addition, patients could take Movicol up to a maximum 
dose of 2 sachets three times per day (TDS) and/or lactulose up to 15ml twice 




Formulary (BNF) describes as having laxative effect or herbal teas that contain 
strong purgatives were discouraged, but if needed (i.e. if symptoms severe) then 
these were permitted but use must be recorded in the concomitant medications 
log. There was no use of enemas. 
(b) The device was demonstrated to the patient by the nurse specialist and then the 
patient practiced setting up the device. The trainer ensured the device was being 
used correctly before home irrigation was commenced. The trainer and patient 
agreed a date for delivery of equipment and commencement of home irrigation. 
Ideally this should be the same as the first training visit, but this may not be 
possible due to delay in supplying irrigation equipment. Any delays were 
recorded on a note to file (CRF 8) to allow data analysis to be adjusted 
accordingly. 
(c) Plenty of optimism, encouragement and personal attention. 
(d) A telephone call was made to the patient 14 days (+/- 3 days) after Visit 2 to 
check everything was proceeding correctly and to resolve any problems (V2.1). If, 
due to delay obtaining equipment etc, the patient had not started irrigation at 
this time then the phone call (and other follow up visits) were re-scheduled for 
14 days later, and the reason for this recorded on CRF 8. 
(e) If there were problems, a further face-to-face session was offered (V2.2). There 
was no specific time requirement and this depended on the difficulties 
encountered and availability of appointments, ideally this visit should have been 
conducted within a week and before visit 3.  
(f) All patients received a further training assessment a 4 weeks (V3). This visit was 




should be face to face. A telephone call was an acceptable alternative if this was 
not possible. 
(g) Patients deciding to switch to the alternative system were trained in the new 
system by the irrigation nurse, and this was recorded on the note to file, CRF8. 
These patients did not need to complete the questionnaires at 1 month and 3 
months as they had already done so. 
(h) Standardised guidance on how to tailor therapy to each patient depending on 
initial response was provided to specialist nurses. Changes in regimen as well as 
system were documented on the CRF. 
 
Telephone support was available from the irrigation nurse between visits (number 
given, office hours only). The therapist completed the intervention CRF at every visit 
or patient contact. For contact with patients after the training period, a note to file 
(CRF 8) was completed, and the patient also made a note of any contact in their 
irrigation journal.  In the instance of new psychological issues being determined 
during consultation, referral for psychological support was deferred until after 
completion of irrigation training. The exception to this rule was applied if there was 
clinical concern regarding the patients acute mental state requiring more urgent 
intervention (see withdrawal from treatment criteria). Further follow-up visits (V4-
V8) were conducted by the research team. If the patient required further input from 
the irrigation nurse this could be arranged as per local practices. Any contact and any 
changes made or advice given regarding irrigation was recorded in the patient 





3.7.2 Switching between anal irrigation systems 
After three months of using one system, patients were allowed to switch to the 
other or discontinue therapy and return to routine clinical care. This was entirely 
patient-led, and reasons for changing systems were explored during follow up visits 
and captured on the CRF. There was therefore no defined protocol for switching 
treatments as patients could do this for any reason; analysis of time to 
switching/discontinuing therapy, as well as the patient-reported reasons for doing 
so, provided insight into why each irrigation system was or was not successful. In 
addition, qualitative interviews with patients who switched or discontinued therapy 





Patients underwent standardised investigations. If INVEST had previously conducted 
within the last 12 months, results could be carried forward. Pregnancy testing was 
conducted as per routine NHS practice (10 day NHS rule) in respect to women 
between menarche and menopause. Women of equivocal status had a serum 
pregnancy test performed as per routine care. 
 
(a) Anorectal manometry using standard or high resolution methods(83–85) to 





(b) Balloon sensory testing using standardised methods (2ml air per second to 
maximum 360 ml) to determine volume inflated to first constant sensation, 
defecatory desire and maximum tolerated volumes. The rectoanal inhibitory 
reflex was also elicited by 50ml rapid inflation (if necessary in 50 mL aliquots up 
to 150ml). 
(c) Fixed volume (50ml) water-filled rectal balloon expulsion test(86,88) in the 
seated position on a commode. Abnormal expulsion was defined as abnormal if 
failure to expel with 1-minute effort for men and 1.5 minutes for women(89). 
(d) Whole gut transit study using serial (different shaped) radio-opaque markers 
over 3 days with single plain radiograph at 120 hours(90). 
Treatment 
All patients underwent trans-anal irrigation therapy irrespective of INVEST results, 
and were followed up in the same way. The purpose of INVEST in this study is to 
identify whether certain radio-physiological results correlate with treatment 
response, i.e. can we predict likelihood of benefitting from irrigation based on pre-
treatment investigations.  
3.7.4 Concomitant Medications 
It was inevitable that patients would seek recourse to laxatives and other dietary 
supplements during the course of the programme. Experience shows that complete 
prohibition can lead to unreported laxative use, which might confound findings. 
Although we strongly discouraged ad libitum medication usage and specified a 
defined breakthrough regimen, we aimed to record co-treatment with sufficient 
fidelity and integrity to enable use these as covariates in analyses using a specific 




of contributory or confounding medications was used to filter on data entry. Patients 
using one system in the medium/long term could revert to the other system or 
pause treatment for a short period (for example while going on holiday) for practical 
reasons. This was permitted but must be recorded in the concomitant medications 
log. This short-term break in treatment was not considered as switching or ending 
treatments. 
 
3.7.5 Criteria for Discontinuation 
The interventions proposed are well-established in current clinical practice. There 
were no defined criteria for discontinuation; however clinicians could withdraw 
treatment where they had therapeutic or safety concerns, consistent with routine 
care. Patients could choose to discontinue treatment at any point and return to 
routine clinical care. Participants had the option of continuing to attend for follow up 
visits or to discontinue trial participation entirely. Any data collected up to this point 
were included in the analysis unless consent was withdrawn. 
 
3.8 FOLLOW-UP PROCEDURES 
The CapaCiTY 02 study duration allows for follow up to a maximum of 12 months 
with data collection at 3, 6 and 12 months post commencement of therapy. Primary 
outcome data were collected at three months. In addition, PAC-SYM, PAC-QOL and 
EQ-5D-5L, EQVAS were recorded at the 1-month visit; this was to capture 
information on early non-responders, and to better understand and characterize this 




Thereafter, participating patients could leave the study and return to ‘routine clinical 
care’ as determined within their local NHS institution (or be recruited to subsequent 
trials). Alternatively they may wish to proceed to enrolment in the next work 
package (Study 3 – Laparascopic Ventral Mesh Rectopexy) within the CapaCiTY 
programme. For the purposes of this thesis, data collected up to 6 months from 
University Hospital of North Durham were analysed. 
 
3.8.1 The following data were collected at each visit up to 12 months: 
 
 Validated symptom and quality of life questionnaires (PAC-SYM and PAC-QOL). 
 A two week patient diary (for 2 weeks before each assessment) to record bowel 
frequency and whether each evacuation was spontaneous (no use of laxatives) 
and/or complete; a patient journal also captured concurrent medication, health 
contacts, time away from normal activities (including work). Patients were 
contacted by telephone to remind them to start the diary. If patients forgot to do 
this, then it was acceptable for them to start recording the diary on the day they 
are seen in clinic and for this to be collected two weeks later. 
 Irrigation journal to record frequency and volume of irrigation and any adverse 
events. 
 Validated generic QOL questionnaires: EQ-5D-5L descriptive system and EQ-VAS. 
Note: EQ-VAS has a SD of approximately 30 points: a 10% difference in VAS 





 Resource use data (using patient journals as a prompt and including concomitant 
medication use). 
 Patient Health Questionnaire-9 (PHQ-9). 
 Generalized anxiety disorder questionnaire (GAD7) 
 Depression, anxiety and somatisation modules of the Patient Health 
Questionnaire. Brief illness perception questionnaire. 
 Global patient satisfaction/improvement score (VAS) and whether they would 
recommend each treatment experienced to other patients. 
 Potentially modifiable cognitive and behavioural psychological variables shown 
to predict onset and perpetuation of other functional bowel symptoms: negative 
perfectionism, avoidant and ‘all or nothing’ behaviour subscales of the 
behavioural response to illness questionnaire (CC-BRQ), and brief illness 
perception questionnaire BIPQ (CC). 
 
3.8.2 Laboratory Assessments 
Serum Pregnancy Testing was performed as per standard care for any women of 
equivocal status undergoing radiological assessments (INVEST).  
3.8.3 Radiology Assessments 
The whole gut transit study usually (90% patients) involved the use of a single plain 
abdominal radiograph (in 10% patients, a maximum of 2 may have been required to 
image whole abdomen and pelvis). This test forms part of routine clinical care for 
patients with CC at many NHS centres. All practitioners (radiologists, radiographers 




3.8.4 Participant withdrawal (including data collection / retention for withdrawn 
participants) 
Individual participants were able to withdraw from treatment at any time by 
notifying healthcare professionals involved with the study, and return to routine 
care without prejudice.  Data will be retained for intent to treat analysis from all 
participants after the point of consent and recruitment, unless participants withdraw 
consent for this. 
 
Withdrawal from treatment Criteria: 
Participant developed any of the following exclusion criteria 
 Participant became pregnant or intended to become pregnant (only in 
baseline and intervention phases). 
 Participant subsequently diagnosed with proven cause for secondary 
constipation e.g. Parkinson’s disease or bowel obstruction. 
 Participant required new medication with proven effects on bowel function 
e.g. opioids. 
 Participant developed significant intercurrent illness precluding participation. 
 Participant required surgery or other intervention (other than minor ops) 
during treatment or follow up phase. 
 Patient developed acute psychological problem causing safety concern. 
 Adverse events secondary to therapy (bleeding, anal fissure, ulceration, pain, 
bowel perforation) – relative indications for withdrawal depended on the 





 Elective withdrawal. 
Loss to Follow Up (no further interventions or follow up data collected) 
 Participants could be withdrawn from the trial if they become lost to follow 
up (LTF) after at least 3 failed attempts by research staff to make contact via 
2 different methods (e.g. phone and letter). 
 Participant chose to withdraw and did not wish to participate in follow up 
data collection. 
 Death or significant incapacity making follow up data collection impossible. 
3.8.5 End of Study Definition 
The end of study is defined as the last patient last visit. The sponsor, REC and local 
R&D departments will be informed of end of study and site closure and archiving 
procedures initiated. For this thesis, patients recruited at University Hospital of 
North Durham with a minimum of three months’ outcome data by 1st October 2016 
were eligible to be included. 
3.8.6 Criteria for Early Termination 
If the Data Monitoring Ethics Committee (DMEC), Programme Steering Committee 
(PSC), Research Ethics Committee (REC) or sponsor determined it was within the 
best interests of the participants or trial to terminate the study, written notification 
would have been given to the CI. This may have been due to, but not limited to; 
serious safety concerns, serious breaches, acts of fraud, critical findings or persistent 
non-compliance that negatively affects patient safety or data integrity. If the study 
was terminated participants would have been returned to the NHS normal follow up 




3.9 STATISTICAL CONSIDERATIONS 
3.9.1 Sample Size calculation for CapaCiTY 02 
PAC-QOL is a 28-item disease-specific measure, with each item scored 0-4, and 
providing an aggregate score 0-4(76). Following discussions between the trial 
statistician, the chief investigator and clinical lead, it was deemed appropriate to 
assume that a clinically important difference in superiority comparing low volume 
with high volume anal irrigation would be demonstrated by a 10% scale difference 
(or more), or 0.4, with a variance estimate conservatively set at SD=1 from the 
published literature(91) To detect an effect size of 0.4 (mean/SD =0.4) between the 
two groups with 90% power and 5% significance at three months requires 133 
patients per arm, and 266 total. Allowing for an anticipated 10% loss to follow up 
(LTFU), then a total sample size of 300 participants was decided upon. With 
approximately ten sites recruiting, this equates to a proposed recruitment rate of 
approximately 1 participant per month per site for the two-year recruitment period. 
The data presented here are for one site for the first year of recruitment, with the 
aim of conducting a feasibility analysis. 
3.9.2 Method of Analysis 
Clinical Outcomes 
Given the proposed recruitment target rate of one participant per month per site, 
the sample size for this MD study was very much smaller than for the CapaCiTY 02 
study as a whole. Therefore meaningful analysis is limited to a descriptive analysis of 
the study findings and a discussion of their implications for the wider study, with 




follow up plan and rate of recruitment. Additionally, the standard deviation of the 
primary outcome measure (PAC-QOL measured three months after starting 
treatment) was calculated to further evaluate the appropriateness of the sample size 
calculation. Final analysis was by intention-to-treat. Statistical calculations were 
performed using Stata 12 (StataCorp, Texas, USA). A full statistical analysis plan for 
the CapaCiTY 02 study has been developed; the key components of this are outlined 
below. 
CapaCiTY 02 study analysis plan 
All analyses will be by the intention-to-treat principle. The primary outcome will be 
PAC-QOL as a continuous variable, analysed at 3-months. The proportion of patients 
continuing with the initial therapy system will be recorded, and the PAC-QOL scores 
will be analysed using a linear mixed model with a random effect for centre and fixed 
effects for intervention, trial stratification variables (participants are stratified by sex 
and females by centre) and baseline PAC-QOL. Secondary outcomes will be analysed 
using the principles outlined for the primary outcome.  
Exploratory modelling will be conducted for baseline characteristics: measures of 
chronic pain, autonomic, joint hypermobility, cognitive, behavioural and mood 
variables share a common hypothesis that they are detrimental to the success of all 
treatments i.e. they perpetuate illness in spite of therapy. We will investigate a 
maximum of 3 interactions between treatment and baseline characteristics. 
Life table data for any irrigation will be presented by initial therapy and for specific 




Kaplan Maier analysis and adjusted using Cox regression. Exploratory analysis will be 
considered to identify characteristics of sub-groups with greatest persistent benefit 
from irrigation.  
Health economics analysis will also be performed using data transferred to the CRF 
from the patient journal. This will include comparative analysis of cost per success 
and cost per QALY, in order to explore overall cost effectiveness of treatment. This 
will be combined with health economics outcomes from the other work packages in 




This study (Study 2 of the CapaCiTY programme) is being carried out in accordance 
with the ethical principles in the Research Governance Framework for Health and 
Social Care, Second Edition, 2005 and its subsequent amendments as applicable and 
applicable legal and regulatory requirements.  
Ethics approval for the CapaCiTY 02 study was granted by the London City and East 
Research Ethics Committee (REC) (study reference number 15/LO/0732). Major 
protocol amendments were also approved by the same body. The study was 
registered with ISRCTN (registration number ISRCTN44563324) in accordance with 




3.10.2 Ethical considerations 
The CapaCiTY 02 protocol was independently peer reviewed by Prof Richard 
Ashcroft, Professor of Medical Ethics and Law at Queen Mary University of London 
(QMUL). Important considerations that informed pragmatic design include (a) 
limitation of intimate examinations: to one time point (not repeated if performed 
before recruitment); (b) timings of outcomes: Within this study outcomes were 
measured at 3 and 6 months from the commencement of the first treatment for all 
patients, with additional recording of key outcome measures (PAC-QOL, PAC-SYM, 
EQ-5D-5L, EQ-VAS, Irrigation Journal and Patient journal). For this period of 6 
months, patients did not progress to further Work Packages (the term used within 
the CapaCiTY programme to describe each stage of the research programme), thus 
preventing outcome ‘contamination’. Additionally there was a 3 month ‘quarantine’ 
from switching irrigation therapy. These delays were akin to that in usual NHS care, 
during which general supportive care was provided. These proposed limitations at 3 
and 6 months conferred no disadvantage and may even have represented an 
acceleration of treatment progression. Ethically, this was viewed as a reasonable 
trade-off for the commitment to the research programme; (c) recruitment & 
consent: study 2 represents one of the 3 studies incorporated in the NIHR-funded 
CapaCiTY programme. Although patients may have moved sequentially through 
treatments (and therefore studies) during the programme course, study 2 was 
consented as a distinct single entity;  
3.10.3 Competing interests 




3.11 SAFETY CONSIDERATIONS 
Patients recruited who had not had previous INVEST procedures conducted within 
the last 12 months underwent one radiological procedure (whole gut transit study) 
using ionising radiation as outlined above. The combined dose of this procedure 
(~0.1mSv) was equivalent to approximately 2.5 weeks annual background radiation 
dose from living in the UK [NB: this is an approximation which will require re-
certification by Barts Health NHS Clinical Physics Dept. based on doses from 20 
equivalent procedures]. Furthermore, this investigation would be carried out in 
routine clinical practice in many centres for patients at the same point as 
recruitment to this study. 
Regarding the intervention, anal irrigation is associated with a very small incidence 
of bowel perforation, as well as other side effects (bleeding, pain, ulceration, painful 
haemorrhoids, anal fissure) (58). These have been outlined in more detail in Chapter 
2. Patients were counselled and fully informed verbally and in writing within the 
ethically approved patient information sheet regarding these risks as part of the 
process of informed consent. In addition, they were trained in the correct use of the 
device before commencing therapy. All adverse events and serious adverse events 
were recorded and therapy suspended while these are investigated 
3.12 DATA HANDLING AND RECORD KEEPING 
3.12.1 Confidentiality 
Information related to participants was kept confidential and managed in 




Governance Framework for Health and Social Care, and the conditions of Research 
Ethics Committee Approval. 
Identifiable information collected from the participants included; full name, DOB and 
hospital number and contact details at screening. This information was used to 
contact participants but did not leave the study site without prior consent and 
approvals. All case report forms were pseudonymised. The participant’s GP was 
informed of their participation in the quantitative study. 
 
The trial data were made available to suitably qualified members of the research 
team, study monitors and auditors, the sponsor, the REC and regulatory authorities 
as far as required by law. The participants will not be identifiable with regards to any 
future publications relating to this study.  
3.12.2 Record Retention and Archiving 
When the research trial is complete, it is a requirement of the Research Governance 
Framework and Trust Policy that the records (including paper records, digital records 
and audio files) are kept for a further 20 years. For trials involving Barts and the 
London NHS Trust patients, undertaken by Trust staff, or sponsored by Barts and the 
London or Queen Mary University of London, the approved repository for long-term 




3.13 SAFETY REPORTING 
3.13.1 Adverse Events (AE) 
An AE is any untoward medical occurrence in a subject to whom an intervention has 
been administered, including occurrences which are not necessarily caused by or 
related to that product. An AE can therefore be any unfavourable and unintended 
sign (including an abnormal laboratory finding), symptom or disease temporarily 
associated with study activities. 
Notification and reporting Adverse Events or Reactions 
The anal irrigation systems are in widespread and established clinical use throughout 
the NHS with known adverse events occurring (22%) being mostly minor and 
reversible. All trial interventions were as per the standard care provided within the 
NHS for chronic constipation. Adverse events were recorded on the CRF. Serious 
adverse events were recorded on the CRF and in the medical notes to enable 
assessment and reporting in line with sponsor and regulatory requirements. 
Causality was at the discretion of the health care provider (e.g. research nurse, 
physiotherapist, principal investigator or delegated member of team). These were 
assessed as outlined below.   
Trial participants were advised to seek medical support from their GP for any 
unrelated signs, symptoms or disease or aggravation of underlying symptoms. 
3.13.2 Serious Adverse Event (SAE) 
In other research other than clinical trials of investigational medicinal products 




(a) Results in death. 
(b) Is life-threatening. 
(c) Requires hospitalisation or prolongation of existing hospitalisation. 
(d) Results in persistent or significant disability or incapacity. 
(e) Consists of a congenital anomaly or birth defect; or 
(f) Is otherwise considered medically significant by the investigator. 
An SAE occurring to a research participant was reported to the main REC where in 
the opinion of the Chief Investigator the event was: 
 Related – that is, it resulted from administration of any of the research 
procedures, and 
 Unexpected – that is, the type of event is not listed in the protocol as an 
expected occurrence.  
3.13.3 Notification and Reporting of Serious Adverse Events 
Serious Adverse Event (SAEs) that were considered to be ‘related’ and ‘unexpected’ 
were reported to the sponsor within 24 hours of learning of the event and to the 
Main REC within 15 days in line with the required timeframe.  
3.13.4 Expected SAEs 





 Hospital admission for exacerbation of constipation symptoms including 
impaction. 
 Hospital admission for unrelated elective surgical procedures or accidental injury. 
3.13.5 Urgent Safety Measures 
The CI  was responsible for taking urgent safety measures to ensure the safety and 
protection of the clinical trial subjects from any immediate hazard to their health 
and safety. The measures would have been taken immediately. In this instance, the 
approval of the REC prior to implementing these safety measures was not required. 
However, it was the responsibility of the CI to inform the sponsor and Main Research 
Ethics Committee (via telephone) of this event immediately.  
The CI had an obligation to inform both the Main REC in writing within 3 days, in the 
form of a substantial amendment. The sponsor (Joint Research Management Office 
[JRMO]) would be sent a copy of the correspondence with regards to this matter. 
However, no such issues were encountered during the study period considered in 
this thesis. 
3.14 PATIENT-PUBLIC INVOLVEMENT AND SITE FEASIBILITY QUESTIONNAIRE  
3.14.1 Patient-Public Involvement (PPI) 
Prior to study commencement, a selection of chronic constipation patients were 
asked to complete a short feasibility questionnaire regarding the study 
methodology. These patients were attending the Durham Constipation Clinic, and 
participation was entirely voluntary. They were not asked to commit to enrolling in 




The following questions were asked: 
 Do you mind random allocation of system? 
 Would you be happy to wait 3 months before switching systems? 
 Are you happy with restricted laxative use? 
 Would you participate in this study if you were eligible? 
Patients were also asked if they would consider reviewing the full research protocol. 
Additionally, some study documents (Patient Information Sheet, Journals and Diary) 
were given to patients for review and comment.  
Members of the local Constipation Research Advisory Group (CRAG), consisting of 
patients not directly involved with the study, were also asked to complete the 
baseline questionnaire booklet, and to provide feedback on this. This was completed 
during a group seminar. Clinicians and research team members also completed the 
questionnaires. Participants were asked to record the time taken to complete each 
questionnaire, and also to score each questionnaire for relevance and ease of use, 
using a five-point Likert scale from 1 (very relevant/ very easy) to 5 (not at all 
relevant/ very difficult). The results of this feasibility exercise are reported in Chapter 
5 (page 103).  
3.14.2 Site Feasibility 
As a multi-centre trial, it was important that the methodology used was acceptable 
and applicable across several hospitals. Therefore, a site feasibility questionnaire 
was sent to all prospective participating centres. The questionnaire was sent to 




following areas: how patients are trained to use irrigation and how the proposed 
methodology compared to this; how patients are followed up (both frequency and 
method of follow-up); which irrigation systems are used, and who prescribes these; 
reasons given for switching or discontinuing therapy in clinical practice; views on the 
suitability of the proposed rescue therapy; availability of resources to allow 
allocation of one blinded and one un-blinded researcher. See Chapter 5 (page 101) 
for a summary of the findings of this questionnaire.  
3.15 CONCLUSIONS 
This study methodology was designed to provide a balance between rigorous 
randomised assessment of an intervention and a pragmatic approach that takes into 
consideration the reality of the clinical situation encountered. This resulted in the 
unusual element of allowing patients to switch between irrigation systems after the 
3-month primary endpoint measurement. This design allows reasonable comparison 
of the two systems under experimental conditions for a long enough time period for 
superiority of one system to be established, but also limits the time patients spend 
using this treatment if it is ineffective for them.  
Equally, the decision to allow controlled laxative use acknowledges the clinical reality 
that many patients require laxative medications alongside irrigation therapy in order 
to manage their symptoms effectively.  
Further design issues concern the impracticality of assessor blinding, given that data 




the impact of bias, the decision was made to conceal the primary outcome (PAC-
QOL) questionnaire as detailed earlier in the chapter. 
Also, the placebo effect of this treatment may be significant; it was not possible to 
devise a suitable placebo for irrigation, therefore several options were explored. A 
cohort study without randomisation was not deemed sufficiently robust, and a 
waiting-list controlled trial would be equally vulnerable to the placebo effect and 
would not provide a comparison between systems. Therefore the present design 
was adopted, with the view that the placebo effect should be similar for both 
systems therefore any difference between the two would be a genuine difference 






CHAPTER 4: QUALITATIVE STUDY METHODOLOGY 
4.1 INTRODUCTION 
Patients with chronic constipation have reported dissatisfaction both with the 
effects of their illness on their quality of life and with some health professionals’ 
attitudes towards them and their condition (36). There is evidence that some 
clinicians hold pejorative opinions about patients with functional gastrointestinal 
disorders(92) and that this is noted by the patients, leading to frustration and 
discontent from either or both parties (36)(92). The view that the condition is ‘all in 
the mind’ can lead to patients being labelled negatively, and patients’ feelings of 
dissatisfaction at not being taken seriously are well described; many feel that a 
functional diagnosis means their symptoms are not being granted legitimacy in the 
eyes of the medical profession (36). Although psychosocial factors contribute to 
symptoms in many cases and should be addressed(38), a perceived ‘dismissing’ of 
symptoms as entirely psychological can have a negative impact on the therapeutic 
relationship (36). 
 
4.2 BACKGROUND AND RATIONALE 
Trans-anal irrigation therapy (TAI) is in widespread use throughout the UK as a 
treatment for bowel dysfunction. It has been used successfully to treat adults and 
children with neurogenic constipation (46)(47)(48), and faecal incontinence(49). 




constipation in adults is not universally accepted, and there are questions about 
long-term benefit (58).  
Despite the significant burden of disease associated with chronic constipation and 
the invasive nature of trans-anal irrigation therapy, there is relatively little evidence 
to support its use or to explore the patient experience of training or using in their 
everyday lives. A systematic literature review was carried out using the terms: bowel 
dysfunction, defecation, constipation and irrigation; the databases Embase, Medline, 
Evidence-Based Medicine (EBM) reviews and Cumulative Index to Nursing and Allied 
Health Literature (CINAHL) yielded a total of seven original quantitative research 
articles studying anal irrigation (See Chapter 2). These were all prospective or 
retrospective uncontrolled studies; a meta-analysis suggested that approximately 
50% of patients experienced an improvement in their symptoms using trans-anal 
irrigation. One piece of qualitative research, conducted by Tod et al (2007)(93), 
explored patients’ experiences using rectal irrigation and found that these were 
generally positive, with significant improvements in quality of life experienced by 
most patients. Key themes included regaining control over their symptoms, 
increased confidence, improved social participation, improved personal 
relationships, and the importance of the care delivered by clinical staff. However, 
this study only recruited women from a diagnostically undifferentiated group and 
did not explore the process of irrigation training or fidelity to treatment. 
Additionally, this was the only qualitative study found in the literature that sought to 
explore specifically the experiences of patients undergoing trans-anal irrigation. 




this area by exploring patients’ lived experiences of using irrigation, as well as 
reasons for the success of failure of therapy from the point of treatment 
commencement onwards. 
4.3 AIMS 
The purpose of this qualitative enquiry is to complement an ongoing clinical trial of 
trans-anal irrigation by exploring the patients’ lived experience of learning, using, 
and continuing irrigation. A phenomenological methodology was employed and 
qualitative data were collected in parallel with the trial.  
4.4 RESEARCH QUESTION 
4.4.1 Primary research question 
 What is the essence of the patient’s lived experience of using trans-anal 
irrigation therapy for the treatment of chronic constipation? 
 
4.4.2 Secondary research questions 
 How was the process of training to use irrigation, experienced by patients? 
 How was the process of follow-up support in the use of irrigation, 
experienced by patients? 
 What factors did patients take into account when deciding whether to 
continue with therapy, and how was this acted upon? 





 Were there differences in the patient’s experience of high-volume and low-
volume irrigation? 
 
4.5 THEORETICAL FRAMEWORK 
This study employed a phenomenological framework. This approach seeks to define 
the ‘essence’ of the experience of a particular phenomenon (in this case, undergoing 
trans-anal irrigation therapy for chronic constipation) from the point of view of the 
person going through it. It has a strong philosophical basis, the core idea being that 
phenomena are perceived by humans as ‘lived experiences’, and that, by bringing 
together themes that emerge through conducting interviews with people who all 
share experience of a particular phenomenon, the researcher can weave together a 
description of the essence of the experience(94) . It is important for the researcher 
to set aside any presuppositions regarding the phenomenon and to suspend 
judgements regarding ‘truth’ until a foundation for these beliefs has been 
established(94). The phenomenon exists within the meaning of the participants’ 
experience rather than being seen as having an objective reality independent of 
consciousness (94). 
 
This approach has been used in healthcare research to explore a wide range of 
topics, for example fatigue in chronic illness(95), HIV/AIDS (96) and heart failure(97). 
It enables the researcher to understand how a particular experience is perceived by 




aimed to assess the effectiveness of the treatment. The combination of qualitative 
and quantitative methods enables a very rich description of the treatment. 
 
A phenomenological approach was chosen in preference to other qualitative 
methods (for example, grounded theory) as comparatively little is known about the 
patient’s lived experiences of using irrigation. It is not known whether different 
themes will emerge depending on which system was used initially, or whether 
patients discontinue or switch treatment. A grounded theory study (for example, to 
establish a theory of why patients discontinue anal irrigation) would be a valuable 
exercise but is narrower in scope, risks imposing a researcher-biased framework, and 
may well require a larger number of participants. A phenomenological study, 
therefore, enabled many aspects of the experience to be described and provided 
valuable insights into what irrigation treatment is like. This can, in turn, enable 
health professionals to counsel people undergoing this therapy as to what to expect, 
and to better understand patient perspectives about treatment. 
 
There are some disadvantages to this approach. Small numbers of patients may limit 
generalisation of findings beyond the group of patients studied. Also, there is a need 
for the interviewer to be neutral, and to divest themselves of any pre-conceived 
ideas regarding the phenomenon. This could be difficult to achieve, especially for a 




an experienced qualitative researcher (HC). The potential challenges of this aspect of 
the study are explored further in section 4.12 of this chapter. 
 
Within the framework of phenomenology there are two approaches; ‘hermeneutic’ 
phenomenology and ‘transcendental’ phenomenology. Broadly speaking, 
hermeneutic phenomenology aims not only to describe the lived experiences of the 
phenomenon being studied, but also to interpret the meaning of these experiences. 
Transcendental phenomenology, by contrast, is focussed on describing the essence 
of the experience. This requires the researcher to ‘bracket’ their experiences of the 
phenomenon in order, as far as possible, to try to perceive it as if for the first time. 
As the aim of this qualitative study was to define the essence of the experience 
rather than place emphasis on the researcher’s interpretation of this, a 
transcendental approach was taken. However, it is acknowledged that it was not 
possible to eliminate a degree of interpretation in the analysis. 
 
4.6 RESEARCH STRATEGY 
4.6.1  Inclusion Criteria  
 Age 18-70 years 
 Patient self-reported problematic constipation 
 Symptom onset > 6 months before recruitment 




 Constipation failed treatment to a minimum basic standard (lifestyle AND dietary 
measures AND≥2 laxatives or prokinetics) tried (no time requirement)  
 Ability to understand written and spoken English (due to interview validity) 
 Ability and willingness to give informed consent 
 Failure of previous nurse-led behavioural therapy  
 Ability of patient / carer to use anal irrigation 
 Consent to enrollment in the CapaCITY trial 
 
The study used the American College of Gastroenterology definition of constipation;  
‘Unsatisfactory defaecation characterized by infrequent stool, difficult stool passage 
or both for at least previous 3 months’ (2). 
 
4.6.2 Exclusion Criteria 
The study interventions necessitated the exclusion of major causes of secondary 
constipation in detail: 
 Significant organic colonic disease (red flag symptoms e.g. rectal bleeding if not 
previously investigated); IBD; megacolon or megarectum (if diagnosed 
beforehand); severe diverticulosis/stricture/birth defects deemed to contribute 
to symptoms (incidental diverticulosis not an exclusion) 
 Major colorectal resectional surgery 
 Current overt pelvic organ prolapse (bladder, uterus, vagina, rectum) or disease 




 Previous pelvic floor surgery to address defaecatory problems: posterior vaginal 
repair, STARR and rectopexy; previous sacral nerve stimulation 
 Previous use of transanal irrigation therapy to treat constipation 
 Rectal impaction (as defined by digital and abdominal examination) 
 Significant neurological disease deemed to be causative of constipation e.g. 
Parkinson’s, spinal injury, multiple sclerosis, diabetic neuropathy (not 
uncomplicated diabetes alone) 
 Significant connective tissue disease: scleroderma, systemic sclerosis and SLE 
(not hypermobility alone) 
 Significant medical comorbidities and activity of daily living impairment [based 
on Bartell index in apparently frail patients,[Bartel index <=11] 
 Physical disability/impairment which prevented use of one or other of the 
irrigation devices 
 Major psychiatric diagnosis [schizophrenia, major depressive illness, mania, self-
harm, drug/alcohol addiction] 
 Chronic regular opioid use (at least once daily use) where this was deemed to be 
the cause of constipation based on temporal association of symptoms with onset 
of therapy; all regular strong opioid use. 
 Pregnancy or intention to become pregnant during study period.  







4.6.3 Sampling strategy 
A purposive sample of approximately 4-12 patients were invited to interview upon 
completion of irrigation training. The plan was then for a further 8-16 patients were 
interviewed at 6 months (these may be the same or different patients). Recruitment 
could be extended if data saturation was not accomplished by the 12th patient. Data 
saturation was defined as the point at which no new or relevant themes emerge. 
Inclusion and exclusion criteria were as above.  
 
A review of a database of approximately 1,000 adult patients attending a chronic 
constipation clinic revealed a male:female ratio of 1:9, with a median age of 41 (18-
70). It can be reasonably assumed that this reflects the typical demographic make-up 
of patients with this condition in this region. Therefore sampling was stratified to 
reflect this as far as possible, with recruitment of approximately equal numbers of 
patients aged <40 years and >40 years. Male patients were not excluded even 
though they are uncommon in the study population. Stratification by ethnicity was 
unlikely to be meaningful, as 94.9% of the population of North East England is ‘white 
British’ or ‘white other’ (98), and there was no evidence to suggest that the 
demographic of the study population would differ from this. 
 





 2-6 patients undergoing low-volume anal irrigation and 2-6 patients 
undergoing high-volume irrigation were selected for interview  at one month 
(+/- 2 weeks) 
 Further interviews were planned six months after starting treatment with 8-
16 patients including; 
o those who discontinue early (<3 months),  
o later (3-5 months),  
o those who continue with their allocated treatment to at least 6 
months,  
o those who switch systems. 
 
Patients enrolled in the quantitative arm of the CapaCiTY 02 study were stored on a 
research database. Purposive sampling was used to select patients based on age and 
irrigation system (baseline interviews – 1 month), and duration of therapy (6-month 
interviews) as outlined above. 
4.6.4 Sampling grids 
At 1 month (+/- 2 weeks) 
 High-Volume Low-Volume 
Age =<40 1-3 1-3 






At 6 Months  
 










1-2 1-2 1-2 1-2 
Age 
>40 
1-2 1-2 1-2 1-2 
 
It should be noted that these proposed sampling grids reflect the ‘ideal’ situation, 
and that numbers recruited were limited by delayed recruitment to the study 
overall. This, and its potential for introducing sampling bias, is detailed further in 
Chapter 6. 
 
4.7 PROCESS AND PROCEDURE OF RECRUITMENT AND DATA COLLECTION 
All patients were told that they may be invited for interview when they were initially 
informed about the study. A purposive sample of patients as described above was 
contacted by telephone by CE with support from the clinical team and if willing to be 
interviewed they were given a patient information sheet. This was then followed up 
with a phone call after a minimum of 24 hours to establish verbal consent and set up 
a mutually convenient interview time and date. Participants were offered a semi-
structured interview in a clinic room immediately before or after their 4-week or 6-
month clinic visits (as appropriate); if the patient was unable or unwilling to be 




request a chaperone to be present if they preferred. Following written consent, the 
interviews were recorded on a digital dictaphone and transcribed into a 
pseudonymised (alphanumeric code) text document. Interviews were planned to be 
conducted by a Clinical Research Fellow at UHND (Christopher Emmett) and/or a 
Health Research Methodologist at Durham University (Dr Helen Close). Following in-
depth training which took into consideration bracketing and the ways in which CE 
might step into a non-clinical research role, it was decided that all interviews would 
be held by CE with close supervision from HC. Both CE and HC reviewed the audio 
file and its transcription file shortly afterwards to ensure appropriate academic 
supervision, and to assess data saturation. 
 
Interviews explored patients’ experiences of recruitment, individual interventions, 
their training and delivery, and patients’ views about outcome measures. Interviews 
at both time points (1 and 6 months) were semi-structured in nature and allowed 
the participants considerable freedom to discuss the issues that were most 
important to them. Questions were necessarily very general, with the aim of eliciting 
the broadest possible range of responses from patients in order to ensure all major 
themes were recorded. Overly prescriptive/detailed interview schedules would risk 
leading patients to address particular issues of importance to the researcher without 
exploring the full range of patient experiences and therefore resulting in a biased or 
incomplete description of the patient experience. Interviews lasted between 10 and 






Interviews were recorded onto a digital recorder. The planned process for data 
transfer was for these audio files to be uploaded as encrypted files to a secure 
Durham University data transfer service. This would allow secure transfer of the 
files. Funding for transcription of qualitative interviews within the CapaCiTY 
programme was allocated to Kings College London; the files would be transferred 
securely to Kings College for transcription and then the pseudonymised transcripts 
would be returned to Durham in a secure fashion (encrypted electronic 
transfer/recorded delivery) to allow analysis as part of this thesis. However, due to 
unforeseen problems with the data transfer service and due to software 
compatibility problems between the trusts, all interviews were transcribed at 
Durham by CE in order that they could be reviewed and analysed in a timely way. 




Patients were invited to one-to-one interviews on completion of irrigation training. 
Patients were recalled up to 6 months after training and offered an interview. For 
the 1-month interviews, these were required to take place no later than 4 weeks 
after their 1-month visit to maximise recall. There was no specific time limit for the 
long term interviews, but they must have taken place no earlier than the day of the 




the same as those interviewed up to six months in order to capture the range of 
types and continuation of treatment. Interviews were timed to capture relatively 
early and later experiences and perceptions of the interventions.  
4.10 ANALYSIS 
Interviews were digitally recorded, anonymised, transcribed verbatim and analysed 
using a pragmatic thematic analysis for data management. Data analysis was 
developed as outlined by Fereday & Muir-Cochrane(99), following a 
phenomenological framework; in the first instance by mapping key concepts derived 
from the transcripts (‘charting’) and extracting emergent themes from the 
transcripts. Textural description and structural description of these themes was 
developed and synthesised into a composite description of the phenomenon, 
incorporating ‘what’ the patients experienced and ‘how’ they experienced it (94). 
Independent analysis was conducted by CE and HC. Emergent themes, together with 
captured observational data, will form the basis of joint analytical interpretation 
with the wider study team including CN (for the larger CapaCiTY 02 study). This wider 
analysis does not form part of this thesis. 
 
4.11 ETHICAL APPROVALS 
The study protocol, comprising both quantitative and qualitative elements, was 






4.12 RISKS AND HAZARDS 
Interviews were in-depth and conducted one-on-one (or with a chaperone if 
requested by the patient) and therefore there were potential (minimal) risks to the 
safety of the interviewer. The intensely personal and private nature of the interviews 
could have led to psychological distress for the participant. It was therefore 
necessary to identify patients who would be at especially high risk in either of these 
ways and to exclude them from the study. Baseline assessment would identify and 
enable exclusion of individuals with pre-existing psychiatric disorders or a history of 
high-risk behaviours (self-harm, drug and alcohol addiction). A process of full 
informed consent took place for each patient as part of the clinical trial before any 
involvement in the qualitative study took place (which has a separate consent form). 
HC and CE are both experienced clinicians used to dealing with patients in distress. 
HC is an experienced qualitative researcher who offered appropriate supervision to 
CE following each interview.  
 
4.13 RESEARCH RELATIONSHIPS 
Because a practising clinician (CE) conducted qualitative interviews, there were 
potential challenges regarding maintaining a degree of objectivity and allowing 
patients to express themselves freely. The patient must be allowed to take control of 
the interview and to dictate the direction of the conversation. This involved a 
conscious setting aside of the ‘clinician persona’ and it was emphasised to the 




experiences, and not attempting to resolve/address any clinical issues that arise. This 
was emphasised at the start of the interview, and again if any attempt was made by 
the participant to ask a clinical question. In this instance, they would have been 
asked to note down the question and contact the clinical team directly (although in 
practice, this did not occur during this study).  
 
If a participant wished to raise any concerns or make a complaint, they were advised 
to contact the Patient Advice and Liaison Service (PALS); the telephone number was 
provided at the bottom of the patient information sheet. PALS is an independent 
service provided by the NHS and not connected in any way to the research study. 
 
4.14 DATA MANAGEMENT 
Patient-identifiable data were collected and stored in accordance with Caldicott 
principles and the Data Protection act. All interview transcripts were pseudonymised 
and patient data were stored electronically on NHS computers or encrypted media, 
in accordance with local IT policies. Paper records were securely stored in the study 





CHAPTER 5: RESULTS: STUDY FEASIBILITY AND PRELIMINARY QUANTITATIVE DATA 
ANALYSIS 
5.1 INTRODUCTION 
In the following chapter, quantitative study data from a single site (UHND) will be 
presented and analysed, along with the outcome of pre-study site feasibility 
assessments and patient-public involvement consultations.  
Data presented here represent interim results from a single trial centre (University 
Hospital of North Durham (UHND)) nested within the large multi-centre CapaCiTY 02 
trial . The purpose of this quantitative data analysis is to assess the feasibility of the 
CapaCiTY 02 study by looking at recruitment rates, completeness of data collection, 
and preliminary descriptive analysis of the primary study outcome (difference in 
mean PAC-QOL between HV and LV groups after 3 months). Calculating the standard 
deviation allows the appropriateness of the sample size calculation (which assumed 
an SD of 1) to be assessed. Although this study was not designed a priori as a 
feasibility study, it is nonetheless instructive to present data in this way in order to 
inform current and future conduct of the study nationally. 
5.2 PRE-STUDY SITE FEASIBILITY ASSESSMENT  
Before recruitment commenced, feasibility questionnaires were sent out to 13 
prospective sites. Responses were received from nine of these. As expected, there 
were considerable variations in practice regarding precisely how patients are trained 
to use the irrigation. Although most centres were fairly consistent in having an initial 




original proposed training regime suggested that the patient should demonstrate 
irrigation in the clinic under the guidance of the irrigation nurse. However, many 
centres said they did not have the resources for this and that it did not form part of 
their usual practice although many centres did have the patient set-up the device in 
clinic to show that they could use it. Follow-up methods and timings varied, with 
telephone follow up being the most common approach, varying between 24 hours 
and 4 week from the initial session. Some centres also offered patient-led or flexible 
follow up.  
Taking these variations into account, it was not possible to design a standardised 
irrigation training regime that met the needs and resource issues of each centre. 
Therefore a flexible approach was adopted, as outlined in Chapter 3, section 3.7.1, 
with the requirement for the patient to use the irrigation in clinic removed. 
However, if the participating centre had the resources available and the patient 
wished to do this, then this demonstration was permitted. Also, each centre used 
different irrigation systems which reflected local availability and prescribing policies, 
so therefore the decision was made that any high-volume system could be used, 
provided it had a similar mechanism of action. There was reasonably good consensus 
that the rescue therapies were sensible, however greater flexibility was incorporated 
to allow patients to use additional laxatives and prokinetics during follow up if their 
symptoms were severe despite irrigation and the rescue therapy. 
5.3 PRE-STUDY PATIENT PUBLIC INVOLVEMENT (PPI) 
Before the study commenced, thirteen patients currently attending the constipation 




ascertaining their views and opinions about key aspects of the proposed trial design. 
These patients were not necessarily to be considered for participation in the trial, 
and were not screened to see whether they were eligible.  Regarding random 
allocation of the irrigation system, twelve out of thirteen patients were willing in 
principle to accept either study intervention. Also, 10 patients were happy in 
principle to accept the restriction in laxative use. However only seven patients said 
they would be happy to wait for three months before switching treatments; 
following some discussion between members of the research team and the Chief 
Investigator, it was decided that the three-month period was necessary to obtain 
meaningful outcome data and therefore retained. It is however acknowledged that 
this represents a compromise between scientific rigour and patient acceptability. 
Overall, nine of the patients said they would participate in the study as described, 
with three saying they would not, and one patient unsure whether they would or 
not. 
Additionally, nine patients were given the study documents (Patient Information 
Sheet, Patient Journal, Irrigation Journal and Patient Diary) and asked to comment 
on them, with five responding. Their comments are summarised below: 
 Patient 1: Happy with all documents; they would like a face-to-face 
explanation of how to use everything 
 Patient 2: Happy with the diaries and patient information sheet. They would 
like something added concerning eating and drinking patterns and their effect 
on symptoms 




 Patient 4: Regarding the patient information sheet, they would like the 
flowchart moved nearer the beginning of the sheet, before the main 
description of visits. They would like more information on the differences 
between systems. Regarding the Irrigation journal, they felt this should be 
daily rather than weekly.  
 Patient 5: Would like ‘less wordy’ section on purpose of study in the patient 
information sheet, and felt bullet points should be used, rather than 
paragraphs. They felt the journal should include dietary information also. 
They described the irrigation journal as ‘excellent’, but would like a box for 
duration and timing of irrigation.  
On the whole, these were taken to be positive comments regarding the study 
documents. There were no major areas for improvement consistently highlighted, 
and collecting data on dietary factors was felt not to be relevant for this study.  
5.4 PRE-STUDY CONSTIPATION RESEARCH ADVISORY GROUP (CRAG) REVIEW OF 
ASSESSMENT QUESTIONNAIRES 
Of the six patients invited to participate in this seminar, three were able to attend. 
Additionally, the questionnaires were completed by three investigators (a 
consultant, a research nurse and a research fellow). Each participant recorded the 
time taken to complete each questionnaire, and the mean time for completion of 
each questionnaire was calculated (see table 1 below). Three participants completed 
scores for relevance, and the mean scores are given below. It should be noted that 
the baseline questionnaire booklet was amended in light of operational problems 




original one, hence the differences between the questionnaires listed below and the 
baseline assessments outlined in Chapter 3. 
It can be seen from the table below that the aggregate time taken to complete the 
booklet was around 40 minutes. Perception of ease and relevance of each 
questionnaire was very variable, with the short outcome questionnaires (PAC-SYM, 
PAC-QOL and EQ-5D-5L) being seen as relevant and straightforward to complete, 
scoring 1-2 for each domain; however others were deemed to be either more 
difficult (MYMOP, CC-BRQ, Cleveland Clinic, ROME III), or less relevant (MYMOP, 











PAC-QOL 02:48 2 2 
PAC-SYM 01:18 1 2 
EQ-5D-5L 01:04 1 2 
MYMOP 2 
Initial 
02:15 3 3 
PHQ-15 02:15 2 3 
GAD-7 00:37 1 4 
PHQ-9 00:44 1 3 
CC-BIPQ 00:54 2 2 
CC-BRQ 02:10 3 2 
Cleveland 
Clinic 
01:47 3 2 
St Marks 01:01 2 3 
Rome III 04:30 4 3 
Joint 
Hypermobility 
00:33 1 3 
*scored from 1 (very easy/relevant) to 5 (very difficult/not at all 
relevant) 
 
Although this was a short exercise involving a small number of patients and 
investigators, it nonetheless shone some light on the participants’ experiences of 
filling out the questionnaires, and helped to guide some amendments to the study, 





5.5 OPERATIONAL PROBLEMS ENCOUNTERED FOLLOWING STUDY 
COMMENCEMENT 
5.5.1 INVEST 
There were several difficulties encountered surrounding the logistics of completing 
the pre-treatment radiophysiological investigations (INVEST) within the timeframe 
specified in the study protocol (i.e. within 8 weeks of informed consent). Originally, it 
was suggested that INVEST should include fluoroscopic defecation proctography and 
high-resolution anal manometry, as well as a transit study. However, many study 
sites (including Durham) did not have the required equipment to perform high-
resolution manometry, meaning that this was not possible.  
Additionally, it was felt that performing defecation proctography on every 
participant was impractical, as it would place undue pressure on radiology 
departments and cause delays in recruitment. It was felt that any scientific benefit 
gained from performing this examination was likely to be minimal, and did not justify 
the additional radiation exposure or expense incurred. Therefore the decision was 
taken to revise the requirements for INVEST to allow both standard and high 
resolution manometry, according to local availability, and to remove the 
requirement for defecation proctography. As recruitment had already commenced 







5.5.2 Completeness of data and outcome assessment 
Initial experience with the first three patients recruited at UHND revealed some 
problems with outcome data being incomplete. This included missing answers on 
the concealed primary outcome questionnaire. In response to this, the issue was 
raised with the chief investigator and it was agreed that the primary outcome 
questionnaire (PAC-QOL) should be inspected briefly by a member of the research 
team in order to ensure completion before being sealed in the envelope. This was 
felt to be a reasonable compromise between the requirement that data be 
concealed adequately and ensuring data are as complete as possible. 
Further issues surrounded the patient-held documents; the diaries were sometimes 
omitted or returned with missing answers, as were the journals (irrigation journal 
and patient journal). There was scope within the study protocol for diaries to be 
completed from the day of the visit and returned by post if they had not been filled 
in beforehand, however on some occasions this was not done. This is analysed in 
greater detail in section 5.9 (also see table 3). 
5.6 PROTOCOL AMENDMENTS MADE IN RESPONSE TO CHALLENGES 
5.6.1 Changes to INVEST 
As detailed previously, amendments were made to the INVEST radio-physiological 
investigations performed before treatment was started. It was decided that 
anorectal physiology was important scientifically in order to evaluate whether 
differences in rectal sensation, manometry or balloon expulsion test results are 




resolution methods did not add to this in a significant way, especially in view of the 
significant operational difficulties encountered in securing funding for procuring this 
equipment for sites not currently using it as standard.  The transit study was felt to 
be useful and easy to implement with minimal costs and only slight radiation 
exposure; it also represents standard care for chronically constipated patients.  
However, the role of barium proctography was less clear cut; it was decided not to 
perform this routinely as it represented a significant cost to the NHS and also a 
significant radiation exposure for the patient, as well as causing a delay in starting 
treatment as waiting lists for the test were long (4-8 weeks). Thus this test was 
removed from the study protocol.  
Another change was to extend the time window for using results from tests done 
before study recruitment from 6 to 12 months. This reduced the need for repeated 
investigations and will not affect the scientific value of the study given the chronic, 
stable nature of the condition being studied  
5.6.2 Changes to questionnaires and follow up duration 
As previously noted, there were problems with incomplete and missing answers on 
questionnaires. Also, there was concern expressed about the burden of 
measurement and study duration, and whether this was causing problems with 
study recruitment and retention of participants. Following discussion between 
investigators and in light of patient feedback (see CRAG results described 
previously), the number of questionnaires was reduced at baseline, three and six 




useful early outcome measurements in patients who discontinue treatment early, or 
are lost to follow up. 
In order to ensure completeness and accuracy of outcome data collection, it was 
agreed with the chief investigator that the PAC-QOL questionnaire could be checked 
by a member of the research team before being placed in the sealed envelope, as 
long as the total score was not calculated and the participant was not influenced in 
any way while completing it (other than by being encouraged to fill in missing 
answers). This ensured that outcome data were as complete as possible without 
compromising the scientific integrity of the study. 
A further major change was to shorten the total study follow-up period from 24 
months to 12 months. The aim of this change was to reduce the commitment being 
asked of participants to a more reasonable level, thereby aiming to increase 
recruitment and retention of participants. 
5.6.3 Online data entry (REDCAP) 
The revised protocol included a mechanism allowing patients to complete their 
patient diaries and outcome questionnaires online (See chapter 3). This enabled 
participants who chose this option to record outcome data in this way, and complete 
the rest of their follow up by telephone. Out of 19 participants, 8 (42%) preferred to 
conduct follow up in this way , and it also ensured completeness of data collection 






5.6.4 Change to randomisation time point 
Operationally, it was found to be challenging to randomise patients and then 
immediately start irrigation. Some sites reported difficulties in obtaining enough 
equipment to start treatment straight away. Therefore, randomisation was instead 
performed at the first study visit, immediately after informed consent and 
completion of the baseline outcome assessment questionnaires. 
5.7 RECRUITMENT AND RETENTION OF PARTICIPANTS TO CapaCiTY 02 
As of the 18th August 2016, six sites are open to recruitment nationally. A total of 23 
participants have been recruited across these sites. Of these, 19 were recruited at a 
single site (University Hospital of North Durham). Recruitment by site is shown in 
figure 1. This is a much slower recruitment rate than is required in order to complete 
recruitment within the planned time frame (see figure 2 below). Reasons for this will 
be explored in the following sections, and proposed strategies for improving this will 










Figure 1: CapaCiTY 02 enrolment by site 
 









5.8 RECRUITMENT AND RETENTION OF PARTICIPANTS AT UNIVERSITY HOSPITAL OF 
NORTH DURHAM (UHND) 
Recruitment to the study at the University Hospital of North Durham commenced in 
September 2015. Additionally, two other sites opened to recruitment a month 
before this. Between 1 September 2015 and 31 July 2016, 33 patients were screened 
at UHND. Of these, 19 consented to participate in the study. This gives a mean of 1.9 
patients recruited per month. The ratio of those enrolled to those screened is 0.58.  
The monthly screening and recruitment figures are given in table 2 below. As of 18 
August 2016, 2 patients have withdrawn from the study (elective withdrawal – 
reasons unknown).  
This demonstrates that the original recruitment target of 1 patient per month per 
site is achievable. However, following delays to study commencement and poor 
recruitment at other sites, this target was revised to 2 patients per site per month in 
order to complete recruitment on schedule. This revised target is also being 
achieved at UHND. The projected withdrawal and loss to follow up rate was 
estimated at 10%; the rate of 2 withdrawals from 19 participants (10.5%) is 
consistent with this. Also, the predicted ratio of those enrolled to those screened of 








Table 2: Screening and enrolment at UHND 
Month Screened (n) Enrolled (n) Ratio enrolled/screened 
Sep 2015 1 - - 
Oct 2015 3 1 0.33 
Nov 2015 4 1 0.25 
Dec 2015 4 3 0.75 
Jan 2016 3 3 1.00 
Feb 2016 3 1 0.33 
Mar 2016 4 3 0.75 
Apr 2016 2 2 1.00 
May 2016 1 1 1.00 
Jun 2016 4 2 0.50 
Jul 2016 4 2 0.50 
Total 33 19 0.58 
 
 
5.9 DEMOGRAPHICS OF STUDY PARTICIPANTS AT UHND 
The numbers of patients screened and enrolled at UHND are given in the CONSORT 
diagram below (Figure 1). There were 19 participants recruited at UHND; the mean 
and median age was 43 years (range 23 – 65 years). There were 18 female 
participants and one male. At the time of writing, 11 participants have had their 
three month primary outcome visit (including one patient who later withdrew from 
the trial). A further 6 participants have not yet reached this outcome time point, and 




continuing with participation currently. The study continues to recruit actively at a 
mean rate of 1.6 participants per month. With the agreement of the study team, the 
following data were extracted from the trial database on 18 August 2016.  
Figure 3: Consoldated Standards of Reporting Trials (CONSORT) diagram for 






5.10 COMPLETENESS OF DATA COLLECTION 
The CapaCiTY 02 study involves the collection of a great deal of outcome data at the 
time points previously described, in the form of case report forms (CRF), 
questionnaires and patient symptom diaries. This represents a potentially onerous 




important to evaluate completeness of data collected to assess whether the 
outcome measures used are appropriate and achievable.  
Table 2 below illustrates the proportion of questionnaires, diaries and investigations 
for each time point that were complete, partially complete, or not completed. Data 
are presented for the 19 participants who had had at least baseline data collected 
(as of 18th August 2016). Of those, 17 had reached the INVEST visit, 15 had provided 
outcome data at 1 month, 11 provided 3-month data, and 4 had reached the 6-
month data collection visit. 
It can be seen that the primary outcome questionnaire (PAC-QOL) has been collected 
for between 93% and 100% of participants at each time point. The one occasion 
where the PAC-QOL was not done was for a participant who did not attend the 1-
month visit, therefore the time point was recorded as missing. Of the baseline PAC-
QOL questionnaires, two had missing answers and a further 2 were not available for 
analysis due to the data not being present on the central database at the time of 
writing. Similar rates of completeness were seen at 1 and 3 months. Missing answers 
for PAC-QOL is not critical since the questionnaire was designed to allow for this, as 
the total score (014) is the sum of the answers given divided by the number of 
questions answered. 
The diaries have been less completely recorded; at baseline, 4 (21%) diaries were not 
completed at all, and a further 4 had at least one missing answer. A similar 
proportion of diaries were not done at three months (4 diaries, 36%). A at six months 
three of four participants (75%) had returned a diary, with two (50%) being 












































12 (80) 12 (80) 10 (91) 10 (91) 5 (45) 4 (100) 3(75) 2 (50) 
1 or more missing 
answers (%) 
2 (11) 5 (26) 4 (21) NA NA 2 (13) 2 (13) 1 (9) 1 (9) 2 (18) 0 (0) 1 (25) 1 (25) 
not done (%) 0 (0) 0 (0) 4 (21) 5 (29) 0 (0) 1 (7) 1 (7) 0 (0) 0 (0) 4 (36) 0 (0) 0 (0) 1 (25) 
not available (%) 2 (11) 2 (11) 2 (11) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)  0 (0) 0 (0) 




Regarding pre-treatment investigations (INVEST), all 17 participants who have 
reached this time point have had a transit study. Ano-rectal physiology was 
performed in 12 (71%) participants; the reason for the omission of this test in 5 cases 
was that this investigation became unexpectedly unavailable for a time. Following 
discussion with the chief investigator, it was decided that the physiology testing 
could be omitted for participants already recruited to the trial, so as to minimize 
delay in treatment. This was recorded as a protocol violation. 
5.11 PRIMARY OUTCOME DATA: INTERIM RESULTS  
In the following section, a descriptive analysis of the primary outcome (PAC-QOL at 3 
months) is presented. Data are from the 11 participants who have reached this point 
in the study. This includes 10 female participants and one male. Of these, 6 were 
randomised to high-volume irrigation and 5 to low-volume irrigation. 
For the whole study population, mean PAC-QOL fell from 1.95 at baseline to 1.56 
after 3 months, a mean reduction of 0.39 (see table 3 and figure 2 below). The 
standard deviation of 0.44 is lower that the SD of 1 used in the power calculation, 
suggesting that the sample size is sufficient to detect a 10% (0.4 point) difference in 
reduction in PAC-QOL between the groups. In this population, the reduction in PAC-
QOL at three months was 0.41 for high-volume users and 0.36 for low-volume users, 
a difference of 0.05 in favour of high volume irrigation. However, the numbers in this 
feasibility study are too small for meaningful conclusions regarding comparative 
efficacy of each system to be drawn. It should also be noted that one of the five LV 
participants (20%) switched to high-volume irrigation after 1 month due to patient-




included in the low-volume data set in accordance with the principle of analysis by 
intention to treat. 
 
Table 4: Mean reduction in PAC-QOL by system 
 Mean (SD) PAC-QOL score  
Irrigation system Baseline 1 Month 3 Months Reduction 
High Volume 1.8 (0.43) 1.04 (0.49) 1.39 (0.60) 0.41 (0.39) 
Low Volume 2.12 (0.80) 1.73 (0.81) 1.76 (0.78) 0.36 (0.54) 
Whole cohort 1.95 (0.61) 1.35 (0.72) 1.56 (0.60) 0.39 (0.44) 
 
 





5.12 SURVIVAL DATA (CONTINUATION OF BENEFIT): INTERIM RESULTS 
As previously noted, 17 study participants had commenced trans-anal irrigation 
therapy as of the 18th August 2016. Although these numbers are small, thereby 
introducing considerable uncertainty into any statistical interpretation, it is 
instructive to present the interim data for survival (i.e. continuing use of treatment) 
here. This may be considered to be a surrogate marker for treatment efficacy as the 
nature of the treatment means that participants will likely not continue to use it if 
they are not deriving some benefit. 
Data are presented for the whole cohort, and are not separated out into high- and 
low-volume users. This is consistent with the analysis plan for the CapaCiTY 02 study. 
As on the 18th August 2016, 5 patients (29%) had discontinued treatment, after a 





Figure 5: Treatment survival plot for trans-anal irrigation
 
 
It can be seen from the wide CI and small numbers that there is considerable 
uncertainty in this analysis: Clearly more data are needed in order to build a 
complete picture of the true duration of benefit. However, this interim analysis is 
instructive as it suggests that the majority of those who discontinue treatment do so 
early (before 3 months of use). Combined with the fact that a further two patients 
switched therapy before three months (as detailed previously), this indicates that 
the one-month data collection time point is justified and useful as it allows data 
capture in these participants while they are still using their allocated system. Of the 
9 participants allocated HV, 4 (44%) discontinued compared to 1 of the 8 allocated 
LV (12.5%). Of the 5 patients who discontinued in total, one reported persistent PR 
bleeding, another reported incomplete evacuation and lack of treatment effect. A 
Kaplan-Meier survival plot showing the proportion of participants continuing with treatment 




further patient reported pain and bloating, as well as lack of efficacy and a sensation 
of incomplete evacuation, and found that the treatment was not acceptable. 
Another participant gave excess pain, defecation at low volumes, and increased 
frequency as reasons for stopping. The final participant withdrew from the study 
without giving specific reasons for this. 
Additionally, four patients out of 17 switched therapy in this time period (23.5%). All 
of these were participants who started with low volume irrigation (50%). Mean time 
to switching treatment was 67 days (SD 29.6). 
5.13 SAFETY OF TREATMENT AND ADVERSE EVENTS 
Data for adverse events are first collected at the 1-month visit. At the time of data 
analysis, 15 patients had reached this time point and therefore had provided data for 
analysis. 
5.13.1: Serious Adverse Events (SAE) 
There have been two unrelated Significant Adverse Events so far in this study. Both 
involved the same patient. This patient underwent elective surgery (planned 
parotidectomy), which necessitated admission, and also had a hospital admission for 
an acute exacerbation of constipation symptoms. After discussion with the study PI 
and having been reported to the CI as per protocol, it was agreed that these were 
unrelated SAEs and that no further action needed to be taken. The participant 





5.13.2: Adverse Events (AE) 
Of the 15 participants from whom 1 month data has been collected, 11 (73%) 
described one or more related adverse events. Of the remaining 4 participants, three 
(20%) reported no AE and the final patient did not attend the 1-month visit, so data 
are not available. Table 5 below summarises the rates of the observed AEs.  
The overall rate of AEs is high in the study population. This is consistent with the 
current evidence, which suggests minor side effects are commonplace (see Chapter 
3: Systematic Review). However, the only SAEs seen in this study so far have been 
unrelated to the trial therapy, and there has been no significant harm to participants 
as a result of trial participation. It can therefore be suggested, based on this 
feasibility study, that trans-anal irrigation therapy is safe and that there have been 
no significant safety concerns that would lead to the termination of the trial. The 
prospective tracking of AEs is an important secondary aim of the CapaCiTY 02 study, 






Table 5: Adverse Events 
Adverse Event N (%) 
Anal pain 3 (20) 
Nausea 1 (7) 
Abdominal pain 6 (40) 
PR bleed 4 (27) 
Bloating 2 (13) 
Lethargy 1 (7) 




Spillage of water 1 (7) 
Urgency 2 (13) 
Increased frequency  
of bowel motions 
1 (7) 
Headache 1 (7) 
Sacral discomfort 1 (7) 
 
Due to the low numbers, further statistical analysis was considered inappropriate. 
The above analysis is sufficient to evaluate the feasibility of the study and to 
comment upon the appropriateness of the outcome framework. This discussion will 





CHAPTER 6: QUALITATIVE STUDY RESULTS AND DATA ANALYSIS 
6.1 INTRODUCTION 
The qualitative research component of this study aimed to define the essence of the 
lived experience of study participants of learning and using trans-anal irrigation 
therapy. A transcendental phenomenological methodology was employed to achieve 
this was through the use of semi-structured interviews with existing study 
participants at two time points in the study; after completion of irrigation training at 
1 month, and after 6 months of study participation. This allowed participants to 
describe their experiences of the training process as well as home use of the 
irrigation. Interviews were transcribed verbatim and key themes identified. Analysis 
of these themes was performed using a phenomenological framework, in which the 
experiences of individuals who experienced trans-anal irrigation therapy were 
captured and analysed to produce a description of the essence of the participants’ 
lived experiences.  
In order to capture as broad a range of experiences as possible, purposive sampling 
was used at each time point, with the aim of ensuring that a diverse range of 
demographics and outcomes was represented. A more detailed description of the 
study aims and methods, as well as the theoretical framework and sampling grids, 
can be found in chapter 4. The following chapter outlines the key themes that 






6.2 STUDY SAMPLE 1: AFTER COMPLETING IRRIGATION TRAINING (1-MONTH VISIT)  
A total of five study participants consented to a single interview after completing 
training in anal irrigation as laid out in the quantitative methods chapter (chapter 3). 
The first eight participants recruited to the quantitative study were considered for 
recruitment into the qualitative study. Of these, one participant had already 
completed irrigation training more than one month previously and was therefore 
ineligible. Another participant did not wish to participate (no specific reason given), 
and another could not spare the time for an additional study visit. The remaining five 
participants agreed to be interviewed and were recruited to the study. There were 
four female participants and one male. Three participants were aged under 40, two 
were aged over 40. Three participants had been using high-volume irrigation and 
two were using low volume. All interviews were conducted face to face. After each 
interview, the transcripts were read by two researchers (CE and HC) and it was 
agreed that data saturation had been reached at this point. In the following, each 
participant has been assigned a letter (A-E), and this is used alongside the irrigation 
system (‘HV’ or ‘LV) to attribute direct quotations to each participant while 
preserving their anonymity. For example, [A HV] is participant A using high-volume 
irrigation. 
6.2.1 CODING AND THEME IDENTIFICATION 
Each transcript was studied line by line and a total of 80 key words or phrases were 
identified. These were then grouped together and the following key themes 
emerged; ‘Experience of the training process’; ‘Pre-treatment expectations and 




6.2.1.1 Theme 1: Experience of the training process. 
Within this theme, key aspects were the support process infrastructure, the 
behaviour of and support from healthcare professionals (the irrigation nurses in 
particular), and participants’ attitudes towards them. Several participants expressed 
a degree of anxiety or discomfort about starting irrigation, as well as undergoing the 
pre-treatment investigations, but the contact with the healthcare professionals 
helped them overcome this. One participant stated; 
 “…I think that the training felt not as intrusive as I thought it would be, the 
questions weren’t as embarrassing, um, and I didn’t need to sort of go into details 
that I found uncomfortable, but we talked about enough past history to reach an 
understanding as to where I was and what I needed to do in the future to help my 
situation. So yeah, I quite liked the way that we talked about it, and it put me at 
ease” [B LV] 
Others reported; 
“…And I felt comfortable as well, and sometimes you think, oh, bowels, you can’t talk 
about it, it’s not a subject to talk about, but I felt comfortable and no embarrassment 
or anything. I think that was positive, I had a good rapport with all the team to be 
honest, everybody’s been great.” [D HV] 
“I was pretty nervous, but when I came I was put at ease by the nurses, 
doctors… I was quite pleased with the treatment.”[A HV] 
 “I was quite happy to go ahead and happy with the situation, and felt 




The on-going support from irrigation nurses was also highly valued by participants. 
Participants expressed reassurance at having a point of contact that they could ring 
up between sessions. This seemed to be valuable even if the participant did not need 
to contact the nurse. One participant commented; 
 “I think that at every stage, what contact with staff has done has provided 
reassurance that this is not an uncommon condition, and that there’s no one right 
way to deal with that, so there’s been flexibility and people have listened in a really 
kind of respectful way, to the problems that I’ve had, and been really kind of helpful 
in offering solutions” 
 “I think the opportunity to gain telephone support – I haven’t done that apart 
from the scheduled one, but I think that’s available, it’s helpful, and it’s reassuring to 
know that advice is there” [C HV] 
Other participants also highlighted the support from nursing staff as being valuable. 
One of these said: 
 “…she [the irrigation nurse] was very thorough, she encouraged me to ask 
questions, so, and reassuring and giving me her phone number and things so I knew 
if I had any problems there’s somebody on the phone so it was reassuring, so I think 
that was positive, knowing that.” [D HV] 
These comments highlight the importance of the nurse-patient relationship in 
successful irrigation training. One dimension of this theme is the dynamic that 
gender differences play in this relationship, and the perceived effect that this can 




participant to be interviewed emphasised that he would have felt more at ease if he 
had been trained by a male nurse, and he perceived a negative effect on his training 
experience as a result of the lack of choice. He was offered the opportunity to 
demonstrate the device in clinic (which is a common practice at the study site), but 
declined this, stating: 
 “…she [irrigation nurse] says if I could, she wanted me to try it, do a trial, in 
the hospital but I didn’t want to do it because it was a woman, I felt a bit, er, a bit 
shy, as it were.” [A HV] 
This has important implications, as some participants found the opportunity to try 
the system out in clinic to be a very helpful aspect of training although other 
(female) participants found it less helpful. One participant found it very helpful, 
describing it as “a really useful learning model”. She went on to explain; 
 “… it’s an odd kind of experience so you’re not quite sure what should be 
normal about the procedure so the opportunity just to, to kind of shout through the 
door and say ‘is this what I’m supposed to be doing, is this right?’ was really useful.” 
[C HV] 
In her opinion, she would have struggled with using the device a lot more had she 
not been able to demonstrate it in clinic; 
 “…I think it was extremely valuable. I think it goes to show that the couple of 
problems I had later… you’re trying to take in a lot of information all at once with a 
procedure that feels really unnatural, so I think there’s lots of kind of sequential 




even with all that really good explanation and opportunity there was still a lot of 
confusion for a wee while... if I hadn’t had that I think it would have been much 
worse” [C HV] 
However, another participant was offered this but declined, preferring to miss out 
this step and carry out the first irrigation at home. This was due to issues around 
embarrassment and privacy, as well as feeling that it would be straightforward 
enough to do at home: 
 “…it’s still something that I feel a bit embarrassed talking about, or doing, so I 
just preferred to do it at home” [B LV] 
This illustrates the importance of flexibility in the training process, and that it is 
essential to elicit a patient’s feelings and concerns in order to maximise the 
effectiveness of the training. 
6.2.1.2 Theme 2: Pre-treatment expectations versus actual experiences 
A common theme across all the interviews was the comparison and contrast 
between participants’ pre-conceptions about undergoing investigations and 
treatment, and the experience of doing so. 
Before beginning training, patients enrolled in the CapaCiTY 02 study underwent a 
series of radiological and physiological investigations, as outlined in Chapter 3. These 
included a colonic transit study (plain abdominal X-ray 5 days after ingesting marker 
capsules), and anorectal physiology studies. These include measurement of 




defecating proctogram originally formed part of this package but was removed 
shortly after recruitment began.  
The prospect of undergoing the investigations was a source of anxiety for some 
participants, particularly the proctogram and the anorectal physiology. It is 
interesting to note from the following excerpts that, while several of the participants 
interviewed expressed anxiety beforehand, the actual experience of using the 
treatment was perceived more positively. 
One participant stated “I thought it would be quite scary but it was fine”. When 
asked to elaborate on this, they replied; 
 “It was just the test…  …the suitability test for it, I wasn’t sure what they were 
going to be, and all these monitoring and things like that so I was a bit apprehensive 
about that but there was no issue with it at all really.” [E LV] 
Another patient was similarly anxious about undergoing investigations. They did not 
have to have the anorectal physiology, but anticipating this had clearly been a source 
of worry; 
 “I was apprehensive, and I was also thinking about what the tests were 
possibly going to be, but then when we were able to bypass that test, I thought 
‘phew!’ we can go straight on to the irrigation.” [D HV]  
Participants also had preconceptions about the nature of irrigation treatment and 
this was explored in the interviews. These ideas were formed from patients’ previous 
experiences of ‘colonic irrigation’ therapy (colonic hydrotherapy provided through 




sources such as the media, as well as the trial patient information sheet. 
Preconceptions included feeling that the procedure would be difficult to do, or that 
it would be messy or uncomfortable: 
 “I felt a bit nervous about doing the irrigation because as I say I’ve done 
colonic irrigation in the past, but since I’ve had my two children that was quite sore, 
on the second of the three occasions it was pretty sore, so I put that down to, like, 
childbirth and repercussions after that, so I was a bit worried that it would be sore, 
but it was fine” [B LV] 
 “I thought it would have been hard, I’d never done anything like that before, 
but I, I tried it, ….really…really good, I felt great with it.” [A HV] 
“Totally different to what I thought. Watching these television programmes 
where people have the irrigation and you’re thinking ‘oh, this is going to be really 
messy’, but it wasn’t. I don’t know what I was expecting, lots of stuff to come away 
and thinking ‘oh, there’s going to be mess, lots and lots of mess’ but it’s just the 
water that’s gone in comes back out, so that was a bit of a shock, cos I was thinking 
‘am I doing it right?’ cos it just seems to be clear water coming back and obviously 
<research nurse> has explained yeah that’s quite natural, so…” [D HV] 
One patient expressed disappointment that they had had to start irrigation therapy 
at all, commenting that they already felt they were ‘not normal’ as a result of their 
condition, and that having to do something ‘mechanical’ like trans-anal irrigation 




 “I suppose just psychologically, you know, living with this condition kind of 
over the years, you already feel that things are not normal, that your body’s not 
working the same as other people’s are, so I think that having to do something to 
mechanical feels… it feels disappointing, it feels like actually, why is my body not kind 
of responding the way that it should. So there’s a bit of a sense of disappointment 
that it has come to the fact that you have to, you know, do something extra.” [C HV] 
This participant expressed a preference for taking medication rather than using the 
irrigation; when asked if they felt their condition was being ‘medicalised’ by 
irrigation treatment, they replied: 
 “Possibly yes, I don’t know why that comparison as opposed to taking pills 
kind of for, you know, for years cos that’s medicalising it too, but I suppose it  is more 
the.. it is easier in some ways to kind of pop a pill, than it is to get all the kit out and 
kind of take the time and then, you know, be in the loo for that amount of time, but 
then I appreciate that there are going to be side effects and disadvantages to 
medication so it is certainly useful to try something that may not give them side 
effects.” [C HV] 
One further interesting aspect to this theme was that before starting treatment, 
some participants expressed a preference for one system or other. Some 
participants based this on their own conceptualisation of the effects of each system, 




 “I remember thinking I hoped I was going to be allocated to the low-volume 
kind of condition, just because intuitively it feels like pumping a reduced amount of 
water would be kind of easier and better” [C HV] 
 “Just intuitively it doesn’t feel kind of natural or normal to be pumping water 
up, you know… … So it kind of felt like actually it would be less comfortable, the kind 
of higher volume would be more uncomfortable than the lower volume” [C HV] 
 “I think I was happy to be honest, I don’t know if it’s [High-volume irrigation] 
a better type of irrigation, but the way I was reading it I thought it would suit my 
symptoms better, so…” [D HV] 
A further participant based their preference on previous (negative) experiences with 
‘colonic irrigation’ therapy; 
“I think I was quite happy to do the low one… … I thought the higher one 
would be more like the colonic irrigation, more painful or more intense.” [B LV] 
 “I just thought there’d be a lot more water and that it would be a lot higher 
pressure. When I did the colonic irrigation they would increase the pressure a lot until 
it was quite painful and then sort of let it go and it would pull everything out, so it 
doesn’t feel like that, it just feels, Um, obviously there’s a lot less water and it’s just 
quite sort of relaxing really” [B LV] 
 “…it’s been very straightforward, and just enough really. I have been doing it 
sort of three squirts each time just to feel that it was quite clean and well done, 




many times. I don’t know, obviously I’ve got nothing to compare with, but yeah, it’s a 
lot different to the colonic irrigation that I’d experienced.” [B LV] 
The transition from the theoretical explanation given in clinic to regular home use 
was another aspect that participants described. One participant found the practical 
aspects of the procedure easier to master than they had expected, and learned 
rapidly how to use it at home: 
 “I thought it was a lot, a lot easier than when you talk about it… … I said I’d 
try it at home, I tried it at home, it was a piece of cake!  
“The first trial was a bit messy on the floor like, with the water on but I tried it 
again and it was quite good but I was sitting this way, I’m right handed;  I had the 
pump on the left hand side so I had to use me right hand and it’s a bit awkward with 
[disability]…<mumbles>…It were great the second time.”[A HV] 
Other patients described positive aspects of using irrigation despite the fact that it 
was not especially effective for them: 
 “Quite easy, yeah, once you get the hang of it. Yeah, it’s quite straightforward 
and you know, you get all the, you know, the throw-away nozzles and it’s all hygienic 
and clean and, you know, it’s fine, yeah fine.”[E LV] 
 “ I don’t know if it’s good about using the treatment in terms of positive 
benefits yet, but I think it’s less bothersome that I first feared it might be. So there’s a 
practice effect clearly, you get used to the routine, it’s not as troublesome as it 




6.2.1.3 Theme 3: Attitudes towards, and experience of, using irrigation 
Participants reported a broad range of attitudes and experiences with regard to 
using irrigation at home. Especially prominent aspects of this included fitting the 
treatment into their daily routine, and finding their own way of using it in order to 
maximise benefit. Elements of this theme that emerged included the importance of 
‘privacy’ and ‘routine’, as well as overcoming some of the technical challenges of the 
procedure. One participant highlighted the differences between using the irrigation 
in the clinic setting and transferring that to their own home environment: 
 “It seemed a bit harder at home, thinking well, I haven’t got this nice little 
sink and I haven’t got the bed with the paper thing, and it was just, right, where do I 
get comfortable, what position do I need to be in, and, two or three times and you 
got used to your own routine.” [D HV] 
The concept of ‘routine’ was common to several participants, along with the logistics 
of setting up the device in the home. Nested within this was the importance of 
privacy and finding a quiet place to perform irrigation. One participant described 
their experience as follows: 
 “…some days I come round to doing it and think I can’t really be bothered to 
go through all the setting up, but once I’ve decided right, I’m going to do it and I’ve 
locked myself in with my jug of water then it’s easy to do; it’s just the initial going in 
and setting it all up, but it takes seconds to do, so once I’ve got in the frame of mind 
that I’ve got some time to myself then it definitely helps me feel a lot better, makes 




“I think [privacy has] been an issue in the past when at work when I was a 
teacher I felt that I could only go to the toilet at definite times, um, and even going 
back to school in the multiple toilet block you didn’t want to go to the toilet and sort 
of pass anything for fear of the noise and smell and things like that, so I just became 
over the years able to hold it in. But now, with the children as well, they like to come 
into the toilet with me and it’s obviously a bit of an issue of they would say things to 
people if I did anything, so I like to be completely on my own with the door locked, 
even in my own house, then I feel like mentally ready to try and pass something.” [B 
LV] 
Other participants gave a clear picture of how they had incorporated the irrigation 
into their regular schedule: 
 “Doing it at the same time every day, I thought if I try and build it into sort of 
like shower time, on a night, right; 15 minutes before shower time this is what’s 
going to happen and then sort of knowing there’s going to be no disruptions, I know 
there’s nobody going to knock on the door, everything’s locked up so that helped, 
doing it at the same time every day” [D HV] 
 “Fine, it’s fine to fit in, it’s easy enough it’s just, you know, obviously you’ve 
got to be at home and everything and things need to be close by, and a bit of privacy 
and things like that, so. But it’s fitted in fine, cos I’ve been quite housebound with 




“…but I think it’s less bothersome that I first feared it might be. So there’s a 
practice effect clearly, you get used to the routine, it’s not as troublesome as it 
originally was.” [C HV] 
Technical problems were encountered by some participants in the early stages of 
using the treatment. Two participants described feeling as if the issues they 
experienced were ‘my fault’ or down to ‘stupidity’ on their part, rather than due to 
inadequate training: 
 “A bit of technical issue with too much air in the tubes and I was inserting the 
air rather than the water which wasn’t very pleasant but that’s my fault for not 
setting it up properly so I wouldn’t say there’s anything negative to do with the 
treatment at all” [D HV] 
 “I encountered a kind of blip that was more my kind of stupidity just in the 
first few trials of it, in that I was turning the kind of device the wrong way round so 
rather than just go to the kind of, the, you know, the kind of white balloon, I was 
skipping round via the green so the balloon was deflating. I worked out that in a 
couple of days, so I suppose the procedure was well explained, I feel that I 
understand it and I’m kind of getting on with it really”[C HV] 
Another participant described getting used to managing the device with a physical 
disability  
 “The first trial was a bit messy on the floor like, with the water on but I tried it 




pump on the left hand side so I had to use me right hand and it’s a bit awkward with 
me (disability)…<mumbles>…It were great the second time.” [A HV] 
One patient actually described the fact that they had to form a routine as having a 
therapeutic benefit in itself, as it caused them to focus on emptying their bowels 
more regularly. When asked what the best aspect of using treatment was, they 
replied: 
 “Probably the routine again, that it’s given me something to focus on every 
day, that I need to give myself 10 minutes on my own and the toilet to actually try 
and do something about the issue.” [B LV] 
In addition to the practical aspects of using treatment, another commonly-expressed 
theme was the idea that it was still ‘early days’, and that they were hoping 
treatment would become more effective or better for them over time. This view was 
expressed most often by patients who had not found the treatment to be very 
effective up to that point, as one might expect, but also by those who had tried 
other therapies and found that they only brought short-term benefits. 
 “I think maybe in another month or so I’ll be able to feel the benefits; at the 
moment I probably do feel a bit better, but I’ve gone through like trying different 
things and feeling better and feeling worse so at the moment it definitely feels like 
it’s making some impact” [B LV] 
 “…it’s only three weeks in… … I’m committed to kind of, you know, to keep 




 “I’m just happy to keep trying and hopefully see if we get some more positive 
results from this, cos it is early days” [D HV] 
One further aspect of this theme was participants’ willingness to try treatments, and 
the fact that they tolerated treatment well even if it was not as effective as they had 
hoped. This reflects the extremely negative impact that constipation symptoms may 
have on quality of life. One participant described their experiences of living with the 
condition: 
 “Well I suppose it’s reflecting over almost a 30-year period, and it’s just you 
become used to a kind of general level of misery, specifically about kind of, bowel 
habits, really. So travelling was difficult, you know, just the kind of normality or the 
regularity of being able to go and kind of empty your bowels the way everybody else 
did, just never happened for me, so there’d be that constant sense of having a full 
bowel, discomfort, you know, abdominal discomfort and not being sure kind of what 
to do about that.” [C HV] 
 “I think that the initial treatment that I had was so, I know it sounds dramatic, 
but was so life-changing that I’m not sure I’m seeing a stepwise improvement from 
the irrigation if you see what I mean. Those early kind of periods of advice were 
wonderful, I can’t praise them highly enough.” [C HV] 
  Participants frequently compared and contrasted irrigation therapy with previous 
treatments, both in terms of the practical aspects of using irrigation and also in 





 “I think that it’s the time that it takes to do it. I know you maybe think 15-20 
minutes isn’t a long time but I suppose you know, well, I could just pop a laxative in 
and in 30 seconds it might do a similar job, or a suppository doesn’t take that time, I 
think it’s just sort of setting it up and the time it takes, just trying to build it into your 
routine” [D HV] 
Despite this, and the perceived lack of efficacy of the treatment, they would 
recommend it to other people, stating: 
 “I’d try anything… … You’ve got to try everything, cos what suits one person 
might not suit another, and if it just eases your symptoms a little bit it’s doing 
something rather than being in pain and suffering. I’d certainly give it a go.” [D HV] 
Another patient found the experience of using irrigation superior to laxative use in 
terms of the practicalities, although the treatment was ineffective for her: 
“…and I’d have been happy to continue it every day, the rest of my life if I had 
to, you know, rather than take laxatives” [E LV] 
However, the experience of side effects were one negative aspect of using treatment 
described by several participants. The degree to which they were tolerated seemed 
to be related to the effectiveness or otherwise of treatment. One participant using 
high-volume irrigation experienced involuntary leakage of water between irrigations, 
something they described as a “potential deal-breaker”, especially as the treatment 
had not brought them much benefit.  
 “ I guess what I’m finding is that problem, that side effect that I’m having 




not feeling that  I’m getting a bowel-emptying  yet from the process, I’m rarely 
passing stool, you know, I’m evacuating water but I’m not doing much more than 
that at this point. Again, that may change so I’m happy to persist to see”. [C HV] 
However another participant who described peri-anal discomfort found this much 
more manageable, and worth going through for the sake of the benefit they were 
getting from treatment. 
 “Um, probably just the slight pain, or the discomfort rather, on the first time 
that I use it. I try to use it three times each session, and the first time that the probe 
goes in it’s always quite sore, so that’s probably the worst bit that I don’t look 
forward to.”[B LV] 
 
It was also interesting to note that one participant spoke more broadly about their 
experiences of participating in research in general: 
 “It’s just that I think that it is really reassuring to know that, as I said before, 
that this is a focus of research, to know that it’s not simply a condition that people 
don’t talk about and you shouldn’t mention, to know that something actively is 
happening.” [C HV] 
It therefore seems that, for this participant, the act of participating in research was, 
in a way, reassuring and beneficial. It is hard to know whether this had any 




These themes illustrate the broad range of lived experiences described by chronic 
constipation patients during training and initial home use of trans-anal irrigation 
therapy. In particular, they demonstrate how the particular attitudes and pre-
treatment experiences of the individual participant can have a significant impact on 
their experience.  
6.3 STUDY SAMPLE 2: AFTER 6 MONTHS OF STUDY PARTICIPATION 
Following on from the themes identified above, further face-to-face interviews were 
conducted after 6 months of study participation, in order to identify new themes 
specific to longer-term use of irrigation, or reasons for discontinuing therapy. This 
also provided an opportunity to re-visit and re-explore some of the themes from the 
previous interviews, in order to deepen and enrich the description of the 
participants’ lived experiences. However, it should be noted that the delays in 
commencing study recruitment, combined with the fact that several patients either 
declined to be interviewed or were unable to travel to the hospital for an additional 
visit, meant that the pool of potential interviewees was smaller than had been 
hoped for initially. Therefore the heterogeneity of the study sample was limited, and 
there was a corresponding lack of depth to the range of experiences discussed. It can 
therefore be said that data saturation has not been reached at this stage. However, 
given that this study is nested within the much larger, multi-site CapaCiTY 02 trial, 
this data provides the first fully described into the phenomenon.  
 Of the participants who had been in the study for at least six months, three were 
willing and able to give consent for a further interview. Of these, one male 




interviewed at the 1-month time-point as well. Of these three, one was still using HV 
irrigation, one was still using LV, and the other had discontinued HV irrigation after 
less than three months. They were anonymised in the same way by being assigned a 
letter (A-C) and an irrigation system (‘HV’ for high volume and ‘LV’ for low volume). 
Additionally, patients were categorised as ‘early discontinuation’ (ED), or ‘continuing 
use’ (CU). 
6.3.1 CODING AND THEME IDENTIFICATION 
As for the previous interviews, transcripts were reviewed and significant words and 
statements were identified; these three interviews yielded 132 such statements. 
These were grouped together into 21 categories, and then into four broader 
‘themes’, as follows: ‘Treatment efficacy’; ‘Practicalities of treatment use’; ‘Impact of 
treatment on wider health and daily life’; ‘Attitudes towards treatment’ 
6.3.1.1 Theme 1: Treatment efficacy 
For all patients interviewed, their perceived treatment efficacy was seen as a very 
significant factor in determining whether they continued to use the treatment, and 
what effect it had on other aspects of their life. Of the three patients, two felt that 
they were still deriving benefit from irrigation after 6 months (one HV, one LV). The 
other patient had discontinued treatment after approximately six weeks of use. 
When asked about their reasons for stopping, they replied: 
 “I didn’t find it was benefitting the symptoms I had; my main symptoms were 
the bloating , so it just didn’t seem to help that so I didn’t feel the need to carry on 




They went on to elaborate that, while they had not found the treatment especially 
difficult or unpleasant to use (see theme 2 below), the lack of efficacy meant it was 
not worth persisting with treatment. 
 “…it didn’t help with any of the symptoms that I had, so, and a lot of the 
substance I was passing just seemed to be watery, there was not a lot of colour in the 
water and things, which [irrigation nurse] said is quite normal anyway, but I just 
didn’t feel it helped” [C HV ED] 
 “I just didn’t want to feel like wasting anybody’s time cos I know you’re all 
busy and you’ve got other patients and I thought, well, if it’s not helping me it might 
be beneficial for someone else to try it” [C HV ED] 
The reference to their main symptom being the bloating was revealing, as it 
demonstrates that particular symptoms will be important to particular patients, and 
that this influences their experience of illness, and therefore informs their attitude 
towards therapy. Bloating was a significant symptom for another participant, but 
they were getting considerable relief from using the irrigation: 
 “I get a really bloated tummy, a really hard tummy, and I don’t know if it’s 
just in my mind or whether it’s definitely working but when I use the irrigation system 
it definitely makes me feel a bit lighter, and able to sort of get rid of maybe the 





Another patient who had persisted with using high-volume irrigation described their 
main symptoms as incomplete evacuation and straining to pass small bowel 
motions, resulting in frequent trips to the toilet: 
 “I can go 5-6 times and not pass anything, and just maybe go, out of the 5-6 
times go once, and just pass half a small finger worth of stool. And I’m wanting to go 
all the time, edgy, on my seat all the time” [A HV CU] 
However, the perceived impact of the treatment for this particular patient was 
dramatic. They said it “worked…100%” and commented; 
 “so I use the water solution and I, it’s there, you just do it straight away, use 
it, you go outside, walk around, clear; if you don’t use it you’re stuck indoors all day” 
[A HV CU] 
Participants’ perceptions of the mode of action of treatment, and how they felt it 
was working, was a further aspect to this theme. One participant commented that 
the sensation/perception of the water going in, and feeling it working, was a 
significant reason why they had persisted with the treatment. They felt that this gave 
the irrigation a clear advantage over some of the oral agents they had tried 
previously: 
 “I think it’s the actual feeling of the water going in and the pressure, a bit like 
colonic irrigation that I’ve tried before, that makes you… it comes out naturally 




This description of bowel motions as being more ‘natural’ with the irrigation was 
only described by one participant, but it was a theme that occurred several time 
during the interview: 
 “it’s not like the products where it’s making me want to go, it actually makes 
it come out with the water, so, um, I don’t need to sort of worry about having to hold 
it in, it just, it comes naturally, so I definitely think this is better than the sachets and 
things like that that I’ve taken in the past” [B LV CU] 
 “I don’t really need to push or do anything, I just go to the toilet, use it and it 
comes out and then after a minute or so I just leave. So, yeah, it’s a different way of 
thinking” [B LV CU] 
This perception can be contrasted with the feelings of another patient interviewed 
at one month (see section 6.2.1.2), who felt that the irrigation was ‘mechanical’ and 
having to use it reinforced their sense of things being abnormal.  
Tied in with the theme of treatment efficacy is the effect of the passage of time. As 
detailed in section 6.2.1.3, several participants expressed the view that, after one 
month, it was still ‘early days’ and they hoped that the treatment would be more 
effective as time went on. Having interviewed participants after six months, diverse 
experiences of temporal aspects emerge. One participant [C] discontinued due to 
lack of perceived treatment effect as outlined previously. However, another 





 “I think it’s got better, um, I think it’s helped more over the time but, um, I 
think I sort of sit and let it work for a longer period of time than I used to so I think 
it’s more beneficial now, but as I say I definitely notice when I haven’t used it for a 
couple of days.”  [B LV CU] 
This idea of symptoms relapsing if therapy was discontinued was important to both 
participants who were continuing to use the treatment. Participant B describes 
above how they notice the difference after a few days of not using the treatment. 
They also describe a degree of anxiety about symptom relapse if they omit this 
treatment, and stated that this was an important factor in making the effort to use 
it: 
 “…I feel that I still need to do it and get in the routine of doing it cos 
sometimes I can go a couple of days without doing it properly, um, and yeah it’s just 
got into a bit of a routine, I’m a bit scared that if I stop doing it then I’ll just go back, 
go backwards.” [B LV CU] 
Additionally, there was an episode when ill health prevented them from using the 
irrigation for a period of time, leading to a relapse in symptoms; 
 “…I did stop for maybe a week or so, um, cos of the anxiety that I was 
suffering from and I did notice then that it seemed to be worse…” [B LV CU] 
Another participant reported stopping the irrigation to see if the benefit was 




 “If I don’t use it I could be on the toilet three quarters of an hour, and it’s the 
size of your small finger, and then you finish, give up, walk downstairs, the feeling’s 
there that you want to go again; so you go back upstairs, nothing. 
 “I tried doing without it [the irrigation] and you can’t do it” [A HV CU] 
The various aspects of this theme demonstrate the breadth of different experiences 
described by participants in this study, even though numbers are small. This 
highlights the highly individualised lived experiences seen amongst this patient 
group. 
6.3.1.2 Theme 2: Practicalities of treatment use  
Interviewing participants after a longer period of treatment use allowed for a focus 
on the practical aspects of treatment. At the one-month stage, participants 
described a ‘practice effect’ (that is, a learning curve), and a process of getting used 
to using the treatment at home and fitting it into their daily routine. Amongst the 
two participants who continued with irrigation, this theme emerged again in a 
number of ways. One patient reflected on their initial difficulties that were quickly 
overcome, and gave a detailed description of the process of using the irrigation in 
relation to bodily position and use of the equipment; 
 “…over the weeks it was, it came, came to us, just, you know, quite easy to 
use, as long as you sit on the toilet, upright, relax, take your time, let it go, flush 
through your system, And it works really good” [A HV CU] 
 “…if you sit upright on the toilet, back straight, relax yourself, it just goes 




They also commented on how the initial experience of being trained by the irrigation 
nurse was relevant to their own experiences of using it independently, and how they 
had adapted this technique to suit them; 
 “I was… what <irrigation nurse> says… showed us how to use it, I’ve used it 
that way. You improve slightly; you do better the next time you do it. You hang it up 
on… you know, your bag up. You improve what you’re doing and you just… I get up 
on a morning, get out me bag, fill up with water, hang it up, straight away ok.” [A HV 
CU] 
Another participant described the process of incorporating irrigation into their daily 
routine, but emphasised the difficulties they were having fitting this in around their 
family commitments. Nonetheless, because of the perceived benefits they were 
getting, this was something that they were prepared to make an effort to do: 
 “…sometimes it’s quite restrictive, in that it’s hard to fit it into my daily life. 
Sometimes I get into a routine with the children and sort of forget about doing it. But 
I do notice if I haven’t done it for a couple of days that I get a really bloated tummy, a 
really hard tummy… 
 “…if I haven’t used it for a couple of days it’s quite easy to get into a routine 
of just ignoring it again. 
“It’s not always easy for me to do it first thing in the morning, um, but I try 
and do it around tea time, and that’s quite a good time for me to fit it in, um, and I 




The participant who discontinued treatment described a similar process of 
overcoming minor technical problems and incorporating it into a routine, which they 
achieved without too many problems; they said that, had the treatment been 
effective, they would have happily continued to use it. 
 “it was absolutely fine, it was easy to set up, it was all explained well by 
[irrigation nurse] and yourself, and [research nurse] had some input. Um, once I got 
used to it, it was relatively easy and didn’t take much time up 
 “…after a couple of times, a little bit  technical issues to start with, where  too 
much water, not enough, too much air in the system, but once you got a couple of 
days out of the way it was fairly easy.”[C HV ED] 
When asked how easy it had been to fit the irrigation into their daily routine, this 
participant replied: 
 “Oh, really easy, yeah. I tended to stick to it the same time every night, so it 
was shower time; do your treatment, go and have a shower, so it was just 10 minutes 
out yer day” [C HV ED] 
Only one of the participants experienced significant adverse events of treatment, as 
they developed anal pain which persisted on most occasions that they used the 
treatment despite taking measures to prevent this: 
 “Just sometimes it’s sore, it’s usually sore on the first time that I use it, 
particularly if it’s been a couple of days since I’ve used it, even if I sort of, um, wet the 
end of it to lubricate it it’s still quite sore when I put it inside, um, so that sort of 




obviously when I use it the second time then it’s ok. But I’d say generally most of the 
time on the first time that I’ve used it, it’s been quite sore” [B LV CU] 
Although this was clearly an unsatisfactory aspect of the treatment, when asked if 
this was something they were prepared to accept if the benefits of therapy were 
maintained, they replied: 
 “Well it would be nice to be different but yeah, I’m willing to accept it because 
I think the benefits outweigh that problem. At the beginning of the trial when the 
nurse did some sort of invasive investigations it was quite sore when she did that so I 
don’t know if there’s an issue that needs to be resolved, I thought it was something 
that would just go away with time but it’s continued, or whether it’s just part and 
parcel of this treatment that I’m following, but it’s definitely worth, it’s manageable. 
It’s not terrible, the pain, it’s just uncomfortable” [B LV CU] 
The participants held contrasting opinions on how irrigation compared with drug 
treatments or other therapies. These attitudes seemed to tie in strongly with other 
aspects of the participants’ experience of illness and what it meant to them.  
In contrast, another participant described how they would rather use a tablet if it 
gave them the same effect, however no medications had worked before trying the 
irrigation so they were happy to continue. 
 “If there was a tablet, a medical tablet what you could give and it gets rid of 
that ‘you could go to the toilet all the time’ I would take it but at the moment there’s 
none. At the moment I’m on the water irrigation and it helps me 100%, so if I stop on 




6.3.1.3 Theme 3: impact of treatment on wider health and daily life 
This theme ties in strongly with treatment efficacy; however, participants made 
several statements about the impact trans-anal irrigation has had on their wider 
health that shed some light on the complex nature and impact of their constipation 
symptoms, and illustrate how a particular therapy can have effects beyond simply 
improving these. Therefore these particular elements of the participants’ experience 
are discussed here. 
One participant gave a clear account of how the constipation symptoms were 
affecting them, causing them to not be able to go out when they wanted due to a 
constant feeling of incomplete evacuation and straining to pass small bowel 
motions. These symptoms were made significantly better by using the irrigation, and 
the participant was extremely happy about this. This is how they described the 
difference: 
 “well If I don’t use it, I’m wanting to go to the toilet all day. I can go 5-6 times 
and not pass anything, and just maybe go, out of the 5-6 times go once, and just pass 
half a small finger worth of stool. And I’m wanting to go all the time, edgy, on my 
seat all the time, so I use the water solution and I, it’s there, you just do it straight 
away, use it, you go outside, walk around, clear; if you don’t use it you’re stuck 
indoors all day.” [A HV CU] 
 “Before I was using it I wasn’t, I wasn’t going out anywhere. I was staying in, 
watching what I was eating, trying to eat wholemeal bread, things what make you 




Cancelled holidays, cancelled a holiday to Mallorca for 2  weeks, full board; didn’t go. 
Me wife went, me daughters went, I stopped at home.” [A HV CU] 
This had clearly made a very significant difference to their quality of life. One specific 
example of this (from the same participant) was as follows: 
 “See I like to go out with the dog and I’m out maybe three hours, four hours 
with the dog, walking her. I’ve got nowhere to go to the toilet if I’m out with the dog, 
if I don’t use it. I’ve got the feeling of wanting to go to the toilet and I want to take 
her out and run straight back home to go to the toilet and when I get back home, 
can’t do anything.  
 “So when I use the irrigation once a day in the morning, I’ll be out all day.” [A 
HV CU] 
These examples illustrate the broader benefits that effective therapy has brought to 
this particular individual. They show in a vivid way how restrictive chronic 
constipation can be.  
For another participant, one very significant aspect of the treatment was the fact 
that it gave them time each day to try and have a bowel motion, whereas previously 
this participant had been in the habit of trying to ‘hold on’ and ‘turn off’ the feeling 
of needing to go to the toilet, which they felt had been exacerbating their symptoms. 
This idea of habit-forming and habit-breaking came across very strongly in the 
interview: 
 “for the whole of my life really I’ve been able to just sort of squeeze it in and 




for maybe 2 weeks without going to the toilet, but it’s quite easy for me to turn off 
the feelings of needing to go…” [B LV CU] 
They went on to describe how they would slip back into old habits if they omitted to 
use the irrigation: 
 “if I don’t get into the routine of using the irrigation system it goes quite 
quickly back into the old routine, so you just have to try to get into the way of doing it 
a specific time every day, when I’ve got a bit of time away from the children, and I 
can be without interruption.” [B LV CU] 
This participant gave a vivid and clear insight into the thought process behind the 
bad habits they had developed over the years, and how doing the irrigation had 
caused them to think differently about their toileting habits: 
 “…it’s a weird feeling, it’s almost like an achievement that I feel that it’s, er… I 
don’t like it at the time, it sort of brings a few tears to my eyes sometimes when I sort 
of hold it in and it can take like a minute or two for the feeling to pass but then once 
it’s gone and I feel like  ‘oh, I’m back to,  I’ll just get back on with my life’. So I don’t 
know, I understand when I’m saying it out loud that it’s not a good thing to do, um, 
that it seems a strange thing to do but I think I’ve just always done it since I was a 
child, so, um, I think when I was a child I didn’t want to stop playing or I didn’t want 
to stop doing what I was doing, so I didn’t like going to the toilet for a long period of 
time, so I’d just hold it in and after a minute or two I’d just get back on with it, so I’ve 




push or do anything, I just go to the toilet, use it and it comes out and then after a 
minute or so I just leave. So, yeah, it’s a different way of thinking” [B LV CU] 
Looking beyond constipation and bowel function, this participant also talked about 
how using the irrigation had brought about positive changes in other areas of their 
life. For example, they described the feeling of excess bloating and having a hard 
abdomen, and wearing baggier clothes to conceal that. This had an adverse impact 
on how the participant viewed themselves, and on body image: 
 “…it makes me feel like I’m a lot bigger than I am 
 “But that’s always been the case, so I like to wear sort of clothes that are a bit 
baggier” [B LV CU] 
They felt that the irrigation treatment had improved things in this area, stating  
“Yeah, it definitely does [help], yeah. It helps a bit”.  
They also reflected on their long-term health, and reported feeling that the 
constipation would have an adverse effect on this, especially in view of the fact that 
a family member had recently been diagnosed with a serious bowel condition. They 
commented: 
 “I was concerned at the beginning it would have an adverse long-term effect 
on my health, so I feel that when I’m using it then at least I’m making some kind of 
positive effort to, to become more healthy” 
 “…the trial’s gone hand in hand with the anxiety I’ve suffered since Christmas 




and that, that helps as well. But yeah, so I think they probably go hand in hand, that 
the lighter I feel the more I want to exercise, the more energy I have.” [B LV CU] 
These statements illustrate some of the ways in which bowel symptoms, and 
effective treatment for these, can have a profound effect on many aspects of 
patients’ quality of life. 
6.3.1.4 Theme 4: Attitudes towards treatment 
This theme uncovered participants’ views on the treatment, irrespective of whether 
or not it worked. Key aspects of this theme included participants’ willingness to try 
new treatments (due to the high symptom burden and lack of success of previous 
therapies), and whether they would recommend this therapy to others.  
While a key reason given for discontinuing therapy was perceived lack of efficacy, 
the participant in this study who discontinued treatment after a short time 
nonetheless expressed positive opinions about it: 
 “Oh, I would try anything, so I’m open to trying any treatment, so it didn’t 
panic me or concern me when they mentioned irrigation 
 “…Nothing nasty or awful about it. People might think ‘ooh, it’s not clean or 
hygienic’ and you read different things, but no, I didn’t have any concerns 
 “I’m quite happy to have tried it, and just unfortunately it didn’t work!” [C HV 
ED] 
When asked if they would recommend trans-anal irrigation therapy to someone with 




 “I would, I would say try anything, personally. If you don’t try it you don’t 
know it’s not suitable or if it is suitable, everybody’s different 
 “It’s not unpleasant; it’s nothing to be embarrassed about. You fit it into your 
daily routine easily, it’s quick to use, it’s discrete; the packaging comes nobody knows 
what you’re getting delivered, and if it works just try it, and if it is working keep 
going.” [C HV ED] 
Participants who had derived benefit from therapy also made very positive 
statements about it. One participant stated: 
 “I’m really satisfied with it; I’d recommend it to anybody. I’d probably go 
round the hospital and show people how to use it!” [A HV CU] 
When asked about how they would feel if they had to continue using irrigation long-
term, this participant replied “[I’m] happy to carry on forever… …if it helped us, yes”.  
Another participant had experienced side effects that they clearly found unpleasant. 
However, they still felt they were deriving sufficient benefit from using the irrigation, 
stating: 
 “Well it would be nice to be different but yeah, I’m willing to accept it [the 
side effects] because I think the benefits outweigh that problem… …I thought it was 
something that would just go away with time but it’s continued, or whether it’s just 
part and parcel of this treatment that I’m following, but it’s definitely worth, it’s 




When asked whether they would recommend the treatment they responded “yeah, 
definitely, I think it gives you peace of mind”. 
This provides some idea of the spectrum of different perspectives on the therapy 
seen in a relatively small study population. Due to the small number of participants 
and the lack of representation from some key groups within the study (for example, 
those who switched therapy and those who discontinued later), it cannot be said 
that data saturation has been reached for the six-month time point. However, the 
themes that have emerged are highly instructive, and add to our understanding of 
the experiences of patients using trans-anal irrigation therapy for chronic 
constipation. 
6.4 DISCUSSION: THE ESSENCE OF THE LIVED EXPERIENCES OF STUDY PARTCIPANTS 
This qualitative enquiry has identified a range of themes and statements from a 
variety of participants that can inform our understanding of the lived experience of 
patients who begin using trans-anal irrigation therapy as a treatment for chronic 
constipation. It has already been suggested in the literature that patients with 
functional and/or other defecatory disorders have had many negative experiences of 
healthcare, including unsatisfactory or ineffective treatment, difficulties in accessing 
healthcare and pejorative attitudes towards them from health professionals 
(92)(93). A previous qualitative study into rectal irrigation had found a range of pre- 
and post- treatment experiences ranging from finding the treatment burdensome, to 




To understand the participants’ experiences of irrigation training and home use, it is 
necessary to set these relatively recent short-term experiences within the much 
more complex long-term context of the participants’ experiences of living with 
chronic constipation. Talking to these participants, it is evident that many of them 
have had strongly negative experiences of their condition over the long-term.  
Several spoke about feeling ‘not normal’ or embarrassed by their condition, as well 
as being severely limited by it in terms of what activities they feel able to undertake. 
Furthermore, chronic constipation is not precisely defined and represents a cluster 
of symptoms; the most significant symptom or symptoms described by a particular 
individual varies significantly between participants. Understanding these broader 
aspects is essential in trying to contextualise a particular individual’s experiences 
with irrigation. 
As regards the irrigation training itself, many interviewees expressed appreciation 
for the irrigation nurses, commenting especially on feeling well-supported and 
feeling at ease in the clinic setting, despite many of them feeling apprehensive 
beforehand. This aspect of clinical care appears to be especially important in a 
patient group who have sometimes had negative experiences of healthcare (92)(38). 
However, it should be noted that the interviews were conducted by a member of the 
clinical team and that this may have resulted in participants being unwilling 
(consciously or unconsciously) to be critical of the care they received. This was one 
potential limitation of this study. It is also possible that patients felt able to be more 
frank and willing to talk honestly about private bodily functions more easily to a 




establish a more complete picture of this element of the patient experience; 
interviews away from the clinical environment, and conducted by interviewers with 
little direct involvement in participants’ clinical care, may give a more complete 
description.  
Following on from the theme of anxiety and embarrassment, it is interesting to note 
that participants expressed a range of differing opinions about aspects of the 
training itself, in particular they were divided on whether carrying out an irrigation in 
the clinic setting was beneficial. Some did not want to do this as it made them feel ill 
at ease,  either due to feeling of embarrassment about their condition, or because 
they were not comfortable being shown by a nurse of the opposite sex. This serves 
to highlight the importance of cultivating good relationships with individual patients, 
and maintaining sufficient flexibility in the training to tailor this to the needs of the 
individual. In addition, it should be recognised that patients have a number of pre-
conceived ideas and attitudes towards trans-anal irrigation therapy and what this 
involves. This study has shown that these may be based either on media sources, the 
study patient information sheet, or on their own experiences of undergoing ‘colonic 
irrigation’ privately. These preconceptions may have a strong effect on how patients 
feel about starting therapy. For instance, in this study one participant spoke of their 
disappointment in having to do something ‘mechanical’ in order to treat their 
constipation. Others spoke about having a preference for one system or the other 
based on what they had read about each one, and how this related to their previous 





The next stage in the patients’ experience concerned adapting the training to their 
own home circumstances and daily routine. There was a commonly-described 
process of learning to use the irrigation, with several participants describing initial 
technical difficulties and practical problems, but it appeared these were swiftly 
overcome. The statements made about this process offer a clear insight into what it 
is like for people to use irrigation at home. Several participants also emphasised the 
importance of finding a private and quiet place in order to carry out the irrigation. 
One participant was actually glad to have the irrigation as they felt it gave them 
focus and made them take the time to go to the toilet, while previously they were in 
the habit of holding stool in and thereby exacerbating their symptoms.  
Once the treatment was an established part of their daily routine, the reported 
experiences of the participants then began to differ markedly, largely based on how 
effective the treatment was perceived to be. Effectiveness of treatment emerged as 
a very significant theme at both time points, and participants’ perception of how 
well (or otherwise) the irrigation therapy was working for their particular illness had 
a very significant bearing on their attitude towards it, and in particular whether they 
persisted with treatment.  
Participants for whom treatment was effective described a sense of freedom and of 
re-gaining control, of being able to break bad habits, and of being able to go 
outdoors for longer without the same degree of anxiety they were experiencing 
previously. One participant, for whom treatment was very effective, described a 





On the other hand, if the treatment was not effective then participants did not 
describe any improvement in their quality of life, and their experiences were nothing 
like as positive. Interestingly, these participants described few negative aspects to 
the therapy besides the lack of efficacy. They were in agreement that if the 
treatment worked, they would happily carry on. One did describe one particular side 
effect (post defecation leakage) as a potential ‘deal-breaker’, and also commented 
on the time it takes to perform irrigation as being a disadvantage, however these 
issues seemed to be much less important in comparison to the symptoms 
experienced. 
In the longer term, continuing use of irrigation (if successfully treating symptoms) 
seemed to bring about more wide-raging health benefits, and to improve the 
participants’ quality of life in a more general sense. Participants described reduced 
anxiety, increased social participation, improved body image and an increased sense 
of control and ownership over their own health. This demonstrated that effective 
treatment can have wide-ranging health benefit for the individual. These effects are 
almost certainly not specific to trans-anal irrigation, and indeed some participants 
expressed the opinion that they would rather take a tablet than do the irrigation, if it 
had the same effect. One participant compared the irrigation (which had not been 
especially effective at that stage) with an oral treatment they had tried initially 
(prucalopride), which had a ‘life-changing’ effect on their symptoms. Others, 
however, reported that they preferred to use the irrigation and that it suited them 




In conclusion, it can be stated that understanding the experiences of patients 
initiating trans-anal irrigation therapy depends on placing the treatment within the 
context of a chronic condition for which they may have undergone numerous other 
treatments with varying degrees of success, and which can have a profound impact 
on many aspects of their lives. The relationship between patient and irrigation nurse 
is of vital importance and the diversity of patients’ pre-irrigation experiences, 
combined with a variety of different attitudes to the proposed treatment, means 
that a flexible and patient-centred approach to training is necessary. 
The implications of this for on-going clinical practice and further research, as well as 
how these qualitative results relate to the quantitative arm of the study, will be 







CHAPTER 7: DISCUSSION AND CONCLUSIONS 
7.1 INTRODUCTION 
Data presented in this thesis represent interim results from a single centre running 
within the Chronic Constipation Treatment Pathway (CapaCiTY) 02 trial. The fact that 
this trial centre (University Hospital of North Durham) had commenced recruitment 
earlier than any other site and had recruited a far larger number of participants than 
other centres at the time of writing means that, although the study was not 
designed as a feasibility study from the outset, it is a worthwhile exercise to present 
results in this way in order to inform ongoing conduct of the trial nationally. This 
feasibility study explores pragmatic, experiential and scientific aspects of running the 
CapaCiTY 02 study as per protocol at a single study centre, in order to identify 
potential challenges and to explore the appropriateness of the study outcome 
framework and follow-up schedule.  Although the numbers recruited at this stage 
are too small to draw definitive conclusions regarding the comparative efficacy of 
each system, and the role of rectal irrigation therapy in treating functional 
constipation, this preliminary analysis of quantitative data, along with the qualitative 
study arm, provides valuable insights into the practicalities of running the study, and 
the feasibility of the recruitment targets and follow-up schedule. Findings have the 
potential to inform the successful conduct of a large publically funded trial, as well as 
future studies in this population.  
In the following chapter, the main study findings will be discussed and their 
implications explored. Implications for further research, as well as an appraisal of 




7.2 SUMMARY OF MAIN FINDINGS 
7.2.1 Current evidence for trans-anal irrigation 
The systematic review and meta-analysis (see chapter 2) assessed the quality of 
current evidence for the use of trans-anal irrigation to treat chronic constipation. 
High quality trial evidence for this treatment is lacking, with all seven studies 
included in the analysis affected by methodological flaws and moderate-to-serious 
risk of bias. A fixed-effects meta-analysis reported a positive response to treatment 
rate of 50.4%, although there was evidence of considerable heterogeneity between 
studies. It can therefore be stated that, while there is some evidence that this 
treatment can be of benefit to patients with chronic constipation, there is a clear 
need for better quality randomised controlled trial evidence to establish a firm 
evidence base for its use. 
 
7.2.2 Study feasibility 
The CapaCiTY 02 study is ambitious in its scope and contains substantial 
complexities. There are no other randomized controlled trials of trans-anal irrigation 
therapy in functional constipation, and therefore it is important that this research is 
completed, in order to add to the (currently relatively weak) evidence base for its 
use. Many aspects of the trial were evaluated in order to determine whether the 
trial design was feasible, and whether it was appropriate for achieving the stated 
primary outcome of the CapaCiTY 02 trial (that is, to assess comparative 




with functional constipation).  In the first instance, the recruitment and retention 
rates were assessed to evaluate whether the study can reasonably be expected to 
recruit appropriate numbers to provide valid conclusions, and whether this can be 
achieved within the stated timeframe. In addition, quantitative data from the 
Durham site have been analysed with a view to evaluating the mean reduction in 
PAC-QOL between systems, along with the standard deviation, to further assess the 
appropriateness of the sample size calculation. The completeness of data collection, 
as well as interim survival analysis and adverse event recording, also form part of 
this feasibility analysis. 
 
7.2.3 Patient recruitment and retention 
Over the course of the study period, the initial target of one patient per month was 
exceeded at the Durham site. However, recruitment did not commence until later 
than originally planned due to delays in the protocol development and ethical 
approval process. This meant that the new recruitment target has been revised to 
two patients per site per month. For the period October 2015 – July 2016, the mean 
recruitment rate at the Durham site was 1.9, suggesting that this is an achievable 
goal. However, it should be noted that many other sites have experienced very 
significant delays in study commencement, and that recruitment overall has been 
well below target estimations. This is illustrated in Chapter 5, figure 1 and figure 2. 
This low recruitment rate nationally led to study sites being contacted to participate 
in a teleconference in order to identify barriers to recruitment and to develop 




and involved five of the study sites recruiting (out of six sites open to recruitment at 
the time). Several reasons for low recruitment were identified, mainly the result of 
variation in local practice (making the protocol difficult to implement), as well as 
service pressures and the pressure on research teams to conduct more than one 
study in the CapaCiTY programme. This highlights the difficulties in implementing 
multi-site studies, and even though attempts were made before study 
commencement to ensure sufficient flexibility in the proposed study design, 
problems were encountered. One notable example was a site where Qufora-Mini 
irrigation was used very frequently as part of their biofeedback regimen, thereby 
excluding these patients from participating in the research. Another centre’s 
standard practice was to train patients to use irrigation in the community rather 
than in the hospital; as the ethics approval for CapaCiTY 02 does not cover 
community working (other than for qualitative interviews), this made conducting the 
study at this site difficult. This illustrates the importance of thorough and complete 
feasibility work at the pre-study stage at each proposed site. 
 
Regarding retention of participants, as of 18th August 2016, two of the 19 
participants recruited to the study at UHND have withdrawn. One of these did so 
after the three-month primary outcome data collection, the other within two weeks 
of starting irrigation. No reason was given for these two elective withdrawals. This 
represents a drop-out rate of 10.5%. The sample size calculation incorporated a loss 
to follow up rate of 10% over the course of the study. This observed rate is therefore 




means it is difficult to give a reliable estimate of the likely loss to follow up at this 
stage. The qualitative work gives clues as to the potential reasons for withdrawal but 
further work is needed to fully understand the patient experience in this regard.  
 
7.2.4 Appropriateness of the outcome framework and completeness of data 
collection 
As previously described, the primary study outcome was assessed using the Patient 
Assessment of Constipation – Quality of Life (PAC-QOL) questionnaire(76), which is a 
validated outcome measure and is extensively used in the medical literature. Its 
purpose is to assess the impact of constipation symptoms on quality of life. Each 
item in the 28-item questionnaire is scored 0-4 by the patient, and the total added 
up to give a score out of a maximum of 112. This is then converted into a score of 
between 0 (no effect on quality of life) and 4 (very severe impact on quality of life) 
by dividing the total score by the number of completed answers (ideally 28). 
Therefore, if answers are missing or invalid, it is possible to allow for this in the score 
by dividing by the number of completed answers only (not by 28 irrespective of 
completeness).  
 
In this study, the great majority of PAC-QOL questionnaires were completed fully 
(79% at baseline, 80% at 1 month, 91% at three months). The practice of checking 
for missing answers (introduced following clarification from the chief investigator 




this crucial outcome is completed appropriately. This suggests it is an appropriate 
and achievable outcome measure to use. Additionally, the PAC-QOL scored highly for 
ease of use and relevance during the pre-study constipation research advisory group 
meeting.  
 
The CapaCiTY 02 study outcome framework is designed to be standardized across 
the three studies that constitute the CapaCiTY programme. In addition to the 
primary outcome (comparison of reduction in PAC-QOL between the systems), there 
are a large number of secondary study outcomes for which data is being collected. 
These are outlined in detail in chapter 3, sections 3.3.2 and 3.8. This has led to a 
fairly high burden of measurement for study participants in the form of 
questionnaires at each study visit, as well as diaries and journals to be completed 
throughout the study. This feasibility study has identified that, although the 
questionnaires are completed on a majority of occasions (see Chapter 5, table 3), the 
patient diaries (completed two weeks before visits 2, 4, 5 and 6)  were much less 
well completed, with less than half of diaries completed (with no missing answers) at 
baseline and three months. At baseline, 21% of diaries were omitted altogether, and 
this rose to 36% at three months. The measures within the protocol to improve diary 
completion (i.e. a telephone call to remind patients, or an email reminder via 
REDCAP) proved unreliable; participants were often not able to answer the 
telephone, and also finding the time to contact patients proved a logistical problem 
for the research team. Furthermore, the REDCAP reminder email would often be 




Currently, discussions are in progress with the trial sponsors as regards improving 
the reliability of the online REDCAP data entry system. If this works efficiently, it may 
well lead to improvement in the proportion of diaries being correctly completed.  
Despite high levels of engagement in this highly committed population, the high 
levels of missing data suggest that the burden on patients is unsustainable. This is a 
key finding with implications for both the Capacity study and future studies in this 
population.  
 
7.2.5 Primary trial outcome: Mean reduction in PAC-QOL 
As previously described, the small numbers included in this feasibility analysis 
significantly limits the extent to which the primary outcome results can be relied 
upon to give a clear picture of what the overall trial result will be. The purpose of 
this analysis, therefore, is to provide descriptive analysis only, including an estimate 
of standard deviation for the purpose of evaluating the appropriateness of the 
sample size calculation. Overall, the mean PAC-QOL for the whole cohort did fall, 
from 1.95 at baseline to 1.35 at 1 month, then it increased slightly to 1.56 after 3 
months (a net reduction of 0.39, SD 0.44). This initial decline followed by a sharp 
increase is very likely a product of the small numbers included; one HV participant 
recorded a very significant drop in PAC-QOL at 1 month followed by a rise at 3 
months. As there were only six HV participants in total, this (potentially anomalous) 
result at 1 month will skew the mean value for the HV group and the whole cohort. It 




from 2.12 at baseline to 1.73 at 1 month, but this was maintained at 3 months (PAC-
QOL 1.76, a reduction of 0.36 SD 0.54). The mean reduction at three months was 
very similar between groups (for HV, it was 0.41 (SD 0.39) after 3 months, a 
difference of 0.04 in favour of HV). This tiny difference, if reproduced across the 
whole study, would not be clinically significant.  
 
The potential for single outliers to affect results from the whole cohort will be 
greatly reduced for the study as a whole due to the large numbers to be included 
(150 participants in each group). The fact that the calculated standard deviations for 
each system and for the cohort overall are less than 1 (the estimated SD used in the 
power calculation) suggests that the sample size is sufficient for detecting a true 
difference between the systems if such a difference exists. 
 
One interesting and potentially relevant element of these initial study results is the 
comparison between quantitative outcomes (PAC-QOL) and the statements reported 
by the same patients during their qualitative interviews. This allows a degree of 
triangulation of study findings, which could help inform understanding of the 
significance of the results. For example, one patient interviewed after 1 month and 
after 6 months reported very significant improvements in quality of life compared to 
before starting irrigation. This is reflected to an extent in his PAC-QOL scores, which 
were 2.28 at baseline and 1.04 after 6 months (a significant reduction of 1.24). 




the 3-month primary outcome reduction is only 0.24. Reasons for this erratic 
reporting are not immediately apparent. The participant’s baseline 1-month PAC-
QOL questionnaires do contain missing answers, but this is taken into account by 
dividing the total score by the number of completed answers, as outlined above, and 
is therefore unlikely to be sufficient to explain this. Furthermore, another participant 
reported significant improvements in their symptoms during their interview, and 
expressed satisfaction with the treatment, but their PAC-QOL score did not reduce 
(in fact there was an increase from 1.18 to 1.57 over the 3 months).  
These two examples illustrate how a patient’s perception of treatment success, or 
the degree of that success, can be highly subjective. This illustrates that any single 
quantitative measure of efficacy must necessarily be a compromise that cannot, of 
itself, provide a complete picture of how well a treatment is working. However, over 
the course of a large randomized study a more reliable picture should emerge which 
will allow valid conclusions to be drawn both as regards comparative efficacy, and 
regarding effectiveness of the treatment as a whole. This comparison also illustrates 
the value of combining qualitative and quantitative methodologies, and the extent 
to which they can combine to provide a fuller and more comprehensive illustration 
of the effectiveness of a treatment. 
 
7.2.6 Safety reporting and adverse events 
The mechanism for tracking and recording adverse events (i.e. participants recording 




each study visit) worked well, and the prospective tracking of adverse events is an 
important secondary outcome of the CapaCiTY 02 trial. 
 
Initial experience of running this study has shown that, while minor adverse events 
are very common (occurring in 73% of participants in this study), no patients have 
come to significant harm as a result of participation in the trial. This is consistent 
with published studies, with one study reporting an adverse event rate of 74 %(50) 
(see Chapter 2: Systematic review). There have been two serious adverse events in 
the study so far, but neither was related to the irrigation treatment. Therefore this 
feasibility study has not highlighted any patient safety concerns as regards trial 
participation, and reported AE rates are consistent with published literature on the 
subject. The limited data on AEs currently in the published literature will be 
strengthened by the results of the full CapaCiTY 02 study once these are known. 
 
7.2.7 Patient experience 
In addition to the qualitative elements to the study outlined above, the qualitative 
work conducted with trial participants shed some light on many aspects of the 
patients’ experience, both of training and home use of trans-anal irrigation, and of 





The nature of the essence of the lived experience of participants undergoing trans-
anal irrigation therapy for chronic constipation is described in detail in Chapter 6, 
section 6.4. Key components of that experience concern the individual’s pre-
treatment experiences of living with constipation, as well as their previous 
experiences with other therapies, and of healthcare utilization more generally. This 
may explain the attitude of an individual when confronted with the prospect of 
starting to use irrigation. Key themes such as anxiety, embarrassment, and 
disappointment all emerged through semi-structured one-on-one interviews. This is 
important to recognise, as anxiety about investigations or treatment options could 
potentially be a barrier for some patients preventing them from starting potentially 
beneficial treatment. The key to overcoming this seems to be the relationship with 
the irrigation nurses, about whom most participants spoke very highly. It appears as 
though support from the irrigation nurses, both at the initial training session and 
afterwards, gave participants the confidence and reassurance to try the treatment.  
It is possible to suggest that irrigation nurses should be more closely involved in the 
recruitment process for this and future trials.  
 
Within this small study cohort, five participants have so far discontinued treatment. 
One of these withdrew from the study without giving clear reasons. The other four 
all cited problems with side effects and/or ongoing severe symptoms of constipation 
as their reasons for stopping treatment. The qualitative research seems to indicate 
that efficacy (or lack thereof) is a more significant factor in whether patients 




continued to use low-volume irrigation, described persistent peri-anal discomfort 
that was clearly an unsatisfactory element of the treatment. However, they went on 
to describe how they were willing to put up with this side effect because of the 
benefits they were getting from the treatment. Conversely, the interviewee who had 
discontinued therapy did not describe any significant adverse events, and said they 
would be happy to have carried on with the treatment if it had been effective. 
 
Another interesting factor to emerge from the interviews was how patients 
described different symptoms as being the most troublesome. Some described 
abdominal pain and bloating as being their most problematic symptom; for others, it 
was a sensation of incomplete evacuation and difficulty passing stool. This 
demonstrates that members of this patient group have a complex and poorly-
understood illness which is very heterogeneous in nature. This lends support to the 
decision to use a quality of life measure as the primary outcome, rather than 
focusing on one particular symptom. It also supports the collection of a diverse 
range of outcome data (including symptomatic data, psychological profiling and 
radio-physiological investigations) in order to build up as complete a picture as 
possible of how effective the treatment is, and in whom it is most effective.  
 
7.3 SUMMARY OF IMPLICATIONS OF THE STUDY FINDINGS 
This study has shown that the CapaCiTY 02 study is, in principle, feasible and 




recruitment rate at the Durham site, combined with adequate patient retention and 
sufficient completeness of primary outcome recording. However, there are some 
causes for concern, notably the overall poor recruitment rate across all sites and the 
delays experienced in commencing recruitment, with several sites yet to open. As 
detailed above (section 7.2.1.1), there has been active engagement with recruiting 
sites throughout the trial to date, aiming to identify and rectify barriers to 
recruitment. 
A further problem identified as a result of this study is the fact that the Patient Diary 
is frequently omitted, or returned incomplete. It appears that the safeguards in the 
protocol aimed at preventing this (telephone call or reminder email 2 weeks in 
advance) have not been successful in overcoming this so far. If the completion rate 
for diaries remains low throughout the study then it is questionable whether valid 
conclusions could be drawn from any analysis of this data. 
 
Nonetheless, this feasibility study does provide an important proof of concept and 
has not highlighted any significant safety concerns. The combination of quantitative 
and qualitative data has enabled diverse aspects of the patients’ experience to be 
described, and this sheds light on important elements of patient care that are not 
explored by quantitative data alone. For example, the qualitative interviews 
highlighted some important aspects of the irrigation training, mainly centering 
around the relationship between the irrigation nurse and the patient. Participants 
gave conflicting views about some elements of the training, notably the option of 




advice. Some participants found this very helpful whereas others found it 
uncomfortable or embarrassing (for example, being shy about being shown to use 
irrigation by a nurse of the opposite sex). This highlights the importance of flexibility 
and sensitivity in the irrigation training regimen, and these are clearly important 
factors to consider when developing this type of service. The fact that patients were 
influenced by pre-conceived views about irrigation gleaned from the media and 
other sources is of particular note and should be borne in mind when preparing 
patient information sheets and recruitment information.  
 
7.4 CONTEXT OF THE STUDY FINDINGS 
As previously described in Chapter 1, ‘constipation’ is a very common symptom 
among adults and children globally. ‘Chronic’ constipation, where symptoms have 
been present for 6 months or more, has an estimated global pooled prevalence of 
14%(1). However, prevalence can vary significantly depending on the definition 
used(4). This is clearly a very heterogeneous condition, with no clear unifying 
pathophysiology to explain the symptoms described. Wide variations are seen 
between patients in terms of symptoms described and results of investigations(8). 
Trans-anal irrigation therapy has become widely available as a treatment for chronic 
idiopathic constipation in the UK, although evidence for its effectiveness in this 
condition is weak, as outlined in Chapter 2. The meta-analysis performed as part of 
this thesis found a pooled response rate of 51% (random effects model), although 




studies were in patients using high-volume irrigation; the Qufora-Mini system has 
been the subject of one trial(68) assessing its effectiveness for patients with passive 
incontinence and evacuatory dysfunction. This reported improvement in symptoms 
in approximately two thirds of the 50 patients included, however the authors did not 
differentiate between the incontinence patients and those with evacuatory 
dysfunction. 
 
There have been no prospective, randomized trials evaluating the role of irrigation in 
functional constipation. Furthermore, it is not known whether it is a better 
treatment for patients with particular symptom profiles or radiophysiological 
parameters. 
 
The best current evidence suggests that, while side effects are common (see Chapter 
2), these are minor and self-limiting. The reported rate of bowel perforation (the 
only serious complication reported in association with this therapy) is very low (2 per 
100,000 irrigations in one study(58)). 
 
7.5 LIMITATIONS OF THE STUDY 
The CapaCiTY 02 study represents the first attempt made to conduct a large-scale 
randomized trial of trans-anal irrigation therapy. This has presented a series of 




study, as previously described, aims to identify and resolve potential pitfalls and to 
establish whether the stated aims and recruitment rate are achievable. The complex 
and poorly-understood nature of functional constipation, combined with the nature 
of the treatment itself, has necessitated a pragmatic approach with several 
compromises being made to try to ensure that the study is feasible. 
 
From a methodological perspective, the fact that neither participant nor assessor 
blinding was feasible (due to the nature of the treatment and the nature of the 
outcome data being collected), leads to the possibility of performance bias and 
reporting bias, as both participants and assessors will (consciously or unconsciously) 
have particular pre-conceived ideas about the likely efficacy of each system. In the 
qualitative interviews, several participants alluded to this, and described being 
pleased or disappointed with their allocated system. Attempts have been made, 
from a methodological and operational perspective, to limit the impact of this. The 
fact that every patient gets treatment is important, as it is a reasonable assumption 
that the placebo effect for each system is similar (this is an advantage over a 
‘matched controls’ trial design), thereby meaning that any observed difference 
between systems is a genuine one. Additionally, the option of switching systems 
after three months is designed to allow participants who have not had success with 
their original system to try the other one. This means that patients do not spend too 
long on ineffective treatment, and also allows longer-term data (>3 months) to 





A further measure to limit the impact of bias was to conceal the primary outcome 
questionnaire in a sealed envelope, thereby preventing the assessors from 
quantifying the improvement in PAC-QOL at each visit. Initially, this led to problems 
with questionnaires not being adequately completed, and in response to this the 
process was modified to allow brief review of the questionnaires before 
concealment to ensure they are completely filled in. This did not compromise the 
principle of concealment as the questionnaire is not meaningful unless the score is 
added up and compared with previous scores.  
 
In summary, therefore, it can be said that although aspects of the study 
methodology represent a compromise in terms of blinding and outcome assessment, 
CapaCiTY 02 is nonetheless a robustly-designed study with the potential to fully 
answer the relevant research questions if conducted as per the study protocol.  
 
Although the methodology employed during the course of this feasibility study is 
robust, there are many factors that limit the nature of the conclusions that can be 
drawn from it. The principle limitation of this study is the fact that the numbers of 
participants included is small. Although a fully-powered study with analysis of the 
complete outcome framework is outside the scope of this thesis, the delays in 
recruitment resulted in a smaller study sample than was initially planned. This has 
led to a feasibility study that is perhaps more limited and less powerful than it 




(possibly anomalous) PAC-QOL result at 1 month has skewed the overall result, 
giving the impression of a sharp initial drop in PAC-QOL at 1 month which then 
partially reverses after 3 months. It is impossible to say at this stage whether this is a 
genuine pattern or whether it is the product of an anomalous result. The full, 
adequately-powered study results will confirm or refute this. 
 
Another consequence of the low study numbers recruited is that the pool of patients 
from which to draw candidates for qualitative interviews was smaller than hoped 
for. Although sufficient participants were interviewed after 1 month for data 
saturation to be reached for this time point, a far smaller number of participants had 
reached the 6-month time point and therefore the numbers interviewed were small. 
In particular, no interviews took place with participants after switching therapy, 
meaning that little has been gleaned regarding the experiences of these patients. 
Nonetheless, the three interviews conducted after 6 months did provide a number 
of interesting themes and concepts which can be explored further at other sites as 
the study progresses. 
A further limitation of the qualitative arm of the study is that the interviewer was 
also a clinician involved in treating the patients. Although it was recognised that this 
could potentially affect the dynamic of the interview and steps were taken to 
minimise the impact of this (see Chapter 4, section 4.12), this nonetheless 
represents a compromise. For example, participants may have felt less able to 




received. The very positive comments made by participants about the irrigation 
nurses and clinical team must be interpreted in light of this. 
 
7.6 WHAT COULD HAVE BEEN DONE DIFFERENTLY? 
Having reviewed the results of this feasibility study, it is apparent that, while the trial 
design appears sound and the recruitment rate at the Durham site is on target, there 
are several areas which could have been improved upon. 
 
Firstly, the delays in recruitment experienced at many sites were in part due to 
differences between the trial-specified training regime for trans-anal irrigation and 
local practices. Feasibility questionnaires were sent to each site and the results used 
to design the training regime (see Chapter 5, section 5.2). However, on reflection 
this questionnaire was not detailed or specific enough to highlight many of the 
problems which later emerged. This highlights the importance of conducting 
appropriately rigorous feasibility work before committing to a particular trial design. 
 
Another major reason for recruitment being delayed was due to difficulty obtaining 
high-resolution manometry equipment (required for INVEST in the original protocol) 
at many sites. This was rectified by amending the protocol to allow standard 
manometry, however this introduced further delays and it would have been far 




stage. These particular issues highlight some of the difficulties of multi-site working, 
and how close collaboration and communication with all participating sites is 
essential at each stage in order to design and run a trial appropriately. 
 
Another potential area for improvement was as regards the number of outcome 
measures, and the duration of follow up. As demonstrated by the involvement of the 
constipation research advisory group (CRAG), the questionnaires evoked mixed 
responses; some (notably the Rome III questionnaire and MYMOP) were seen as 
difficult to complete, and not relevant. There were also concerns expressed about 
the total length of time required to complete the baseline questionnaire booklet. 
Following consultation with the trial steering committee, the total follow up duration 
was reduced from 24 months to 12 months, and the number of questionnaires was 
reduced. However, this required a major protocol amendment. A smaller and more 
focused set of outcomes, targeted to answer a more clearly-defined set of research 
questions, would have potentially improved matters in this regard.  
 
The rate of completeness for patient diaries is also a concern highlighted by this 
study. As previously noted (section 7.3), the protocol includes several strategies for 
improving diary completion (namely a telephone call to the patient, or an email, 2 
weeks before the study visit). However these have so far not proven practical; 
participants frequently have not answered the telephone, and there have been 




resolved. One further possible reason for the poor completion of diaries is the 
potential for confusion between the various patient-held documents; the ‘Patient 
Journal’, ‘Irrigation Journal’ and ‘Patient Diary’.  Although the PPI consultation had 
not identified any concerns with these documents, over the course of the study 
there were cases of participants losing the documents, or mixing them up. Reducing 
the number of patient-held documents (for example, using the irrigation journal 
only), or synthesizing the key information into a single journal, may have helped to 
reduce these problems. It remains to be seen whether the improvements to the 
online system will lead to an improved rate of diary completion. 
 
7.7 WHAT FURTHER RESEARCH IS NEEDED? 
There are many unanswered questions concerning the use of trans-anal irrigation 
therapy in chronic constipation, and the current evidence base for its use is weak. 
Nonetheless, there is trial evidence that it can be effective, as outlined in chapter 2 
and in section 7.4 above. Given the complex and poorly-understood nature of 
chronic constipation, it is necessary to conduct a trial which not only determines the 
overall effectiveness of treatment, but also attempts to identify patient groups in 
whom it is especially effective. This will enable a more focused, targeted approach to 
therapy, and reduce the time patients spend trying ineffective treatments. 
 
The CapaCiTY programme as a whole aims to construct a rigorously evidence-based 




this will provide a valuable resource for clinicians dealing with this condition, and will 
lead to more effective and more cost-effective therapy. CapaCiTY 02, with its specific 
focus on trans-anal irrigation therapy, aims to answer important questions about the 
comparative effectiveness of each irrigation system as well as the effectiveness of 
the treatment in general. Additionally, the planned analysis of pre-treatment 
symptom profiles and radio-physiological characteristics will enable conclusions to 
be drawn regarding which types of patients derive the most benefit from irrigation, 
and which system they should use. These findings could form the basis of more 
focused research in this area. 
 
The qualitative component of this study has yielded valuable information regarding 
the lived experience of patients commencing treatment with trans-anal irrigation, 
and this needs to be expanded on to include a broader range of participants with a 
more diverse range of experiences, especially at the 6 month time point. The 
CapaCiTY 02 study protocol includes interviews not only with patients at the 1 and 6 
month time points, but also with health professionals involved in irrigation training. 
This study, conducted nationally, should provide a very rich description of the nature 
of the lived experiences of trans-anal irrigation therapy from patients’ and health 
professionals’ perspectives. 
 
One final aspect of the feasibility analysis that may merit further investigation is the 




effectiveness (expressed during qualitative interviews) and the measured efficacy 
(the reduction in PAC-QOL). This raises interesting questions about patients’ 
perception of treatment success and how this relates to their own personal 
experiences of illness. It also highlights the limitations of using numerical scores as a 
primary outcome measure in a study looking at a very complex and heterogenous 
illness. Furthermore, this demonstrates the value of the mixed-methods approach 
employed in this study, and illustrates how both qualitative and quantitative 
elements of a study can combine effectively to build up a more nuanced picture of 
the nature of a treatment’s therapeutic benefits than would be possible through 
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Short Title CapaCiTYstudy2 
Methodology 
 
Pragmatic randomised trial comparing low volume with high 
volume initiated anal irrigation therapy in adult patients with 
CC who have not responded to nurse-led biofeedback or 
bowel habit training. 
Research Sites 
 
NHS Trusts in England focussing on specialist pelvic floor 
centres; primary care networks in England; trial oversight by 
Pragmatic Clinical Trials Unit, Queen Mary University of 




(1) The impact upon patient disease specific quality of life 
of transanal irrigation (TAI) initiated with a low-volume 
(LV) versus high-volume (HV) system in patients with 
CC. 
(2) Survival (continuation of benefit) and acceptability by 
type of system. 
(3) The influence of patient characteristics (urge to 
defaecate, balloon sensory testing results) upon 
treatment success, and response by type of system 
used. 
(4) Strategies for tailoring treatment to patients’ symptoms 
and acceptability of each system to patients. 
(5) The safety of each system. 
(6) The cost-effectiveness of care. 
Number of Patients 300 (1:1 allocation) 
Main Inclusion Criteria 
 
Chronic constipation in adults (18-70 years) as defined by 
pragmatic clinical criteria [self-reported symptom duration > 6 
months; failure of laxatives and lifestyle modifications, failure 
of previous nurse led behavioural therapy]. 
Statistical Methodology 
and Analysis (if 
applicable) 
 
A superiority trial design will test the null hypothesis that:  
 There is no difference in outcome (PAC-QOL) when 
initiating transanal irrigation with a low-volume or high-
volume system after 3 months of therapy. 
Outcomes (at 3 6 and 12 months) will include: 
 PAC-QOL, PAC-SYM, EuroQoL measures, , GAD7, PHQ-
9, global patient satisfaction, CC-BRQ, BIPQ (CC). 
 A survival curve of duration of benefit from treatment will 
be used as a further marker of treatment efficacy. 
 Pre-treatment patient characteristics informed by 
pathophysiological investigation (INVEST) will be used to 
assess the relationship between response to treatment 
and investigation results. 
A full analysis plan will be signed off before allocation codes 
are made available to the statistician. The standardised 




programme of studies will be employed, including clinical and 
health economic outcomes as well as qualitative assessments. 
Proposed Start Date 01.08.15 
Proposed End Date 31.10.18 






Burden of disease  
Constipation is common in adults and up to 20% of the population report this 
symptom depending on definitions used1-3, with a higher prevalence in women145 and 
older people67. Chronic constipation (CC), usually defined as more than 6 months of 
symptoms, is less common8 but results in 0.5 million UK GP consultations per 
annum. A proportion of the population suffer symptoms which are both chronic and 
more disabling (about 1-2% population)9. Such patients, who are predominantly 
female10, are usually referred to secondary care with many progressing to tertiary 
specialist investigation. Patient dissatisfaction is high in this group; nearly 80% feel 
that laxative therapy is unsatisfactory11 and the effect of symptoms on measured 
quality-of-life (QOL) is significant12. CC consumes significant healthcare resources. In 
the US in 2012, a primary complaint of constipation was responsible for 3.2 million 
physician visits13 resulting in (direct and indirect) costs of $1.7 billion. In the UK, it is 
estimated 10 per cent of district nursing time is spent on constipation14 and the 
annual spend on laxatives exceeds £80m, with 17.4 million prescriptions in 2012 
(Health and Social Care Information Centre, 2013)15. 
 
Pathophysiological basis of chronic constipation 
The act of defecation is dependent on the coordinated functions of the colon, rectum 
and anus. Considering the complexity of neuromuscular (sensory and motor) 
functions required to achieve planned, conscious, and effective defaecation16 it is no 
surprise that disturbances to perceived ‘normal’ function occur commonly at all 
stages of life. Clinically, such problems commonly lead to symptoms of obstructed 
defaecation e.g. straining; incomplete, unsuccessful or painful evacuation; bowel 
infrequency; abdominal pain and bloating. After exclusion of a multitude of secondary 
causes (obstructing colonic lesions, neurological, metabolic and endocrine 




colonic contractile activity and thus stool transit and problems of the pelvic floor. 
Thus, with specialist physiological testing (hereafter referred to as INVEST in this 
protocol), patients may be divided into those who have slow colonic transit, 
evacuation disorder, both or neither (no abnormality found with current tests). 
Evacuation disorders can be then subdivided into those in which a structurally-
significant pelvic floor abnormality is evident e.g. rectocele or internal prolapse 
(intussusception) and those in which there is a dynamic failure of evacuation without 
structural abnormality: most commonly termed ‘functional defaecation disorder 
(FDD)’. 
 
Chronic constipation management overview 
Management of CC is a major problem due to its high prevalence and lack of 
widespread specialist expertise. In general, a step-wise approach is undertaken, with 
first line conservative treatment such as lifestyle advice and laxatives (primary care) 
followed by nurse-led bowel re-training programs, sometimes including focused 
biofeedback and psychosocial support (secondary/tertiary care). Although these 
treatments may improve symptoms in more than half of patients, they are very poorly 
standardised in the UK and are not universally successful17. Thus, patients with 
intractable symptoms and impaired QOL may be offered a range of costly, 
irreversible surgical interventions with unpredictable results18, 19, sometimes resulting 
in major adverse events or a permanent stoma.  
 
Overall rationale for the CapaCiTY programme 
The current trial forms part of an NIHR-funded programme (PGfAR: RP-PG-0612-
20001). This programme aims to develop the evidence base for the management of 
chronic constipation (CC) in adults which is currently lacking. This is in contrast to the 
management of CC in children for which NICE guidance has been recently published 
(http://pathways.nice.org.uk/pathways/constipation-in-children-and-young-people)20, 
21; and for adults with faecal incontinence22. Thus the current situation is one where 
there are considerable variations in practice, particularly in specialist services. With a 
number of new drugs gaining or seeking NHS approval23-26  and technologies at a 
horizon scanning stage18, 27, 28it is timely that the currently limited evidence base for 
adult CC is developed for resource-constrained NHS providers to have confidence 
that new and sometimes expensive investigations and therapies are appropriate and 
cost-effective. A cost-conscious pathway of care may help reduce healthcare 
expenditure by appropriately sequencing the care provided, while targeting more 
expensive therapies at those most likely to benefit. Such data will inform the 
development and commissioning of integrated care pathways. An overview of the 
CapaCiTY programme is provided as a scheme [APPENDIX 1] and includes a series 
of interlinked work packages (WPs) that answer the important questions for patient 
care. A rolling program of national recruitment will provide a large cohort of well-
defined patients for subsequent studies within sequential WPs over 5 years. The 




provide valid clinical outcome measures, patient acceptability and cost. Armed with 
such data it will be possible to develop an NHS management algorithm for CC which 
will meet patient, clinician and policy aims. 
 
4.2 Specific clinical background to the prospective cohort study of anal 
irrigation 
Anal irrigation, using a variety of commercially available devices, has been rapidly 
disseminated internationally over the past 3-5 years, first in patients with neurological 
injury 29, 30and subsequently in other CC groups31, 32. Despite a lack of published data 
other than from small selected case series, it is now available on the drug tariff and 
generally considered to be the next step in patients failing other nurse-led 
interventions such as biofeedback. Anal irrigation has permeated the UK market 
without robust efficacy data and with on-going concerns regarding longevity of 
treatment and complications 29, 33. Retrospective clinical audit data and 
review33suggest a continued response rate after one year of approximately 50% with 
such patients thus avoiding or delaying surgical intervention. An accurate 
assessment of response rate and acceptability of this intervention requires 
confirmation in a large prospective cohort, together with clinico-physiological 
predictors of success. In addition, two alternative systems for delivery of trans-anal 
irrigation exist; low-volume systems delivering approximately 70ml per irrigation, and 
high-volume systems delivering up to 2 litres of irrigation (although typically only 0.5 
– 1.5 litres is required per irrigation). The low-volume system is cheaper, costing 
approximately £750 p.a. based on alternate-day use, compared with approximately 
£1400-1900 for high-volume irrigation, and may be more acceptable to patients, and 
so a randomised study comparing the two systems is needed. 
 
4.3 Rationale and Risks/Benefits 
Robust data for the use of anal irrigation therapy in chronic (idiopathic) constipation 
are lacking. In addition, there are no data demonstrating superiority of high-volume 
irrigation over low-volume systems. Given the differences in cost between the two 
systems, a randomised study of well-characterised patients comparing the two 
methods would provide useful information on whether one system holds a clear 
advantage over the other. Also, the short- and long-term efficacy and acceptability of 
therapy in chronic constipation could be evaluated. This is timely and informative 
given the rapidly increasing popularity of this treatment and the fact that anal 
irrigation is an invasive therapy for which patient selection should also be optimised 
to maximise benefit. 
 
In practice, patients will use one system only (plus defined ‘rescue therapies’ – see 
below) for a minimum of three months. After this time point they may switch to the 
other system if their initial therapy was ineffective/unsatisfactory. Thus consenting 
patients will be randomised to initiate therapy with one of these systems but will have 




to identify response rates to each system in the short term (three months), and 
thereafter this study is a comparison between treatment strategies (low-volume 
initiated therapy versus high-volume initiated therapy) rather than a pure comparison 
of the two techniques. This is a patient-centred study design aiming to limit the time 
patients spend using ineffective therapy without being allowed to try an alternative. 
This also allows estimation of comparative cost-effectiveness of the two treatment 
pathways, and whether one system works better depending on the radio-
physiological profile of the patient. Recent data estimates approximately 85% of 
patients are still using irrigation at 1 month; this represents a significant short-term 
treatment failure rate 34. Once patients have switched therapy, they may not switch 
back to the first system; once they have tried both systems and discontinued them 
then they will be considered to have completed the intervention and they will return to 
routine clinical care. 
 
Patient and Public Involvement (PPI) consultation with current patients in secondary 
care with this condition has explored the acceptability of this study design to patients, 
and we have found that this is likely to be acceptable. The study design, proposed 
rescue therapy and patient diaries/journals have been reviewed as part of this 
process. 
 
Irrigation is a maintenance therapy rather than a cure. In addition to outcome 
measures of PAC-QOL score at three months, patients will provide survival data 
(time until cessation of irrigation therapy due to lack of benefit). Switching systems 
does not affect this; the survival data is based on use of irrigation irrespective of 
system. A survival analysis is appropriate since anal irrigation is time-consuming and 
inconvenient as a therapy and patients may find the process distasteful. Patients are 
unlikely to continue with treatment if they are not gaining worthwhile benefit from it; 
treatment continuation is a useful patient-centric assessment. 
 
Consideration of the findings from both groups (individually and together) will be 
used to model the net value to patients of anal irrigation, considering persistence of 
benefit. 
 
The risk of non-participation is considered very low. The interventions proposed are 
those already offered to patients in specialist centres throughout the UK and 
internationally. All interventions pose acceptable and minimal risks. For instance, the 
only invasive tests (INVEST) have been performed daily in most specialist centres for 
up to 30 years without any recorded complication (Barts Health experience > 10,000 
patients). A small ionising radiation dose is required for two tests (covered below). A 
number of questionnaires contain personal questions about bowel problems and the 
effect of these on quality of life and psycho-behavioural functioning, however all have 





Risks of anal irrigation therapy 
Trans-anal irrigation has been shown to be a low-risk intervention and is widely used 
in a variety of defecatory disorders such as neurogenic bowel dysfunction, idiopathic 
constipation and faecal incontinence. Serious adverse events are rare, with one 
study reporting 2 non-fatal bowel perforations out of approximately 110,000 irrigation 
treatments 29. Other potential side effects include pain, bleeding, painful 
haemorrhoids and anal fissure. A recent study reported an overall adverse event rate 
of 22% when all minor and reversible events were considered.13% reported 
technical problems with equipment and 13% reported minor side effects/adverse 
events34. 
 
The benefits of participation are that patients will receive a very high standard of 
monitored care as a consequence of the detailed protocol. Participation will inform 
future treatment options for patients with chronic constipation 
5. TRIAL OBJECTIVES 
 
5.1 Primary objectives 
2. To compare the impact upon patient disease specific quality of life of transanal 
irrigation initiated with a low-volume versus high-volume system in patients with 
chronic constipation, measured at 3 months. 
 
5.2 Secondary objectives 
To determine: 
. 
7. Survival (continuation of benefit) and acceptability in the longer term 
(up to 12 months). 
8. Disease specific outcomes at 3 6 and 12  months  
9. The influence of patient characteristics (urge to defecate, balloon 
sensory testing results) upon treatment success, and response by type 
of system used. 
10. The acceptability of each system to patients. 
11. Strategies for tailoring therapy to meet patients’ individual needs, and 
the factors involved in this. 
12. The safety of each system and prospective tracking of AEs. 
13. The cost-effectiveness of care. 









All clinical endpoints will be in common with a single standardised outcome 
framework (consistently used within all CapaCiTY programme studies). All outcomes 
will be recorded at baseline, 3, 6 and 12 months in face-to-face clinics (or by 
telephone call if necessary). PAC-QOL, PAC-SYM and EQ-5D-5L, EQ-VAS will 
additionally be collected at 1 month; this is to capture reasons for early non-response 
to therapy, as well as to better characterise the patients group and provide more data 
for economic analysis. The primary endpoint will be at 3 months.  
 
Primary Clinical Outcome 
 .Patient Assessment of Constipation Quality of Life questionnaire (PAC-
QOL35, 36) at 3 months  
Secondary Clinical Outcomes  
 PAC-QOL score and individual domain scores at 1, 3, 6, and 12 months 
 Time to cessation of each system of irrigation; total time in treatment with either 
system (from irrigation journal) at 1, 3, 6, or 12 months. 
 Reason for cessation (of each system) (irrigation journal and qualitative 
interviews) at 1, 3, 6, and 12 months. 
 Patient Assessment of Constipation Symptoms (PAC-SYM): aggregate and 
domain scores at 1, 3, 6, and 12 months. 
 Volume and duration of irrigation (irrigation journal) at 1, 3, 6, and 12 months. 
 Number and nature of bowel motions (captured in 2-week patient diary) at 3, 6 
and 12 months 
 Symptom scores derived from diary records (taken over two weeks before or 
around each follow-up contact.  These will include number of spontaneous 
complete bowel motions at 3, 6 and 12 months 
 .  
 Generalized anxiety disorder questionnaire (GAD7) at 3, 6 and 12 months 
 Depression, anxiety and somatisation modules of the PHQ-9 at 3, 6 and 12 
months 
 Global patient satisfaction / improvement score (VAS) at 3, 6 and 12 months 
 Patient acceptability and recommendation to other patients (qualitative 
interviews) see section 7.16 
 Behavioural response to illness questionnaire (CC-BRQ), and brief illness 
perception questionnaire BIPQ (CC) at 3, 6 and 12 months 
 Generic quality of life: EuroQol EQ-5D-5L and EQ-VAS scores 1, 3, 6, and 12 
months.  
 Use of healthcare resources, adverse events, and concomitant medications 
(collected using patient journal) at 3, 6, and 12 months  
 




 Interventions, treatment sequelae and other health resource use related to the 
care of CC will be recorded in natural units and cost applied where possible using 
national reference costs. Additionally, patient costs related to constipation and 
the opportunity cost of time away from normal activities will be valued using 
national reference sources. 
 
 
Patient experience (See section 7.16: Qualitative interviews) 
 Face-to-face, digitally recorded, semi-structured interviews will be conducted 
involving a purposive, diverse sample of patients throughout the programme, with 
participants reflecting a range of ages, geographical locations, and where 
possible other pertinent attributes such as ethnicity and gender, continuing until 
data saturation when no new themes emerge. Participants will be approached by 
a member of the research team and will undergo a separate consent process if 




6.1 Inclusion Criteria 
 Age 18-70 years. 
 Patient self-reports problematic constipation. 
 Symptom onset > 6 months before recruitment. 
 Symptoms meet American College of Gastroenterology definition of constipation. 
 Non-response to constipation treatment to a minimum basic standard ( see NHS 
Map of Medicine 2012)37: Comprising lifestyle AND dietary measures AND ≥2 
laxatives or prokinetics tried (no time requirement) [APPENDIX II]. 
 Ability to understand written and spoken English (due to questionnaire validity). 
 Ability and willingness to give informed consent. 
 Failure of previous nurse-led behavioural therapy.  
 Ability of patient/carer to use anal irrigation. 
 
The study will use the American College of Gastroenterology definition of 
constipation38  
(which is reasonable, simple and extensively published): unsatisfactory defaecation 
characterized by infrequent stool, difficult stool passage or both for at least previous 
3 months. This avoids the more complex Rome definitions (which are likely to 
change with Rome IV in 2015). 
 
 
6.2 Exclusion Criteria 
The study interventions necessitate the exclusion of major causes of secondary 





 Significant organic colonic disease (red flag’ symptoms e.g. rectal bleeding 
previously investigated); IBD; megacolon or megarectum (if diagnosed 
beforehand) [the study will provide a useful estimate of the prevalence of such 
cases in referral practice]; severe diverticulosis/stricture/birth defects deemed to 
contribute to symptoms (incidental diverticulosis not an exclusion). 
 Major colorectal resectional surgery. 
 Current overt pelvic organ prolapse (bladder, uterus, vagina, rectum) or disease 
requiring surgical intervention. 
 Previous pelvic floor surgery to address defaecatory problems: posterior vaginal 
repair, STARR and rectopexy; previous sacral nerve stimulation. 
 Previous use of transanal irrigation therapy to treat constipation. 
 Rectal impaction (as defined by digital and abdominal examination: these form 
part of the NHS Map of Medicine basic standard)37. 
 Significant neurological disease deemed to be causative of constipation e.g. 
Parkinson’s, spinal injury, multiple sclerosis, diabetic neuropathy (not 
uncomplicated diabetes alone). 
 Significant connective tissue disease: scleroderma, systemic sclerosis and SLE 
(not hypermobility alone). 
 Significant medical comorbidities and activity of daily living impairment [based on 
Bartell index in apparently frail patients39, Barthel index <=11]. 
 Physical disability/impairment which prevents use of one or other of the irrigation 
devices. 
 Major psychiatric diagnosis [schizophrenia, major depressive illness, mania, self-
harm, drug/alcohol addiction]. 
 Chronic regular opioid use (at least once daily use) where this is deemed to be 
the cause of constipation based on temporal association of symptoms with onset 
of therapy; all regular strong opioid use. 
 Pregnancy or intention to become pregnant during study period.  
 
NOTE:  Red flag symptoms are not an exclusion if they have been investigated 
before enrolment and organic disease excluded. Previous transanal irrigation therapy 
does not include private (non-NHS) ‘colonic irrigation’ therapy; prior use of such 
treatments is not an exclusion criterion. 
 
6.3 Study Design / Plan – Study Visits 
 
6.3.1 Setting 
Specialist centres across England with a mix of urban and rural referral bases. 
 
6.3.2 Recruitment 
Patients attending specialist centres (outpatient clinics, GI physiology units) for 
constipation and who have already failed to respond to a minimum basic standard of 
treatment (see above), as well as nurse-led interventions (biofeedback or habit 
training) will be eligible for recruitment screening based on criteria. Patients will be 
recruited from those failing treatment in CapaCiTY01 but also those patients seen 
outside the trial who have had nurse led behavioural therapies without response.  
 
Trial posters will be displayed in primary care and community care settings, directing 




website for more information, including the patient information sheet. The same 
posters may be used to advertise the study via the internet and social media. 
 
6.3.3. Visit 0: Pre-Screening: Eligibility assessment 
A GCP-trained and delegated local researcher will screen for basic eligibility by 
phone (or face-to-face interview based on patient choice). Potentially eligible patients 
will be identified either in clinic, from referral letters from GPs/other consultants to the 
constipation clinic, and from patients participating in CapaCiTY01 who did not 
respond or have ceased to respond to habit training/biofeedback. Participants will be 
provided with adequate explanation of the aims, methods, anticipated benefits and 
risks of anal irrigation therapy and will take away or be posted an invitation letter and 
a patient information sheet. Patients will be given at least 24 hours to consider 
participation and invited to attend clinic for Visit 1 (see below). 
 
The study screening number will be allocated as follows: 
Study Code 02 
Site Code – 3 letter code for each site (APPENDIXIII) 
Participant Code – 4 digit code given consecutively and attributed at each site 
 
For example the first participant recruited at Barts Health Trust would be assigned 
the code 02-BLT-0001. 
 
Patients progressing to other studies within the CapaCiTY programme will keep this 
number for pathway tracking. 
 
6.3.4 Visit 1: Screening, consent and baseline assessments 
Visit 1 will be conducted face to face in clinic. Following a detailed discussion about 
the trial, potentially eligible and agreeable patients will complete written informed 
consent, followed by a more thorough screening and confirmation of eligibility for 
randomisation by brief history and physical examination (the latter if not already 
performed within the previous 3 months).  
 
Patients who decide not to opt for treatment will be invited to offer reasons and these 
will be recorded when provided. Patients declining participation will continue to 
receive usual care as locally provided. There is no obligation for patients to give 
reasons for non-participation. 
 
For those patients entering the study, additional baseline outcome assessments will 
be conducted. These include several key validated assessments that profile patient 
characteristics, informing disease pathophysiology and potential predictors of 
treatment response. All have been selected on the basis of trade-off between 
adequate detail and achievable brevity. These instruments will be combined into a 




Confirmation of Eligibility 
 
Screening/Confirmation of Eligibility 
 Standardised history by interview including previous medication usage. 
 Clinical examination findings (carried forward if performed previously within last 3 





Baseline outcome assessments 
 Baseline outcome assessments [PAC-QOL, PAC-SYM,, EQ-5D-5L & EQVAS, 
PHQ9, GAD7, CC-BRQ and BIPQ-CC, see endpoints above]. 
 Baseline 2-week patient diary will be given. Training in completion of the diary will 
be conducted at visit 1 and the diary will be completed at home and returned at 
visit 2. 
 Training and retrospective completion of the patient journal will occur at visit 1 for 
collection of resource data. Prospective completion will occur continuously, with 
review at each follow up visit from 3 to 12 months. 
 
Other baseline only assessments 
 Constipation (2006) and IBS (2006) modules of Rome III questionnaire. 
 Cleveland Clinic constipation questionnaire. 
  
 Brief, chronic pain, autonomic and joint hypermobility assessments. 
 St Marks Incontinence score (for concurrent symptoms). 
 
Randomisation to be conducted by a member of the research team 
 
INVEST radio-physiology investigations (See section 7.5.3): There is no defined time 
period for this, but it is suggested INVEST should be completed within 4 weeks of 
Visit 1 baseline visit to allow for diary completion before stopping laxatives for 
INVEST. A maximum of 8 weeks tolerated to conduct INVEST.  
 
Those with INVEST completed in the previous 12 months do not need these 
repeated and can be booked for visit 2, commencing in minimum of 2 weeks to allow 
completion of baseline diary. 
 
 
6.3.5 Visits 2-3: Interventions 
Visit 2: 
 Collection of baseline diary completed before stopping laxative (i.e. before 
INVEST in patients who need this done). 
 
 
 Training in Anal Irrigation - Patients will undergo a single nurse-led training 
session before starting treatment. 
 
 Training in completion of irrigation journal and provision of irrigation journal to 
be completed weekly. The irrigation journal consists of, volume of water 
introduced, frequency of use adverse events and side effects e.g. pain, 
bleeding. 
 
 Start date for home irrigation agreed with the patient (this is to allow for any 
delay in delivery of equipment). Ideally this should be the same day as Visit 2, 
or within 1 week maximum.  If any issues or delays have been encountered, a 
new commencement date is agreed; This should be recorded as a 
deviation/note to file (CRF 7/8), along with reasons for delay 
 





Patients will be contacted by telephone 14 days (+/- 3 days) after Visit 2 to ensure no 
problems have been encountered including a review of adverse events and 
concomitant medications. 
 
Visit 2.2 (if needed) 
If there are problems then a further face-to-face training session will be offered, 
including a review of adverse events and concomitant medications. This can occur 
any time before visit 3 (2 weeks +/- 1 week from visit 2.1) or in conjunction with visit 3 
if not before. 
 
Patients will continue the self-administered therapy using a commercially-available 
device until the end of the study. Patients will be followed up until the end of the data 
collection phase of the study (variable follow up 12-24 months depending on date of 
recruitment) or until they decide to discontinue either the therapy or the trial follow 
up. Irrigation will be performed at an agreed frequency initially (see section 7.5.2). 
Once established on this therapy patients may adjust the frequency and volume of 
irrigation to suit their particular condition.  
 
Information about treatment will be recorded in an irrigation journal. This information 
shall consist of: frequency of use of irrigation; volume of water introduced; adverse 
events and side effects e.g. pain, bleeding. Where a patient switches to the other 
irrigation device or discontinues treatment (patient choice) the reason for this, as well 
as the duration of therapy, will be documented. If a patient chooses to switch 
devices, which they may do at any stage after the 3 month follow up visit, they will 
receive training in the other device. They will receive a follow up by the irrigation 
nurse as required to resolve any outstanding issues and to check progress. This 
should be documented on the irrigation journal and a note to file, (CRF 8) and 
change/discontinue, (CRF 12) should be completed. However they will not be asked 
to repeat the questionnaires and diaries already completed at 1 and 3 months. 
 
Visit 3 
This takes place 2 weeks (+/- 1 week’s tolerance if needed) after Visit 2.1. PAC-QOL, 
PAC-SYM and EQ-5D-5L will be recorded at this visit, and irrigation journal is 
reviewed. A new patient diary, journal and irrigation journal are provided for collection 
at next follow up visit. 
 
6.3.6 Visits 4-6: Follow-up outcome assessments: visits or 
telephone consultations 
A full standardised outcome framework and health economic dataset will be recorded 
at baseline, 3, 6 and 12 months (+/- 1 week) after initiation of intervention at Visit 2. 
To maximise completeness of data collected, follow up visits will be conducted face-
to-face in clinic wherever possible. Where this is not possible, a telephone 
consultation will be used. 
 
 
The patient diary and journal and irrigation journal will be provided for review at each 





Within the follow up period at least 3 attempts via 2 different methods (e.g. phone 
and letter), will be made by research staff to make contact and collect follow up data 





































Patient Failing Behavioural 
Therapy no previous anal 
irrigation (CapaCiTY01) 
~300 
Secondary Referrals - Failing 
Behavioural Therapy no 






Patient Randomised (1:1) 
~300 
Low Volume Anal Irrigation  
~150 





Primary outcome analysis (3 months) 
~270 
 
Secondary outcome analysis (6 months) 
~240 







Long-term follow up (12, months) ~120 






7. STUDY PROCEDURES 
 
7.1 Informed Consent Procedures 
Written informed consent will be obtained at visit 1 from research participants by an 
appropriately trained and delegated researcher in a face to face setting in clinic. 
 
7.2 Screening, Enrollment 
A brief screening questionnaire will be used to determine whether patients meet 
inclusion and exclusion criteria (see eligibility above). Screening will be performed by 
suitably trained study personnel to minimise logistic hurdles, and as determined by 
geographic availability.  
 
The brief screening questionnaire will also be made available on the study website, 
with the participant information sheet for patients to self-screen and contact their 
nearest research site if interested in taking part. All basically eligible participants will 
then undergo formal face to face consent, screening and enrolment session prior to 
randomization. 
 
7.3 Randomisation Procedures 
Patients will be randomised 1:1 into two groups; those who commence therapy with a 
low-volume device and those starting with a high-volume device. Patients will be 
stratified by sex and females by centre. Randomisation will be performed by a GCP-
trained member of the research team using an online system. 
 
7.4 Blinding 
Patients and clinicians are necessarily aware of both INVEST and treatment 
allocations. The need to collect data on frequency and volume of irrigation, as well as 
reasons for discontinuing or switching between systems, means assessor blinding is 
not possible with respect to these outcomes. Any researcher collecting CRFs or 
handling journals will therefore be unblinded. However, the primary outcome (PAC-
QOL at three months) will be concealed; the patients will complete this questionnaire 
without a researcher present. This will be accomplished in one of the following ways; 
 
1. Direct entry to online secure database, with built in validation and prompting to 
ensure data completeness. 
2. Completing paper questionnaire by following instructions on an information card to 
ensure all questions are answered. This will be placed in a sealed envelope marked 
with the patients pseudonymised study code and will not be opened until the time 





7.5 Study interventions 
7.5.1 Anal Irrigation therapy 
Anal irrigation training will be provided by trained nurse or physiotherapist with 
experience in delivering care for chronic constipation. They must have initiated 
irrigation therapy in at least three patients independently, and be a nurse/therapist of 
good standing within a clinical team regularly seeing patients with chronic 
constipation. A standardised approach and intervention will be provided via use of an 
intervention manual. For the first three months of participation in the study, patients 
may not use other therapies besides anal irrigation and those rescue therapies 
specified below. They may discontinue therapy at any point (elective withdrawal from 
intervention) and may switch from one system to the other after 3 months.  Switching 
anal irrigation systems before completing the three-month waiting period will be 
discouraged. If it does occur, it will be documented as a protocol violation with the 
timing and reason documented. If symptoms are severe despite use of irrigation and 
rescue therapies then other medications may be used on compassionate grounds, 
but this must be recorded in the CRF/concomitant medications log. 
 
The course of therapy will include a nurse-led training session (or more if required to 
ensure the device is being used effectively) followed by patient-led home irrigation 
therapy. The low-volume system commonly used in practice is Qufora® Mini (MBH-
International). Various high-volume systems are used, all of which have very similar 
mechanisms of action; these include Peristeen™ (Coloplast) and Qufora-
Toilet/Qufora-Balloon™ (MBH-international).  
 
 
These are commercially-available transanal irrigation systems available on 
prescription in NHS practice. 
 
Low-volume Irrigation 
This system consists of a small reservoir attached to a cone. The reservoir holds 
approximately 70ml of water and is squeezed to inject water into the rectum. The 
regime used will be as follows: Initial irrigation once daily for 14 days using 1 -3 
insufflations (each of 70ml approximately). This may then be reduced to alternate 
days depending on response. Patients may then adjust frequency and volume 
depending on response. They may irrigate as much and as often as they feel is 
necessary to give them benefit and this information will be captured on the CRF with 
the aid of an irrigation journal. 
 
High-volume irrigation 
High-volume systems consist of an irrigation bag connected to a tube. The water 
flows into the rectum, either by gravity or using a pump. Some systems employ a 
balloon to hold the device in place during irrigation; others require the patient to hold 
it in place. The mechanism of action is the same for all systems. Initial frequency of 
irrigation is the same as for low-volume irrigation; i.e. daily for 14 days, then alternate 
days. Patients will commence with irrigations of 300ml and increase this by 100 ml 
every two days until satisfactory defaecation is achieved or the procedure becomes 
uncomfortable, up to a maximum of 1500ml. Patients may adjust therapy depending 
on response, as for low-volume irrigation. 
 
Training sessions (45-60 min) (V2-V3) 






(i) Regulation/standardisation of laxative use: Bisacodyl may be used orally as a 
rescue therapy (up to 20mg at night), plus glycerine suppositories 1-2 if needed, 
if no stool for 3 days. In addition, patients may take Movicol up to a maximum 
dose of 2 sachets three times per day (TDS) and/or lactulose up to 15ml twice 
per day (BD). Prokinetic drugs and any other drug that the British National 
Formulary (BNF) describes as having laxative effect or herbal teas that contain 
strong purgatives will be discouraged, but if needed (i.e. if symptoms severe) 
then these are permitted but use must be recorded in the concomitant 
medications log. There will be no use of enemas. 
(j) The device will be demonstrated to the patient by the nurse specialist and then 
the patient will practice setting up the device. The trainer will ensure the patient 
knows how to use the device correctly before home irrigation is commenced. The 
trainer and patient will agree a date for delivery of equipment and 
commencement of home irrigation. Ideally this should be the same as the first 
training visit, but this may not be possible due to delay in supplying irrigation 
equipment. Any delays should be recorded on a deviation log/note to file (CRF 
7/8) to allow data analysis to be adjusted accordingly. 
(k) Plenty of optimism, encouragement and personal attention. 
 
Visit 2.1: 
(l) A telephone call will be made to the patient 14 days (+/- 3 days) after Visit 2 to 
check everything is proceeding correctly and to resolve any problems (V2.1). If, 
due to delay obtaining equipment etc, the patient has not started irrigation at this 
time then the phone call (and other follow up visits) should be re-scheduled for 14 
days later, and the reason for this recorded on CRF 7/8. 
 
Visit 2.2: 
(m) If there are problems, a further face-to-face session will be offered (V2.2). There 
is no specific time requirement and will depend on the difficulties encountered 
and availability of appointments, ideally this visit should be conducted within a 
week and before visit 3.  
 
Visit 3: 
(n) All patients will receive a further training assessment at 2 weeks (+/- 1 week) 
after Visit 2.1, allowing for any delay as described previously (V3). This visit will 
be combined with collection of PAC-QOL, PAC-SYM and EQ-5D-5L, EQVAS and 
should be face to face. The irrigation journal will be reviewed at this visit. A 
telephone call is an acceptable alternative if this is not possible. 
(o) Patients deciding to switch to the alternative system will be trained in the new 
system by the irrigation nurse and this will be recorded on the note to file, CRF 8 
and change/discontinue, CRF12. These patients will not need to complete the 
questionnaires at 1 month and 3 months if they have already done so. 
(p) Standardised guidance on how to tailor therapy to each patient depending on 
initial response will be provided to specialist nurses/therapists. Changes in 
regimen as well as system will be documented on the CRF. 
 
Telephone support will be available from the therapist between visits (number given, 
office hours only). The therapist will complete the intervention CRF at every visit or 
patient contact. For contact with patients after the training period, a note to file (CRF 
8) should be completed, and the patient will also make a note of any contact in their 
irrigation journal. In the instance of new psychological issues being determined 
during consultation, referral for psychological support will be deferred until after 
completion of irrigation training. The exception to this rule would be where there is 
clinical concern regarding the patients acute mental state requiring more urgent 




the irrigation nurse team to the research team, and these would be evaluated by the 
PI (or a medically-trained deputy) and appropriate action taken. Further follow-up 
visits (V4-V8) will be conducted by the research team. If the patient requires further 
input from the irrigation nurse this may be arranged as per local practices. Any 
contact and any changes made or advice given regarding irrigation should be 
recorded in the patient journal and irrigation journal. 
 
7.5.2 Switching between anal irrigation systems 
After three months of using one system, patients may switch to the other or 
discontinue therapy and return to routine clinical care. This will be entirely patient-led, 
and reasons for changing systems will be explored during follow up visits and 
captured on the CRF. There is therefore no defined protocol for switching treatments 
as patients may do this for any reason; analysis of time to switching/discontinuing 
therapy, as well as the patient-reported reasons for doing so, will provide insight into 
why each irrigation system is or is not successful. In addition, qualitative interviews 
with patients who have switched or discontinued therapy will be used to explore 




Patients will undergo standardised investigations. If INVEST previously conducted 
within the last 12 months, results can be carried forward. Pregnancy testing will be 
conducted as per routine NHS practice (10 day NHS rule) in respect to women 
between menarche and menopause. Women of equivocal status will have a serum 
pregnancy test performed as per routine care. 
 
(e) Anorectal manometry using standard or high-resolution methods40-42, depending 
on local availability, to determine defined abnormalities of rectoanal pressure 
gradient during simulated evacuation43-45. 
(f) Balloon sensory testing using standardised methods46, 47(2ml air per second to 
maximum 360 ml) to determine volume inflated to first constant sensation, 
defaecatory desire and maximum tolerated volumes. Rectal hyposensation and 
hypersensation defined in accord to gender-specific normative data on 91 healthy 
adults48. The rectoanal inhibitory reflex will also be elicited by 50ml rapid inflation 
(if necessary in 50 mL aliquots up to 150ml). 
(g) Fixed volume (50ml) water-filled rectal balloon expulsion test43,44,49,50in the seated 
position on a commode. Abnormal expulsion is defined as abnormal if failure to 
expel with 1-minute effort for men and 1.5 minutes for women51. 
(h) Whole gut transit study using serial (different shaped) radio-opaque markers over 
3 days with single plain radiograph at 120 hours52,53. 
 
NOTE: INVEST procedures conducted prior to recruitment to the study (i.e. within the 
past 12 months) may be done using locally available devices and methods. 
 
Treatment 
All patients will undergo trans-anal irrigation therapy irrespective of INVEST results, 
and will be followed up in the same way. The purpose of INVEST in this study is to 
identify whether certain radio-physiological results correlate with treatment response, 
i.e. can we predict likelihood of benefitting from irrigation based on pre-treatment 
investigations. Balloon sensory testing in combination with patient-reported urge to 






7.6 Concomitant Medications 
It is inevitable that patients will seek recourse to laxatives and other dietary 
supplements during the course of the programme. Experience shows that complete 
prohibition can lead to unreported laxative use, which might confound findings. 
Although we will strongly discourage ad libitum medication usage and specify a 
defined breakthrough regimen, we will record co-treatment with sufficient fidelity and 
integrity to enable use as covariates in analyses using a specific patient journal for 
this purpose (see standardised outcome framework). A concomitant medications list 
including a shortlist of contributory or confounding medications will be used to filter 
on data entry. Patients using one system in the medium/long term may wish to revert 
to the other system or pause treatment for a short period (for example while going on 
holiday) for practical reasons. This is permitted but must be recorded in the 
concomitant medications log. This will not be considered as switching or ending 
treatments as it is only a short-term measure. 
 
7.7 Criteria for Discontinuation 
The interventions proposed are well-established in current clinical practice. There are 
no defined criteria for discontinuation; however clinicians may withdraw treatment 
where they have therapeutic or safety concerns, consistent with routine care. 
Patients may choose to discontinue treatment at any point and return to routine 
clinical care.  
 
7.8 Procedure for Collecting Data including Case Report Forms (CRFs) and 
storage 
The data collected for the trial will be a mixture of routinely collected data, verifiable 
against the medical record and patient reported outcome (PRO) or questionnaire 
data, collected directly to CRF. The following table outlines the data sources, 
collection requirements and transfer of data. 
 
Study Assessment Data Sources Data Transfer 
Brief screening and eligibility criteria 
check 
Patient Interview CRF1 (OpenClinica) 
Informed Consent Consent Form none 
Structured history including eligibility 
assessment, demographics, medical 
history, medications and clinical 
examination  
Patient interview and  
Medical Notes - routine data 
CRF2 (OpenClinica) 
Pregnancy Test where applicable 
Laboratory Test Result - 
routine data 
CRF2 (OpenClinica) 
Baseline Only Assessments (Rome 
III ConstipationQ & IBSQ, Cleveland 
ClinicQ, St Marks,  joint 









Randomisation Online system CRF 4 
Rectal balloon sensory testing Medical Notes - routine data CRF3 (OpenClinica) 
Balloon expulsion test Medical Notes - routine data CRF3(OpenClinica) 
Anal manometry Medical Notes - routine data CRF3 (OpenClinica) 
Radio-opaque marker transit study Medical Notes - routine data CRF3 
   
In therapy assessments (Anal 
Irrigation) 
Medical Notes - routine data 




SYM , , EQ-5D-5L, EQVAS, PHQ9, 
GAD7, VAS, CC-BRQ, BIPQ-CC) 





Short outcome assessment (PAC-
QOL, PAC-SYM, EQ-5D-5L) 





 2 week Patient Diary (bowel)  
PROM  –  2 week Patient 
Diary (eCRF/CRF)  
Patient Diary 
(REDCAP) 
AE log  Medical Record and PROM CRF5 (OpenClinica) 
ConMed Log  Medical Record and PROM CRF6 (OpenClinica) 
Deviation Log  CRF7 CRF7 (OpenClinica) 
Note to File/Contact Log CRF8 CRF8 (OpenClinica) 
Early Withdrawal Medical Record    CRF9 (OpenClinica) 
Study Completion Medical Record 
CRF10 
(OpenClinica) 
Follow Up – resource use 
PROM – Irrigation Journal 
and Patient Journal 
CRF11 
(OpenClinica) 




Each recruiting site will be required to keep accurate and verifiable source notes in 
the medical record relevant to each study participant’s inclusion and continued 





Data will be collected, transferred and stored in accordance with GCP guidelines and 
data protection requirements. The PCTU SOPs and study data management plan will 
define the exact process of data collection, transfer and storage and control of study 
data.  
 
A secure online OpenClinica trial database will be provided by the PCTU to enable 
remote data entry at sites where this is feasible. This database will provide built in 
data validation checks with quality control checks performed by checking a 
predefined percentage of CRF data against data entered into the database. In 




Patient reported outcome measures (PROMs), including questionnaires and diaries 
may be collected directly to eCRF using a secure and controlled REDCAP database. 
An automated email reminder will be sent to participants to remind them to complete 
the questionnaires and diaries every 12 weeks. Alternatively, participants can 
complete paper questionnaires and diaries to be entered by the central study team. 
 
All patient identifiable data, such as consent forms, screening and identification logs 
will be stored in the investigator site files in secure locked cabinets and/or offices, 
accessible only to delegated members of the study team. Secure methods of data 
transfer will be used to return CRFs to the coordinating site for centralized data entry, 
monitoring, quality control and in compliance with GCP. A copy of the CRF held at 
the site in accordance with GCP. 
 
7.9 Follow-up Procedures 
The study duration allows for follow up to a maximum of 12 months with data 
collection at 3, 6 and 12 months post initiation of therapy. Primary outcome data will 
be collected at three months. Each participant will have a minimum of 3, 6 and 12 
months follow up data for collecting the primary and secondary outcomes. In 
addition, PAC-SYM, PAC-QOL and EQ-5D-5L, EQVAS will be recorded at the 1-
month visit; this is to capture information on early non-responders, and to better 
understand and characterize this group of patients. Participants will leave the study 
and return to ‘routine clinical care’ as determined within their local NHS institution (or 
be recruited to subsequent trials). Alternatively they may wish to proceed to 
enrolment in the next work package (Study 3 – Laparascopic Ventral Mesh 
Rectopexy) within the CapaCiTY programme. 
 
The following data will be collected at each visit up to 12 months: 
 
 Validated symptom and quality of life questionnaires (PAC-SYM and PAC-
QOL).Validated generic QOL questionnaires: EQ-5D-5L descriptive system and 
EQ-VAS53. Note: EQ-VAS has a SD of approximately 30 points: a 10% difference 
in VAS deemed clinically significant can be detected with the large sample sizes 
proposed. 
 
 Patient Health Questionnaire-9 (PHQ-9) 56-58. 
 Generalized anxiety disorder questionnaire (GAD7) 59. 
 Depression, anxiety and somatisation modules of the Patient Health 
Questionnaire56-59.illness perception questionnaire60. 
 Global patient satisfaction/improvement score (VAS) and whether they would 




 Potentially modifiable cognitive and behavioural psychological variables shown to 
predict onset and perpetuation of other functional bowel symptoms: negative 
perfectionism, avoidant and ‘all or nothing’ behaviour subscales of the 
behavioural response to illness questionnaire (CC-BRQ), and brief illness 
perception questionnaire BIPQ (CC). 
 A two week patient diary (for 2 weeks prior to each assessment at 3, 6 and 12 
months) to record bowel frequency and whether each evacuation was 
spontaneous (no use of laxatives) and/or complete; patient journal will also 
capture concurrent medication, health contacts, time away from normal activities 
(including work). Patients will be contacted by telephone to remind them to start 
the diary. If patients forget to do this, then it is acceptable for them to start 
recording the diary on the day they are seen in clinic and for this to be collected 
two weeks later. 
 Resource use data (using patient journals as a prompt and including concomitant 
medication use). 




7.10 Laboratory Assessments 
Serum Pregnancy Testing will be performed as per standard care for any women of 
equivocal status undergoing radiological assessments (INVEST).  
 
7.11 Radiology Assessments 
The whole gut transit study usually (90% patients) involves the use of a single plain 
abdominal radiograph (in 10% patients, a maximum of 2 may be required to image 
whole abdomen and pelvis). This procedure forms part of routine clinical care for 
patients with CC at many NHS centres. All practitioners (radiologists, radiographers 
etc.) directing these studies will hold appropriate IR(ME)R certification. 
 
 
7.12 Participant withdrawal (including data collection / retention for withdrawn 
participants) 
Individual participants will be able to withdraw from treatment at any time by notifying 
healthcare professionals involved with the study, and return to routine care without 
prejudice.  Data will be retained for analysis from all participants after the point of 
consent and recruitment. 
 
Withdrawal from treatment Criteria: 
 
Participant develops any of the following exclusion criteria 
 Participant becomes pregnant or intends to become pregnant (only in 
baseline and intervention phases). 
 Participant subsequently diagnosed with proven cause for secondary 
constipation e.g. Parkinson’s disease or bowel obstruction. 





 Participant develops significant intercurrent illness precluding participation. 
 Participant requires surgery or other intervention (other than minor ops) 
during treatment or follow up phase. 
 Participant develops acute psychological problem causing safety concern. 
 Adverse events secondary to therapy (bleeding, anal fissure, ulceration, pain, 
bowel perforation) – relative indications for withdrawal depending on the 
views of the patient and doctor (NB perforation is an absolute indication for 
withdrawal). 
 Elective withdrawal. 
 
Loss to Follow Up (no further interventions or follow up data collected) 
 During follow up (up to12 months), participants may be withdrawn from the 
trial if they become lost to follow up (LTF) after at least 3 failed attempts by 
research staff to make contact via 2 different methods (e.g. phone and letter). 
 Participant chooses to withdraw and does not wish to participate in follow up 
data collection. 
 Death or significant incapacity making follow up data collection impossible. 
 






































Minimum Timeframe between visits+ 
(Maximum Timeframe) 




(+ 8 weeks) 
+ 2 weeks 
(+/- 3 days) 
+2 weeks 
(+/- 1 week) 
+ 2 months 
(+/-1 week) 
+ 3 months 
(+/-1 week) 
+ 6 months  
(+/-1 week) 
Brief screening and providing PIS x        
Informed Consent  x       
Structured history including eligibility assessment, 
demographics, medical history, medications, clinical 
examinations  





Pregnancy Test where applicable  x       
Baseline only assessments  x       
Rectal balloon sensory testing*  x               
Balloon expulsion test*  x       
Anal manometry*  x       
Radio-opaque marker transit study*  x       
Randomisation  x       







V1.1 = INVEST – A minimum timeframe of 2 weeks to allow completion of baseline diary prior to INVEST and maximum of 8 weeks (for logistical purposes).  
V2 = commencement of therapy and TAI training; V2.1 = Phone call within 2 weeks  
**V2.2 = further training if needed to be conducted prior to or in conjunction with V3 if necessary. V3 = 4 week follow up session (Face-to-face if possible or telephone) 
All follow up time points measured from commencement of therapy (V2) 
 *** Resource use data is collected in patient journal training and retrospective completion of this journal occurs at visit 1. 
Standardised outcome framework assessments  x    x x x 
Short Outcome Assessment     x    
Patient Diary Provided  x   x x x  
Patient Diary Collected 
*** 
  x   x x x 
Patient Journal Provided   X       
Patient Journal Collected       x x x 
Irrigation Journal Provided   x  x x x  
Irrigation Journal Review     x x x x 




7.14 End of Study Definition 
The end of study is defined as the last patient last visit. The sponsor, REC and local R&D 
departments will be informed of end of study and site closure and archiving procedures 
initiated. 
 
7.15 Criteria for Early Termination 
If the DMEC, PSC, REC or sponsor determine it is within the best interests of the 
participants or trial to terminate the study, written notification will be given to the CI. This may 
be due to, but not limited to; serious safety concerns, serious breaches, acts of fraud, critical 
findings or persistent non-compliance that negatively affects patient safety or data integrity. 
If the study is terminated participants will be returned to the NHS normal follow up and 
routine care. 
 
 7.16 Qualitative interviews 
The purpose of this qualitative enquiry is to complement the quantitative study of anal 
irrigation. A phenomenological methodology will be employed and qualitative data will be 
collected in parallel with the quantitative study. Participants will be recruited separately from 
the quantitative study, with separate patient information sheets and consent processes. 
 
Sampling   
A purposive sample of approximately 35 patients will be invited to interview upon completion 
of irrigation training and then again at 6 months. Participants do not have to participate in 
both sets of interviews; a separate set of patients can be interviewed at 6 months. 
Recruitment can be extended if data saturation is not accomplished by the 35th patient data 
saturation is defined as the point at which no new or relevant themes emerge. Inclusion and 
exclusion criteria are as above. Participants will be selected from a sampling grid of potential 
interviewees to reflect a range of ages, geographical locations, and where possible other 
pertinent attributes such as ethnicity and gender. An approximately equal number of patients 
will be selected from each trial arm as follows:  
17 patients undergoing low-volume anal irrigation and 18 patients undergoing high-volume 
irrigation and including those who discontinue early (<3 months), later (3-5 months), those 
who continue with their allocated treatment, and those who switch. In addition, 
approximately 10 health professionals involved in delivering the treatment will be 




All participants will be told that they might be invited for interview when they are initially 
informed about the study. Participants will be contacted by a member of the clinical team 




offered a semi-structured interview in a clinic room or in their own home according to their 
preference, and will be offered a chaperone to be present if they would prefer. Professionals 
will be interviewed in a clinic setting. Following written consent, the interviews will be 
recorded on a digital dictaphone and transcribed into a pseudonymised (alphanumeric code) 
text document. Interviews will be conducted by the following:  
An experienced qualitative researcher working within the wider CapaCiTY research 
programme, A Clinical Research Fellow at UHND and/or a Health Research Methodologist 
at Durham University will conduct interviews recruited from the Durham site. 
 
Interviews will explore health professionals’ and participants’ experiences of recruitment, 
individual interventions, their training and delivery, and patients’ views about outcome 
measures. A topic guide for each of the interviews and focus groups, informed by the 
existing literature and our patient advisors, will be developed. 
 
Timing  
Patients will be invited to one-to-one interviews on completion of training and will be 
interviewed a maximum of 4 weeks after training to maximise recall. Patients will be recalled 
up to 6 months after training and offered an interview. The patients interviewed at baseline 
do not have to be the same as those interviewed up to six months. Interviews will be 




Interviews will be digitally recorded, anonymised, transcribed verbatim and analysed using a 
thematic analysis and NVivo8 software (QSR International Ltd, Warrington, UK) for data 
management. Data analysis will be developed as outlined by Fereday & Muir-Cochrane61 in 
the first instance by mapping key concepts derived from the transcripts (‘charting’) and 
extracting emergent themes from the transcripts. Prof Norton will co-ordinate and conduct 
analysis, while for the purposes of Christopher Emmett’s MD, independent analysis will be 
conducted by CE and Dr Helen Close. Emergent themes, together with captured 
observational data, will form the basis of analytical interpretation. Data will be handled in a 
confidential manner at all times, and only transferred on encrypted media or via secure 
electronic transfer. 
8. STATISTICAL CONSIDERATIONS 
 
8.1 Sample Size 
PAC-QOL is a 28-item disease-specific measure, with each item scored 0-4, and providing 
an aggregate score 0-435. Superiority of either low volume or high volume anal irrigation is 




conservatively set at SD=1 from the published literature. To detect an effect size of 0.4 
(mean/SD =0.4) between the two groups with 90% power and 5% significance at three 
months requires 133 patients per arm, and 266 total. Allowing for an anticipated 10% loss to 
follow up (LTFU), then 300 patients will be recruited. 
 
8.2 Method of Analysis 
8.2.1 Clinical Outcomes 
A full analysis plan will be signed off before allocation codes are made available to the 
statistician. The codes will not indicate which treatment arm is which so that as far as 
possible the statistician will remain blind to allocation throughout the analysis. All analyses 
will be by the intention-to-treat principle. The primary outcome will be PAC-QOL as a 
continuous variable, analysed at 3-months while the quarantine period is in effect. The 
proportion of patients continuing with the initial therapy system will be recorded, and the 
PAC-QOL scores will be analysed using a linear mixed model with a random effect for 
centre and fixed effects for intervention, trial stratification variables (participants are stratified 
by sex and females by centre) and baseline PAC-QOL. 
 
Secondary outcomes will be analysed using the principles outlined above for the primary 
outcome.  
 
Exploratory modelling will be conducted for baseline characteristics: measures of chronic 
pain, autonomic, joint hypermobility, cognitive, behavioural and mood variables share a 
common hypothesis that they are detrimental to the success of all treatments i.e. they 
perpetuate illness in spite of therapy. We will investigate a maximum of 3 interactions 
between treatment and baseline characteristics. These will be described in the statistical 
analysis plan a priori. Appropriate regression models including interaction terms will be 
developed to determine the influence of these pre-treatment characteristics on the success 
of treatments in all work packages. 
 
Life table data for any irrigation will be presented by initial therapy and for specific therapy 
from date of commencement. Survival analysis will be presented using Kaplan Maier 
analysis and adjusted using Cox regression. Exploratory analysis will be considered to 
identify characteristics of sub-groups with greatest persistent benefit from irrigation. These 
will be described in the statistical analysis plan a priori. 
 
Analysis will be performed using proprietary software, (Stata Corp. Texas). P<0.05 will be 
taken to indicate statistical significance. No analyses will be conducted until an analysis plan 





Multiple imputation will be considered to address missing covariate values. Details of any 
imputation to be performed will be described in the statistical analysis plan which will be 
finalised after initial checks on completeness of the data but before performing any analysis 
or un-blinding of the data.  
 
8.2.2 Health economic outcomes 
The patient journal will facilitate the capture of health economic data which will be recorded 
on the CRF at each visit. This will be combined with the initial cost of the device and weekly 
consumables. 
 
Within-trial stochastic analysis will compare the cost/success and cost/QALY of anal 
irrigation. Patient-level cost-effectiveness analysis will use standard bootstrapping methods 
to generate cost-effectiveness acceptability curves exploring value-for-money. Within-cohort 
combined stochastic/probabilistic epidemiological models will be used to assess irrigation 
and surgery options, exploring relative effectiveness and cost-effectiveness according to 
patient characteristics. 
 
Cost-effectiveness models that extrapolate beyond 3-6 months duration are problematic in 
adult constipation, as subsequent care and outcomes are contingent upon subsequent care 
received and the underlying disease process. However, the programme of work packages, 
and inclusion of time to failure data capture, provides a unique opportunity to construct 
probabilistic models exploring optimal pathways from effectiveness and cost-effectiveness 
perspectives.  
 
Since patients will (within the CapaCiTY programme) be followed along a pathway that 
includes a series of steps of care, it will be possible to construct costs and outcomes for a 
range of patient pathways providing comparative longer term cost effectiveness estimates. 
Patient-level data from recruitment through the various work packages will be used to 
construct pragmatic, probabilistic models to explore optimal pathways from effectiveness 
and cost-effectiveness perspectives. 
 
Analyses from NHS and societal perspectives will be supported by recording relevant 
resource use during each work package, and a common panel of outcomes. Adjustment for 
time preference will be at the socially accepted rate for cost effectiveness analyses 
(currently 3.5%/annum for costs and benefits).  
 
 8.2.3 Data analysis for MD thesis 
The study will form the basis of a thesis for an MD at Durham University by a research fellow 




UHND and the Royal Victoria Infirmary, Newcastle-upon-Tyne up to 1st October 2016 
(estimated 50 patients) will be analysed in this thesis, including those recruited to the 
qualitative arm of the study at this site (section 8.17 above). These patients will have a 
minimum of 3 months of study data. The release of data from the UHND and Newcastle sites 
for this purpose has been approved by the Chief Investigator on the condition that it may be 
used for thesis examination but is not published or made publically available until the 
CapaCiTY programme results are published in full. The qualitative data from the Durham 





This study (Study 2 of the CapaCiTY programme) will be carried out in accordance with the 
ethical principles in the Research Governance Framework for Health and Social Care, 
Second Edition, 2005 and its subsequent amendments as applicable and applicable legal 
and regulatory requirements.  
 
Ethics approval for the whole CapaCiTY programme (studies 1 to 3) will be sought from one 
of the London NRECs (exact committee to be determined based on timings and availability). 
Within the programme, the three studies will however be consented separately as if they 
were distinct entities. This is necessary to limit patient information which would otherwise be 
over-burdensome. We have discussed the use of sequential consent forms within one 
pragmatic enriched design with Dr Art Tucker, national ethics advisor and Chair of the East 
London and the City REC who confirms this will be practicable. 
 
9.2 Ethical considerations 
The protocol has been reviewed by Prof Richard Ashcroft, Professor of Medical Ethics and 
Law at QMUL. Important considerations that have informed pragmatic design include (a) 
limitation of intimate examinations: to one time point (not repeated if performed before 
recruitment); (b) timings of outcomes: Within this study outcomes will be undertaken at 3 and 
6 months from the commencement of the first treatment for all patients, with additional 
recording of key outcome measures (PAC-QOL, PAC-SYM, EQ-5D-5L, EQ-VAS, Irrigation 
Journal and Patient journal). For this period of 6 months, patients will not progress to further 
WPs thus preventing outcome ‘contamination’. Additionally there will be a 3 month 
‘quarantine’ from switching irrigation therapy. These delays are akin to that in usual NHS 
care, during which general supportive care will be provided. This proposed limitations at 3 
and 6 months confers no disadvantage and may even represent an acceleration of treatment 
progression. Ethically, this is viewed as a reasonable trade-off for the commitment to the 
research programme; (c) recruitment & consent: study 2 represents one of the 3 studies 
incorporated in the NIHR-funded CapaCiTY programme. Although patients may move 




2 will be consented as a distinct single entity; (d) qualitative interviews: these will be in-depth 
interviews conducted one-on-one (plus a chaperone if requested by the patient) and 
therefore there are potential risks to the safety of the interviewer. Also, the thorough nature 
of the interviews could lead to psychological distress for the participant. It is therefore 
necessary to identify patients who would be at especially high risk in either of these ways 
and to exclude them from the study. Baseline assessment would identify and enable 
exclusion of individuals with pre-exiting psychiatric disorders or a history of high-risk 
behaviours (self-harm, drug and alcohol addiction). Counselling and support from healthcare 
professionals involved in patient care will be available for any subject experiencing untoward 
distress. 
 
The investigating team have no conflicts of interest. 
 
10. SAFETY CONSIDERATIONS 
Patients recruited who have not had previous INVEST procedures conducted within the last 
12 months will undergo a radiological procedure (whole gut transit) using ionising radiation 
as outlined above. The average dose of this procedure (~0.1mSv) is equivalent to about 2½ 
weeks annual background radiation dose from living in the UK [NB: this is an approximation 
which will require re-certification by Barts Health NHS Clinical Physics Dept. based on doses 
from 20 equivalent procedures]. Further, these investigations would be carried out in routine 
clinical practice in many centres for patients at the same point as recruitment to this study. 
Regarding the intervention, anal irrigation is associated with a very small incidence of bowel 
perforation, as well as other side effects (bleeding, pain, ulceration, painful haemorrhoids, 
anal fissure). Patients will be counselled regarding these risks as part of the process of 
informed consent. In addition, they will be trained in the correct use of the device prior to 
commencing therapy. All related adverse events and all serious adverse events will be 
recorded and therapy suspended while these are investigated (see ‘Safety Reporting’ 
below). 
 
11. DATA HANDLING AND RECORD KEEPING 
 
11.1 Confidentiality 
Information related to participants should be kept confidential and managed in accordance 
with the Data Protection Act, NHS Caldecott Principles, The Research Governance 






Identifiable information to be collected from the participants include, full name, DOB and 
hospital number and contact details at screening. This information will be used to contact 
participants but will not leave the study site without prior consent and approvals. All case 
report forms will be pseudonymised. The participant’s GP will be informed of their 
participation in the study. 
 
The trial data will be made available to suitably qualified members of the research team, 
study monitors and auditors, the sponsor, the REC and regulatory authorities as far as 
required by law. The participants will not by identifiable with regards to any future 
publications relating to this study.  
 
11.2 Record Retention and Archiving 
When the research trial is complete, it is a requirement of the Research Governance 
Framework and Trust Policy that the records (including paper records, digital records and 
audio files) are kept for a further 20 years. For trials involving BH Trust patients, undertaken 
by Trust staff, or sponsored by BH or QMUL, the approved repository for long-term storage 
of local records is the Trust Modern Records Centre. 
 
Each site will be required to archive local site files and patient identifiable information such 
as consent forms and screening logs for a period of 20 years. At the end of the 20 year 
retention period, permission should be obtained in writing from the sponsor prior to 
destruction. 
 
12. LABORATORIES (if applicable) 
Serum pregnancy testing will be performed by local NHS biochemistry laboratories. 
 
13. PRODUCTS, DEVICES, TECHNIQUES AND TOOLS 
 
13.1 Devices 
The following is a list of all devices used. None are specific to the research itself and all are 
currently used in routine clinical. All are CE marked and approved for use in the UK. 
 
1. Disposable proctoscope (supplier as local NHS practice). This will be commonly be 
used as part of clinical examination at baseline and is also used to introduce balloon 
catheters into the rectum during INVEST. 
2. High Resolution Anorectal Manometry (HRAM system + Unisensor HRaM catheter 
(200 uses) and balloons, software, cables, calibration kit, isolation transformer and 
laptop. Insertion and use are outlined under interventions section [equipment 




3. Standard anorectal manometry catheter, balloons, software, cables, calibration kit 
and associated equipment; standard equipment in many NHS centres for performing 
anorectal physiology. Can be used as an alternative where high-resolution 
manometry is not available (Part of INVEST – see above). 
4. Balloon catheters for balloon expulsion test (part of INVEST – see above). 
5. Radio-opaque markers for colonic transit study: various suppliers (part of INVEST – 
see above). 
6. Standard departmental X-ray equipment (part of INVEST- see above). 
7. Peristeen™ anal irrigation system (Coloplast), Qufora®Balloon/Qufora-Toilet anal 
irrigation systems (MBH-International): Established anal irrigation systems available 
on prescription in NHS practice. Other systems with the same mechanism of action 
may also be used (dependent on local funding and prescribing arrangements). 
8. Qufora® Mini anal irrigation system (MBH-International): Established anal irrigation 
system available on prescription in NHS practice. 
 
All devices are maintained, calibrated and serviced according to standard NHS policies and 
procedures according to manufacturer’s guidance. Training on devices is provided by the 
supplier’s representatives. Additional study SOPs and training will be provided to ensure 
standardisation across sites, but will be in line with current NHS standard practice. 
 
13.2 Techniques and interventions 
There are no experimental techniques within the study. The intervention is outlined in detail 
above  
 
13.3 Data Collection Tools 
The permissions/licenses to use the below instruments have been sought on the 
understanding sites are permitted to utilise these within this study only, they will be provided 
to sites as part of the CRF for the study: 
 
• PAC-QOL score: from MAPI Research Trust  
• PAC-SYM score: from MAPI Research Trust 
• EQ-5D-5L: from EuroQol 
The below listed questionnaire-based tools are free to use within the public domain and will 
be provided to sites as part of the CRFs for the study. 
 
• Depression, anxiety and somatisation modules of the Patient Health Questionnaire. 
• Illness perception questionnaire. 
• Composite Rome III / Cleveland Clinic constipation questionnaire: free to use. 
• Brief, chronic pain, autonomic and joint hypermobility: free to use. 
• Negative perfectionism. 






13.4 Medicinal product 
None 
 
14. SAFETY REPORTING 
 
14.1 Adverse Events (AE) 
An AE is any untoward medical occurrence in a subject to whom an intervention has been 
administered, including occurrences which are not necessarily caused by or related to that 
product. An AE can therefore be any unfavourable and unintended sign (including an 
abnormal laboratory finding), symptom or disease temporarily associated with study 
activities. 
 
Notification and reporting Adverse Events or Reactions 
The anal irrigation systems are in widespread and established clinical use throughout the 
NHS with known adverse event occurring (22%) being mostly low grade and reversible. All 
trial interventions are as per the standard care provided within the NHS for chronic 
constipation. Adverse events will be recorded on the CRF. Serious adverse events will be 
recorded on the CRF and in the medical notes to enable assessment and reporting in line 
with sponsor and regulatory requirements. Causality will be at the discretion of the health 
care provider (e.g. research nurse, physiotherapist, principal investigator or delegated 
member of team). These will be assessed as outlined below.   
 
Trial participants will be advised to seek medical support from their GP for any unrelated 
signs, symptoms or disease or aggravation of underlying symptoms. 
 
14.2 Serious Adverse Event (SAE) 
In other research other than CTIMPs, a serious adverse event (SAE) is defined as an 
untoward occurrence that: 
(a) Results in death. 
(b) Is life-threatening. 
(c) Requires hospitalisation or prolongation of existing hospitalisation. 
(d) Results in persistent or significant disability or incapacity. 
(e) Consists of a congenital anomaly or birth defect; or 





An SAE occurring to a research participant should be reported to the main REC where in the 
opinion of the Chief Investigator the event was: 
 Related – that is, it resulted from administration of any of the research 
procedures, and 
 Unexpected – that is, the type of event is not listed in the protocol as an 
expected occurrence.  
14.3 Notification and Reporting of Serious Adverse Events 
Serious Adverse Event (SAEs) that are considered to be ‘related’ and ‘unexpected’ are to be 
reported to the sponsor within 24 hours of learning of the event and to the Main REC within 
15 days in line with the required timeframe. For further guidance on this matter, please refer 
to NRES website and JRMO SOPs. 
 
Please note in the case of a blinded study, it is recommended the treatment code for the 
patient is broken in the reporting of an ‘unexpected and related’ SAE. Please seek advice on 
how this can be achieved whilst maintaining the team blind. The unblinding of single cases 
by the PI/CI in the course of a clinical trial should only be performed if necessary for the 
safety of the trial subject. 
 
14.4 Expected SAEs 
The following SAEs are expected to occur rarely in this patient population and will not be 
reported: 
 
 Hospital admission for exacerbation of constipation symptoms including 
impaction. 
 Hospital admission for unrelated elective surgical procedures or accidental injury. 
14.5 Urgent Safety Measures 
The CI may take urgent safety measures to ensure the safety and protection of the clinical 
trial subjects from any immediate hazard to their health and safety. The measures should be 
taken immediately. In this instance, the approval of the REC prior to implementing these 
safety measures is not required. However, it is the responsibility of the CI to inform the 
sponsor and Main Research Ethics Committee (via telephone) of this event immediately.  
The CI has an obligation to inform both the Main REC in writing within 3 days, in the form of 
a substantial amendment. The sponsor (Joint Research Management Office [JRMO]) must 
be sent a copy of the correspondence with regards to this matter. For further guidance on 





14.6 Annual Safety Reporting 
The CI will send the Annual Progress Report to the main REC using the NRES template (the 
anniversary date is the date on the MREC “favourable opinion” letter from the MREC) and to 
the sponsor. Please see NRES website and JRMO SOP for further information 
 
14.7 Overview of the Safety Reporting responsibilities 
The CI/PI has the overall pharmacovigilance oversight responsibility. The CI/PI has a duty to 
ensure that safety monitoring and reporting is conducted in accordance with the sponsor’s 
requirements. 
 
Communication organogram for reporting SAEs 
 
 
SAE recorded on AE log and followed up until resolution 
 
PI assesses SAE and reports to CI within 24 hours, PI reports to local 
institution as per local 
protocol 
 
CI reports related and unexpected SAE’s to PCTU QA 
manager and Sponsor within 24 hours of PI 
becoming aware of the event 
 
CI reports related and unexpected SAE’s to 
MREC within 15 days 
 
 
CI reports to DMC every 6-12 months                             CI reports annually to MREC  
 
 




15. MONITORING &AUDITING 
The PCTU quality assurance manager will conduct a study risk assessment in collaboration 
with the CI. Based on the risk assessment, an appropriate study monitoring and auditing 
plan will be produced according to PCTU SOPs. This monitoring plan will be authorised by 
the sponsor before implementation. Any changes to the monitoring plan must be agreed by 
the PCTU QA manager and the sponsor. 
 
Definition:  
“A systematic and independent examination of trial related activities and documents to 
determine whether the evaluated trial related activities we re-conducted, and the data 
were recorded, analysed and accurately reported according to the protocol, sponsor's 
standard operating procedures (SOPs), Good Clinical Practice (GCP), and the applicable 
regulatory requirement(s).” 
 
A study may be identified for audit by any method listed below:  
 
1. A project may be identified via the risk assessment process. 
2. An individual investigator or department may request an audit. 
3. A project may be identified via an allegation of research misconduct or fraud or a 
suspected breach of regulations. 
4. Projects may be selected at random. The Department of Health states that Trusts 
should be auditing a minimum of 10% of all research projects. 
5. Projects may be randomly selected for audit by an external organisation. 
 
Internal audits may be conducted by a sponsor’s or funder representative. 
 
16. TRIAL COMMITTEES 
The project will be under the auspices of the Chief Investigator and the PCTU. The project 
will be overseen by a Programme Steering Committee (PSC). 
 
The composition and responsibilities of the PSC will comply with the NIHR guidance and 
PCTU SOP on Trial Oversight Committees. The role of the PSC is to provide overall 
supervision of the study on behalf of the sponsor and funder to ensure study is conducted in 
accordance with the principles of Good Clinical Practice (GCP) relevant regulations. 
 





 Ensuring that views of users and carers are taken into consideration. 
 Advising on the trial protocol. 
 Advising on changes in the protocol based on considerations of feasibility and 
practicability. 
 Assisting in resolving problems brought to it by the PMG. 
 Monitoring the progress of the trial and adherence to protocol and milestones. 
 Considering new information of relevance from other sources. 
 Considering and act on the recommendations of the data monitoring 
committee (DMC), sponsor and/or MREC. 
 Review initial reports and papers for publication. 
 
The PSC will meet to review the protocol before the start of the programme and then soon 
after the first participants are recruited and either meet or teleconference every 6 months 
thereafter throughout the lifetime of the programme.  
PSC membership includes: 
 
 Programme CI (Knowles) 
 Study 1 lead PIs (Emmanuel & Norton) 
 Senior statistician (Eldridge) 
 Health Economist (Mason) 
 Study 2 lead (Yiannakou) 
 Joint Study 3 lead (  Brown & Lacy Colson) 
 An independent chair (Professor John McClaughlin, Professor of 
Gastroenterology and Nutrition, University of Manchester) 
 Programme Manager (Stevens) 
 Patient and Public Representatives including (Deborah Gilbert, CE Bowel and 
Cancer Research and Louise Smalley and Mr Ian McCurrach as patient 
representative). 
Representatives of the trial sponsor and funder will be invited to attend. 
 
A Programme Management Group (PMG) will meet monthly initially during study set up and 
then less frequently, every 2 months. The PMG will be responsible for day to day project 
delivery across participating centres, and will report to the PSC. It will include: 
 
 The programme CI (Knowles) 
 Study 2 lead PI (Yan Yiannakou) 
 Programme Manager (Stevens) 




 Research nurses 
 Research fellows 
 Trial Coordinator 
 Junior trial statistician  
 Data manager 
 QA manager 
A data monitoring & ethics committee (DMEC) will be convened. The DMEC will meet at 
least four weeks prior to the PSC to enable recommendations to be fed forward. The DMEC 
will comprise: 
 Independent Chair (Prof David Jayne, Professor of Surgery, University of 
Leeds) 
 An independent medical statistician (Neil Corrigan, Leeds Institute of Clinical Trials 
Research, University of Leeds) 
  Leeds) 
 Clinician (Dr Rupert Pearce, Professor & Consultant in Intensive Care 
Medicine, Royal London Hospital) 
A DAMOCLES charter will be adopted, and the project team will provide the DMEC with a 
comprehensive report, the content of which should be agreed in advance by the Chair of the 
DMEC and follow guidelines set out in the charter. 
 
A constipation research advisory group (CRAG) will be formed as part of a well-developed 
patient and public involvement (PPI) strategy at QMUL (in close association with the Charity 
Bowel and Cancer Research).  This advisory group will comprise 8 patients and 2 lay 
members derived from London and Durham. This group will have geographical diversity 
(North and South) and a disease-appropriate demographic (8 female, 2 male). The CRAG 
will be involved in; 
 
 Review of participant information sheets, booklets, diaries and advertising/marketing 
materials. 
 Project management by representation on the PSC. 
 Parallel qualitative analysis. 
 Dissemination of results and lay summaries. 
 Presentations at local research events. 
 Patient focus groups and workshops. 
17. PROJECT MANAGEMENT 
 
17.1 Local Co-ordination 
Each participating centre will identify a site specific PI who will nominate a local contact for 




 Be familiar with the Trial.  
 Liaise with the PCTU and PMG.  
 Ensure that all staff involved in the trial are informed about the trial and have 
received requisite training.  
 Ensure that mechanisms for recruitment of eligible participants, including the 
availability of participant information and data collection tools, are in place; 
monitor their effectiveness and discuss the reasons for non-recruitment with 
relevant staff.  
 Ensure site staff collect necessary trial data and perform quality checks. 
 Notify the CI of any SAE‟s. 
 Make data available for verification, audit and inspection processes as 
necessary, and respond to requests for documentation and data required for 
centralised monitoring. 
 Ensure that the confidentiality of all information about trial participants is 
respected by all persons. 
 
17.2 Site initiation and training 
A central study launch meeting and/or site initiation will be conducted with each site. This will 
include training in the trial protocol and standard operating procedures, such as data 
collection, randomisation and taking informed consent. Evidence of appropriate training, 
local approvals and essential documentation will be required before participants being 
enrolled at each site. Training will be documented on training logs.  
 
17.3 Project timetable, milestones and projected recruitment 
The PMG will be responsible for monitoring adherence to the study timelines and expected 
recruitment rates. Regular reports will be produced to enable deviations from the project 
plan to be identified and contingencies planned, discussed and executed in a timely fashion.  
 
A Gantt chart is included in APPENDIX X. Projected recruitment rates are: 
 
01.08.15 First participant 
31. 04.16 100 participants 
30.11.16 200 participants 
30.06.17 300 participants 
30.10.17 Last patient intervention 




31.10.18 12 month secondary endpoint 
 
 
18. FINANCE AND FUNDING 
The study is being financed as part of an NIHR PGfAR award RP-PG-0612-20001: 
£1,971,934. Additional resource will be provided via host CLRNs. The calculation of all costs 
and contracting has been performed in conjunction with the sponsor. 
 
19. INDEMNITY 
Queen Mary University London has agreed to act as study sponsor. Insurance and 
indemnity will be provided by the sponsor. 
 
20. PUBLICATION POLICY 
The Chief Investigator will co-ordinate dissemination of data from this trial. All publications 
using data from this trial to undertake original analyses will be submitted to the PSC for 
review before release. To safeguard the scientific integrity of the trial, data will not be 
presented in public before the main results are published without the prior consent of the 
PSC. The success of the trial depends on a large number of clinicians. For this reason, 
credit for the results will not be given to the committees or central organisers, but to all who 
have collaborated and participated in the trial. Acknowledgement will include all local co-
ordinators and collaborators, members of the trial committees, the PCTU and trial staff. All 
contributors to the trial will be listed at the end of the report, with their contribution to the trial 
identified.  Those responsible for other publications reporting specific aspects of the trial may 
wish to utilise a different authorship model, such as “[name], [name] and [name] on behalf of 
the collaborative Group”. Decisions about authorship of additional papers will be discussed 
and agreed by the trial investigators and the PSC.  
A lay summary of the final results of the trial will be made available for participants on the 
Bowel and Cancer Research charity website with a link to the full paper.  
 
21. DISSEMINATION OF RESEARCH FINDINGS 
Scientific findings will be subjected to international reporting and peer review (targeting 
appropriate clinical journals e.g. BMJ, Lancet or Gastroenterology). The assimilation of data 
from this trial with those from other studies and convening of a national CC working group to 
consider the findings will lead to prototype national guidance that will inform NHS pathway 
development and commissioning of services. As such, it will be logical to initiate discussions 




progress adoption by specialist medical and nursing organisations. Although the 
development of this guidance should naturally facilitate dissemination of the main 
programme findings to health care planners, policy makers and practitioners, we will also 
direct this information (and that of individual studies) to the following groups:  
 
1. Study participants and carers: Feedback to all the individual participants, users 
and carers who have been involved in, or otherwise contributed to, the 
programme (via a participant newsletter).  
2. Charity links and patient groups: results of the studies will be disseminated using 
the strong web-based and media infrastructure already developed by the Charity 
Bowel and Cancer Research (B&CR). This infrastructure includes the B&CR 
website (www.bowelcancerresearch.org which has 2,500 unique web visitors 
monthly), social media e.g. Facebook site (12,000 followers and), Twitter, and a 
public relations officer (a free-lance journalist who is employed by B&CR for one 
day per week who will help develop and edit press releases: 50 local and national 
news publications in 2012). B&CR is dedicated to breaking down the taboos 
concerning discussion of bowel problems such as CC. B&CR and several of the 
applicants have links with other patient organisations and charities e.g. Core, GI 
Blues, Ileostomy Association and the Bladder and Bowel Foundation. 
3. Local health service providers including developing clinical commissioning groups 
via specially convened local meetings and written reports (led by Janet 
Sedgewick). 
4. The Primary Care Society for Gastroenterology by direct engagement through 
established connections (Dr James Dalrymple). 
5. School children: At an educational level, there are plans for development of an 
interactive learning tool centred on the theme of embarrassing bowel diseases 
within the award winning Centre of the Cell, an educational charity based within 
QMUL and dedicated to inspiring curiosity and learning by connecting science to 
everyday life (www.centreofthecell.org). 
6. NIHR collaboration: The CI is Director of the Barts NIHR HTC for GI disease. 
Results will be disseminated by the HTC newsletter / website to all UK industrial 
(n= 90) and clinical partners (25 colorectal centres). 
Finally, we will repeat the highly successful 2 day international meeting entitled ‘Current 
perspectives in chronic constipation’ organised by Dr Scott and hosted by QMUL in February 
2009 which was attended by over 250 scientists and clinicians and led to a supplement in 
the journal Neurogastroenterology & Motility dedicated to CC. This meeting will be planned 
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APPENDIX I – CapaCiTY programme 
Fig 1: DESIGN OVERVIEW 
with approximate numbers at each stage
CHRONIC CONSTIPATION ~ 1500 pts
in primary / intermediate care
CC treatment to basic standard a
WP5: Pathway development
FROM WP 1-4: Characterisation (physical, clinical & psychosocial) of patients 
with chronic constipation; Effectiveness, acceptability & cost; The patient 
experience of treatments and care; Cost-effectiveness analysis; 

























~ 450 pts from 600 eligible referrals b
CHRONIC CONSTIPATION ~ 1500 pts
referred from secondary care
INVEST d
(if not previously performed)
~100 pts
STUDY RECRUITMENT ~ 700 pts
from 1000 eligible referrals c




No previous behavioural therapy 
Habit training & biofeedback
Failed behavioural therapy 
No previous anal irrigation ~ 300pts 
Failed behavioural therapy and meet 















WP1: Patient selection and characterisation
WP3 – Trial02 WP4 – Trial03
KEY: a. Secondary causes of constipation excluded; 2 laxatives tried for minimum of 3 months
b. Patients with symptoms > 6 months. Previous failure of fibre supplements, oral and rectal 
laxatives. Prokinetics may have been used. No gross structural abnormalities, major psychiatric 
disease or medical comorbidities. Otherwise INVEST & therapy naïve. 
c. As b. but may have had INVEST and previous hospital-based treatments
d. A standardised protocol of radiological and physiological tests (see text)
e. 2-3 procedures will be evaluated (see text)
f. Failures are eligible for recruitment to WP3 or 4 via WP1B






















APPENDIX III – Site Codes 
 
NHS Trust Site Code 
Bart’s Health NHS Trust [Allison] BLT 
St Marks Hospital at London North West Healthcare NHS Trust 
[Vaizey] 
SMH 
University College Hospital London [Emmanuel] UCL 
Guy’s and Thomas’ NHS Foundation Trust London [Williams] GST 
Sandwell and West Birmingham NHS Trust [Gill] SWB 
County Durham and Darlington NHS Foundation Trust [Yiannakou] CDD 
University Hospital Southampton NHS Foundation Trust [Nugent] SOT 
Norfolk and Norwich University Hospitals NHS Foundation Trust 
[Speakman] 
NNH 
University Hospital of South Manchester NHS Foundation Trust [Telford] USM 
University Hospital Leicester NHS Foundation Trust [Miller] ULH 
Sheffield Teaching Hospital NHS Foundation Trust [Brown] STH 
University Hospitals Bristol NHS Foundation Trust [Mabey/Randall] BRI 
  
North Bristol NHS Foundation Trust [Dixon] NBT 
Newcastle Upon Tyne [Plusa] NUT 









CapaCITY programme CHRONIC CONSTIPATION TREATMENT PATHWAY
Year 2014 2015 2016 2017 2018 2019
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63














Recruitment Epidemiology Study 01
Recruitment Study 2
Interventions Study 2
Assessments Study 2 last PEP last SEP
Qualitative assessments
Milestones / reports














NRES Committee London - City & East 
Bristol Research Ethics Committee Centre 
Whitefriars 







06 July 2015 
 
Professor Charles Knowles 
Deputy Director National Centre for Bowel Research Surgical Innovation 
Queen Mary and Westfield College, University of London 
1st Floor, Abernethy Building 




Dear Professor Knowles 
 
Study title: PRAGMATIC RANDOMISED TRIAL OF LOW 
VERSUS HIGH VOLUME INITIATED
 TRANS- ANAL 
IRRIGATION THERAPY IN ADULTS WITH 
CHRONIC CONSTIPATION 
REC reference: 15/LO/0732 
IRAS project ID: 172401 
 
Thank you for your letter responding to the Committee’s request for further information on the 
above research and submitting revised documentation. 
 
The further information was considered in correspondence by a Sub-Committee of the REC. A 
list of the Sub-Committee members is attached. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this favourable opinion letter. The expectation is that this information will be published 
for all studies that receive an ethical opinion but should you wish to provide a substitute 




the REC Manager, Mr Rajat Khullar, nrescommittee.london-cityandeast@nhs.net. Under very 
limited circumstances (e.g. for student research which has received an unfavourable opinion), 
it may be possible to grant an exemption to the publication of the study. 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 




Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
 
You should notify the REC in writing once all conditions have been met 
(except for site approvals from host organisations) and provide copies of 
any revised documentation with updated version numbers. The REC will 
acknowledge receipt and provide a final list of the approved 
documentation for the study, which can be made available to host 
organisations to facilitate their permission for the study. Failure to 
provide the final versions to the REC may cause delay in obtaining 
permissions. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought from 
the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database. This should be before the first participant is recruited but no 
later than 6 weeks after recruitment of the first participant. 
There is no requirement to separately notify the REC but you should do so at the earliest 




the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered but 
for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to request a deferral for study registration within the required timeframe, 
they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will 
be registered, however, in exceptional circumstances non registration may be permissible with 
prior agreement from NRES. Guidance on where to register is provided on the HRA website. 
 
It is the responsibility of the sponsor to ensure that all the conditions 
are complied with before the start of the study or its initiation at a 








The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 




The Committee has not yet completed any site-specific assessment (SSA) for the non-NHS 
research site(s) taking part in this study. The favourable opinion does not therefore apply to 
any non-NHS site at present. We will write to you again as soon as an SSA application(s) has 
been reviewed. In the meantime no study procedures should be initiated at non-NHS sites. 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
Document Version Date 
Copies of advertisement materials for research participants 
[Advertisement 1] 
2 25 November 2014 
Copies of advertisement materials for research participants 
[Advertisement 2] 
2.0 25 November 2014 
Copies of advertisement materials for research participants 
[Business Card] 
1.0 25 November 2014 
Covering letter on headed paper [Covering Letter]  01 April 2015 
Covering letter on headed paper [Covering Letter]  25 June 2015 
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Verification of Insurance ] 
 29 July 2014 
GP/consultant information sheets or letters [GP Letter] 1.0 02 April 2015 
Interview schedules or topic guides for participants [Interview 
Schedule] 
2.0 08 January 2015 
Letter from funder [Award Confirmation Letter]  21 February 2014 
Letter from sponsor [Letter of provisional sponsorship]  02 April 2015 
Letters of invitation to participant [Patient Invitation Letter] 1 20 August 2014 
Non-validated questionnaire [Patient Journal]   
Non-validated questionnaire [Irrigation Journal ]   
Non-validated questionnaire [Patient Diary] V2 15 June 2015 
Non-validated questionnaire [Patient Diary Track Changes ] 2.0 15 June 2015 
Non-validated questionnaire [Patient Journal] 3.0 12 June 2015 
Non-validated questionnaire [Patient Journal Track Changes] 3.0 12 June 2015 
Non-validated questionnaire [Irrigation Journal ] 3.0 19 June 2015 
Non-validated questionnaire [Irrigation Journal Track Changes] 3.0 19 June 2015 
Other [GCP certificate Prof Knowles  ]  21 May 2014 
Other [External Trial Oversight Committees] 2.0 03 September 2013 




Other [Summary of required REC Changes]  25 June 2015 
Participant consent form [Consent Form] 1.0 20 August 2014 
Participant consent form [Interview Consent Form] 2.0 08 January 2015 
Participant information sheet (PIS) [PIS Main Study ] 2.0 22 June 2015 
Participant information sheet (PIS) [Participant Information Sheet 
(PIS) Main Study Track Changes ] 
2.0 22 June 2015 
Participant information sheet (PIS) [PIS Interviews] 2.0 20 January 2015 
Participant information sheet (PIS) [PIS Staff Interviews] 2.0 20 January 2015 
REC Application Form [REC_Form_30062015]  30 June 2015 
Referee's report or other scientific critique report [Peer Review]  05 February 2015 
Referee's report or other scientific critique report [Peer Review]  15 February 2015 
Referee's report or other scientific critique report [Institute Approval 
Peer Review] 
 30 March 2015 
Research protocol or project proposal [Study Protocol] 2.0 22 June 2015 
Summary CV for Chief Investigator (CI) [CV for CI]  30 July 2014 
Summary CV for student [Student CV]  07 April 2015 
Summary CV for supervisor (student research) [Professor Yan 
Yiannakou] 
 17 July 2014 
Validated questionnaire [EQ-5D telephone questionnaire ]   
Validated questionnaire [Baseline Assessment Questionnaire] 1.0 13 February 2015 
Validated questionnaire [Standard Outcome Assessment 
Questionnaire] 
V2 18 June 2015 
Validated questionnaire [Standard Outcome Assessment 
Questionnaire Track Changes] 
2.0 18 June 2015 
Validated questionnaire [Short Outcome Assessment Questionnaire 
] 
1.0 13 February 2015 
 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 
 




The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 




 Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 






The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received and 
the application procedure. If you wish to make your views known please use the feedback form 



















Enclosures: List of names and professions of members 
who were present at the meeting and those who submitted written 
comments 
“After ethical review – guidance for 
researchers” 
 
Copy to: Mrs Shiva Taheri, Queen Mary and Westfield College, University of 
London 
Dr Sally Burtles, Director of Research Services and Business 
Development 




NRES Committee London - City & East 
 









Also in attendance: 
 
Name Position (or reason for attending) 




Name Profession Present Notes 
Dr Ayse Baxter Pharmaceutical 
Physician 
Yes  
Dr John Keen GP (REC Chairman) Yes  










London - City & East Research Ethics Committee 
Bristol Research Ethics Committee Centre 
Whitefriars 






24 February 2016 
 
Professor Charles Knowles 
Deputy Director National Centre for Bowel Research Surgical Innovation 
Queen Mary and Westfield College, University of London 
1st Floor, Abernethy Building 




Dear Professor Knowles 
 
Study title: PRAGMATIC RANDOMISED TRIAL OF LOW VERSUS HIGH 
VOLUME INITIATED TRANS- ANAL IRRIGATION THERAPY IN ADULTS WITH 
CHRONIC CONSTIPATION 
REC reference: 15/LO/0732 
Amendment number: 1 
Amendment date: 28 January 2016 
IRAS project ID: 172401 
 




The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation. 
 





The Committee noted that on the e-mail to participants, it is mentioned that the participant is to 
inform the researcher if questionnaire is not completed prior to the next visit. This applies to the 
Baseline, Follow Up questionnaires and the baseline diary. It is however not clear how the 
researcher will be informed. The committee suggested that it would be helpful to add the method in 
the PIS. 
 
Ms Natasha Stevens provided the revised email document and the Committee was satisfied 








Document Version Date 
Covering letter on headed paper [Initial Submission Cover Letter]  26 January 2016 
GP/consultant information sheets or letters[CapaCiTY Study 2 GP letter ] 2 22 January 2016 
Letters of invitation to participant [CapaCiTY 2 Patient Invitation Letter] 2 22 January 2016 
Notice of Substantial Amendment (non-CTIMP) 1 28 January 2016 
Other [Baseline Questionnaire Booklet] 2 22 January 2016 
Other [CapaCiTY02 web advertisement] 1 22 January 2016 
Other [Emails to participants ] 2 18 February 2016 
Other [Patient Journal study 2_] 4 22 January 2016 
Other [short outcome questionnaires] 2 22 January 2016 
Other [Standard outcome questionnaires ] 3 22 January 2016 
Other [Summary of changes MA-172401]  27 October 2015 
Participant consent form [CapaCiTY Consent Form study ] 2 22 January 2016 
Participant information sheet (PIS) [CapaCiTY02_Participant Information 
Sheet] 
3.0 22 January 2016 
Research protocol or project proposal [CapaCiTY02_Protocol] 3 22 January 2016 
 
Membership of the Committee 
 





All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 



















Copy to: Dr Sally Burtles, Barts Health NHS Trust 





London - City & East Research Ethics Committee 





Name Profession Present Notes 
Dr  Ayse Baxter Pharmaceutical 
Physician 
Yes  
Ms Lisa Johnson CRO Yes  
 
Also in attendance: 
 
Name Position (or reason for attending) 








Dr David Ekers 
Clinical Senior 





School of Medicine, Pharmacy and 





Re: CapaCiTY 02 trial, a multi-centre randomised trial of anal irrigation 
therapy in chronic constipation 
 
As Chair of the Ethics Sub-Committee, I can confirm Chairs Action approval in relation 
to the ethics of the above named study. This study been approved by NHS REC 
(London City and East) and you have confirmed all documentation and procedures will 
be as per that approval, therefore re- application to the SPMH Ethics Sub-Committee 
for full ethical review is not required. 
 
The governance arrangements of the study being delivered through Durham 
University sites and insurance cover should be confirmed with Andrew Watt and the 
Research Office. 
 
Good luck with your study and please contact me if you require any further 












Dr David Ekers 
Clinical Senior 





School of Medicine, Pharmacy and 





Re: CapaCiTY 02 trial, a multi-centre randomised trial of anal irrigation 
therapy in chronic constipation 
 
As Chair of the Ethics Sub-Committee, I can confirm Chairs Action approval in relation 
to the ethics of the above named study. This study been approved by NHS REC 
(London City and East) and you have confirmed all documentation and procedures will 
be as per that approval, therefore re- pplication to the SPMH Ethics Sub-Committee for 
full ethical review is not required. 
 
The governance arrangements of the study being delivered through Durham 
University sites and insurance cover should be confirmed with Andrew Watt and the 
Research Office. 
 
Good luck with your study and please contact me if you require any further 









Appendix II: Patient Information Sheets and Consent forms 
 Patient Information Sheet CapaCiTY 02 Quantitative Study 
 Consent Form CapaCiTY 02 Quantitative Study 
 Patient Information Sheet CapaCiTY 02 Qualitative Study 
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Did you know, 1 in 10 people suffer from 
chronic constipation? To find out more 
about current treatments we are 





    
Participant Information Sheet   
Study Title: Chronic Constipation Treatment Pathway, Study 02 





We would like to invite you to take part in our research study. Before you decide we would like 
you to understand why the research is being done and what it would involve for you. Please 
take time to read the following information carefully. One of our team will go through the 
information sheet with you and answer any questions you have. We would suggest this should 
take about 15 minutes. We will give you at least a day to make your decision, but you can take 
as much time as you like. Talk to others about the study if you wish. Part 1 tells you the purpose 
of this study and what will happen to you if you take part. Part 2 gives you more detailed 
information about the conduct of the study. Please ask us if there is anything that is not clear.  
                             
Part 1: About the research 
 
What is the purpose of the study? 
Constipation is a common condition that most people will suffer with at some point in their life. In 
some people the symptoms can become chronic and severely affect their day to day activities. 
Chronic constipation is described as someone having  
 
symptoms that last for over 6 months and has not responded to simple lifestyle changes and 
laxatives.  
 
The condition can be very difficult to treat even in specialist centres. The treatments available 
include laxatives, newer drugs, specialist led bowel retraining programmes, anal irrigation and 
surgery. There are also specialised investigations that can be carried out to see if an underlying 
cause can be found (these are described under visit 1.1). However, the benefits of these tests 
are still unclear.  
 
The main aim of this study is to assess how effective anal irrigation therapy is in treating chronic 
constipation in people who have not been helped by specialist-led bowel retraining therapy. Anal 
irrigation involves putting water into the bottom to stimulate a bowel motion. There are two main 
systems used to perform anal irrigation and they are slightly different. However, we do not know 
which one is the better treatment or if in fact they have a similar effect.  One system uses a 
smaller amount of water (low-volume system) and the other uses a higher volume of water (high-
volume system). The study will look at how well the symptoms of chronic constipation improve 
with each of these systems. We will also use specialist tests to investigate the underlying causes 




better than the low volume system in certain patients. This may be helpful for clinicians when 
deciding whether to prescribe one system over the other.  In addition, the cost effectiveness to 
the NHS will be assessed. 
The low volume system consists of a small pump attached to a disposable cone. This is used to 
insert a small amount (70ml) of lukewarm tap water into the bottom, and this can be repeated as 
needed.  
The high-volume system consists of a bag attached to a tube which is passed into the back 
passage and held there either by hand or with an inflatable balloon. A larger volume (up to 1.5 















Figure 2: High volume irrigation system 
Why have I been invited? 
You have been asked to take part in this study because you are between the age of 18-70 and 
have symptoms of chronic constipation. You have also undergone specialist-led bowel re-
training (such as habit training and/or bio-feedback) without improvement of your symptoms. 
Your doctor or specialist nurse have decided anal irrigation would be the next suitable treatment 
option for you. This research is taking place at approximately ten NHS practices across the UK 
and this study will be one of three interlinked studies for chronic constipation taking place over 5 
years. You may be asked if you wish to participate in more than one study. 
 
Do I have to take part? 
Participation is entirely voluntary. It is up to you to decide to join the study. We will describe the 





to sign a consent form. You are free to withdraw at any time without giving a reason. If you 
decide not to participate, or withdraw at any time, the standard of care you receive will not be 
affected.  
 
What will happen to me if I take part? 
The anal irrigation therapy you receive will be no different to that already offered on the NHS. 
However, you and your doctor will not be able to choose which irrigation system you will use. 
You will be asked to complete a number of questionnaires, diaries and journals to help 
researchers assess the effectiveness and cost effectiveness of the treatment.  
 
Your participation in this particular study will last for up to 12  months and will involve up to 6  
visits to the hospital (please see diagram below). Each visit will take up to an hour. This study is 
a randomised trial, which means we put people into 2 different groups and start each group on a 
different treatment. The results are then compared to see if one treatment is better than the 
other. To try to make sure the groups are the same to start with, each patient is put into a 
treatment group by chance (randomly). This is because sometimes we don‘t know which way of 
treating patients is best. Patients have a fifty-fifty chance of going to each of the groups. You 
need to continue with this therapy for three months, at which point you will answer a series of 
questionnaires to help us assess whether this has been an effective treatment for you. These 
questionnaires only take 10-20 minutes to complete.  
 
Visit 1: Initially you will have a medical history taken and undergo a physical examination 
including a brief examination of your back passage (if not already performed in the last 3 
months). Women of childbearing potential will be asked to take a urine pregnancy test and use 
effective contraception whilst in the study. You will be asked to complete quality of life 
questionnaires. A 2 week bowel diary will be given to complete at home, this should take only a 
couple of minutes at the end of each day. You will also receive a ‘patient journal’ to record 
information about your medications and visits with healthcare professionals for your constipation. 
You will keep this journal throughout your involvement in the study and this information will be 
reviewed at each follow-up visit. You have the option to complete all quality of life questionnaires 
and the diaries either on paper or on a secure online database, using any handheld device or 
computer. If you complete your assessments online, your email address will be shared with the 
coordinating centre, Queen Mary University, and you will receive an automated email reminder 





Visit 1.1: Specialist Gastrointestinal (GI) Physiological Investigations  
You will then undergo a number of more precise tests looking at the structure of the lower bowel 
and back passage and how it works and any abnormalities (these will not be repeated if 
performed within the last 12 months). This may require 1-2 additional visits to the hospital and 
waiting times of approximately 4 weeks, which is the normal NHS waiting time for these tests.  
1. Anorectal manometry with sensory testing– This includes insertion of a balloon 
catheter (see figure 3) into the back passage to measure sensation and contractions 
and also your ability to push out the balloon. 
 
2. Gut transit study – Measures the movement of food through the stomach and 
intestines. This requires you to swallow 3 gel capsules (size of a normal antibiotic 
capsule) filled with markers that will show up on an X-ray. The markers look like 
white spots or rings in the X-ray pictures, taken 120 hours after swallowing the 
capsules. You will be required to stop taking laxatives before having this test. 
 
Figure 3: Balloon catheter for investigations  
One of these tests includes an X-ray with a very small dose of radiation equivalent to about 2½ 
weeks annual background radiation dose from living in the UK. As there will be use of X-rays, it 
is very important to let the research team know if there is any likelihood that you are pregnant. 
For this reason you may be asked to perform a pregnancy test and will be excluded from the 
study if you are pregnant or trying to get pregnant. Women entering the study will also be asked 
to use proven methods to prevent pregnancy throughout the course of the study. Women must 
advise the research team if they become pregnant or would like to start trying to become 
pregnant. If this happens you will be withdrawn from the study treatment but may continue to 





Visit 2: You will be trained by a nurse to use the anal irrigation system you have been randomly 
assigned to during a face-to-face visit lasting approximately 45 minutes to 1 hour. You will then 
begin to use the treatment as directed at home. You will also be asked to keep an irrigation 
journal to describe how many times you use anal irrigation each week and if you have needed 
more or less water. This journal will also record any side effects. You will continue to keep the 
journal until the end of the study, it should only take you a couple of minutes each week to 
complete. One of the team will contact you after two weeks by telephone so that any problems 
can be addressed. If you require a further observed training visit then this will be arranged at this 
time. Your 2 week patient diary provided at visit 1 will be reviewed at this visit.  
 
Visit 3: You will then be seen at the clinic 4 weeks after starting treatment to see how you are 
getting on. You will be asked to complete a short set of questionnaires and your irrigation journal 
will be reviewed at this point.  
 
Visit 4-6: You will then be followed up initially 3 months after starting treatment, then after 6 
months and then12 months. At these follow up visits you will be asked to complete further quality 
of life questionnaires, and return your bowel diary, patient journal and irrigation journal.  If you 
need to see the irrigation nurse for advice during this time then this is permitted. You will be 
asked to record any contact with irrigation nurses, along with advice given and changes to your 
irrigation regime, in the irrigation journal. 
 
Switching Anal Irrigation Systems 
After 3 months if the irrigation system you were assigned to is not working, you can switch to the 
other system to see if that works better for you. We will record the date on which you stopped 
one irrigation system and started the other, as well as your reasons for doing so. If you do 
decide to switch treatments then you will need another training visit to learn how to use the new 
system. You will also be contacted after about 7-14 days of starting the new treatment and again 
at 4 weeks. You will not be asked to repeat the questionnaires and diaries. 
 
Allowed Rescue Medications 
If you are having severe symptoms despite your irrigation treatment, you will be advised which 
laxative medications you may take to alleviate this. These will include several laxatives available 
on prescription (Bisacodyl, Movicol, Lactulose) as well as glycerine suppositories. You will then 




What will I have to do?  
If you choose to be part of this study, it is important for you to: 
 Discontinue other therapies apart from the anal irrigation and the defined ‘rescue’ 
therapies. 
 Attend your visits on the scheduled dates. 
 Complete your diaries, journals and questionnaires.  
 Follow the instructions you receive during the visits. 
 You should check with the researcher of this study before joining in any other research 
trials. 
 Women of child-bearing potential should use proven method of contraception throughout 
the course of the study.  
You may also be approached to take part in one to one interviews. This is up to you to 
decide separately to this part of the study. If you are interested, your contact details will 
be used to give you further information and you will be consented to take part at a later 
date 
 
Expenses and Payments 
If you decide to take part you will be reimbursed for your expenses incurred with the extra visits 
to the hospital. This will be £60 given out over the course of the study e.g. £20 each after 





Participant flow chart 
Visit 1: Initial Visit 
Medical history/Clinical examination/Questionnaires 
Complete diary at home (2 weeks) 
V1.1: Specialist investigations 
 
Visit 2: Randomised into the different groups 







Visit 2.1: Phone call after 14 days 
 
Visit 2.2: Additional training if needed 
 
 
Visit 3: Follow up 4 weeks after starting treatment with questionnaires. 
Visit 4: All Participants undergo a follow up visit at 3 months post 
treatment where they fill out a bowel diary before the visit and then 
questionnaires are filled out at the visit. If the current treatment system 
does not work, participants can elect to switch to the other system. This 
requires further training. 
+3 months 
Visit 5: All Participants undergo a follow up visit at 6 months post 
treatment where they fill out a diary before the visit and then 
questionnaires are filled out at the visit. 
+3 months 
2-8 weeks  
+6 months Visit 6: All Participants undergo a follow up visit at 12 months post 
treatment where they fill out a diary before the visit and then 




What are the possible disadvantages, risks and side effects of taking part?  
The study involves procedures that are done routinely in normal care and have been done daily 
in specialist centres for a long time. One of the routine tests uses X-rays. We are all exposed 
daily to ‘Background Radiation’ that comes from natural sources all around us. The X-rays you 
could receive during the test are equal to about 2½ weeks annual background radiation and 
considered minimal risk.  
 
The possible side effects of anal irrigation include pain, bleeding, painful haemorrhoids and anal 
fissure. Some minor discomfort can be experienced, including leakage of water or leakage of 
stool post-irrigation. You may experience some sort of technical issue with using equipment (for 
example burst balloon). Approximately a quarter of patients experience some form of minor side 
effect but these are often well tolerated and reverse by themselves upon stopping irrigation. The 
only serious risk is of perforation (making a hole in the bowel). This however has only been 
described in a tiny proportion (less than 1 in 10 000) of patients. 
 
What are the possible benefits of taking part?  
We cannot promise the study will help your constipation but you will receive treatments which 
are considered the routine therapy at the current time. In addition the information we get from 
this study will help inform future treatment options for people with chronic constipation.  
 
What happens when the research study stops?  
If you require further treatment you will return to being looked after in the regular NHS clinic. 
What if there is a problem?  
Any complaint about the way you have been dealt with during the clinical trial or any possible 
harm you might suffer will be addressed. The detailed information concerning this is given in Part 
2 of this information sheet.  
 
Will my taking part in the study be kept confidential?  
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2.  
 
This completes part 1.  
If the information in Part 1 has interested you and you are considering participation, please read 






What if relevant new information becomes available? 
If new information becomes available about the treatments being studied or the way in which 
we are planning to conduct the study, you will be notified so that you have an opportunity to re-
consider your involvement. This is very unlikely to occur but if it does the researcher will discuss 
this with you and ask you to sign a document confirming the changes were explained and you 
have agreed to either continue or withdraw and return to routine care. 
 
What will happen if I don’t want to carry on with the study?  
You are free to drop out of this study at any time by notifying the study doctor and without having 
to give a reason. This would not affect the care you receive. If you withdraw from the study any 
information collected up to that point will still be used but no further information will be collected. 
You may also be given the option to withdraw from treatment but continue to complete 
questionnaires and diaries if you wish.  
 
What if there is a problem?  
If you have a concern about any aspect of this study, you should ask to speak to the researchers 
who will do their best to answer your questions (Please insert local investigator contact details 
here). If you remain unhappy and wish to complain you should contact the Patient Advice and 
Liaison Service (PALS) <insert local Pals contact here> 
We do not expect you to suffer any harm or injury as a result of this research. Anal irrigation is 
relatively low risk with rare, minor and reversible side effects as explained in the risks section of 
part 1. In the event that something does go wrong and you are harmed during the research and 
this is due to someone’s negligence then you may have grounds for legal action against the 
sponsor Queen Mary University of London, but you may have to pay your legal costs. 
 
Will my taking part in this study be kept confidential?  
If you consent to take part in this study, doctors, nurses and other personnel involved in the 
study may need access to your medical records and test results. The records obtained while you 
are in this study will remain strictly confidential at all times. The information will be held securely 
on paper and electronically under the provisions of the 1998 Data Protection Act. Your relevant 
data will not be passed to anyone else outside the research team or the Sponsor, who is not 




number, a hospital code and a number given in order of enrolment. This code will be used to 
identify you on all trial forms. Your identifiable records will be available to people authorised to 
work on the trial but may also need to be made available to people authorised by the Sponsor, 
which is the organisation responsible for ensuring that the study is carried out correctly. Your 
email address and/or phone number may be shared with the coordinating centre at Queen Mary 
University and Kings College University in order to arrange your follow up assessments and/or 
interviews. By signing the consent form you agree to this access for the current study and any 
further research that may be conducted in relation to it, even if you withdraw from the current 
study.  
In line with the regulations, at the end of the study your data will be securely archived for a 
minimum of 20 years. Arrangements for confidential destruction will then be made.  
 
Will my GP be informed of my involvement?  
Your GP, and other doctors who may be treating you, will be notified that you are taking part in 
this study. 
 
What will happen to the results of the research study?  
The results of the study will be available after it finishes and will usually be published in a 
medical journal or be presented at a scientific conference. The data will be anonymous and none 
of the patients involved in the trial will be identified in any report or publication.  
Should you wish to see the results, or the publication, please ask your study doctor after the 
study has ended. The results will also be published at the end of the study on the bowel and 
cancer website at www.bowelcancerresearch.org 
 
Who is organising and funding the research?  
The sponsor, who is responsible overall for this study is Queen Mary University of London. The 
research is being funded by the Department of Health through the National Institute for Health 
Research (NIHR).  
 
Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a Research Ethics 
Committee, to protect your safety, rights and wellbeing.  This study has been reviewed and 
approved by London City and East Research Ethics Committee.  
 




You are encouraged to ask any questions you wish, before, during or after your treatment. If you 
have any questions about the study, please speak to your study nurse or doctor, who will be able 
to provide you with up to date information about the procedures involved.  
Principle Investigator 
Name add name    Tel. Number: add Tel. number 
Your Research/Specialist Nurse/Research Fellow delete as appropriate 












STUDY CONSENT FORM 
Title of Project:   Chronic Constipation Treatment Pathway, Study 02 
Name of Researcher: Professor Yan Yiannakou, professor of Neurogastroenterology 
   County Durham and Darlington NHS Foundation Trust 
   (Yan.yiannakou@nhs.net. Tel: 07584387147) 
 
 
Place initials in 
each box 
1. I confirm that I have read and understand the Patient Information Sheet 
dated 22 Jan 2016 (version 3) for the above study.  I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care or 
legal rights being affected. 
 
3. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from Queen Mary, 
University of London, from regulatory authorities or from the NHS Trust, 
where it is relevant to my taking part in this research.  I give permission for 
these individuals to have access to my records. 
 
4. I agree to undergo GI Physiological tests including tests using X-rays.  
5. I agree for my contact details to be passed to study interviewers so I can be 
contacted about taking part in one to one interviews 
 
6. I agree to my GP being informed of my participation in the study.    
 
7. I agree to take part in the above study.    
 
 
     
Print Name of Participant  Date  Participant’s Signature 
     
Print Name of person taking consent  Date  Signature of person taking consent 




                             [insert Trust logo] 
 
Participant Information Sheet   
Study Title: Chronic Constipation Treatment Pathway, Patient Interview Study 02 
 
We would like to invite you to take part in our research study. Before you decide we would like 
you to understand why the research is being done and what it would involve for you. Please 
take time to read the following information carefully. One of our team will go through the 
information sheet with you and answer any questions you have. We‘d suggest this should take 
about 15 minutes. We will give you at least a day to make your decision, but you can take as 
much time as you like. Talk to others about the study if you wish. Part 1 tells you the purpose of 
this study and what will happen to you if you take part. Part 2 gives you more detailed 
information about the conduct of the study. Ask us if there is anything that is not clear. 
 
Part 1: About the research 
 
What is the purpose of the study? 
The Capacity-2study compares two systems of trans-anal irrigation (TAI) treatment for chronic 
constipation. This part of the study uses interviews to ask participants about their experiences of 
the different systems of transanal irrigation, and whether they feel their constipation has 
improved or not. This will help to improve how chronic constipation is treated in the future. 
 
Why have I been invited? 
You are currently taking part in CapaCiTY study 2 where you are undergoing trans-anal irrigation 
therapy with one of two different systems. You have told us that you were willing to be 
interviewed.  
 




Participation is entirely voluntary. It is up to you to decide to join the study. We will describe the 
study and go through this information sheet. If you agree to take part, we will then ask you to 
sign a consent form. You are free to withdraw at any time without giving a reason, even after you 
have agreed to take part. This would not affect the standard of care you receive.  
 
What will happen to me if I take part? 
If you agree to take part you will be interviewed by a researchereither at your home or in the 
clinic where you are being treated, whichever is better for you. The researcher has a lot of 
experience of working with people with bowel problems, including those with chronic 
constipation, and will help you talk about the treatment you have received or are receiving and 
your suggestions for changing or improving the treatment. You will be able to talk about your 
feelings in a way that makes you feel comfortable. The interview will take no more than an hour 
and will be recorded on a digital voice recorder. The interview will be typed out by a professional 
transcriber and the audio file will then be deleted. 
 
What are the possible benefits or risks of taking part?  
By sharing your experiences with us you could help a great many other people with chronic 
constipation. What we learn from you will help in the development of future treatments.  
 
Talking about tough issues can be hard for people. We know that it can help a lot to be able to 
talk freely with someone who is keen to hear what you want to say and will not judge you in 
anyway. As we are talking about a very personal subject there is a risk that you will find it 
upsetting. The researchers you will be talking to are experienced in talking to patients. 
 
 
Will my taking part in the study be kept confidential?  
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2. The professional who will transcribe your 
interview is also bound by a code of conduct to keep your information confidential. 
 
This completes part 1.  
If the information in Part 1 has interested you and you are considering participation, please read 









What will happen if I don’t want to carry on with the study?  
You are free to drop out of this study at any time by notifying the study doctor and without having 
to give a reason. This would not affect the care you receive. If you withdraw from the study any 
information collected up to that point will still be used but no further information will be 
collected.If you become unable to complete the study you will be withdrawn but the data 
collected up until then will still be used. 
 
What if there is a problem?  
If you have a concern about any aspect of this study, you should ask to speak to the researchers 
who will do their best to answer your questions (Please insert interviewer contact details here). If 
you remain unhappy and wish to complain you should contact the Patient Advice and Liaison 
Service (PALS) <insert local Pals contact here> 
 
Will my taking part in this study be kept confidential?  
The information will be held securely on paper and electronically under the requirements of the 
1998 Data Protection Act. Your name will not be passed to anyone else outside the research 
team or to the Sponsor, who is not involved in the trial. You will have already been allocated a 
unique participant number, consisting of study numbergiven in order of enrolment. This code will 
be used to identify you. Before anything is published, all information that could identify you, for 
example, names and places,will be taken out.  
 
In line with the regulations, at the end of the study your data will be securely archived for a 
minimum of 20 years. Arrangements for confidential destruction will then be made.  
 
Will my GP be informed of my involvement?  
Your GP will not need to be informed about your participation in this part of the study. 
 
What will happen to the results of the research study?  
The results of the study will be available after it finishes and will usually be published in a 




of the participants involved in the trial will be identified in any report or publication.We will not 
refer to you by name in the published information. 
Should you wish to see the results, or the publication, please ask your interviewer or a member 
of the research team (see contact details at the end). The results will also be published at the 
end of the study on the bowel and cancer website at www.bowelcancerresearch.org 
 
Who is organising and funding the research?  
The sponsor, who is responsible overall for this study is Queen Mary University of London. The 
research is being funded by the Department of Healththrough the National Institute for Health 
Research (NIHR).  
 
Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a Research Ethics 
Committee, to protect your safety, rights and wellbeing.  This study has been reviewed and 
approved by London City and East Research Ethics Committee.  
 
 
Further information and contact details  
You are encouraged to ask any questions you wish, before, during or after your treatment. If you 
require any further information or have any concerns while taking part in the study please 
contact one of the following people: 
 
YourInterviewer 
Name add name    Tel. Number: add Tel. number 
Your local investigator 
Name add name    Tel. Number: add Tel. number 










INTERVIEW CONSENT FORM 
Title of Project:   Chronic Constipation Treatment Pathway, Study 02 
Name of Researcher: Professor Yan Yiannakou, Professor of Neurogastroenterology, County 
Durham and Darlington NHS Foundation Trust 





Place initials in 
each box 
8. I confirm that I have read and understand the Information 
Sheet dated 20 January 2015 (version 2) for the above study.  I 
have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
9. I understand that my participation is voluntary and that I am 
free to withdraw at any time without giving any reason, without 
my medical care or legal rights being affected. 
 
10. I agree to take part in a 60 minute interview and I understand 
that this will be audio taped and transcribed. 
 
11. I agree to take part in the above study.    
 
 
     
Print Name of Participant  Date  Participant’s Signature 
     








Appendix III: Publications 
 Trans-anal irrigation therapy to treat adult chronic functional constipation: Systematic 
review and meta-analysis. Emmett C, Close H, Yiannakou Y, Mason J; BMC 
Gastroenterology (2015)15:139. DOI 10.1186/s12876-015-0354-7 
 Low-volume versus high-volume initiated trans-anal irrigation therapy in adults with 
chronic constipation: study protocol for a randomised controlled trial.  Emmet C, Close 
H, Mason J, Taheri S, Stevens N, Eldridge S, Norton C, Knowles C, Yiannakou Y; BMC Trials 












Trans-anal irrigation therapy to treat 
adult chronic functional constipation: 
systematic review and meta-analysis 




RESEARCH ARTICLE Open Access 
Abstract 
Background: Trans-anal irrigation (TAI) is used widely to treat bowel dysfunction, although evidence for its use in 
adult chronic functional constipation remains unclear. Long-term outcome data are lacking, and the effectiveness of 
therapy in this patient group is not definitively known. 
Methods: Evidence for effectiveness and safety was reviewed and the quality of studies was assessed. Primary 
research articles of patients with chronic functional constipation, treated with TAI as outpatients and published in 
English in indexed journals were eligible. Searching included major bibliographical databases and search terms: 
bowel dysfunction, defecation, constipation and irrigation. Fixed- and random-effect meta-analyses were performed. 
Results: Seven eligible uncontrolled studies, including 254 patients, of retrospective or prospective design were 
identified. The definition of treatment response varied and was investigator-determined. The fixed-effect pooled response 
rate (the proportion of patients with a positive outcome based on investigator-reported response for each study) was 
50.4 % (95 % CI: 44.3–56.5 %) but featured substantial heterogeneity (I2 = 67.1 %). A random-effects estimate was similar: 
50.9 % (95 % CI: 39.4–62.3 %). Adverse events were inconsistently reported but were commonplace and minor. 
Conclusions: The reported success rate of irrigation for functional constipation is about 50 %, comparable to or better 
than the response seen in trials of pharmacological therapies. TAI is a safe treatment benefitting some patients with 
functional constipation, which is a chronic refractory condition. However findings for TAI vary, possibly due to varying 





Overview of the condition 
Chronic constipation may be defined as ‘a 
symptom-based disorder defined as 
unsatisfactory defecation characterised by 
infrequent stools, difficult stool passage, or 
both, for at least three months’ [1]. For the 
purposes of this review, ‘chronic functional 
constipation’ refers to any condition fitting 
broadly within this definition, with no clear 
under- lying cause. This includes obstructed 
defecation syndrome (ODS), functional 
defecation disorder (FDD), chronic idio- 
pathic constipation (CIC), and constipation-
predominant irritable bowel syndrome (IBS-
C). This reflects the consid- erable overlap in 
symptoms between each of these condi- 
tions [2], and also the fact that 
observational studies 
 
* Correspondence:   Christopher.Emmett@nhs.net 
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Durham DH1 5TW, UK 
Full list of author information is available at the end of the article 
indicate many patients reporting constipation 
do not fulfil the Rome III criteria for chronic 
functional constipation [1]. This definition 
does not include constipation sec- ondary to 
a neurological cause (for example, spinal 
cord injury, stroke, Parkinson’s disease, 
Multiple Sclerosis), opioid-induced  
constipation or  constipation secondary to 
any other medical  diagnosis. 
Chronic constipation is a common condition 
in the com- munity: a recent systematic review 
[3] gave a pooled preva- lence of 14 %, 
although it becomes more common in older 
people and women. There is a considerable 
burden of symptoms and decreased quality of 
life [1]: one  recent  study reporting 
‘extremely/very bothersome’  symptoms  in 72 
% of IBS-C patients, 62 % of CIC patients with 
abdom- inal symptoms and 40 % of CIC 
patients without abdominal symptoms [2]. The 
costs of treating constipation are sig- nificant 
and appear to be increasing; one American 
study reported  aggregate  national  (U.S.)  
costs  of  Emergency 
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Department attendances due to constipation of 
$1.6 billion in 2011 [4]. 
 
Trans-anal irrigation 
Trans-anal irrigation therapy (TAI) is in 
widespread use throughout the UK as a 
treatment for bowel dysfunction. Irrigation 
involves instilling tap water  into  the  rectum 
via the anus, using either a balloon catheter 
or cone de- livery system. This is attached via 
a plastic tube to an ir- rigation bag holding up 
to 2 l of water; alternatively a low-volume 
system consisting of a hand pump and  a  
cone may be employed. Low-volume systems 
deliver ap- proximately 70 ml per irrigation; 
high-volume systems deliver up to 2 l of 
irrigation, although typically only 0.5–1.5 l is 
required. Patients vary in the frequency and 
volume of irrigation depending on their 
response to treatment; typically, irrigation is 
used 2–3 times  per  week. The low-volume 
system is cheaper, costing ap- proximately 
£750 p.a. based on alternate-day use, com- 
pared with approximately £1400–1900 for 
high-volume irrigation, and may be more 
acceptable to patients. It is not known which 
system is more  effective. 
Irrigation has been used successfully to  treat  
adults  and children with neurogenic 
constipation [5–7], and faecal incontinence [8]. 
Proposed mechanisms of action include 
simple mechanical washout, colonic 
movement stimulated by the washout, or a  
combination  of  these  [8]. However, evidence 
for the use of trans-anal irriga- tion therapy for 




universally acknowledged, and there are 
questions about  long-term benefit [9]. 
A review of current evidence for irrigation 
was under- taken to define what is known 
about this treatment  as well as to identify 
areas where evidence is lacking and further  
research  is required. 
 
Research question 
What is the strength of the evidence for trans-
anal irri- gation therapy for chronic functional 
constipation, with reference to effectiveness, 
safety and methodological quality of studies? 
Methods 
Eligibility criteria 
Primary research articles that include patients 
with chronic functional constipation as 
defined above, treated with retrograde trans-
anal irrigation at home as outpa- tients, and 
published in English in indexed journals were 
eligible. The following were not eligible for 
inclusion: arti- cles solely studying patients with 
a known cause for their constipation (e.g., 
neurogenic constipation, opioid-induced 
constipation, other organic cause); conference 
abstracts, audits, letters and commentaries; 
articles studying ante-  grade irrigation (Table 
1). Reviews were not included but relevant 
review articles [8, 10] were screened for further 
relevant studies, as were citations of retrieved 
studies. No protocol was registered, however  
the  review  was reported in accordance with 
the PRISMA statement (2009) [11]. 
 
Search strategy 
The following databases were systematically 
searched through  Ovid Online: 
 
• “All EBM Reviews” (comprising: Cochrane 
Database of Systematic Reviews (2005 to March 
2015), ACP Journal Club (1991 to March 2015), 
Database of Abstracts of Reviews of Effects (1st 
Quarter 2015), Cochrane Central Register of 
Controlled Trials (March 2015), Cochrane 
Methodology Register 
(3rd Quarter 2012), Health Technology 
Assessment (1st Quarter 2015), NHS 
Economic Evaluation Database (1st 
Quarter 2015)); 
• Embase  (1974–2015  Week 15); 
• Ovid MEDLINE(R) (1946–April Week 2 2015). 
The following search terms were used 
(searched in ‘all fields’): “bowel dysfunction”; 
“defaecation.”; “defecation”; “constipation”; 
“irrigation”. The Boolean Operators “AND” 
and “OR” were used to combine these terms 
appropriately and refine the search (Table 2). 
The search was limited to English language 
articles and to studies in  humans. 
Abstracts and citations were screened by 
one re-  searcher  (CDE)   and   potentially  





Table 1 Inclusion and exclusion criteria 
Inclusion Exclusion 
 
Primary research Audit/letters/commentaries/opinion/review   articles 
Patients with Chronic Functional Constipation 
(Obstructive defaecation and/or slow transit/IBS-C) 
Studies in children (<18 years) only 
Full articles published in peer-reviewed journals Studies in neurogenic constipation only 
English Language Studies where all patients have undergone colorectal surgery (resection or rectopexy, etc.) 
Retrograde irrigation using standard equipment 
performed at home 
Primary outcome is patient symptom 
improvement/response to treatment 
Studies in stoma patients only 









Table 2 Search of bibliographic databases 
 
Number Searches Results 
1 Constipation.afa 90438 
2 Bowel dysfunction.af 2264 
3 Defecation.af 25606 
4 Defaecation.af 1921 
5 Irrigation.af 55773 
6 1 OR 2 OR 3 OR 4 110886 
7 5 AND 6 517 
8 Limit 7 to English language 452 
9 Limit 8 to Humans 405 
10 Remove Duplicates from 9 292 
aaf all fields (includes  Subject  headings and all   test  fields) 
 
retrieved. Articles that fulfilled the inclusion 
criteria were included in the review. 
Reference lists of eligible ar- ticles were 
searched to identify potentially relevant arti- 
cles missed by the original database 
search. Another researcher (HJC) reviewed 
10 % of the citations and ab- stracts, as 
well as 100 % of the full-text articles, to 
con- firm appropriate implementation of the 
eligibility criteria and accuracy of data 
extraction. For practical and re- source 
reasons a grey literature search was not 
per- formed, as the likelihood of finding 
appropriate studies not identified in 
retrieved citations or reviews was con- 
sidered very small. 
 
Data collection 
Data were extracted from eligible studies using 
standardised data collection forms. Data items 
included study method- ology, patient 
information (including demographic details and 
definition of ‘constipation’ used), primary 
outcome data (including follow up period), 
duration of use of treatment, and adverse 
events reported. The Cochrane assessment of 
bias  for  non-randomised  studies  tool   
(ACROBAT-NRSI) 
[12] was used to evaluate methodological 




The primary outcome was the  proportion  of  
patients with an investigator-reported positive 
outcome to trans- anal  irrigation therapy. 
Secondary outcomes include response by 
constipation type, duration of treatment use 
and safety of treatment assessed by adverse 
event reporting in studies. 
 
Analysis 
Both qualitative review of study results and 
quantitative analysis was performed. Rates of 
complications are re- ported and statistical 
pooling  of  proportion  estimates was  
explored  using  fixed  and  random  effect  
models 
within StatsDirect © Version 3. Both Q and I2 
statistics 
 
were calculated to assess study 
heterogeneity. An Egger test was performed 
to assess risk of publication bias. 
 
Results 
Of 292 abstracts and citations reviewed, 19 
full-text arti- cles were retrieved. Of these, six 
were suitable to be in- cluded in the review [9, 
13–17]. Reference lists of these articles were 
reviewed and a further eligible article was 
identified [18], giving a total of 7 articles (Fig. 
1). All eli- gible studies reported outcomes 
using high-volume irriga- tion only. One 
further study using low-volume irrigation was 
found, not reporting constipation-specific 
outcomes and was excluded from the final 
analysis [19]. Studies identified were 
prospective cohort studies, or retrospect- ive, 
uncontrolled case series from European 
nations  (Table 3). In each study the patient 
case mix included pa- tients with faecal 
incontinence, soiling and following colo- rectal 
surgery. However the articles reported 
outcomes separately for each group, making 
it possible to evaluate outcomes for chronic 
functional constipation. Reported mean 




to 102 months (range 1–216 months 
across studies). 
Studies were small, with an average 
number of patients per study of 36 (range 
10–79); there was no evidence of   a power 
calculation  being performed for any study. 
 
Outcome of anal irrigation therapy 
Patient-reported satisfaction, either 
subjective or using a visual-analogue scale, 
was the outcome most commonly reported 
(5 studies) [13, 15–18]. One study used 
reso- lution of symptoms as the outcome 
measure [14], another used a combination 
of patient-reported symptom im- provement 
and ongoing use of treatment [9]. If a patient 
died while still using the treatment this was 
also consid- ered successful. One study [13] 
reported both patient- reported satisfaction 
and change in Cleveland constipation score 
as markers of treatment success; the 
patient- reported satisfaction outcome was 
included in this analysis as it enabled 
meaningful comparison with other studies. 
Studies report variable response rates to 
therapy (Table 4). The proportion of 
patients who had a posi- tive outcome to 
therapy varied from 30 % [14] to 65 % [13, 
16]. Overall, 254 patients with chronic 
functional constipation were included in 
studies, with 128 having a positive 
response to irrigation therapy (Table 4). 
A fixed effect analysis of proportions gave a 
pooled re- sponse rate of 50.4 % (95 % CI: 
44.3–56.5 %). Although there  was no 
evidence  of publication  bias  (Egger:  bias = 
0.259, p = 0.91), there was evidence of 
substantially hetero- geneity  between  
studies  (Q[6] = 18.2,  p = 0.0057;   I2 = 
67.1 %). A random effects estimate was 
similar, if less pre- cise: 50.9 % (95 % CI: 
39.4–62.3 %), (see Fig. 2). 
Four studies reported results for different 
sub-types of constipation (Table 5). Sample 











































Fig. 1 PRISMA flowchart. Flowchart showing number of abstracts and articles reviewed, numbers excluded, reasons for exclusion, numbers 





Table 3 Study characteristics 




Definition of constipation Definition of successful 
treatment 
Chan [13] Prospective cohort study III Infrequent passage of stool 
+/− straining/ digitation/ incomplete emptying 
i) → Improvement in 
Cleveland Constipation Score 
ii) → Patient-reported 
satisfaction 
Christensen [9]  Retrospective questionnaire 
survey and case note review 
III Idiopathic constipation including slow transit, 
obstructed defecation and ‘undetermined’ 
i) → Ongoing use 
ii) → Resolved symptoms 
iii) → Still using irrigation at 
time of death 
Koch [14] Prospective cohort study III <2 bowel motions per week, straining or incomplete 
evacuation >50 % motions in previous year 
Resolution of incomplete 
emptying or straining 
symptoms 
Cazemier [15]   Retrospective case series 
questionnaire survey 
III Constipation according to Rome II criteria Patient-reported satisfaction 
Gosselink [16]  Retrospective case series, 
questionnaire survey 
Gardiner [18] Case series; not stated if 
prospective or retrospective 
Crawshaw [17]  Retrospective case note 
review and questionnaire 
survey 
III Obstructed defecation based on; straining, incomplete 
evacuation, digitation, fullness, <3 motions/ week 
III Obstructive defecation and slow transit 
(?which criteria used) 
III The inability to evacuate the rectum when desired 




10 mm increase on VAS 
(10 % improvement) 
 
 








Table 4 Demographics and overall response to treatment 
Study Patients with Chronic Average age Male:Female Positive Time to assessment Duration of therapy 
 Constipation (n) (Years)  response n(%) (Months (range)) (Months (range)) 
Chan [13] 60 46 8:52 39 (65) 6a 10.7a 
 
Christensen [9] 79 52a 25:62a 27 (34) 21 (1–116)a 8 (1–85)a 
Koch [14] 10 55.4 4:7a 3 (30) 3a - 
Cazemier [15] 12 46 1:3 6 (50) - 102 (30–216)a 
Gosselink [16] 37b 54 5:32 24 (65) 56 (8–154)a d 
Gardiner [18] 41 - - 21 (51) - - 
Crawshaw [17] 15 54 (41–61)a 13:35a 8 (53) 12ac - 
Total 254 - - 128 
aWhole cohort 
bObstructed Defaecation only 
cInferred from study  report 
dNot stated, but  73 % of patients  still  using  TAI  at 30 months 
-Data  not available 
 
very small (10–37 patients with OD) and and 
differences between sub-groups remain 
anecdotal. When results from all  four 
studies where results for  different types   of 
constipation are reported  are  combined,  
there  was no consistent pattern of outcome 
between subtypes. Methodological 
weaknesses, inconsistencies in out- come 
measures and small sample sizes limit 
meaning-  ful comparison. 
 
Safety of anal irrigation therapy 
The most clinically significant risk associated 
with irriga- tion is bowel perforation. Only one 
study reported this complication [9] and this 
occurred in two patients. If re- liably reported, 
this represents 2 perforations in approxi- 
mately 110,000 irrigations, or less than 0.002 
% risk per irrigation. No studies reported 
mortality associated with irrigation. Studies 
were inconsistent in their reporting of adverse  
events  and  the  level  of  disaggregation 
between 
pathologies treated, thus only a narrative 
summary is possible. 
Minor and self-limiting adverse events 
were common- place in studies but may to 
some extent have been toler- ated by 
patients, with up to 74 % of long term 
continuing users reporting some form of 
related and ex- pected adverse events in 
one study [16]. The most commonly-
reported adverse events included 
abdominal cramps/discomfort (33–40 %) [9, 
15, 16]; anorectal pain 
(5–25 %) [9, 16]; anal canal bleeding (1–20 
%) [9, 13]; leakage of irrigation fluid (30–75 
%) [9, 16]; and expul- sion of the  rectal  
catheter (39 %)  [9]. One study reports  a 43 
% incidence in ‘technical problems’ with 
irrigation [16]. In one study, 28 % of those 
discontinuing therapy gave side effects or 
technical issues with irrigation as a reason for  
discontinuing [9]. 
Therefore, whilst one or more side effects 
were experi- enced by a large proportion of 
























Fig. 2 Proportion Meta-analysis plot [random effects] Forest plot showing response rates for each study, plus pooled response (diamond) with 









Table 5 Risk of bias assessment 
Risk of bias by type 







Chan [13] Moderate Low Low Low Moderate Moderate Low Moderate 
Christensen [9] Moderate Moderate Moderate No 
information 
Low Serious Low Serious 
Koch [14] Moderate Low Low Low Low Moderate Low Moderate 
Cazemier [15] Serious Serious Serious Low Low Serious Low Serious 
Gosselink [16] Low Serious Moderate Low Moderate Serious Low Serious 






Low Serious No 
information 
Serious 
Crawshaw [17] Moderate Serious Serious Low Serious Serious Low Serious 
 
irrigation, the risk of major life-threatening, 





Generally, the studies were of weak 
methodology. There were no randomised 
controlled studies or case- controlled studies 
and most articles were retrospective 
questionnaire and case note based case 
series (Table 3). Two studies [13, 14] were 
prospectively designed with fixed follow up 
points, but numbers were relatively small 
(only 60 and 11 chronic functional 
constipation patients respectively). A further 
study [18] did not state whether data 
collection was prospective  or retrospective. 
Risk-of–bias assessment suggests that five 
studies were at serious risk of bias, and the 
other two were at moder- ate risk (Table 5). 
The retrospective questionnaire-based 
studies also suffered from non-response to 
surveys and missing data. This is likely to 
lead to bias and the results must be 
interpreted in light of this (i.e., were 
responders significantly more or less likely 
to have responded well to irrigation 
therapy?). Given the limitations  of design 
and size, available studies are unable to 
provide robust evidence for the treatment 
effect of trans-anal irrigation. Patient 
heterogeneity was also an issue. One study 
in- cluded both children and adult patients 
together [9] and the proportion of children 
was not reported.  Neither was it stated 
whether there was a difference in outcome 
between the adults and children. One study 
[15] in- cluded three patients with neurological 
problems in its constipation cohort, 
representing 25 % of this study population. 
As neurogenic constipation may respond dif- 
ferently to irrigation [20], this may have 
affected the re- sults. A further study included 
5 patients out of 11 with chronic constipation 
who had had colorectal  surgery (one 
resection and four rectopexies) [14]. Another 
study 
[17] also included patients who had undergone 
pelvic surgery or rectopexy in the  chronic 
constipation cohort. It  is  not  known  




had on response to treatment but these 
remain a poten-   tial source of confounding. 
 
Discussion 
This review brings together the findings of 
seven  pri- mary research studies which 
examine outcomes of trans-anal irrigation 
therapy in patients with chronic functional  
constipation. 
Studies retrieved are small and not of 
robust methodo- logical quality; only two are 
prospectively-designed, and there is the 
potential for reporting bias in the four stud-  
ies that use questionnaires. This finding 
underlines the fact that the evidence for use 
of irrigation in functional constipation is 
currently  weak. 
The aggregate success rate of irrigation 
therapy is around 50 % based on these 
seven studies. Given the chronic and 
refractory nature of the symptoms in many   
of these patients this may be considered 
adequate, espe- cially given the simple and 
reversible nature of the treat- ment [8]. By 
comparison, response rates for drug 
treatments in this group of patients has been 
reported as 20–40 %, though these are 
prospective RCTs reporting symptom based 
primary end-points [21–23]. Addition- ally, 
reported response rates  in neurogenic  
constipa- tion are only slightly higher-around 
60 % [5]. Mean duration  of use   of   
treatment  was  reported  between  8 
months and 102 months. Inconsistencies in 
reporting findings, methodological 
differences and weak study design mean 
that there is insufficient evidence to state 
with any confidence exactly what the 
duration of  bene- fit of treatment should  
be. 
The majority of patients experience some 
form of ad- verse event although these are 
mostly minor, reversible and self-limiting. 
This may be a factor in determining the 
success of therapy: the need for high levels 
of patient mo- tivation, as well as support 
from specialist nurses, is recog- nised [8]. 
The rates of life threatening complications 
are very low throughout the studies: Irrigation 
can be consid- ered a safe therapy, when 









There is insufficient evidence to state with 
any certainty how best to tailor therapy to 
patient symptoms. A recent review based on 
expert consensus [24] has proposed a 
number of regimes to overcome problems 
with irrigation and so improve outcomes, but 
experimental trial evidence is lacking, 
especially for functional constipation patients. 
In spinal cord injured patients, it has been 
found that emptying the rectosigmoid using 
irrigation stimulates co- lonic transit [24] 
however it is not clear whether this is 
transferable to patients with slow colonic 
transit and func- tional constipation. 
Scintigraphic studies have suggested that 
these patients have a different response to 
irrigation, with reduced colonic clearance 
compared with spinal cord injured patients 
[20]. In addition, none of the studies as- sess 
outcomes of low-volume anal irrigation 
systems. 
Two previous systematic reviews examining 
trans-anal irrigation were found [8, 10]. These 
reviews, while valu- able, have several 
limitations: They focus on irrigation as a 
therapy for several conditions including 
neurogenic con- stipation, faecal 
incontinence, idiopathic constipation and 
mixed symptoms; also, one review [10] 
incorporates stud- ies of inpatient pulsed 
irrigation which is a very different therapy 
from home irrigation described in  this  
review. The findings of this review are similar 
to the previous studies with respect to the 
weak nature of current evi- dence and the 
heterogeneity of the studies included. Sub- 
sequent to these reviews further studies have 
been identified and this review is the first to 
address irrigation therapy in idiopathic 
constipation only. This is also the first 
systematic review on this topic to be 
conducted in ac- cordance with the PRISMA 
statement. Additionally, this is the first meta-
analysis of the effectiveness of irrigation in 
chronic functional constipation. 
 
Conclusion 
This review suggests that trans-anal irrigation 
may be an effective therapy for chronic 
constipation, and may be considered in 
patients who have not responded to medical 
management. Irrigation is safe and its 
effectiveness is at least comparable with 
pharmacological therapies. How- ever, the 
evidence to guide its use in chronic functional 
constipation is weak, and its long-term benefits 
are un- clear. There are no reported data on 
cost-effectiveness of irrigation: whether 
treatment provides good value for money from 
scarce health service resources. There is a 
clear need for well-designed prospective trials 
to evaluate the effectiveness, duration, and 
adverse consequences of treatment, as well 
as to assess how best to tailor therapy   to 
individual patients. Future studies should have 
defined outcome measures, for example 
improvement in validated quality-of-life 
questionnaires within a defined time point. 
More evidence about the comparative 
effectiveness and cost-effectiveness of low-
volume and high-volume irriga- tion systems 






TAI: Trans-anal irrigation; ODS: Obstructed defecation syndrome; 
FDD: Functional defecation disorder; CIC: Chronic idiopathic 
constipation; IBS-C: Irritable bowel syndrome (constipation-
predominant); 
PRISMA: Preferred reporting items for systematic review and meta-
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Low-volume versus high-volume 
initiated trans-anal irrigation therapy in 
adults with chronic constipation: study 
protocol for a randomised controlled 
trial 
Christopher Emmett1*, Helen Close2, James Mason3, Shiva Taheri4, Natasha Stevens4, Sandra 
Eldridge5, Christine Norton6, Charles Knowles4 and Yan Yiannakou1 
 
Abstract 
Background: Constipation is common in adults and up to 20% of the population report this symptom. 
Chronic constipation (CC), usually defined as more than 6 months of symptoms, is less common but results in 
0.5 million UK GP consultations per annum. The effect of symptoms on measured quality of life (QOL) is 
significant, and CC consumes significant health care resources. In the UK, it is estimated that 10% of district 
nursing time is spent on constipation. Trans-anal irrigation therapy has become a widely used treatment 
despite a lack of robust efficacy data to support its use. The long-term outcome of treatment is also 
unclear. A randomised comparison of two different methods of irrigation (high- and low-volume) will 
provide valuable evidence of superiority of one system over the other, as well as providing efficacy data for 
the treatment as a whole. 
Methods: Participants will be recruited based on predetermined eligibility criteria. Following informed 
consent, they will be randomised to either high-volume (HV) or low-volume (LV) irrigation and undergo 
standardised radiological and physiological investigations. Following training, they will commence 
home irrigation with the allocated device. Data will be collected at 1, 3, 6 and 12 months according to a 
standardised outcomes framework. The primary outcome is PAC-QOL, measured at 3 months. The study 
is powered to detect a 10% difference in outcome between systems at 3 months; this means that 300 
patients will need to be recruited. 
Discussion: This study will be the first randomised comparison of two different methods of trans-anal 
irrigation. It will also be the largest prospective study of CC patients treated with irrigation. It will provide 
evidence for the effectiveness of irrigation in the treatment of CC, as well as the comparative effectiveness 
of the two methods. This will enable more cost-effective and evidence-based use of irrigation. Also, the 
results will be combined with the other studies in the CapaCiTY programme to generate an evidence-based 
treatment algorithm for CC in adults. 
Trial registration: ISRCTN, identifier: ISRCTN11093872. Registered on 11 November 2015. Trial not retrospectively 
registered. Protocol version 3 (22 January 2016). 
Keywords: Constipation, Irrigation, Chronic 
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Burden of disease 
Constipation is common in adults and up to 
20% of the population report this symptom 
depending on the defi- nitions used [1–3], 
with a higher  prevalence in women  [1, 4, 5] 
and older people [6, 7]. Chronic constipation 
(CC), usually defined as more than 6 months 
of symp- toms, is less common [8] but results 
in 0.5 million  UK  GP consultations per 
annum. A proportion of the popu- lation suffer 
symptoms which are both chronic and more 
disabling (about 1–2% of the population) [9]. 
Such pa- tients, who are predominantly 
female [10], are usually referred to secondary 
care with many progressing to ter- tiary 
specialist investigation. Patient dissatisfaction  
is high in this group; nearly 80% feel that 
laxative therapy   is unsatisfactory [11] and 
the effect of symptoms on measured quality 
of life (QOL) is significant [12]. CC consumes 
significant health care resources. In the US in 
2012, a primary complaint of constipation 
was respon- sible for 3.2 million physician 
visits [13] resulting in (direct and indirect) 
costs of US$1.7 billion. In the UK,   it is 
estimated that 10% of district nursing time is 
spent  on constipation [14] and the annual 
spend on laxatives exceeds £80 million, with 
17.4 million prescriptions be- ing issued in 
2012 (Health and Social Care Information 
Centre, 2013) [15]. 
 
Pathophysiological basis of chronic constipation 
The act of defaecation is  dependent  on  the  
coordi- nated functions of the colon, rectum 
and anus. Con- sidering the complexity of 
neuromuscular   (sensory  and motor) 
functions required to achieve planned, 
conscious and effective defaecation [16] it is 
no  sur-  prise that disturbances to perceived 
‘normal’ function occur commonly at all 
stages of life. Clinically, such problems 
commonly lead to symptoms of obstructed 
defaecation, e.g. straining; incomplete, 
unsuccessful or painful evacuation; bowel 
infrequency; abdominal pain and bloating. 
After exclusion of a multitude of sec- ondary 
causes (obstructing colonic lesions, 
neurological, metabolic and endocrine 
disorders), the pathophysiology of CC can 
broadly be divided  into  problems  of  co- 
lonic contractile activity and thus stool transit 
and problems of the pelvic floor. Thus, with 
specialist physiological testing (using a 
standard panel of radio- physiological tests of 
colonic and anorectal function, hereafter 
referred to as INVEST in this protocol),  pa- 
tients may be divided into those who  have  
slow  co- lonic transit, evacuation disorder, 
both or neither (no abnormality found with 
current tests). Evacuation dis- orders can be 
then subdivided into those in which a 
structurally significant pelvic floor abnormality 
is evident, 
e.g. rectocoele or internal prolapse 
(intussusception) and those in which there  is  




without structural abnormality: most 
commonly termed 
‘functional defaecation disorder (FDD)’. 
 
Chronic constipation management overview 
Management of CC is a major problem due 
to its high prevalence and lack of 
widespread specialist expertise. In general, 
a step-wise approach is undertaken, with 
first- line conservative treatment, such as 
lifestyle advice and laxatives (primary care), 
followed by nurse-led bowel retraining 
programmes, sometimes including focussed 
biofeedback and psychosocial support 
(secondary/tertiary care). Although these 
treatments may improve symptoms in more 
than half of patients, they are very poorly 
standar- dised in the UK and are not 
universally successful [17]. Thus, patients 
with intractable symptoms and impaired 
QOL may be offered a range of costly, 
irreversible surgical interventions with 
unpredictable results [18, 19], some- times 
resulting in major adverse events (AEs) or a 
per- manent stoma. 
 
Overall rationale for the CapaCiTY programme 
The current trial forms part of an NIHR-
funded programme (PGfAR: RP-PG-0612-
20001). This prog- ramme aims to develop 
the evidence base for the man- agement of 
CC in adults which is currently lacking. This 
is in contrast  to  the management  of  CC 
in  children  for which NICE guidance has 




[20, 21]; and for adults with faecal incontin- 
ence 
(http://pathways.nice.org.uk/pathways/faecal-
incontin- ence). Thus, the current situation is 
one where there are considerable variations in 
practice, particularly in specialist services. With 
a number of new drugs gaining or seeking 
NHS approval [22–25] and technologies at a 
horizon- scanning stage [18, 26, 27] it is timely 
that the currently limited evidence base for 
adult CC is developed for resource-constrained 
NHS providers  to  have  confidence that new 
and sometimes expensive investigations and 
ther- apies are appropriate and cost-effective. 
A cost-conscious pathway of care may help to 
reduce health care expenditure by 
appropriately sequencing the care provided, 
while target- ing more expensive therapies at 
those most likely to benefit. Such data will 
inform the development and commissioning of 
integrated care pathways. An overview of the 
CapaCiTY programme is provided as a 
scheme (See Additional file 1) and includes a 
series of interlinked work package signature 
pages (WPs) that answer the important 
questions  for  pa- tient care. A rolling 
programme of national recruitment will provide 
a large cohort of well-defined patients for 
subse- quent studies within sequential WPs 
over  5  years.  The focus will be on generating 
real-life evidence from prag- matic studies 
which will provide valid clinical outcome 
measures,  patient  acceptability  and cost.  





data it will be possible to develop an NHS 
management algorithm for CC which will 
meet patient, clinician and policy aims. 
 
Specific clinical background to the prospective cohort 
study of trans-anal irrigation (TAI) 
Anal irrigation, using a variety of 
commercially available devices, has been 
rapidly disseminated internationally over the 
past 3–5 years, first in patients with neuro- 
logical injury [28, 29] and subsequently in 
other CC groups [30, 31]. Despite a lack of 
published data other than from small selected 
case series, it is now  available on the drug 
tariff and generally considered  to  be  the  
next step in patients failing other nurse-led 
interventions such as biofeedback. Anal 
irrigation has permeated the UK market 
without robust efficacy data and with on- going 
concerns regarding longevity of treatment and 
complications [28, 32]. Retrospective clinical 




continued response rate after 
1 year of approximately 50% with such 
patients, thus avoiding or delaying surgical 
intervention. An accurate assessment of 
response rate and acceptability of this 
intervention requires confirmation in a large 
prospective cohort, together with clinico-
physiological predictors of success. In 
addition, two alternative systems for delivery 
of TAI exist; low-volume systems delivering 
approxi- mately 70 ml per irrigation, and high-
volume systems delivering up to 2 L of 
irrigation (although typically only 0.5–1.5 L is 
required per irrigation). The low-volume 
system is cheaper, costing approximately 
£750 p.a. based on    alternate-day   use,    
compared   with  approximately 
£1400–1900 for high-volume irrigation, and 
may  be more acceptable to patients, and so 
a randomised study comparing the two 
systems is  needed. 
 
Trial design: rationale 
Robust data for the use of TAI therapy in 
chronic (idiopathic) constipation are lacking. 
In  addition,  there are no data demonstrating 
superiority of high-volume ir- rigation over 
low-volume systems. Given the differences in 
cost between the two systems, a randomised 
study of well-characterised patients 
comparing the two methods would provide 
useful information on whether one sys-  tem 
holds a clear advantage over the other. Also, 
the short- and long-term efficacy and 
acceptability of ther- apy in CC could be 
evaluated. This is timely and inform- ative 
given the rapidly increasing popularity of this 
treatment and the fact that  TAI  is  an  
invasive  therapy for which patient selection 
should also be optimised to maximise benefit. 
In practice, patients will use one system 
only (plus de- fined ‘rescue therapies’ – see  
below)  for a minimum of   3 months. After 
this time point they may switch to the other  
system  if  their  initial  therapy  was  
ineffective/ 
 
unsatisfactory. Thus, consenting patients will 
be rando- mised to initiate therapy with one of 
these systems  but will have the option of 
switching to the other after an initial 3-month 
period. This allows us to identify re- sponse 
rates to each system in the short term (3 
months), and thereafter this study is a 
comparison between treat- ment strategies 
(low-volume initiated therapy versus high-
volume initiated therapy) rather than a pure 
com- parison of the two techniques. This is a 
patient-centred study design aiming to limit 
the time that patients spend using ineffective 
therapy without being allowed to try an 
alternative. This also allows estimation of 
comparative cost-effectiveness of the two 
treatment pathways, and whether one system 
works better depending on the radio-
physiological profile of the patient. Recent 
data es- timates that approximately 85% of 
patients are still using irrigation at 1 month; 
this represents a significant short- term 
treatment failure rate [33]. Once patients 
have switched therapy, they may not switch 
back to the first system; once they have tried 
both systems and discontin- ued them then 
they will be considered to have com-  pleted 
the intervention and they will return to routine 
clinical care. 
Irrigation is a maintenance therapy rather 
than a cure.   In addition to outcome 
measures of the Patient Assessment of 
Constipation Quality of Life question- naire 
(PAC-QOL) [34, 35] score at 3 months,  
patients will provide survival data (time until 
cessation of irriga- tion therapy due to lack of 
benefit). Switching systems does not affect 
this; the survival data is based on the use of 
irrigation irrespective of system. A survival 
analysis is appropriate since anal irrigation is 
time-consuming and inconvenient as a 
therapy and patients may find the process 
distasteful. Patients are unlikely to continue 
with treatment if they are not gaining  
worthwhile benefit from it; treatment 
continuation is a useful patient- centric 
assessment. 
Consideration of the findings from both 




used to model the net value to patients of 




The interventions proposed are those 
already offered to patients in specialist 
centres throughout the UK and 
internationally. All interventions pose 
acceptable and minimal risks. For instance, 
the only invasive tests (INVEST) have been 
performed daily in most specialist centres for 
up to 30 years without any recorded compli- 
cation (Barts Health experience of over 
10,000 patients). A small ionising radiation 
dose is required for one of the tests (covered 
below). A number of questionnaires contain 
personal questions about bowel  problems  






functioning; however, all have been used in 
studies of similar patients previously. 
Trans-anal irrigation has been  shown  to  
be a  low- risk intervention and is widely 
used in a variety of defaecatory disorders 
such as neurogenic bowel dys- function, 
idiopathic constipation and faecal  incontin- 
ence. Serious adverse events (SAEs) are 
rare, with one study  reporting  two  nonfatal  
bowel  perforations  out   of approximately 
110,000 irrigation treatments [28]. Other 
potential side effects include pain, bleeding, 
painful haemorrhoids and anal fissure. A 
recent study reported an overall adverse 
event (AE)  rate  of 22% when all minor and 
reversible events were considered. Thirteen 
percent reported technical problems with 
equipment and 13% reported minor  side  
effects/AEs [33]. The risk of nonparticipation  
is  considered  very low. 
The benefits of participation are that 
patients will re- ceive a very high standard of 
monitored care as a conse- quence of the 
detailed protocol. Participation will inform 






1. To compare the impact upon patient disease-
specific QOL of TAI initiated with a low-volume 
versus a high-volume system in patients with CC, 





1. Survival (continuation of benefit) and acceptability 
in the longer term (up to 12 months) 
2. Disease-specific outcomes at 1, 3, 6 and 12 months 
3. The influence of patient characteristics (urge to 
defaecate, balloon sensory testing results) upon 
treatment success, and response by type of system 
used 
4. The acceptability of each system to patients 
5. Strategies for tailoring therapy to meet patients’ 
individual needs, and the factors involved in this 
6. The safety of each system and prospective tracking 
of AEs 
7. The cost-effectiveness of care 





Specialist centres across the UK with a mix of 





Recruiting sites (initial) 
 
• Barts Health NHS Trust [Allison] 
• St. Mark’s Hospital at London North 
West Healthcare NHS Trust [Vaizey] 
• University College Hospital London [Emmanuel] 
• Guys and Thomas’ Hospitals London [Williams] 
• Sandwell and West Birmingham NHS Trust [Gill] 
• County Durham and Darlington NHS Foundation 
Trust [Yiannakou] 
• University Hospital Southampton NHS 
Foundation Trust [Nugent] 
• Norfolk and Norwich University Hospitals NHS 
Foundation Trust [Speakman] 
• University Hospital of South Manchester 
NHS Foundation  Trust [Telford] 
• Sheffield Teaching Hospital NHS Foundation Trust 
[Brown] 
• North Bristol NHS Foundation Trust  [Dixon] 
• University Hospitals Bristol, NHS Foundation Trust 
[Mabey/Randall] 
• Newcastle Upon Tyne, NHS Foundation Trust [Plusa] 
• Homerton University Hospital, NHS 









• Bart’s and the London, Pragmatic Clinical Trials 
Unit. Centre for Primary Care and Public Health, 
Queen Mary University London (QMUL) 
• County Durham and Darlington NHS Foundation 
Trust, Durham Clinical Trials Unit. Wolfson 




• Age  18–70 years 
• Patient  self-reports problematic constipation 
• Symptom onset more than 6 months 
before recruitment 
• Symptoms meet American College of 
Gastroenterology definition of 
constipation 
• Nonresponse to constipation treatment to a 
minimum basic standard (see NHS Map of 
Medicine 2012) [36]: Comprising lifestyle 
and dietary measures and two or more 
laxatives or prokinetics  tried  (no  time 
requirement) 
• Ability to understand written and spoken English 




• Ability and willingness to give informed consent 
• Failure of previous nurse-led behavioural therapy 
• Ability of patient/carer to use anal irrigation 
The study will use the American College of 
Gastro- enterology definition of constipation 
[37] (which is reasonable, simple and 
extensively published): unsatisfac- tory 
defaecation characterised by infrequent stool, 
difficult stool passage or both for at least 
previous 3 months. This avoids the more 
complex Rome definitions. 
 
Exclusion criteria 
The study interventions necessitate the 
exclusion of major causes  of secondary 
constipation. In detail: 
 
• Significant organic colonic disease (‘red flag’ 
symptoms, e.g. rectal bleeding previously investigated); 
inflammatory bowel disease (IBD); megacolon or 
megarectum (if diagnosed beforehand) (the study will 
provide a useful estimate of the prevalence of such 
cases in referral practice); severe diverticulosis/ 
stricture/birth defects deemed to contribute to 
symptoms (incidental diverticulosis not an exclusion) 
• Major colorectal resectional surgery 
• Current overt pelvic organ prolapse (bladder, uterus, 
vagina, rectum) or disease requiring surgical 
intervention 
• Previous pelvic floor surgery to address defaecatory 
problems: posterior vaginal repair, STARR and 
rectopexy; previous sacral nerve stimulation 
• Previous use of TAI  therapy to treat constipation 
• Rectal impaction (as defined by digital and abdominal 
examination: these form part of the NHS Map of 
Medicine basic standard) [36] 
• Significant neurological disease deemed to be 
causative of constipation, e.g. Parkinson’s disease, 
spinal injury, multiple sclerosis, diabetic neuropathy 
(not uncomplicated diabetes alone) 
• Significant connective tissue disease: scleroderma, 




• Significant medical comorbidities and activity of 
daily living impairment (based on Bartell index in 
apparently frail patients [38], Barthel Index ≤11) 
• Physical disability/impairment which prevents 
the use of one or other of the irrigation  devices 
• Major psychiatric diagnosis (schizophrenia, major 
depressive illness, mania, self-harm, drug/alcohol 
addiction) 
• Chronic regular opioid use (at least once daily use) 
where this is deemed to be the cause of 
constipation based on temporal association of 
symptoms with onset of therapy; all regular strong 
opioid use 
• Pregnancy or intention to become pregnant during 
study period 
 
Note: ‘red flag’ symptoms are not an 
exclusion if they have been investigated 
before enrollment and organic disease 
excluded. Previous TAI therapy does not 
include private (non-NHS) ‘colonic irrigation’ 
therapy; prior use of such treatments is not 
an exclusion criterion. 
 
Study interventions: trans-anal irrigation therapy 
Trans-anal irrigation training will be provided 
by trained nurse or physiotherapist with 
experience in delivering care for CC. They 
must have initiated irrigation  therapy  in at 
least three patients independently, and be a 
nurse/therapist  of good standing within a 
clinical team regularly seeing pa- tients with 
CC. A standardised approach and intervention 
will be provided via the use of an intervention 
manual. For the first 3 months of participation 
in the study,  patients  may not use other 
therapies besides anal irrigation  and  those 
rescue therapies specified below. They may 
discon- tinue therapy at any point (elective 
withdrawal from inter- vention) and may switch 
from one system  to  the  other after 3 months. 
Switching anal irrigation systems before 
completing the 3-month waiting period will be 
discour- aged. If it does occur, it will be 
documented as a protocol deviation with the 
timing and reason documented. If symptoms 
are severe despite the use of irrigation and 
res- cue therapies then other medications may 
be used on com- passionate grounds, but this 
must be recorded in the Case Report 
Form(CRF)/concomitant medications  log. 
The course of therapy will include a nurse-
led training session (or more if required to 
ensure that the device is being used 
effectively) followed by patient-led home irri- 
gation therapy. The low-volume system 
commonly used in practice is Qufora® Mini 
(MBH-International). Various high-volume 
systems are used, all of which have very 
similar  mechanisms  of  action;  these  
include  Peristeen™ (Coloplast)  and  Qufora  
Toilet/Qufora  Balloon™  (MBH- international). 
These are commercially available TAI sys- 







This system consists of a small reservoir 
attached to a cone. The reservoir holds 
approximately 70 ml of water and is 
squeezed to inject water into the rectum. 
The re- gime used will be as follows: initial 
irrigation once daily for 14 days using one to 
three insufflations (each of 70 ml 
approximately). This may then be reduced 
to  alternate days depending on response. 
Patients may then adjust fre- quency and 
volume depending on response. They may ir- 
rigate as much and as often as they feel is 
necessary to give them benefit and this 
information will be captured on the CRF with 
the aid of an Irrigation Journal. 
 
High-volume irrigation 
High-volume systems consist of an irrigation 
bag con- nected  to  a  tube.  The  water  





either by  gravity or using a pump. Some 
systems em- ploy a balloon to hold the 
device in place during irri- gation; others 
require the patient  to  hold  it  in  place. The 
mechanism of action is the same for all  
systems. Initial frequency of irrigation is the 
same as for low- volume irrigation; i.e. daily 
for 14 days, then alternate days. Patients will 
commence   with   irrigations   of   300 ml and 
increase this by 100 ml every 2 days until 
satisfactory defaecation is achieved or the 
procedure becomes uncomfortable, up to a 
maximum of 1500 ml. Patients may adjust 
therapy depending on response, as for low-
volume irrigation. 
 
Switching between anal irrigation  systems 
After 3 months of using one  system,  
patients  may switch to the  other  or  
discontinue  therapy  and  return  to routine 
clinical care. This  will  be  entirely  patient-  
led, and reasons for changing  systems  will 
be ex- plored during follow-up  visits  and  
captured  on  the CRF. There is, therefore, 
no defined protocol for switching treatments 
as patients may do this for any reason; 
analysis of time to switching/discontinuing 
therapy, as well as the  patient-reported  
reasons  for doing so, will provide insight into 
why each irrigation system is or is not 
successful. In addition, qualitative interviews 
with patients who have switched or discon- 
tinued therapy will be  used  to  explore  




All clinical endpoints will be in common with a 
single standardised outcome framework 
(consistently used within all CapaCiTY 
programme studies). All outcomes will be 
recorded at baseline, 3, 6 and 12 months in 
face- to-face clinics (or by telephone call if 
necessary). PAC- QOL, the Patient 
Assessment of Constipation Symptoms (PAC-
SYM) and the EuroQol Health Outcome 
measure (EQ-5D-5 L) and the EuroQol Visual 
Analogue Scale (EQ-VAS) will additionally be 
collected at 1 month; this is to capture 
reasons for early nonresponse to therapy,      
as well as to better characterise the patient 
group and provide more data for economic 
analysis. The primary endpoint  will be at 3 
months. 
 
Primary clinical outcome 
 
• Patient Assessment of Constipation Quality of Life 
questionnaire (PAC-QOL [34, 35]) at 3 months. 
 
Secondary clinical outcomes 
 
• PAC-QOL score and individual domain scores at 1, 3, 





• Time to cessation of each system of irrigation; 
total time in treatment with either system (from 
Irrigation Journal) at 1, 3, 6 or 12 months 
• Reason for cessation (of each system) 
(Irrigation Journal and qualitative interviews) 
at 1, 3, 6 and 12 months 
• Patient Assessment of Constipation Symptoms 
(PAC-SYM): aggregate and domain scores at 1, 3, 
6 and  12 months 
• Volume and duration of irrigation 
(Irrigation Journal) at 1, 3, 6 and 12  
months 
• Number and nature of bowel motions (captured 
in 2-week Patient Diary) at 3, 6 and 12  months 
• Symptom scores derived from Diary records 
(taken over 2 weeks before or around each 
follow-up contact. These will include number of 
spontaneous complete bowel motions at 3, 6 
and 12 months 
• Generalised Anxiety Disorder Questionnaire 
(GAD-7) at 3, 6 and 12 months 
• Depression, anxiety and somatisation modules of 
the PHQ-9 at 3, 6 and  12 months 
• Global patient satisfaction/improvement score 
(Visual Analogue Scale; VAS) at 3, 6 and 12 months 
• Patient acceptability and recommendation to 
other patients (qualitative interviews) 
• Behavioural Response to Illness Questionnaire 
(CC- BRQ) and Brief Illness Perception 
Questionnaire BIPQ (CC) at 3, 6 and 12 months 
• Generic quality of life: EuroQol EQ-5D-5 L and EQ- 
VAS scores 1, 3, 6, and 12 months 
• Use of health care resources, AEs, and concomitant 
medications (collected using Patient Journal) at 3, 6 
and  12 months 
 
Health  economic outcomes 
 
• Interventions,  treatment  sequelae  and  other  
health resource use related to  the  care of CC will 
be recorded  in  natural  units  and  cost  applied 
where possible using national reference costs. 
Additionally, patient costs related  to  constipation 
and the  opportunity  cost  of  time  away  from 
normal activities will be valued using national 
reference sources. 
 
Patient experience (see ‘Qualitative interviews’) 
 
• Face-to-face, digitally recorded, semistructured 
interviews will be  conducted involving  a 
purposive, diverse sample of patients 
throughout the programme, with  
participants  reflecting  a range of ages, 
geographical locations and, where 
possible,  other  pertinent  attributes,  
such as 






saturation  when  no  new  themes 
emerge. 
Participants will be approached by a 
member of the  research  team  and  
will  undergo  a separate 
consent process if they are willing to 
participate   in  the  qualitative study. 
 
Study design/plan – Study visits 
The following section provides an overview of 
patient study visits. This is provided in 
diagrammatic format in the attached 
Standard Protocol Items: Recommendations 
for Interventional Trials (SPIRIT) figure (Fig. 
1. See Additional file 2 for the SPIRIT 
Checklist). 
 
Visit 0: Prescreening: eligibility assessment 
A Good Clinical Practice (GCP)-trained  and 
dele- gated local researcher will  screen  for  
basic  eligibility  by telephone (or face-to-face 
interview based  on  pa- tient choice). 
Potentially eligible patients will be identified 
either in clinic, from referral letters from 
GPs/other consultants to the constipation  
clinic,  and from patients participating in  
CapaCiTY  01  who  did  not respond, or have 
ceased  to respond, to habit training 
(HT)/biofeedback (HTBF). Participants   will  
be provided with adequate explanation of the 
aims, methods, anticipated benefits and risks 
of  anal  irriga- tion therapy and will take away 
or be posted  an invi- tation letter and a 
Participant Information   Sheet  (PIS). 
Patients will be given at least 24 h to consider 
participation and  invited  to  attend  clinic  for 





The study screening number will be 
allocated as follows: 
 
• Study code 02 
• Site code – three-letter code  for each site 
• Participant Code – four-digit code given 
consecutively and attributed at each site 
 
For example, the first participant recruited 
at Barts Health Trust would be assigned the 
code 02-BLT-0001. Patients progressing to 
other studies within the CapaCiTY 
programme will keep this number for path- 
way tracking. 
 
Visit 1: Screening, consent, baseline assessments and 
randomisation 
Visit 1 will be conducted face to face in 
clinic. Following a detailed discussion about 
the trial, potentially eligible and agreeable 
patients will complete a written informed 
consent, followed by a more thorough 
screening and confirmation of eligibility for 
randomisation by standar- dised medical 
and surgical history and physical examin- 
ation (the latter if not already performed 
within the previous 3 months). 
Patients  who  decide  not  to  opt  for  
treatment  will be invited to offer reasons and 
these will be  recorded when provided. 
Patients declining participation will continue 
to receive usual care as locally  provided. 
There is no obligation for patients to give 









For those patients entering the study, 
additional base- line outcome assessments 
will be conducted. These in- clude several 
key validated assessments that  profile 
patient characteristics, informing disease 
pathophysi- ology and potential predictors of 
treatment response. All have been selected 
on the basis of trade-off between ad- equate 
detail and achievable brevity. These 
instruments will be combined with the 
standardised outcome frame- work into a 
single booklet (design and presentation have 
been optimised by patient  representatives). 
 
Confirmation  of eligibility 
 
• Standardised history by interview including previous 
medication usage 


















V4 V5 V6 
3 month FU 6 month FU 12,month 
visit  visit  FU visit 





(+ 8 weeks) 
+ 2 weeks  +2 weeks + 2 months + 3 months + 6 months 
(+/- 3 days) (+/- 1 week) (+/-1 week) (+/-1 week) (+/-1 week) 
Brief screening and providing PIS 
Informed Consent 
Structured history including eligibility assessment, 
demographics, medical history, medications, clinical 
examinations 
Pregnancy Test where applicable 
Baseline only assessments 
Rectal balloon sensory testing* 
Balloon expulsion test* 
Anal manometry* 
Radio-opaque marker transit study* 
Randomisation 
In therapy assessments (Anal Irrigation)** 
Standardised outcome framework assessments 
Short Outcome Assessment 
Patient Diary Provided 
Patient Diary Collected 
*** 
Patient Journal Provided 
Patient Journal Collected 
Irrigation Journal Provided 













x x x 





























V1.1 = INVEST – A minimum timeframe of 2 weeks to allow completion of baseline diary prior to INVEST and maximum of 8 weeks (for logistical purposes). 
V2 = commencement of therapy and TAI training; V2.1 = Phone call within 2 weeks 
**V2.2 = further training if needed to be conducted prior to or in conjunction with V3 if necessary. V3 = 4 week follow up session (Face-to-face if possible or telephone) 
All follow up time points measured from commencement of therapy (V2) 
*** Resource use data is collected in patient journal training and retrospective completion of this journal occurs at visit 1. 




performed previously within last 3 months): 
standardised  exam  of perineum/anus/rectum 
 
Baseline outcome assessments 
 
• Baseline outcome assessments (PAC-QOL, PAC- 
SYM, EQ-5D-5 L and EQ-VAS, PHQ-9, GAD-7, CC-
BRQ  and  BIPQ-CC,  see  endpoints above) 
• Baseline 2-week Patient Diary will be given. Training 
in completion of the diary will be conducted at visit  
1 and the diary will be completed at home and 
returned at visit 2 
• Training and retrospective completion of the Patient 
Journal will occur at visit 1 for collection of resource 
data. Prospective completion will occur continuously, 
with review at each follow-up visit from 3 to 
12 months 
 
Other baseline only assessments 
 
• Constipation (2006) and IBS (2006) modules of the 
Rome III Questionnaire 
• Cleveland Clinic Constipation Questionnaire 
• Brief, chronic pain, autonomic and joint 
hypermobility assessments 




Conducted by a member of the research 
team. 
 
INVEST  radio-physiology investigations 
There is no defined time period for this, but it 
is sug- gested that INVEST should be 
completed within 4 weeks of the visit 1 
baseline visit to allow for diary completion 
before  stopping  laxatives  for  INVEST.  A  
maximum of 
8 weeks is tolerated to conduct INVEST. 
Those with INVEST  completed  in  the  
previous  12  months  do  not 
 
need these repeated and can be booked for 
visit 2, com- mencing in a minimum  of 2 
weeks to allow  completion of the baseline 
diary. 
 
Training  sessions (45–60  min) (V2–V3) 
This will use a standardised proforma and will 
always be face to face. Patients will receive: 
 
Visit 2: First training session 
Visit 2.0 
 
1. Collection of baseline diary completed before 
stopping laxative (i.e. before INVEST in patients 
who need this done) 
2. Training in TAI: patients will undergo a single, 
nurse-led training session before starting  
treatment. 
The device will be demonstrated to the 
patient by   the nurse specialist and then 
the patient will practice setting up the 
device. The trainer will ensure that   the 
patient knows how to use the device 
correctly before home irrigation is 
commenced 
3. Training in completion of the Irrigation Journal and 
provision of the Irrigation Journal to be completed 
weekly. The Irrigation Journal consists of: volume of 
water introduced, frequency of use, AEs and side 
effects, e.g. pain, bleeding 
4. The trainer and patient will agree a date for delivery 
of equipment and commencement of home 
irrigation. Ideally, this should be the same as the 
first training visit, but this may not be possible due 
to delay in supplying irrigation equipment. Any 
delays should be recorded on a deviation log/note 
to file (CRF 7/8) to allow data analysis to be adjusted 
accordingly 
5. Start date for home irrigation agreed with the  
patient (this is to allow for any delay in delivery of 
equipment). Ideally this should be the same day as 
visit 2, or within 1 week maximum. If any issues or 
delays have been encountered, a new 
commencement date is agreed; this should be 
recorded as a deviation/ note to file (CRF 7/8), along 
with reasons for delay 
6. Regulation/standardisation of laxative use: 
bisacodyl may be used orally as a rescue therapy 
(up to 20 mg at night), plus glycerine suppositories, 
one or two, if needed, if no stool for 3 days. In 




maximum dose of two sachets three times per day 
(TDS) and/or lactulose up to 15 ml twice per day 
(BD). Prokinetic drugs  and any other drug that the 
British National Formulary (BNF) describes as 
having laxative effect or herbal teas that contain 
strong purgatives will be discouraged, but if 
needed (i.e. if symptoms severe) then these are 
permitted  but use must be recorded  in the 
concomitant medications log. There will be  no 









Visit 2.1: First intervention assessment 
A telephone call will be made  to  the  patient  
14  days (±3 days) after visit 2 to check that 
everything is pro- ceeding correctly and to 
resolve any problems. If, due to delay in 
obtaining equipment, etc., the patient has not 
started irrigation at this time  then  the  
telephone call (and other follow-up visits)  
should  be  rescheduled  for 14 days later,  
and the reason for this recorded on CRF 7/8. 
Adverse events and concomitant medications 
will also be reviewed. 
 
Visit 2.2: Second intervention assessment (if needed) 
If there are problems then a further face-to-
face training session will be offered, including 
a review of AEs and concomitant 
medications. This can occur any time  be- 
fore visit 3 (2 weeks ±1 week from visit 2.1) 
or in con- junction with visit 3 if not  before. 
Patients will continue the self-administered 
therapy using a commercially available 
device until the end of    the study. Patients 
will be followed up until the end of   the data 
collection phase of the study (variable follow-
up 12–24 months depending on date of  
recruitment)  or until they decide to 
discontinue either the therapy or the trial 
follow-up. Irrigation will be performed at an 
agreed frequency initially. Once established 
on this therapy pa- tients may adjust the 
frequency and volume of irrigation to suit 
their particular   condition. 
Information about treatment will be 
recorded in the Irrigation Journal. Where a 
patient switches to the other irrigation device 
or discontinues treatment (patient choice) the 
reason for this, as well as the duration of 
therapy, will be documented. If a patient 
chooses to switch devices, which they may 
do at any stage after the 3-month follow-up 
visit, they will receive training in the other 
device. They will receive a follow-up by the 
irriga- tion nurse as required to resolve any 
outstanding issues and to check progress. 
This should  be  documented  on the 
Irrigation Journal and a note to file, (CRF 8) 
and change/discontinue, (CRF 12) should be 
completed. However, they will not be asked to 
repeat the question- naires and diaries 
already completed at 1 and 3 months. 
 
Visit  3:  1-month  follow-up review 
 
1. All patients will receive a further training assessment 
at 2 weeks (±1 week) after visit 2.1, allowing for any 
delay as described previously (V3). This visit will be 
combined with collection of PAC-QOL, PAC-SYM and 
EQ-5D-5 L and EQ-VAS and should be face to face. The 
Irrigation Journal will be reviewed at this visit. A 
telephone call is an acceptable alternative if this is not 
possible 
2. Standardised guidance on how to tailor therapy to 





provided to specialist nurses/therapists. 
Changes in regimen, as well as system, 
will be documented on the CRF. As 
outlined previously, switching between 
irrigation systems before the 3-month 
visit is discouraged, and represents a 
protocol deviation. 
However, it is recognised that some 
patients may need to switch systems 
before 3 months: if this occurs it must 
be recorded on CRF 12 and on the 
deviation log. Primary outcome 
analysis at 3 months will be by 
intention-to-treat 
 
Telephone support will be available from 
the therapist between visits (number given, 
office hours only). The therapist will 
complete the intervention CRF at  every  
visit or patient contact. For  contact  with  
patients  after the training period, a note to 
file (CRF 8) should be completed, and the 
patient will also make a note of any contact 
in their Irrigation Journal. In the instance of 
new psychological issues being determined 
during consult- ation, referral for 
psychological support will be deferred until 
after completion of irrigation training. The 
excep- tion to this rule would be where there 
is clinical concern regarding the patient’s 
acute mental state requiring more urgent 
intervention (see ‘Criteria for withdrawal 
from treatment’). Concerns would be raised 
by the irrigation nurse team to the research 
team, and these would be evaluated by the 
principal investigator (PI) (or a medic- ally 
trained deputy) and appropriate action  
taken.  Fur- ther follow-up visits (V4–V8) will 
be conducted by the research team. If the 
patient requires further input from  the 
irrigation nurse this may be arranged as per 
local practices. Any contact and any 
changes made or advice given regarding 
irrigation should be recorded in the Patient 
Journal and the Irrigation Journal. 
 
Visits 4–6: Follow-up outcome assessments: visits or 
telephone consultations 
A full, standardised outcome framework and 
health eco- nomic dataset will  be  recorded  
at  baseline,  3,  6  and 12 months (±1 week) 
after initiation of intervention at visit 2. To 
maximise completeness of data collected, 
follow-up visits will be conducted face-to-face 
in clinic wherever possible. Where this is not 
possible, a tele- phone consultation will be 
used. The Patient Diary and Journal and 
Irrigation Journal will be provided for review 
at each follow-up visit. 
Patients deciding to switch to the  
alternative  system will be trained in the new 
system by the irrigation nurse and this will be 
recorded on the note to file, CRF 8 and 
change/discontinue, CRF 12. These patients 
will not need  to  complete  the  
questionnaires  at  1  month  and   3 months 
if they have already done so. 
Within the follow-up period at least three 
attempts via two different methods (e.g. 
telephone and letter), will be 









made by research staff to make contact and 
collect follow-up data at each time point, after 
which the time point will be recorded as  
missing. 
 
Recruitment and  strategies  for  achieving  enrollment 
Patients attending specialist centres 
(outpatient clinics, gastrointestinal (GI) 
physiology units) for constipation  and who 
have already failed to respond to a minimum 
basic standard of treatment (see above), as 
well as nurse- led interventions (biofeedback 
or habit training), will be eligible for 
recruitment screening based on criteria. Pa- 
tients will be recruited from those failing 
treatment in CapaCiTY 01 but also those 
patients seen  outside  the trial who have 
had nurse-led behavioural therapies with- 
out response. 
Trial posters will be displayed in primary 
care, phar- macy and community care 
settings, directing patients to their nearest 
research site and contact person, as well as 
the study website for more information, 
including  the  PIS. The same posters may be 
used to  advertise  the  study via 
newspapers, trial websites, social media, and 
patient groups such as Bowel and Cancer 
Research charity. 
Patient and Public Involvement (PPI) 
consultation with CC patients in secondary 
care has explored the ac- ceptability of this 
study design, and we have found that this is 
likely to be acceptable to patients. The 
proposed rescue therapy and patient 
diaries/journals used in the study have been 
reviewed  as part of this process. Care has 
been taken to ensure that the study design is 
patient-centred, with flexibility of laxative use 
incorpo- rated into the protocol, as well as the 
option to switch treatment after 3 months. 
This aims to ensure that pa-   tient 
experience of the trial is similar  to  a  nontrial 
patient in terms of treatment received, within 




A brief screening questionnaire will be used to 
determine whether patients meet the inclusion 
and exclusion criteria (see ‘Eligibility’ above). 
Screening will be performed by suitably trained 
study personnel to minimise logistic hur- dles, 
and as determined by geographic availability. 
The brief screening questionnaire will also be 
made available on the study website, with the 
PIS for patients to self-screen and contact 
their nearest research site if inter- ested in 
taking part. All basically eligible participants 
will then undergo a formal face-to-face 
consent, screening and enrollment session 
prior to randomisation. 
 
Randomisation procedures 
Patients will be randomised 1:1 into two 
groups; those who  commence  therapy  with  
a  low-volume  device and 




those starting with a high-volume  device.  
Patients will be stratified by sex and women 
by centre. Randomisa- tion will be 
performed by a GCP-trained member of the 
research team using a bespoke, secure 
online system de- veloped by the Pragmatic 
Clinical Trials Unit (PCTU). 
 
Blinding 
Patients and clinicians are necessarily 
aware of both INVEST and treatment 
allocations. The need to collect data on 
frequency and volume of irrigation, as well 
as reasons for discontinuing or switching 
between systems, means that assessor 
blinding is not possible with respect to these  
outcomes. Those involved  in the 
development   of the statistical analysis plan 
(SAP) will not have access to any data that 
will lead them  to  become  unblended  and, 
therefore, they will remain blind. Any 
researcher collecting CRFs, handling 
journals or performing statis- tical analysis 
on the above outcomes will be unblinded. 
However, in order to control for observer 
bias, the pri- mary outcome (PAC-QOL at 3 
months) will be con- cealed; the patients will 
complete this questionnaire without a 
researcher present. This will be 
accomplished   in one of the following ways: 
 
1. Direct entry to online secure database, with built-
in validation and prompting to ensure data 
completeness 
2. Completing paper questionnaire by following 
instructions on an information card to ensure that 
all questions are answered. This will be placed in a 
sealed envelope marked with the patients 
pseudonymised study code and will not be 
opened until the time  comes for data entry 
 
Radio-physiological investigations (INVEST) 
Patients will undergo standardised 
investigations. If INVEST previously 
conducted within the last 12 months, results 
can be carried forward. Pregnancy testing will 
be conducted as per routine NHS practice 
(10-day  NHS rule) in respect to women 
between menarche and meno- pause. 
Women of equivocal status will have a 
pregnancy test performed as per routine 
care. 
 
1. Anorectal manometry using standard or high- 
resolution methods [39–41], depending on local 
availability, to determine defined abnormalities 
of recto-anal pressure gradient during simulated 
evacuation [42–44] 
2. Balloon sensory testing using standardised 
methods [45, 46] (2 ml air per second to maximum 
360 ml)  to determine volume inflated to first 
constant sensation, defaecatory desire and 
maximum tolerated volumes. Rectal hyposensation 






normative data on 91 healthy adults [47]. 
The recto- anal inhibitory reflex (RAIR) 
will also be elicited by a 50-ml rapid 
inflation (if necessary in 50-ml aliquots up 
to 150 ml) 
3. Fixed volume (50 ml) water-filled rectal balloon 
expulsion test [42, 43, 48, 49] in the seated position  
on a commode. Abnormal expulsion is defined as 
abnormal if failure to expel with a 1-min effort for 
men  and  1.5  min  for women [50] 
4. Whole gut transit study using serial (different 
shaped) radio-opaque markers over 3 days with 
a single plain radiograph at 120 h [51, 52] 
 
Note: INVEST procedures conducted prior 
to recruit- ment to the study (i.e. within the 
past 12 months) may be done using locally 
available devices and methods. 
All patients will undergo TAI therapy 
irrespective of INVEST results, and will be 
followed up  in  the same way. The purpose of 
INVEST in this study is to identify whether 
certain radio-physiological results correlate 
with treatment response, i.e. can we predict 
likelihood of benefitting from irrigation based 
on pretreatment inves- tigations. Balloon 
sensory testing in combination with patient-
reported urge to defaecate will be analysed as 
co- variates to determine whether such a 






It is inevitable that patients will seek recourse 
to laxa- tives and other dietary supplements 
during the course of the programme. 
Experience shows that complete prohib- ition 
can lead to unreported laxative use, which 
might confound findings. Although we will 
strongly discourage ad libitum medication 
usage and specify a defined break- through 
regimen, we will record cotreatment with 
suffi- cient fidelity and integrity to enable use 
as covariates in analyses using a specific 
patient journal for this purpose (see 
‘Standardised outcome framework’). A 
concomitant medications list, including a 
shortlist of contributory or confounding 
medications, will be used to filtre on data 
entry. Patients using one system in the  
medium/long term may wish to revert to the 
other system or pause treatment for a  short  
period (for example, while going  on holiday) 
for practical reasons. This is permitted but 
must be recorded in the concomitant 
medications  log. This will not be considered 
as switching or ending treat- ments as it is 
only  a  short-term measure. 
 
Criteria  for discontinuation 
The interventions proposed are well-
established in current clinical practice. There 
are  no  defined  criteria  for discontinuation; 
however, clinicians may withdraw treatment 
where they have therapeutic or safety con- 
cerns, consistent with routine care. Patients 
may choose 
 
to discontinue treatment at any point and 
return to rou- tine clinical care. 
 
Procedure for collecting data including Case Report 
Forms (CRFs) and storage 
The data collected for the trial will be a 
mixture of routinely collected data, 
verifiable against the medical record and 
patient-reported outcome (PRO) or 
question- naire data, collected directly to 
CRF. 
Each recruiting site will be required to keep 
accurate and verifiable source notes in the 
medical record rele- vant to each study 
participant’s inclusion and continued 
participation in the study. Data will be 
collected, trans- ferred and stored in 
accordance  with  GCP  guidelines and data 
protection requirements. The PCTU standard 
operating procedures (SOPs) and study data 
manage-  ment plan will define the exact 
process of data collec- tion, transfer and 
storage and control of study data. 
A secure online OpenClinica trial database 
will be pro- vided by the PCTU to enable 
remote data entry at sites where this is 
feasible. This database will provide built-in 
data-validation checks with quality control 
(QC) checks performed by checking a 
predefined percentage of CRF data against 
data entered into the database. In addition, 
on-site monitoring will enable source 
document verifica- tion (SDV) of records. 
Patient-reported outcome measures 
(PROMs), includ- ing questionnaires and 
diaries, may be collected directly to the 
eCRF using a secure and controlled 
REDCap database. An automated email 
reminder will be sent to participants to 
remind them to complete the question- 
naires and diaries every 12 weeks. 
Alternatively, partici- pants can complete 
paper questionnaires and diaries to be 
entered by the central study team. 
All patient-identifiable data, such as 
Consent Forms, screening and identification 
logs will be stored in the in- vestigator site 
files in secure locked cabinets and/or of- 




of the study team. Secure methods of data 
transfer will be used to re- turn CRFs to the 
coordinating site for centralised data entry, 
monitoring, QC in compliance with GCP. A 
copy of the CRF will be held at the site in 
accordance with GCP. 
 
Follow-up procedures 
The study duration allows for follow-up to a 
maximum of 12 months with data collection 
at 3, 6 and 12 months post initiation of 
therapy. Primary outcome data will be col- 
lected at 3 months. Each participant will 
have a minimum of 3, 6 and 12 months’ 
follow-up data for collecting the pri- mary and 
secondary outcomes. In addition, PAC-SYM, 
PAC-QOL and EQ-5D-5 L and EQ-VAS will 
be recorded at the 1-month visit; this is to 
capture information on early nonresponders  




this group of patients. Participants will leave 
the study and return to ‘routine clinical care’ as 
determined within their local NHS institution (or 
be recruited to subsequent trials). 
Alternatively, they may wish to proceed to 
enrollment in  the next WP (study 3 – 
Laparoscopic Ventral Mesh Rectopexy) within 
the CapaCiTY programme. 
 
The following data will be collected at each visit up to 
12 months 
 
• Validated symptom and QOL questionnaires (PAC- 
SYM and PAC-QOL). Validated generic QOL ques- 
tionnaires: EQ-5D-5 L descriptive system and EQ- 
VAS. Note: EQ-VAS has a standard deviation (SD) of 
approximately 30 points: a 10% difference in VAS 
deemed clinically significant can be detected with 
the large sample sizes proposed 
• Patient Health Questionnaire-9 (PHQ-9)  [53–55] 
• Generalised Anxiety Disorder Questionnaire 
(GAD-7) [56] 
• Depression, anxiety and somatisation modules of 
the Patient Health Questionnaire [53–56] and the 
Illness Perception Questionnaire [57] 
• Global patient satisfaction/improvement score 
(VAS) and whether they would recommend each 
treatment  experienced  to other patients 
• Potentially modifiable cognitive and behavioural 
psychological variables shown to predict onset and 
perpetuation of other functional bowel symptoms: 
negative perfectionism, avoidant and ‘all or 
nothing’ behaviour subscales of the Behavioural 
Response to illness Questionnaire (CC-BRQ), and 
the Brief Illness Perception Questionnaire BIPQ 
(CC) 
• A 2-week Patient Diary (for 2 weeks prior to each 
assessment at 3, 6 and 12 months) to record bowel 
frequency and whether each evacuation was 
spontaneous (no use of laxatives) and/or complete; 
the patient journal will also capture concurrent 
medication, health contacts, and time away from 
normal activities (including work). Patients will be 
contacted by telephone to remind them to start the 
diary. If a patients forget to do this, then it is 
acceptable for them to start recording the diary on 
the day that they are seen in clinic and for this to be 
collected 2 weeks later 
• Resource use data (using patient journals as a 
prompt  and including concomitant  medication use) 
• Irrigation Diary to record frequency and volume of 
irrigation and any AEs 
 
Laboratory assessments 
Serum or urine pregnancy testing may be 
performed as per standard care for any 
women of equivocal status undergoing 





The whole gut transit study usually (90% 
patients) in- volves the use of a  single, plain 
abdominal radiograph   (in 10% patients, a 
maximum of two may be required to image 
the whole abdomen and pelvis). This 
procedure forms part of routine  clinical care 
for patients with CC   at many NHS centres. 
All practitioners (radiologists, radiographers, 
etc.) directing these studies will hold ap- 
propriate IR(ME)R certification. 
 
Participant withdrawal (including data collection/ 
retention for withdrawn participants) 
Individual participants will be able to 
withdraw from treat- ment at any time by 
notifying health care professionals in- volved 
with the study, and return to routine care 
without prejudice. Data will be retained for 
analysis from all partic- ipants after the point 
of consent and  recruitment. 
Criteria for withdrawal from  treatment: 
 
Participant develops any of the following exclusion criteria 
 
• Participant becomes pregnant or intends to 
become pregnant (only in baseline and 
intervention  phases) 
• Participant is subsequently diagnosed with a 
proven cause for secondary constipation, e.g. 
Parkinson’s disease or bowel obstruction 
• Participant requires new medication with 
proven effects on bowel function, e.g. opioids 
• Participant develops significant intercurrent 
illness precluding participation 
• Participant requires surgery or other intervention 
(other than minor ops) during treatment or follow- 
up phase 
• Participant develops acute psychological 
problem causing safety concern 
• Adverse events secondary to therapy (bleeding, 
anal fissure, ulceration, pain, bowel perforation) – 
relative indications for withdrawal depending on the 
views of the patient and physician. (Note: bowel 
perforation is an absolute indication for withdrawal) 
• Elective withdrawal 
Loss to follow-up (no further interventions or follow-up 
data collected) 
 
• During follow-up (up to 12 months), participants 
may be withdrawn from the trial if they become lost 
to follow-up (LTFU) after at least three failed 
attempts by research staff to make contact via two 
different methods (e.g. telephone and letter) 
• Participant chooses to withdraw and does not 
wish to participate in follow-up data collection 
• Death or significant incapacity making follow-up 





End of study definition 
The end of study is defined as the last patient 
last visit. The sponsor, REC and local R&D 
departments will be informed of end of study 
and site closure and archiving procedures 
initiated. 
 
Criteria  for  early termination 
If the Data Monitoring and Ethics Committee 
(DMEC), Programme Steering Committee 
(PSC), Research Ethics Committee (REC) or 
sponsor determine that it is within the best 
interests of the participants or trial to 
terminate the study, written notification will 
be given to the chief investigator (CI). This 
may be due to, but not limited to: serious 
safety concerns, serious breaches, acts of 
fraud, critical findings or persistent 
noncompliance that nega- tively affects patient 
safety or data integrity. If the study is 
terminated participants will be returned to the 
NHS normal follow-up  and  routine care. 
 
Qualitative  interviews 
The purpose of this qualitative enquiry is to 
complement the quantitative study of TAI. A 
phenomenological methodology will be 
employed and qualitative data will be 
collected in parallel with the quantitative study. 
Par- ticipants will be recruited separately from 
the quantita- tive study, with separate PISs 
and consent processes. 
 
Sampling 
A purposive sample of  approximately  35  




completion of irrigation training and then  
again  at  6  months.  Participants  do not 
have to participate in both sets of interviews; 
a separate   set    of    patients    can    be    
interviewed    at  6 months. Recruitment can 
be extended if data  satur-  ation is not 
accomplished by the 35th patient. Data 
saturation is defined as the point at which no 
new or relevant themes emerge. Inclusion 
and  exclusion  cri- teria are as above. 
Participants will be selected from a sampling 
grid of potential interviewees  to  reflect  a 
range of ages, geographical locations and, 
where pos- sible, other pertinent attributes 
such as ethnicity and gender. An 
approximately  equal  number  of patients  
will be selected from each trial arm as 
follows: 
 
• Seventeen patients undergoing low-volume anal 
irrigation and 18 patients undergoing high-volume 
irrigation and including those who discontinue early 
(before 3 months), later (3–5 months), those who 
continue with their allocated treatment, and those 
who switch 
• In addition, approximately 10 health professionals 
involved in delivering the treatment will be 
interviewed. These health care professionals will 
be evenly distributed across participating centres 
 
Data collection 
All participants will  be told that they might be 
invited   for interview when  they  are  initially  
informed  about the study. Participants  will  
be  contacted  by  a  member of the clinical 
team and if interested in  being  inter- viewed 
a separate PIS  will  be  provided.  
Participants will be offered a semistructured 
interview in a clinic  room or in their own 
home according to  their  prefer- ence, and 
will be offered a chaperone to  be  present  if 
they would prefer. Professionals will be 
interviewed in    a clinic setting. Following 
written consent, the inter- views will be 
recorded on a digital dictaphone and 
transcribed into a pseudonymised 
(alphanumeric code) text document. 
Interviews will be conducted by an ex- 
perienced qualitative researcher working 
within the  wider CapaCiTY research 
programme. A clinical re- search fellow at 
UHND and/or a health research 
methodologist at Durham University will 
conduct in- terviews  recruited  from  the  
Durham site. 
Interviews will explore health professionals’ 
and partic- ipants’ experiences of recruitment, 
individual interven- tions, their training and 
delivery, and patients’ views about outcome 
measures. A topic guide for each of the 
interviews and focus groups, informed by the 
existing literature and our patient advisors, 
will be developed. 
 
Timing 
Patients will be invited to one-to-one 
interviews on completion of training and will 
be interviewed a max- imum of 4 weeks after 
training to maximise recall. Pa- tients will be 
recalled up to 6 months after training and 
offered an interview. The patients interviewed 
at base- line do not have to be the same as 
those interviewed up   to 6 months. 
Interviews will be conducted throughout to 
capture relatively early and later experiences 






Interviews will be digitally recorded, 
anonymised, transcribed verbatim and 
analysed using a thematic analysis and 
NVivo8 software (QSR International Ltd., 
Warrington, UK) for data management.  
Data analysis will be developed as outlined 
by Fereday and Muir- Cochrane [58] in the 
first instance by mapping key con- cepts 
derived from the transcripts (‘charting’) and 
extract- ing emergent themes from the 
transcripts. Professor Norton will coordinate 
and conduct analysis, while for the purposes 
of Christopher Emmett’s MD, independent 
ana- lysis will be conducted by CE and Dr. 
Helen Close. Emer- gent themes, together 
with captured observational data, will form the 
basis of analytical interpretation. Data will be 
handled in a confidential manner at all times, 
and only transferred on encrypted media or 






PAC-QOL is a 28-item disease-specific 
measure, with each item scored 0–4, and 
providing an aggregate score 0– [34]. 
Superiority of either low-volume or high- 
volume anal irrigation is demonstrated by a 
10% scale difference (or more), or 0.4, with a 
variance estimate conservatively set at SD = 
1 from the published medical literature [59]. 
To detect an  effect  size  of  0.4  (mean/ SD 
= 0.4) between the  two  groups  with  90%  
power and 5% significance at 3 months 
requires 133 patients   per arm, and  266 
total. Allowing for an  anticipated 10% loss 
to follow-up  (LTFU),  then  300  patients  will 
be  recruited. 
 
Clinical outcomes 
A full analysis plan will be signed off before 
allocation codes are made available to the 
statistician. The codes   will not indicate 
which treatment arm is which so that     as far 
as possible the statistician will remain blind to 
al- location throughout the analysis. All 
analyses will be by the intention-to-treat 
principle. The  primary  outcome will be PAC-
QOL  as a continuous variable, analysed at   
3 months while the quarantine period is in 
effect. The proportion of patients continuing 
with the initial therapy system will be 
recorded, and the PAC-QOL scores will  be 
analysed using a linear mixed model with a 
random effect for centre and fixed effects for 
intervention, trial stratification variables 
(participants are stratified by sex and women 
by centre) and baseline PAC-QOL. Second- 
ary outcomes will be analysed using the 
principles out- lined above for the primary  
outcome. 
Exploratory modelling will be conducted for 
baseline characteristics: measures of chronic 
pain, autonomic, joint hypermobility, cognitive, 
behavioural and mood variables share a 
common hypothesis that they are detri- mental 
to the success of all treatments, i.e. they 
perpetu- ate illness in spite of therapy. We will 
investigate a maximum of three interactions 
between treatment and baseline 
characteristics. These will be described in the 
SAP a priori. Appropriate regression models, 
including interaction terms, will be developed 
to determine the in- fluence of these 
pretreatment characteristics on the suc- cess 
of treatments in all  WPs. 
Life table data for any irrigation will be 
presented by initial therapy and for specific 
therapy from date of com- mencement. 
Survival analysis will be presented using 
Kaplan-Maier analysis and adjusted using Cox 
regres- sion. Exploratory analysis will be 
considered to identify characteristics of 
subgroups with greatest persistent  benefit 
from irrigation. These will be described  in  the 
SAP a priori. 
Analysis will be performed using proprietary 
software, (Stata  Corp., College Station, TX, 




taken to indicate statistical significance. No 
analyses will be conducted until an analysis 
plan has been written, reviewed by an 
independent  statistician and signed off. 
Multiple imputation will be considered to 
address missing covariate values. Details of 
any imputation to be performed will be 
described in the SAP which will be finalised 
after initial checks on completeness of the 
data but before performing any analysis or 
unblinding of the data. 
 
Health economic outcomes 
The patient journal will facilitate the capture 
of health economic data which will be 
recorded on the  CRF  at each visit. This will 
be combined with the initial cost of the 
device and weekly consumables. 
Within-trial stochastic analysis will 
compare the cost/ success and cost/quality-
adjusted life year (QALY) of  anal irrigation. 
Patient-level cost-effectiveness analysis will 
use standard bootstrapping methods to 
generate cost-effectiveness acceptability 
curves exploring value for money. Within-
cohort combined stochastic/probabilistic 
epidemiological models will be used to 
assess irrigation and surgery options, 
exploring relative effectiveness and cost-
effectiveness according to patient 
characteristics. 
Cost-effectiveness models that extrapolate 
beyond 3–6 months’ duration are  
problematic  in  adult  constipation, as 
subsequent care and outcomes are 
contingent upon subsequent care received 
and the underlying disease process. 
However, the programme of WPs, and 
inclusion of time to failure data capture, 
provides a unique oppor- tunity to construct 
probabilistic models exploring  opti- mal 
pathways from effectiveness and cost-
effectiveness perspectives. 
Since patients will (within the CapaCiTY 
programme) be followed along a pathway 
that includes a  series  of steps of care, it will 
be possible to construct costs and outcomes 
for a range of patient pathways providing 
comparative longer-term cost-effectiveness 
estimates. Patient-level data from recruitment 
through the various WPs will be used to 
construct pragmatic, probabilistic models to 
explore optimal pathways from effectiveness 
and cost-effectiveness perspectives. 
Analyses from NHS and societal 
perspectives will be supported by recording 
relevant resource use  during  each WP, and 
a common panel of outcomes. Adjustment for 
time preference will be at the socially 
accepted rate  for cost-effectiveness 
analyses (currently 3.5%/annum for costs 
and benefits). 
 
Data  analysis for MD  thesis 
The study will form the basis of a thesis for 
an MD at Durham University by a research 
fellow (Christopher Emmett) at University 
Hospital of North Durham (UHND).  Patients  





Victoria Infirmary, Newcastle upon Tyne up 
to 1  October 2016 (estimated 50 patients) 
will be analysed in this thesis, including those 
recruited to the  qualitative  arm of the study 
at this site. These patients will have a 
minimum of 3 months of study data. The 
release of data from the UHND and 
Newcastle sites  for  this  purpose has been 
approved by the chief investigator (CI) on the 
condition that it may be used for thesis 
examination but   is not published or made 
publically available until the CapaCiTY 
programme results are published in full. The 
qualitative data from the Durham site may be 
published separately as agreed. 
 
Laboratories (if applicable) 
Serum pregnancy testing will be performed  by  





Products, devices, techniques and 
tools 
Devices 
There are no investigative medicinal products 
or investi- gative devices under study. The 
following is a list of all devices routinely used 
in clinical care and none are spe- cific to the 
research itself. All are CE-marked and ap- 
proved for use in the  UK. 
 
1. Disposable proctoscope (supplier as local NHS 
practice). This will be commonly be used as part of 
clinical examination at baseline and is also used to 
introduce balloon catheters into the rectum during 
INVEST 
2. High-resolution anorectal manometry (HRAM 
system + Unisensor HRAM catheter (200 uses) and 
balloons, software, cables, calibration kit, isolation 
transformer and laptop. Insertion and use are 
outlined under the ‘Interventions’ section 
(equipment provided at study outset) 
3. Standard anorectal manometry catheter, balloons, 
software, cables, calibration kit and associated 
equipment; standard equipment in many NHS 
centres for performing anorectal physiology. Can 
be used as an alternative where high-resolution 
manometry is not available (part of INVEST – see 
above) 
4. Balloon catheters for balloon expulsion test (part 
of INVEST – see above) 
5. Radio-opaque markers for colonic transit 
study: various suppliers (part of INVEST – see 
above) 
6. Standard departmental X-ray equipment (part 
of INVEST – see above) 
7. Peristeen™ anal irrigation system (Coloplast), 
Qufora® Balloon™/Qufora Toilet anal irrigation 
systems (MBH-International): established anal 
irrigation systems available on prescription in NHS 
practice. Other systems with the same 
mechanism 
 
of action may also be used (dependent 
on local funding and prescribing 
arrangements) 
8. Qufora® Mini anal irrigation system (MBH- 
International): established anal irrigation 
system available on prescription in NHS 
practice 
 
All devices are maintained, calibrated and 
serviced ac- cording to standard NHS policies 
and procedures ac- cording to manufacturer’s 
guidance. Training on devices is provided by 
the supplier’s representatives. Additional 
study SOPs and training will be provided to 
ensure standardisation across sites, but will 
be in line with current  NHS  standard 
practice. 
 
Data collection tools 
The permissions/licenses to use the below 
instruments have been sought on the 
understanding that sites are permitted to 
utilise these within this study only, they will be 
provided to sites as part of the CRF for the 
study: 
 
• PAC-QOL score: from MAPI Research Trust 
• PAC-SYM score: from MAPI Research Trust 
• EQ-5D-5 L: from EuroQol 
The below-listed questionnaire-based tools 
are free to use within the public domain and 
will  be  provided  to sites as part of the CRFs 
for the study. 
 
• Depression, anxiety and somatisation modules of 
the Patient  Health Questionnaire 
• Illness Perception Questionnaire 
• Composite Rome III/Cleveland Clinic Constipation 
Questionnaire: free to use 
• Brief, chronic pain, autonomic and joint 
hypermobility: free to use 
• Negative perfectionism 
• Avoidant and ‘all or nothing’ behaviour subscales of 
the Behavioural Response to Illness Questionnaire 
 
Safety reporting 




An AE is any untoward medical occurrence 
in a  subject  to whom an intervention has 
been administered, includ- ing occurrences 
which are not necessarily caused by, or 
related to, that intervention. An AE  can,  
therefore,  be any unfavourable and 
unintended sign (including an ab- normal 
laboratory finding), symptom or disease 
tempor- arily associated with study 
activities. 
 
Notification and reporting adverse events or reactions 
The anal irrigation systems are in 
widespread and estab- lished clinical use 
throughout the NHS with known AEs 
occurring (22%) being mostly low grade 
and reversible. All  trial  interventions  are  









provided within the NHS for CC. Related AEs 
will be re- corded on the CRF. Serious 
adverse events (SAEs) will be recorded on 
the CRF and in the medical notes to en- able 
assessment and reporting in line with 
sponsor and regulatory requirements. 
Causality will be at the discre- tion of the 
health care provider (e.g. research nurse, 
physiotherapist, PI or delegated member of 
team). These will be assessed as outlined 
below. 
Trial participants will be advised to seek 
medical sup- port from their GP for any 
unrelated signs, symptoms or disease or 
aggravation of underlying  symptoms. 
 
Serious adverse event (SAE) 
In other research other than CTIMPs, a 
SAE is defined as an untoward occurrence 
that: 
 
1. Results in death 
2. Is  life-threatening. 
3. Requires hospitalisation or prolongation of 
existing hospitalisation 
4. Results in persistent or significant disability or 
incapacity 
5. Consists of a congenital anomaly or birth defect,  or 
6. Is otherwise considered medically significant by 
the investigator 
 
An SAE occurring to a research 
participant should be reported to the 
sponsor and Main Research Ethics 
Committee (MREC) where, in the opinion 
of the CI, the event was: 
 
• Related – that is, it resulted from administration 
of any of the research procedures,  and 
• Unexpected – that is, the type of event is not listed 
in the protocol as an expected occurrence (see 
Additional file 3) 
 
Notification and reporting of SAEs 
Serious adverse events (SAEs) that are 
considered to be ‘related’ and ‘unexpected’ 
are to be reported to the spon- sor within 24 h 
of learning of the event  and  to  the MREC 
within 15 days in line with the required time- 
frame. For further guidance on this matter, 
please refer   to the HRA website and Joint 
Research Management Office (JRMO) SOPs. 
 
Expected SAEs 
The following SAEs are expected to occur 
rarely in this patient population and will not 
be reported: 
 
• Hospital admission for exacerbation of constipation 
symptoms including impaction 
• Hospital admission for unrelated elective surgical 





Urgent safety measures 
The CI may take urgent safety measures to 
ensure the safety and protection of the 
clinical trial  subjects from  any immediate 
hazard to their health and safety. The 
measures should be taken immediately. In 
this instance, the approval of the REC prior 
to implementing these  safety measures is 
not required. However, it is the re- 
sponsibility of the CI to inform the sponsor 
and the MREC (via telephone) of this event 
immediately. 
The CI has an obligation to inform both the 
MREC in writing within 3 days, in the form of 
a substantial amendment. The sponsor, 
JRMO, must be sent a copy of the 
correspondence with regards to this matter. 
For fur- ther guidance on this matter, please 
refer to the HRA website and JRMO SOPs. 
 
Annual safety reporting 
The CI will send the Annual Progress Report 
to the MREC using the HRA template (the 
anniversary date is the date on the MREC  
‘favourable opinion’ letter from the MREC) 
and to the sponsor. Please see the HRA 
web- site and JRMO SOP for further 
information. 
 
Overview of the safety reporting responsibilities 
The CI/PI has the overall responsibility for 
oversight of safety reporting. The CI/PI also 
has a duty to ensure that safety monitoring 
and reporting is conducted in accord- ance 
with  the sponsor’s requirements. 
 
Monitoring and auditing 
The PCTU quality assurance (QA) manager 
will conduct  a study risk assessment in 
collaboration with the CI. Based on the risk 
assessment, an appropriate study mon- 
itoring and auditing plan will be produced 
according to PCTU SOPs. This monitoring 
plan will be authorised by the sponsor 
before implementation. Any changes to the 
monitoring plan must be agreed by the PCTU 




‘A systematic and independent 
examination of trial- related activities and 
documents to determine whether the  
evaluated trial-related  activities  we 
reconducted, and the data were recorded, 
analysed and accurately reported 
according to the  protocol,  sponsor’s  
SOPs, Good Clinical Practice (GCP) and 
the applicable regulatory requirement(s).’ 
 
A study may be identified for audit by any  
method listed below: 
 










2. An individual investigator or department may 
request  an audit. 
3. A project may be identified via an allegation of 
research misconduct or fraud or a suspected 
breach of regulations 
4. Projects may be selected at random. The 
Department of Health states that trusts should be 
auditing a minimum of 10% of all research projects 
5. Projects may be randomly selected for audit by 
an external organisation 
 
Internal audits  may  be  conducted  by  a  
sponsor’s  or  a funder’s representative 
according to JRMO/NIHR SOPs. 
 
Safety considerations 
Patients recruited who have not had previous 
INVEST procedures conducted within the last 
12 months will undergo a radiological 
procedure (whole gut  transit) using ionising 
radiation as outlined above. The average 
dose of this procedure (approximately 0.1 
mSv) is equivalent to about 2.5 weeks’ 
annual background radi- ation dose from 
living in the UK Further, these investiga- tions 
would be carried out in routine clinical 
practice in many centres for patients at the 
same point as  recruit- ment  to this study. 
Regarding the intervention, anal irrigation is 
associated with a very low incidence of  
bowel  perforation, as well as other side 
effects (bleeding, pain, ulceration, painful 
haemorrhoids, anal fissure). Patients will be 
counselled regarding these risks as part of 
the process of informed consent. In addition, 
they will be trained in the correct use of the 
device prior to commencing therapy. All re- 
lated AEs and all SAEs will be recorded and 




The project will be under the auspices of the 
CI and the PCTU. The project will be 
overseen by a Programme Steering 
Committee (PSC). 
The composition and responsibilities of the 
PSC will comply with the NIHR guidance and 
PCTU  SOP  on Trial Oversight Committees. 
The role of the PSC is to provide overall 
supervision of the study on behalf of the 
sponsor and funder to ensure that study is 
conducted in accordance with the principles of 
Good Clinical Practice (GCP)  relevant 
regulations. 
The responsibilities of the PSC will include: 
 
• Ensuring that the views of users and carers are 
taken  into consideration 
• Advising on the trial protocol 
• Advising on changes in the protocol based on 





• Assisting in resolving problems brought to it by 
the Programme Management  Group (PMG) 
• Monitoring the progress of the trial and 
adherence to protocol and milestones 
• Considering new information of relevance 
from other sources 
• Considering and acting on the recommendations 
of the Data Monitoring Committee (DMC), 
sponsor and/or MREC 
• Review initial reports and papers for publication 
The PSC will meet to review the protocol 
before the start of the programme and then 
soon after the first par- ticipants are 
recruited and either meet or teleconference 
every 6 months thereafter throughout the 
lifetime of the programme. 
Representatives of the trial sponsor and 
the funder will be invited to  attend. 
A PMG made up of core staff from the 
coordinating centres and the PCTU will 
meet monthly initially during study set-up 
and then less frequently, every 2 months. 
The PMG will be responsible for day-to-day 
project delivery across participating centres, 
and will report to the PSC. 
An independent Data Monitoring and 
Ethics Committee (DMEC) will be 
convened. The DMEC will meet at least 4 
weeks prior to the PSC to enable 
recommendations to be fed forward. 
A DAMOCLES charter will be adopted, 
and the pro- ject team will provide the 
DMEC with a comprehensive report, the 
content of which should be agreed in  ad-  
vance by the chair of the DMEC and follow 
guidelines   set out in the  charter. 
A Constipation Research Advisory Group 
(CRAG) will be formed as part of a well-
developed Patient and Public Involvement 
(PPI) strategy at QMUL. This advisory group 
will comprise eight patients and two lay 
members derived from London and Durham. 
This group will have geographical diversity 
(north and south) and a disease- 
appropriate demographic (eight women, two 
men). The CRAG will be involved in: 
 
• Review of PISs, booklets, diaries and 
advertising/ marketing materials 
• Project management by representation on the PSC 
• Parallel  qualitative analysis 
• Dissemination of results and lay summaries 
• Presentations at local research events 
• Patient focus groups and workshops 
Project  management 
Local coordination 
Each participating centre will identify a site-
specific PI who will nominate a local contact 
for that  centre (this  may be themselves). 








• Be familiar with the   trial 
• Liaise with the PCTU and the  PMG 
• Ensure that all staff involved in the trial are 
informed about the trial and have received 
requisite  training 
• Ensure that mechanisms for recruitment of eligible 
participants, including the availability of 
participant information and data collection tools, 
are in place; monitor their effectiveness and 
discuss the reasons for nonrecruitment  with 
relevant staff 
• Ensure that site staff collect necessary trial data 
and perform quality checks 
• Notify the CI of any  SAE’s 
• Make data available for verification, audit and 
inspection processes as necessary, and respond 
to requests for documentation and data required 
for centralised monitoring 
• Ensure that the confidentiality of all information 
about trial participants is respected by all  
persons 
 
Site initiation and training 
A central study launch meeting and/or site 
initiation will be conducted with each site. 
This will include training in the trial protocol 
and SOPs, such as data collection, ran- 
domisation and taking informed consent. 
Evidence of appropriate training, local 
approvals and essential docu- mentation will 
be required before participants being en- 
rolled at each site. Training will be 
documented on training logs. 
 
Project timetable, milestones  and  projected  recruitment 
The PMG will be responsible for monitoring  
adherence to the study timelines and 
expected recruitment rates. Regular reports 
will be produced to enable deviations  from 
the project plan to be identified and 
contingencies planned,  discussed and 
executed  in a timely fashion. 
Projected  recruitment  dates are: 
 
1 Aug 2015: first participant 
31 Apr 2016: 100 participants 
30 Nov 2016: 200 participants 
30 Jun 2017: 300 participants 
30 Oct 2017: last patient intervention 
31 Apr 2018: 3-month primary  endpoint 
31 Oct 2018: 12-month secondary  endpoint 
 
Discussion 
The CapaCiTY 02 study is a large and 
potentially very rich study in terms of 
hypothesis-testing and generating robust 
evidence. As previously noted, its primary aim 
of establishing superiority of one system of 
irrigation over another will provide valuable 
information that can be  used to guide the 
choice of therapy in patients with CC. 






outcomes, and will also evaluate the 
association between pretreatment baseline 
characteristics (e.g. psychological profile, 
joint hypermobility, colonic transit, anorectal 
physiology) and treatment success. 
Alongside these ele- ments, a qualitative 
component of the study will explore the lived 
experiences of patients and health care 
profes- sionals who are using irrigation,  or  
training patients in  its use. 
The multisite nature of the study, along 
with the broad range of outcome measures 
being employed, could po- tentially lead to 
several practical challenges in imple- 
menting the study  protocol.  Attempts  have  
been  made to anticipate and address these 
before commencing study recruitment. 
Prestudy site feasibility questionnaires were 
circulated to all sites wishing to participate,  
and these were used to identify the key 
components of irriga- tion training and 
treatment at each site. The training process 
described in this protocol aims to be as 
applic- able as possible to as broad a range 
of sites as feasible, without causing the 
study sites to make significant alter- ations 
to their standard practice. 
The protocol also aims to be flexible as 
regards pre- treatment investigations. These 
have been limited to anorectal physiology 
and a transit study (see section above: 
‘INVEST’). It was felt that these provided im- 
portant information necessary for 
characterising pa- tients before starting 
treatment, thereby allowing analysis of the 
relationship between pretreatment 
characteristics and  treatment  success.  It  
was  decided, as few sites had access to 
HRAM, that standard man- ometry was 
sufficient for the purposes  of  this  study.  
This increased participation by allowing sites 
not in possession of the  necessary  high-
resolution  equipment  to  still  recruit  to  the 
study. 
It is recognised that the study design has 
several limi- tations. From a methodological 
perspective, the fact that neither participant 
nor assessor blinding was  feasible (due to 
the nature of  the  treatment  and  the  
nature  of  the outcome data being collected), 
leads to the possibil- ity of performance bias 
and reporting bias, as both participants and 
assessors will (consciously or uncon- 
sciously) have particular preconceived ideas 
about the likely efficacy of each system. 
Attempts have been made, from a 
methodological and operational perspective, 
to limit the impact of this. The fact that every 
patient re- ceives treatment is important, as it 
is a reasonable as- sumption that the placebo 
effect for each system is  similar, thereby 
meaning that any observed difference 
between systems is a genuine one. 
Additionally, the op- tion of switching systems 
after 3 months is designed to allow 
participants who have not had success with 
their original system to try the other one. This 
means that pa- tients do not spend too long  
on  ineffective  treatment,  and  also  allows  





Additional file 1: CapaCiTY programme overview. (DOCX 152 kb) 
Additional file 2: SPIRIT Checklist. (DOCX 66 kb) 
Additional file 3: Communication organogram for reporting serious 
adverse events (SAEs). (DOCX 52 kb) 
Additional file 4: Consent Form (quantitative study). (DOCX 64 kb) 





to evaluate the effectiveness of the treatment 
as a whole   in the long  term. 
As can be seen from the ‘Trial status’ 
section below, recruitment nationally has 
fallen below the planned rate of recruitment. 
Several reasons for low recruitment have 
been identified through discussions with 
participating sites; these are mainly the result 
of variation in local practice (making the 
protocol difficult to implement), as well as 
service pressures and the pressure on 
research teams from doing more than one 
study in the CapaCiTY programme. This 
highlights the difficulties in imple- menting 
multisite studies, and even  though  attempts 
were made before study commencement to 
ensure suffi- cient flexibility in the proposed 
study design, problems have  nonetheless  
been encountered. 
Since recruitment has opened, recruitment  
rates  at each study site are monitored and 
monthly meetings are held to discuss 
progress and to identify problems at an early 
stage. Teleconferences have been held with 
recruit- ing sites in order to discuss and 
resolve barriers to recruitment. 
 
Trial status 
As of 31 August 2016, the study has seven 
sites open to recruitment. The first patient 
was enrolled on 15 October 2015. 
Currently, 39 patients have been screened 
and 22 randomised. Of these, two have 
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The study is being financed as part of an NIHR PGfAR award RP-PG-0612- 
20001: £1,971,934. Additional resource will be provided via host CLRNs. The 
calculation of all costs and contracting has been performed in conjunction 
with the sponsor. 
Indemnity 
Queen Mary University London has agreed to act as study sponsor. 
Insurance and indemnity will be provided by the sponsor. 
 
Availability of data and  materials 
The trial data will be made available to suitably qualified members of the 
research team, study monitors and auditors, the sponsor, the REC and 
regulatory authorities as far as required by law. The participants will not be 
identifiable with regards to any future publications relating to this study. 
When the research trial is complete, it is a requirement of the Research 
Governance Framework and trust policy that the records (including paper 
records, digital records and audio files) are kept for a further 20 years. For 
trials involving BH Trust patients, undertaken by trust staff, or sponsored by 
BH or QMUL, the approved repository for long-term storage of local records 
is the Trust Modern Records Centre. 
Each site will be required to archive local site files and patient-identifiable 
information, such as Consent Forms and screening logs, for a period of 
20 years. At the end of the 20-year retention period, permission should be 
obtained in writing from the sponsor prior to destruction of this material. 
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Consent  for publication 
The CI will coordinate dissemination of data from this trial. All publications 
using data from this trial to undertake original analyses will be submitted to 
the PSC for review before release. To safeguard the scientific integrity of the 
trial, data will not be presented in public before the main results are 
published without the prior consent of the PSC. The success of the trial 









depends on a large number of clinicians. For this reason, credit for the 
results will not be given to the committees or central organisers, but to all 
who have collaborated and participated in the trial. Acknowledgement will 
include all local coordinators and collaborators, members of the trial 
committees, the PCTU and trial staff. All contributors to the trial will be listed 
at the end of the report, with their contribution to the trial identified. Those 
responsible for other publications reporting specific aspects of the trial may 
wish to utilise a different authorship model, such as ‘[name], [name] and 
[name] on behalf of the collaborative Group’. Decisions about authorship of 
additional papers will be discussed and agreed by the trial investigators and 
the PSC. 
A lay summary of the final results of the trial will be made available for 
participants on the Bowel and Cancer Research charity website with a link to 
the full paper. 
 
Ethics  approval and consent  to participate 
General 
This study (study 2 of the CapaCiTY programme) will be carried out in 
accordance with the ethical principles in the Research Governance 
Framework for Health and Social Care, Second Edition, 2005 and its 
subsequent amendments as applicable and applicable legal and regulatory 
requirements. 
Ethics approval for the whole CapaCiTY programme (studies 1 to 3) has 
been sought from one of the London NRECs (London City and East). Within 
the programme, the three studies will be distinct studies and protocols, and 
thus consented separately. This is necessary to limit patient information 
which would otherwise be over-burdensome. The REC reference and IRAS 
number for CapaCiTY 02 are given below. 
REC Reference 15/LO/0732. 
IRAS 172401. 
Informed  consent procedures 
Written informed consent will be obtained at visit 1 from research participants 
by an appropriately trained and delegated researcher in a face-to-face setting in 
clinic. For study Consent Forms, see Additional files 4 (quantitative study) and 5 
(qualitative study). 
Ethical  considerations 
The protocol has been reviewed by Professor Richard Ashcroft, Professor of 
Medical Ethics and Law at QMUL. Important considerations that have 
informed pragmatic design include (a) limitation of intimate examinations: to 
one time point (not repeated if performed before recruitment), (b) timings of 
outcomes: within this study outcomes will be undertaken at 3, 6 and 
12 months from the commencement of the first treatment for all patients, 
with additional recording of key outcome measures (PAC-QOL, PAC-SYM, 
EQ-5D-5 L and EQ-VAS, Irrigation Journal and Patient Journal). For this period 
of 6 months, patients will not progress to further WPs thus preventing 
outcome ‘contamination’. Additionally there will be a 3-month ‘quarantine’ 
from switching irrigation therapy. These delays are akin to that in usual NHS 
care, during which general supportive care will be provided. This proposed 
limitations at 3 and 6 months confers no disadvantage and may even 
represent an acceleration of treatment progression. Ethically, this is viewed 
as a reasonable trade-off for the commitment to the research programme, 
(c) recruitment and consent: study 2 represents one of the three studies 
incorporated in the NIHR-funded CapaCiTY programme. Although patients 
may move sequentially through treatments (and, therefore, studies) during 
the programme course, study 2 will be consented as a distinct single entity 
and (d) qualitative interviews: these will be in-depth interviews conducted 
one-on-one (plus a chaperone if requested by the patient) and, therefore, 
there are potential risks to the safety of the interviewer. Also, the thorough 
nature of the interviews could lead to psychological distress for the 
participant. It is, therefore, necessary to identify patients who would be at 
especially high risk in either of these ways and to exclude them from the 
study. Baseline assessment would identify and enable exclusion of individuals 
with pre-existing psychiatric disorders or a history of high-risk behaviours 
(self-harm, drug and alcohol addiction). Counselling and support from health 
care professionals involved in patient care will be available for any subject 
experiencing untoward distress. 
Protocol  amendments 
In the event of a protocol amendment being required, details of the 
proposed amendment will be submitted to the sponsor initially for review 
and authorisation of submission as either a minor or substantial amendment. 
For substantial amendments, an IRAS amendment form, cover letter and all 




amended documents (along with a summary of changes) will be 
submitted to the REC for approval. Once approved, details of the 
amendments and any action required will be circulated to each 
participating site PI and local R&D/ CRN. The CI will submit all 
nonsubstantial/minor amendments to HRA for classification according 
to HRA guidelines, the results of which will be provided to participating 
site PI, R&D and CRN as required. 
Confidentiality 
Information related to participants should be kept confidential and 
managed in accordance with the Data Protection Act, NHS Caldecott 
Principles, The Research Governance Framework for Health and Social 
Care, and the conditions of REC approval. 
Identifiable information to be collected from the participants includes, full 
name, date of birth and hospital number and contact details at screening. 
This information will be used to contact participants but will not leave the 
study site without prior consent and approvals. All CRFs will be pseudonymised. 
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